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ABSTRACT
The aim of this study was to investigate the role of the
acute phase protein (C-reactive protein) as a possible
diagnostic aid in periodontal disease activity using
gingival crevicular fluid (GCF), saliva and serum, and to
investigate the value of measuring CRP in predicting
periodontal disease activity.
Fifty-four patients with chronic periodontitis and twenty
five healthy dental students (controls) from Edinburgh
Dental Hospital and School were recruited for the study,
and were seen at two months intervals over one year.
Clinical parameters were recorded, microbiological samples
taken and biological fluids sampled at each of the six
examinations over the study period. GCF, saliva and serum
samples were analysed for CRP levels using a modified ELISA
technique developed during the study.
The clinical, microbiological and CRP data was subjected to
statistical analysis using a general statistic package.
The results confirm the presence of CRP in GCF for both the
patient and control groups, and this is the first report
for CRP being present in GCF.
The results indicated a significant positive correlation
between attachment level change and changes in CRP levels
for both short and long term.
However, within the limitations of this study, CRP levels
in GCF failed to predict periodontal disease activity as
v
measured by attachment level loss.
It is concluded that CRP is present in GCF and that its
level in GCF is significantly associated with attachment
level change. The level of CRP in GCF cannot be used as a
diagnostic aid in predicting periodontal disease activity
over a period of two months or one year.
It is suggested that further investigation should be
carried out to monitor CRP levels within a very short time
period as the level rapidly increases during chronic
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Periodontal diseases are regarded as a range of different
diseases for each of which certain individuals form a
minority group and are at relatively high risk.
The epidemiological evidence for the existence of high-risk
groups has shown that world-wide the prevalence of severe
destructive periodontitis is of the order of only 7-15% of
the adult dentate population. Successful identification of
such groups, individuals or sites will undoubtedly permit
scientifically valid, rational and targeted prevention and
treatment of destructive periodontal disease.
Periodontitis is an inflammatory disease of the
periodontium which is characterised by a progressive
destruction of the tissues supporting the tooth, with loss
of bone, loss of attachment and tooth mobility. Three
different patterns of periodontal disease activity have
been suggested, the three patterns being incorporated in
three hypotheses for periodontal destruction. These are
continuous paradigm, random burst and synchronous burst
hypotheses.
Periodontal disease activity may manifest in different
patterns at different sites and within different subjects.
The disease is currently considered to be episodic with,
relatively short episodes of rapid tissue destruction
followed by some repair, and prolonged intervening periods
of disease remission. The dental surgeon can determine that
an episode of disease has occurred, rather than being able
to document the present state of disease activity, but he
1
is unable to determine a future progression of the disease.
The fundamental concepts of measuring periodontal disease
emphasise the need for improved diagnostic and prognostic
tests. It would be of immense value to be able to identify-
both those individuals at particular risk of disease as
well those who have active disease at examination time.
The usual clinical parameters of periodontal disease are
only capable of identifying disease retrospectively, and it
has emerged that there is a need for longitudinal, rather
than cross sectional, studies in the search for clinical
and laboratory markers of current disease activity and
susceptibility. Such markers are likely to be present in
the gingival crevice where the destructive process starts
and where the products of the tissue destruction can be
detected as well as other factors which may be involved in
the destructive process. Both the clinical detection of
disease progression and the study of laboratory markers
including microbiological and immunological factors will in
future no doubt be of great value in determining the course
of the disease and influence treatment. Traditional
clinical criteria of periodontal disease (e.g.pocket depth,
bleeding on probing and gingival index) are inadequate in
both determining an active disease site in periodontitis
and the response to therapy, and in measuring the degree of
susceptibility to future breakdown. The criteria are
inadequate for predicting or monitoring clinical attachment
loss. With the exception of attachment loss, they are of
limited value in detecting individuals at high risk.
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Biochemical methods in periodontal disease diagnosis have
centred primarily on gingival crevicular fluid (GCF) and
its constituents. Biochemical markers in GCF have been
related to gingivitis and periodontitis,and most recently
to periodontal disease activity. The analysis of GCF for
biochemical markers of disease is envisioned to be one of
a battery of adjunctive diagnostic tests available which
might enable the dental surgeon to identify patients at
risk of disease progression. This requires distinguishing
between the extent of tissue damage and current disease
activity. Tissue damage is estimated at the time of
examination using clinical measures including probing
depth, clinical attachment level, tooth mobility, and the
level of alveolar bone support. Disease activity is
evidenced by the progression of periodontal disease,
determined primarily by changes in the clinical attachment
level or alveolar bone loss. The biochemical analysis of
GCF may offer a means of assessing the nature of the host
response in the periodontal tissues, and may provide a
method for the identification of patients at risk for the
development of active periodontal disease.
GCF is a promising source of markers for the detection of
disease activity because it contains components derived not
only from plasma, from connective tissue and from host
cells in the periodontium, but also components from the
subgingival microbial plaque, and thus an extremely broad
range of candidate markers can be investigated. Examination
of components of this fluid might permit the determination
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of disease markers at specific sites in the dentition.
Although the identification of one or more of these markers
may be shown to identify or predict disease activity, the
use of standard clinical measurements of periodontal
disease is not likely to be replaced in the near future.
Rather, identification of markers will comprise a battery
of biochemical, microbiological, and immunological tests
that will allow careful, in-office monitoring of patients
with periodontal disease. There is now an urgent need for
the identification of accurate and sensitive markers of
destructive periodontitis in order to place the diagnosis
and management of disease on a more rational basis. The
most appropriate biochemical markers of disease activity
would be mediators or regulators of the inflammatory
process, which should show dramatic quantitative changes in
the presence of inflammation.
There are many potential markers which increase during the
acute phase of the inflammatory process. Among these are
the acute phase proteins such as serum amyloid protein, C9
and C-reactive protein (CRP).
CRP is normally present in the serum within the range of
0.05-4.0 ug/ml with a median of 0.8 ug/ml in 95% of healthy
persons. This protein is increased in the serum during the
acute stage of the inflammatory process up to 100-1000 fold
of its normal level. It can thus be used as a marker of
infection or disease activity, particularly if changes in
the levels of CRP are interpreted along with other markers
such as (ESR) and the peripheral white blood cell count.
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CRP levels are used in this way in the diagnosis and
monitoring of disease activity in cystic fibrosis,
rheumatoid arthritis, rheumatic fever, myocardial
infarction and malignancy.
C-reactive protein is secreted by hepatocytes under the
induction of interleukin-1 (IL-1) or/and IL-6. The serum
level starts to increase within 6-8 hours after the onset
of acute inflammation, reaches its peak at 48-72 hours and
starts to decrease by the fourth or fifth day to return to
a normal level within one week of the onset, provided that
there is no continuing inflammation.
C-reactive protein has been found to be deposited locally
at the site of the inflammatory process, on the walls of
damaged or necrotic cells, and it is thought that CRP
participates directly in the inflammatory process. It has
been shown also that CRP increases in the serum of patients
with destructive diseases such as rheumatoid arthritis.
Although the exact biological function in vivo of CRP has
not yet been established, it has been suggested on the
basis of in vitro studies that CRP influences the functions
of phagocytes (macrophages and polymorphs) with particular
influence on polymorphs.
CRP provides one of the several signals that trigger and/or
regulate immune surveillance by augmentation or inhibition
of various components of the immune response. This is an
essential and beneficial function of CRP. CRP provides a
synergistically acting signal only, a help which often
facilitates homeostasis and which appears in some instances
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to be an essential factor for homeostasis to occur.
It influences chemotaxis (as a chemotactic factor),
opsonization of pathogens both directly and indirectly
through complement, and initiates the respiratory burst
activity of polymorphs and macrophages/monocytes.
CRP can be considered as an immunoregulator of acute
inflammation and it can participate in a negative feedback
mechanism to limit the potentially destructive effects of
polymorphs on the tissues. It is therefore considered a
protective factor in the non-specific immune mechanisms of
the body. Furthermore, CRP activates complement through its
classical pathway of activation to increase the protective
function of complement, while at the same time causing a
reduction of lytic complex formation from complement (C7,
C8, C9) through its interruption of the alternative pathway
of activation and thus preventing the ultimate damaging
effect of complement on the cells. CRP also influences
immunoglobulin function, particularly IgG, through the Fc
receptors of both polymorphs and monocytes, as CRP is
thought to stimulate the burst activity of the cells
through the activation of IgG Fc receptors.
CRP has effects on platelets as it prevents their
aggregation. It also inhibits prostaglandin formation and
in this way minimises the damaging effect in inflammation
of prostaglandins PGE-l and PGE2. Finally, CRP has effects on
both B lymphocytes and T lymphocytes. It activates T
lymphocytes and increases natural killer cell activity and
cell-mediated cytotoxicity. It also activates T suppressor
6
cells and decreases B cell colony formation,thus decreasing
IgA, IgG and IgM synthesis.
From its biological functions it seems that CRP influences
most of the factors which participate in and regulate the
inflammatory process both locally at a site of inflammation
and systemically in the serum. The predominant function of
CRP is on polymorphs which are the cells that appear first
and in greatest number at the site of inflammation such as
in an acute exacerbation or an increase of activity of
periodontal disease which is cyclic and episodic in nature
and lead to loss of attachment level and alveolar bone.
It was thus thought worthwhile to investigate the possible
role of CRP in destructive periodontal disease and that is
the most significant part of the laboratory studies
reported in this thesis which were carried out in parallel
with clinical measurements of periodontal disease. It was
hoped that this clinical and laboratory investigation might
indicate biochemical markers of disease activity which
could have value in identifying the current status and
predicting the future status of periodontal disease, and
might be used in determining the most appropriate
preventive and therapeutic measures in the management of
destructive periodontal disease.
The current review of literature in this thesis consists of
two parts. The first part covers the literature on
periodontal disease, while the second part reviews the
literature on CRP and its role in the acute phase response
as well as its relation to oral diseases.
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1.2 Clinical features and histological appearance
of the periodontium in health and disease
1.2.1 The periodontium in health
The periodontium consists of the supporting tissues of the
teeth which are the gingiva, periodontal ligament, cementum
and alveolar bone. These supporting tissues together form
a functional unit called the "attachment apparatus"
(Lindhe, 1990). The term "clinically healthy periodontium"
is appropriate for all sites that are disease-free,
including those which have extensive attachment loss and
recession as a result of previous episodes of periodontitis
as occurs in successfully treated sites (Wennstrom, 1988).
The periodontium, clinically, is characterised by a healthy
gingiva which has a uniform pale pink colour which may vary
due to the degree of keratinisation, thickness and
vascularity (Ainamo and Loe, 1966).
The gingiva consists of dense connective tissue and
stratified squamous epithelium (Ainamo and Loe, 1966;
Selvige, 1977) . It extends from the gingival margin to the
mucogingival junction except in the palate (Ainamo and
Talari, 1976; Ainamo et al., 1981). It is firm in texture
and nonmobile. The surface may be smooth or stippled (Amino
and Loe, 1966) . The gingiva in health fills the interdental
space between adjacent teeth (Wennstrom, 1988).
The predominant cells in a healthy periodontium include
fibroblasts and mast cells,while cementoblasts, osteoblasts
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and osteoclasts are also present. In addition small numbers
of inflammatory cells (but not dense inflammatory
infiltrates) are found primarily within and adjacent to the
junctional epithelium. This inflammatory infiltrate
consists of both polymorphonuclear leukocytes (PMNL) and
mononuclear cells such as macrophages, lymphocytes,and
plasma cells (Schroeder, 197 6; Cooper et al. , 1983 ; Thilo
et al. , 1986; Seymour et al., 1983) . Gingival crevicular
fluid may or may not be detected in healthy gingiva
depending on the method of collection (Brill and Krass
1958; Loe and Holm-Pedersen, 1965; Alfano, 1974; and
Cimasoni, 1983) . Gingival margin bacterial plaque
associated with periodontal health consists primarily of
Gram positive and coccal forms and a few spirochaetes and
motile forms (Theilade et al. , 1966; Listgarten et al.,
1975; Listgarten, 1976, and Listgarten, Lindhe and Hellden,
1978) .
1.2.2 Periodontal disease
The term periodontal disease generally denotes all the
diseases of the periodontium. In this thesis,the term is
only used to describe chronic periodontitis.
1.2.2.1 Epidemiological studies on periodontal disease
Periodontitis is a global disease which may affect a high
proportion of the population and is associated with
deficient oral hygiene and increasing age. It generally
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begins as a gingivitis at an early age with some
individuals subsequently developing periodontitis if no
treatment is given.
On the basis of epidemiological evidence it has been
concluded that the world-wide prevalence of severe
destructive periodontitis is of the order of only 7-15% of
the adult dentate population (Johnson et al. , 1988) . In a
cross sectional study Loe et al.(1986) reported that 8% of
the population show advanced periodontal disease as
determined by interproximal attachment loss and tooth
mortality rates. Periodontal disease can no longer be
regarded as a universally prevalent condition to which all
members of the world's population are at equal risk in the
absence of good oral hygiene. Periodontal disease should be
regarded as a range of different diseases for each of which
certain individuals are at a relatively high risk.
Many studies have shown that a relatively few individuals
in each age group may have progressive periodontal disease
and account for most of the sites showing severe
periodontal destruction (Jenkins and Kinane, 1989) .
Papapanou et al. (1988) found that 23% of the subjects
studied accounted for 75% of the sites found with
attachment loss of more than 2mm. Longitudinal studies have
shown that relatively few sites developed advanced
periodontal destruction over the observation periods
(Lindhe et al., 1983; Haffajee et al., 1983a,b).
Lindhe et al.(1983) found that only 3.9% and 11.6% of sites
showed attachment loss more that 2mm from baseline at 3
10
years and 6 years respectively in 64 Swedish subjects with
untreated destructive periodontitis. They also found a
similar percentage (3.2%) of such sites in American
subjects, followed for only 1 year. Subsequently, Lindhe et
al. (1989b) reported that 12% of Japanese subjects studied
over 2 years accounted for 70% of sites with periodontal
deterioration of 3mm or more in attachment level. It seems
therefore that relatively few subjects account for the
majority of sites with active periodontal destruction over
observation periods up to 6 years.
It can be concluded from these studies that periodontal
disease is subject related, and only a small subset of
individuals within a given population have advanced
periodontal destruction. It also can be concluded that
relatively few sites undergo active periodontal
destruction.
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1.2.2.2 Clinical and histopathological features of
periodontal disease
1.2.2.2.1 Gingivitis
Gingivitis is defined as inflammation of the gingiva (Hurt
et al., 1986) and is shown clinically by a change in colour
(redness) and an oedematous appearance, together with an
increasing tendency to bleeding on gentle probing.
Page and Schroeder (1976) described, on the experimental
induction of gingivitis in dogs, a temporal sequence of the
histopathological changes in the inflammatory lesions of
gingivitis and periodontitis. Four different stages of the
inflammatory condition were described; initial, early ,
established and advanced. There is no clear cut division
between these stages of the inflammatory process in human
spontaneous gingivitis, and all the changes may occur
simultaneously, with the acute changes being superimposed
on the chronic changes.
Clinical gingivitis is histopathologically separated into
three stages following plaque accumulation at the gingival
margin. These stages are:
a.Initial lesion:it occurs within 2 to 4 days after plaque
accumulation in the dentogingival region, as an acute
inflammatory reaction (Loe et al. , 1965; Schroeder and
Graf-deBeer, 1975). This lesion, which is clinically
indistinguishable from normal, is characterised by
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increased vascular permeability and the emigration of PMN
from the vessels in the connective tissue around the base
of the gingival sulcus into the gingival sulcus, having
migrated through the junctional epithelium with disruption
of the intercellular spaces. A protein-rich fluid exudate
(gingival crevicular fluid) accompanies the cellular
exudate in the gingival sulcus.
b.Early lesion: this follows the initial lesion after 4 to
7 days of undisturbed plaque accumulation, and may persist
for 21 days or longer as clinically undetectable gingivitis
(Schroeder et al. , 1973; Seymour et al.,1983). It is
characterised by persistence of the initial lesion and the
development of an inflammatory infiltrate dominated by
lymphocytes and macrophages. Migration of PMN into the
junctional epithelium and gingival sulcus continues and
crevicular fluid flow reaches a peak at 6 to 12 days
following the onset of clinically detectable gingivitis
(Lindhe et al., 1973). Early loss of perivascular collagen
is seen.
c.Established lesion: within two to three weeks after
plaque accumulation, there is a shift to a plasma cell
domination in the inflammatory infiltrate which affects a
larger gingival area, while plasma cells predominate, B
lymphocytes are present in addition to the continued
presence of PMN. Disruption and hyperplasia of the
junctional epithelium is seen and gingival pocket lined
with pocket formation (Lindhe et al. , 1980; Seymour and
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Greenspan, 1979). There is continued loss of perivascular
collagen, and increased exudation of GCF. Gingival
inflammation is evident clinically and can be severe
(Seymour et al., 1983). This lesion can persist for months
or years without progression (Page 1986) . The initial and
early lesions are associated with a primarily Gram
positive,aerobic microflora in the gingival crevice.
Subgingival profileration of Gram negative anaerobes and
spirochaetes occur after epithelial detachment from the
tooth surface (Loe et al., 1965,Theilade et al., 1966) .
1.2.2.2.2 The Advanced Lesion- Chronic Periodontitis
This is chracterised by the loss of connective tissue
attachment and alveolar bone. Ulceration of the pocket
epithelium may be present and osteoclasts may be found at
bone resorption areas. The 'advanced' lesion is synonymous
with periodontitis, both destruction of the connective
tissue attachment to the root surface and resorption of
alveolar bone are seen (Schroeder and Lindhe, 1975; Seymour
et al., 1979).
Periodontitis maintains all the features of the established
lesion in addition to apical migration of the junctional
epithelium and true pocketing (Slots, 1977). Clinically, it
is characterised by the presence of gingival inflammation,
periodontal pocketing, and loss of probing attachment while
the loss of alveolar bone may be radiographically apparent.
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1.2.2.3 Classification of chronic periodontitis
Periodontitis has been classified into four major forms
depending on the severity pattern of the disease and the
age of onset. These forms are:
a.Adult periodontitis:
This is the most common form of chronic periodontitis. It
probably starts in adolescence and continues for the life
of the individual, but it is first clinically significant
in the mid-thirties (Page and Schroeder, 1982). It has no
sex predilection. The prevalence and severity of the
disease increase with age, and the progress is generally
slow and continuous when evaluated by pooled data
(Marshall-Day 1955, Listgarten 1986a). The presence and
severity of adult periodontitis is directly associated with
the presence of plaque and calculus (Marshall-Day , 1955;
Listgarten, 1986a). Bone loss can be either localized or
generalized, horizontal or vertical, but not of the
distinct pattern seen in juvenile periodontitis. The
affected subjects have normal PMN and lymphocyte function
(Van Dyke et al. , 1980 and 1985) . The pocket microflora
varies depending on the rate of periodontal destruction,
disease activity, and host resistance (Newman and Saglie,
1984) . The subgingival plaque is usually composed of Gram
negative rods (Actinomyces israelii, A. viscosus) and
spirochaetes, but without a significant population of P.
qinqivalis or Actinobacillus actinomycetemcomitans.
15
b.Juvenile periodontitis:
Clinically this form starts around puberty and is
characterised by severe angular bony defects on the first
permanent molars and/or maxillary incisors (Hurt et al. ,
1986) . The lesions are often bilaterally symmetrical
(Kaslick and Chasens, 1968). It is characterised by less
acute clinical inflammation than would be expected based on
the severity of the disease. The rate and severity of
destruction are not consistent with the relatively sparse
plaque and absence of severe clinical signs of inflammation
(Baer, 1971). Deep periodontal pockets can be present while
the gingival tissues appear healthy. Systemically,depressed
PMN chemotaxis and phagocytosis are frequent findings (Van
Dyke et al., 1982). The predominant subgingival organisms
in this form of periodontitis are A. actinomycetemcomitans,
Capnocytophaqa orchracea and Prevotella intermedius (Slots
,1976). Juvenile periodontitis may be either localized or
generalized. Localized juvenile periodontitis affects only
permanent first molars and/or the incisors and mostly
starts at puberty. In generalised juvenile periodontitis
the first molars and incisors are frequently involved, but
the periodontal destruction extends to other parts of the
dentition. It occurs at an early age (12 to 30 years) and
is characterised by rapid and severe periodontal
destruction around most of the teeth (Manson and Lehner,
1974) .
c.Rapidly progressive periodontitis:
This form occurs in a young adult population, and typically
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in the early twenties through to the mid-thirties. It is
characterised by severe gingival inflammation and rapid
loss of connective tissue attachment and alveolar bone loss
(Page and Schroeder, 1982; Page et al. , 1983) affecting
most of the teeth. A depressed PMN chemotaxis response has
been found in a high percentage of affected subjects (Van
Dyke et al. , 1982). Bacteria associated with rapidly
progressive periodontitis include pigmenting Bacteroides
(P. qinqivalis, Prevotella intermedius), Fusobacterium
nuc lea turn and Wolinella recta (Moore et al. , 1983) in
addition to spirochaetes (Listgarten 1976) .
d.Prepubertal periodontitis:
This is a rare form of periodontitis which may be either
generalised or localised. The generalised form affects both
primary and secondary dentitions and begins with the
eruption of the deciduous teeth (Page et al., 1983) . It is
characterised by severe gingival inflammation, rapid bone
loss, mobility and tooth loss. The patients often have PMN
and/or mononuclear leukocyte defects and are subject to
other infections such as otitis media and respiratory tract
infections (Suzuki, 1988). Localized prepubertal
periodontitis affects some of the primary teeth only and is
less aggressive, showing either PMN or mononuclear
leukocyte defects.
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1.3 Aetiology and pathogenesis of periodontitis
Pathogenic mechanisms:
The exact mechanisms involved in the pathogenesis of
periodontitis have not been established, but the importance
of bacteria is beyond doubt.
Chronic inflammation is the hallmark of periodontal disease
and the accumulation of bacterial plaque has been
established as responsible for the initiation and
maintenance of the inflammatory process (Theilade et al. ,
1966; Axelsson and Lindhe, 1978). Loe et al.(1965) were the
first who confirmed that plaque accumulation causes
gingival inflammation. The possible means by which bacteria
and their products cause periodontal damage have been
explained already by Page and Schroeder (1982) and well
explained and reviewed by Southam and Soames (1993). The
induction and subsequent progression of the disease result
from the diffusion of bacterial products through the
junctional and, later, pocket epithelium into the
underlying tissues, the mechanisms actually involved in the
induction and progression of the destructive, chronic
inflammatory lesions are unclear.
The microbial flora contains organisms which could
elaborate many potentially pathogenic substances. These
substances are capable of causing direct cellular damage
(e.g.ammonia, hydrogen sulphide), enzymes which are capable
of causing direct damage to the intercellular matrix (e.g.
collagenase, non-specific proteases and hyaluronidase), as
well as substances that could induce indirect tissue damage
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by activating of destructive aspects of the host's own
inflammatory and immune response (e.g. endotoxins,
peptidoglycans).
Currently, the interactions of bacterial products with the
host immune response are thought to be major importance,
and numerous potential mechanisms have been suggested by
which inappropriate activation of host defence systems
could damage periodontal tissues.
Activation of humoral immunity leads to the differentiation
of plasma cells and production of immunoglobulins, which in
turn could be involved in the inflammatory response via
complement activation and antibody-mediated
hypersensitivity reactions. Microbial products also can
cause complement activation through alternative pathway.
The activation of complement results in biologically active
substances which can induce vascular permeability and are
chemotactic for PMN. Activation products have been
identified in crevicular fluid and probably enhance the PMN
migration seen in periodontal disease. Other chemotactic
factors are also present and include substances produced by
plaque organisms and released by injured tissues. Although
PMN have a significant role in the local defence of the
dentiriu gingival unit, they may damage periodontal tissues
by mechanical disruption, release of lysosomal enzymes and
specific collagenase, and the generation of eicosanoids
particularly prostaglandin E2.
The presence of antibodies to oral bacteria and the
diffusion of plaque antigen into the tissues also provides
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the necessary factors for immune complex formation,
although no equivalent evidence for their participation in
periodontal disease has been established. Immune-complex-
induced injury, mediated through type III hypersensitivity,
is associated with complement activation, the accumulation
of PMN to release lysosomal enzymes and other factors
including interleukin-1, collagenase, and prostaglandins
which could be involved in connective tissue degradation
and stimulation of osteoclastic activity. Cell-mediated
immunity to oral bacteria is active in gingivitis and
periodontitis and type IV delayed hypersensitivity could
contribute to tissue injury.
The potentially damaging effects of activation of T cells
by plaque antigens could be mediated by direct cytotoxic T-
cell activity or through release of lymphokines affecting
macrophage function, attracting them into an area of
inflammation and increasing their biological activity. The
increased release of cytokines, enzymes and other
inflammatory mediators from lymphokine-activated
macrophages is a potential mechanism which could lead to
damage of periodontal tissues. Osteoclast activating factor
produced by T-cells could also cause bone destruction.
It can be concluded that all the mechanisms involved in the
immunopathogenesis of chronic inflammation might be
involved in periodontal disease. The early lesion of
experimental gingivitis has features characteristic of
delayed hypersensitivity reaction, suggesting that cell-
mediated immunity is involved, while the established and
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advanced lesions are dominated by plasma cells suggesting
that these are predominantly B-cell lesions.
1.4 Patterns of destructive periodontal disease
(Periodontal disease activity)
Periodontitis is a progressively destructive change leading
to loss of alveolar bone and periodontal ligament (Hurt et
al., 1986) . The natural history of periodontitis is marked
by periods of active destruction and relative quiescence,
even though the periodontal tissue remain chronically
inflamed throughout (Goodson et al. , 1982) .
Periodontal disease activity is episodic. The duration and
frequency of the periods of tissue destruction are unknown.
Periodontal disease activity refers specifically to the
stage of the disease associated with loss of alveolar bone
and connective tissue attachment (Listgarten, 1986a), and
occurs at different rates in different sites and in
different patients. Different rates of disease progression
have also been reported in different age groups of both
untreated patients and treated patients including those on
maintenance therapy. A high rate of disease progression
seems to occur at a few sites in the mouth only and in a
relatively small proportion of the population. Destruction
of the periodontal supporting tissues, as reported by
disease activity, has been explained in three models by
Socransky et al. (1984) . These are the continuous paradigm
hypothesis, the random burst theory, and the asynchronous
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multiple burst hypothesis.
The continuous paradigm (continuous disease) hypothesis
implies slow, constant, and progressive tissue destruction.
In this model periodontal disease has been thought to
slowly and continuously progress until tooth loss occurs.
This model has been supported by both cross-sectional
studies (Loe et al., 1978) and longitudinal studies of
sites not responsive to therapy (Badersten et al., 1985a).
This hypothesis has been refuted by Socransky et al.1984.
The random burst hypothesis proposes that short periods of
destruction are followed by periods without destruction,
occurring randomly with respect to time and at random sites
within an individual (Socransky et al., 1984). Some sites
show no activity, while others show one or several bursts
of activity with time. The time of onset and cumulative
extent of destruction vary from site to site. Certain sites
within a patient's mouth may demonstrate an active burst of
destructive disease which could last from a few days to a
few months before going into a period of remission. Sites
showing destructive periodontal activity may subsequently
never undergo destructive activity again or may be subject
to one or more bursts of activity at a later time. These
bursts appear to occur randomly at periodontal sites
throughout the mouth. Other sites may be free of
destructive periodontal disease throughout the life of the
individual. It is suggested that in this model there may be
relatively short periods in an individual's life in which
many sites undergo periodontal destruction followed by
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periods of extended remission.
The asynchronous multiple burst hypothesis proposes that
destruction occurs during a defined period of life and the
disease then goes into remission (Socransky et al., 1984) .
In this model,many sites may show bursts of activity over
a limited period of time, followed by an indefinite period
of inactivity. The major amount of periodontal destruction
occurs over a period of a few years. In this model the
bursts of destructive periodontal disease activity occur
with a higher frequency during certain periods of an
individual's life. Several sites demonstrate bursts of
destructive periodontal disease which take place
synchronously. These sites show repeated bursts of activity
over a definite period of time, followed by prolonged
periods of inactivity. Occasional bursts may infrequently
occur at certain sites at later time periods. Other sites
remain free of destructive periodontal disease at all
times. The difference from the random burst theory is that
the majority of destructive disease activity takes place
over a few years of an individual's life. Many studies
support all three temporal patterns of periodontal
destruction occurring and it is possible that the disease
may manifest in different patterns in different individuals
and sites, depending on the type of periodontal disease
present (Haffajee et al., 1988).
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1.5 Diagnosis of Periodontal Disease
Consequent to current concepts of the mechanisms involved
in periodontal disease, diagnostic methods can be divided
into those parameters which measure the lesion or defect
produced by the disease (e.g.bone loss), and those which
measure characteristics of the disease process (e.g.
gingival inflammation ).
Periodontal diseases are inflammatory in nature and visual
signs of inflammation such as redness, swelling, gingival
bleeding or suppuration are routine measures by which
inflammatory lesions within the periodontium can be
detected. Periodontal diseases are also infections and the
microbial assessment of plaque may be also useful in the
diagnosis of periodontal disease. The various types of
destructive periodontal disease produce anatomical changes
which can usually be documented. These include probing
pocket depth, gingival recession, probing attachment level,
tooth mobility, and radiographically determined bony
changes.
The most important measure in the diagnosis of periodontal
disease involves the assessment of its activity, and this
can only be achieved clinically by measuring the attachment
loss. Disease progression can be assessed by longitudinal
documentation of probing attachment level and/or
radiographic interproximal bone height.




The clinical diagnosis of periodontal disease is based on
using certain clinical parameters or indices which may
clinically differentiate between healthy tissues, gingival
inflammation, and destructive periodontal disease. These
diagnostic methods are based on visual examination, use of
instruments such as the periodontal probe for measuring the
pocket depth and attachment level changes, as well as
radiographic examination for detecting changes in the
alveolar bone. Measurement of gingival crevicular fluid
flow rates may also be a useful method for diagnosis.
The characteristics of reliable diagnostic methods are
usually expressed as sensitivity, specificity, simplicity
and diagnostic accuracy. Sensitivity is the ability of a
test to detect disease progression if it is truly there. A
test with high sensitivity will give relatively few false
negative results. Specificity is the ability of a test to
exclude disease progression if it truly is not there, and
a test with high specificity will have relatively few false
positive results. The ideal index or clinical parameter to
be considered a diagnostic test, should have a reliable
predictive value and be acceptable to clinical design and
statistical analysis.
The methods used for the clinical detection of disease
progression and analytic methods used to detect changes in
data over time will influence the apparent prevalence of
periodontal disease activity even in the same population.
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The clinical methods used in the assessment or diagnosis of
periodontal disease are:
1.5.1.1 Assessment of oral hygiene
Various plaque indices which can measure plaque
accumulation on the surfaces of the teeth, have been used
for the assessment of oral hygiene. These indices measure
the area and/or thickness of plaque or material covering
the tooth surface.
Indices used are the oral hygiene index (OHI) consisting of
the debris and calculus indices (Greene and Vermillion,
1960) and the modified OHI (Greene and Vermillion, 1964 )
which assesses the tooth area covered by soft debris. Other
indices include the plaque index (PI) by Silness and Loe
(1964) and Loe (1967), which measures the thickness of the
plaque at the gingival margin. PI (Silness and Loe 1964) is
widely used today in the assessment of oral hygiene and
scores plaque accumulation on a scale from 0 to 3 as
follows:
Score 0 = tooth surface is clean.
Score 1 = tooth surface looks clean but plaque can be
removed from the gingival third with a sharp explorer.
Score 2 = visible plaque on the tooth surface.
Score 3 = abundant plaque on the tooth surface.
The PI can give a separate recording for each of the 4
smooth surfaces of a tooth, and can be used to score
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individual sites (surfaces) as a single site score, teeth
as averages of four sites per tooth, and individuals or
groups of teeth. The mean of the total scores for the
individuals or group of teeth is generally used for the
assessment. The plaque index can assess the very subtle
changes in plaque accumulation (Lindhe, 1990), and can be
used to study correlations between plaque and gingivitis in
periodontal research. It is also useful in the assessment
of oral hygiene particularly during the maintenance phase
of periodontal therapy.
1.5.1.2 Assessment of the gingival inflammatory-
condition
The clinical signs of inflammation, including redness,
swelling (oedema), and bleeding, are the primary indicators
of gingival inflammation and have been incorporated in
gingival and bleeding indices.
1.5.1.2.1 Gingival indices
The gingival index (GI), developed by Loe and Silness
(1963) and fully described by Loe (1967), is widely used.
Other types of gingival indices are the PMA index (Schour
and Massler, 1947), and the modified gingival index (MGI)
(Lobene et al, 1986). Both GI and MGI have been found to be




These have been used in the assessment of gingival
inflammation, examples being the sulcus bleeding index
(SBI) (Muhlemann and Son, 1971), the bleeding index (BI)
using dichotomous scoring of bleeding on probing after 10
seconds (Ainamo and Bay, 1975), and bleeding on probing
(WHO, Technical report 1979; Van der Velden, 1978,1979).
The GI scores both the severity and location of the
inflammation. Inflammation is scored on a scale from 0-3
and the severity of gingivitis can be assessed separately
at the 4 smooth surfaces of the tooth. Whenever the
gingival margin appears inflamed, it is massaged with the
side of a periodontal probe, If this massage does not
result in bleeding the unit score is 1; if bleeding occurs,
the score is given as 2, while ulceration and "spontaneous"
bleeding scores 3.
The GI was modified by Loe (1967), with regard to the
manner in which bleeding is demonstrated. Originally, a
score 2 was given to gingival bleeding occurring after
"pressure" (Loe and Silness, 1963), but this was
subsequently changed to bleeding after "probing" by Loe in
1967. So the presence or absence of bleeding is now
determined after running a blunt probe along the soft
tissue wall of the entrance of the gingival crevice. GI can
be used to measure the gingival inflammation for specific
sites, teeth, groups of teeth or individuals in a similar
way to PI. A high GI has been found to be associated with
increase in volume of gingival crevicular fluid (Egelberg,
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1964), but both have low predictive values for periodontal
disease activity (Haffajee et al. , 1983b). Pressure
sensitive probes have been used for the measurement of
bleeding (van der Velden and De Vries, 1978) to give more
accurate determinations. Gingival bleeding has been found
generally to be an earlier and more sensitive sign of
inflammation than other clinical signs such as redness
(Muhlemann and Son, 1971), although visually inflamed sites
do not always bleed (Greensten, 1984).
Gingival bleeding has been shown to be of high sensitivity
but low specificity when used as a clinical parameter for
predicting disease activity as measured by a statistically
significant probing attachment loss (Haffajee et al. ,
1983b; Badersten et al. , 1985c).
Van der Velden et al. (1985) found that patients susceptible
to periodontal breakdown had more bleeding, and less plaque
than those not showing periodontal breakdown. They
hypothesized that a high value for the ratio between
bleeding and plaque may act as a prognostic indicator for
periodontal breakdown. Abbas et al. (1986a) found that
individuals with a high bleeding to plaque ratio developed
significantly more clinical inflammation in terms of
bleeding and swelling of the gingiva than individuals with
a low bleeding/plaque ratio. They suggest that the
bleeding/plaque ratio of an individual may be regarded as
a prognostic indicator for the severity of gingivitis in
terms of bleeding and swelling of the gingiva.
Gingival bleeding was found to be associated with
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significantly increased percentages of both spirochaetes
and other motile forms (Armitage et al., 1982), and these
morphotypes have been linked with periodontally diseased
sites (Listgarten and Heliden 1978; Listgarten and Levin
1981; Evian et al., 1982). Gingival bleeding was also
related to an increased flow of gingival crevicular fluid
(Hancock et al., 1979), which has been found to be
positively associated with the presence of gingival
inflammation (Cimasoni, 1974).
Bleeding on probing (BOP):
It was introduced by Ainamo and Bay in 1975, and has been
used in the development of clinical indices for the
assessment of periodontal health and disease (Loe and
Silness, 1963; Ainamo and Bay, 1975; Muhlemann and Son,
1971). A pressure sensitive probe with a standard force is
the most appropriate instrument for the assessment of
bleeding on probing. BOP for pocket depth has been found to
be associated with gingival inflammation and may be more
appropriate than GI for identifying inflammation located
deeper within the periodontium as at sites affected with
periodontitis (Alfano et al. , 1976). BOP is interpreted as
indicating the presence of inflammation in the periodontal
tissues, while the absence of BOP indicates the absence of
inflammation (Lang et al.,1991).
A disadvantage of indices incorporating the BOP component
is that they can not distinguish between gingival
inflammation and inflammation at the base of a pocket in
periodontitis. So in periodontitis, it is better to use
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separate indices, one for the assessment of visual changes
of the gingival tissue and one for assessing BOP.
Badersten et al. (1985c) found that the predictability of
BOP for periodontal breakdown never exceeded 30%,and this
was confirmed by Lang et al. (1986) . Recent clinical trials
of the diagnostic value of BOP have generally showed that
BOP has modest sensitivity and specificity, and rather low
positive but high negative predictive values (Badersten et
al., 1985c; Lang et al., 1986; Claffey and Shanley, 1985;
Lang et al.,1991).
Cessation of gingival bleeding has been found to be
associated with pocket depth reduction and gain of
attachment loss (Badersten et al, .1984c) . It has been found
that continuously bleeding sites on probing over a two
years period were more likely to develop 2mm or greater of
attachment loss than sites not showing continuous bleeding
although the ability of bleeding to predict this loss never
exceeded 30% (Badersten et al., 1985c,Lang et al.1986).
Lang et al.1986 in their study evaluating the prognostic
value of BOP in identifying sites at risk for periodontal
destruction during maintenance therapy, found that pockets
with probing pocket depth greater or equal to 5mm had a
significantly higher incidence of BOP. Patients with 16% or
more BOP sites had a higher chance of attachment loss equal
to or greater than 2mm.
Sensitivity and predictability calculations have shown that
BOP is a limited but yet useful prognostic indicator in
clinical diagnosis for patients during periodontal
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maintenance phase.
1.5.1.2.3 Gingival crevicular fluid (GCF) flow
It has been used in the assessment of gingival inflammation
in many studies, and a positive correlation has been found
between GCF flow and the severity of gingival inflammation
(Egelberg, 1966; Loe and Hom-Pederson, 1965).
1.5.1.2.4 Suppuration
It has been found that suppuration from the periodontal
pocket has been related to increased gingival inflammation
in sites with advanced periodontitis (Bouwsma et al. ,
1988) .
1.5.1.3 Measurement of probing pocket depth and clinical
attachment level
1.5.1.3.1 Definitions
Probing Depthrdefined as the distance from the gingival
margin to the location of the periodontal probe tip. This
term is preferred to the term "probing pocket depth".
Clinical Attachment Level: the relative probing depth
corresponding to the distance from the cemento-enamel
junction (CEJ) to the location of the periodontal probe
tip. This term is preferred to the term "probing attachment
level".
Relative Attachment Level: the distance from a fixed
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reference point on the tooth surface or a stent to the
location of the periodontal probe tip.
1.5.1.3.2 Measurement and detection of periodontal
disease activity (PDA)
Currently, there is no known practical clinical test for
detecting deteriorating periodontal sites.
Probing depth and clinical attachment level are both used
to assess the amount of periodontal destruction and
periodontal disease activity and may be supplemented by
radiographic examination for the presence of alveolar bone
loss. The probing depth and clinical attachment level
measurements depend on the identification of the most
apical depth of the periodontal probe tip in the gingival
crevice.
The "gold standard" for measurement of periodontal disease
activity is the loss in attachment level measured at a
particular periodontal site (Goodson, 1986). Active disease
has occurred if there is a statistically significant loss
in the clinical attachment level.
Due to numerous sources of error inherent in probing
measurements, progression of periodontitis has been defined
as a loss of clinical attachment of a certain magnitude
over time. This magnitude has varied from > or equal to a
range from l-3mm. A loss of greater than 2 mm must occur
before a reliable determination can be made that disease
activity has occurred at the site (Haffajee et al.1983a,b).
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Many periodontologists have used either > or equal to 2 mm
(Muller et.al, 1987,-Harley et al., 1987) or > or equal to
3 mm (Lindhe et al., 1983; Haffajee et al., 1983a) loss in
clinical attachment level to determine whether or not a
real change has taken place. The lesser threshold of
attachment loss being used, the greater the frequency of
deteriorating sites will be recorded (Lindhe et al., 1983) .
The greater the critical value chosen, the smaller is the
chance of obtaining false positive results. On the other
hand, the proportion of false negative results increases.
The diagnosis of periodontal disease activity becomes more
specific when stricter criteria are used, but this is at
the expense of sensitivity. So small increments in
attachment loss may occur which can not be detected because
of limitations in the current methods of measurements
(Ranney et al.,1987).
Determination of probing pocket depths and clinical
attachment levels remain an integral part of periodontal
diagnosis and determining past disease activity.
Determination of disease activity should include sequential
measurements of relative or clinical attachment levels. The
longitudinal monitoring of attachment levels is a reliable
method for determining the stability of the periodontal
supporting tissues. The periodontal probe is used primarily
to measure probing depth and attachment levels. These
measurements estimate two important consequences of
periodontitis and represent an historical record of past
periodontal disease activity (Listgarten, 1972).
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A disadvantage of probing measurements is that they only
detect past changes in clinical attachment levels and such
changes can only be detected once they have occurred.
1.5.1.3.3 Incidence of Attachment Level Changes
Frequency, magnitude, and rate of attachment loss:
Longitudinal studies of untreated periodontal patients have
indicated that attachment loss occurs at small number of
sites in relatively few subjects (Haffajee et al. , 1983a
;Goodson et al. , 1982; Lindhe et al., 1983; Harley and
Watts 1987; Muller and Flores 1987; Okamoto et al., 1988;
Papapanou et al. , 1989). It has been found that subjects
with many affected sites exhibited more new attachment loss
than subjects with few affected sites (Haffajee et al.,
1988). Older subjects seemed to be more at risk of disease
activity than younger subjects (Haffajee et al., 1988;
Papapanou et al., 1989).
The number of sites with attachment loss occurring during
a given time period has been reported to be relatively low.
For instance, Goodson et al.(1982) found that sequential
attachment level measurements made at monthly intervals for
a year when analyzed by regression analysis (at PcO.Ol),
demonstrated significant increase in probeable attachment
level in 5.7%, while 11.5% of all sites monitored in 22
subjects became significantly shallower.
Haffajee et al. (1983a) when using regression analysis found
that 5.1% of sites showed significant loss of attachment
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and 2.3% of sites showed significant attachment gain (at P<
0.01) over 1 year.
Lindhe et al.(1983) in their longitudinal studies over 1-6
years on patients with untreated periodontitis found that
3.9% of sites showed attachment loss of more than 2mm over
the first three years in a Swedish group. During the 6
years period, 11.6% of sites showed loss of attachment
>2mm, 37% at 2mm, while 0.2% of sites showed gain of >2mm
in attachment level. In an American group, 3.5% of sites
showed >2mm of additional attachment loss over one year,
while 4.3% of sites showed a gain of >2mm. They found that
1.9% of sites per year exhibited attachment loss of >2mm in
the 6-year study in untreated Swedish subjects with
moderate periodontitis. With a less stringent criterion of
periodontal breakdown, an observed attachment loss of equal
to or > 2mm was found in 6.2% of Swedish subjects and in
9.1% of American subjects.
Badersten et al. (1985b) identified the sites with probing
attachment loss in patients following initial nonsurgical
therapy using analysis of regression (P< 0.05). They found
that 5% of sites lost attachment level of >1.5mm and 10% of
sites became deeper by >lmm over 24 months with 3 months
intervals between examinations.
Lang et al. (1986) found that only 3.1% of sites exhibited
attachment loss of 2mm or more over one year in a 2-year
study in patients receiving maintenance therapy.
Badersten et al. (1987) in their studies over 2 years with
subjects examined at 3 month intervals, used regression and
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end-point analysis, found 12% of sites became deeper and 4%
became shallower in their probing attachment level at equal
or > 1.5mm threshold.
Harley et al.(1987) found that only 6 sites (0.6%) showed
loss of clinical attachment of >2mm over 12 weeks.
Lindhe et al. (1989a) monitored longitudinal changes in
periodontal disease in untreated subjects over 2 years at
12 months interval. They demonstrated that these subjects
did not generally undergo marked additional deterioration
of their periodontal conditions, and only a small number of
subjects (in most age groups) showed significant amounts of
additional attachment loss.
Lindhe et al.(1989b) found also that 70% of loser sites at
equal to or > 3mm, occurred in 12% of the subjects who
showed loser sites during both the first and second years.
Most of the loser sites were at surfaces with initially
advanced loss of attachment, and were most frequently
detected in older subjects. They found only 0.7% of the
sites they studied had lost attachment of >2 mm from base
line to year 2, and 0.35% of sites were detected as loser
sites in the first 12 months.
Jenkins et al.(1988) investigated the use of certain
clinical parameters (pocket depth, PI and gingival redness)
and microbiological criteria to predict periodontal
breakdown (clinical attachment loss) during a 1-year period
examined at 2-months interval in 11 subjects with untreated
advanced periodontitis. Using regression analysis (P<0.05),
they found that 1.9% of sites demonstrated loss of
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attachment of more than 2mm over the year, 9.8% of sites
showed attachment loss of equal to or >2mm, while 12% of
sites showed loss of attachment of more than 1mm. Only 6%
of sites studied showed a gain in attachment level.
Grbic et al.(1991) using a cut off point of equal to or >
2mm, found that 1% of the patients studied demonstrated
clinical attachment loss at one site only and 21% for two
sites over 6 months.
Haffajee et al.(1991) investigated the association of
baseline clinical parameters of periodontal disease with
disease progression represented by further attachment loss
in untreated periodontal patients in the following year.
They found that only 27.3% of subjects exhibited additional
attachment loss of 3mm or more at 1 or more sites after 1
year. When they used a criterion of 2mm or more as a cut
off point, 73% of subjects showed additional attachment
loss .
Zappa et al.(1990) found that 5.0% of sites showed probing
attachment loss of 2mm or more during the 10-months
observation period of patients with untreated
periodontitis.
1.5.1.3.4 Errors associated with attachment level
measurement s
1.Errors due to the probe:
These include thickness (diameter) of the probe tip,
location, angulation, and the degree of penetration which
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is probably due to uncontrolled probing forces (Listgarten,
1972) . There are also errors in the graduation and
placement of the probe (Van der Velden, 1978) . Variation in
the probing force and size (diameter) of the probe (Van der
Velden (1979) can influence the penetration of the probe
through the junctional epithelium and gingival tissue.
Attempts have been carried out to reduce measurement error
by using a conventional periodontal probe to measure
probing attachment level with and without an occlusal stent
(Hafajjee et al., 1983b; Badersten et al., 1984d; Isidor et
al., 1984; Clark et al., 1987; Best et al., 1990) .
Pressure-controlled probes have been introduced to control
probing force (van der Velden and de Vries, 197 8) . An
automated sensitive pressure probe has been introduced with
automated detection of the CEJ (Jeffecot et al. , 1986) .
Gibbs et al.(1988) developed a Florida probe, which is an
electronic pressure sensitive probe capable of measuring
probing depths to the nearest 0.2mm.
2.Errors in precision of the measurement:
The precision in the measurement may be due to examiner
him/her self or the type of probe used (Jeffecot et al. ,
1986) .
3.Errors related to the identification of the gingival
margin location, and the texture of the gingival tissue:
Transient fluctuations in gingival margin location may
produce errors in pocket depth measurements. Probe
penetration may be influenced by the inflammatory status of
the gingiva and deeper penetration of the probe is obtained
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in areas with increased inflammation (Armitage, Svanberg
and Loe, 1977) . Changes in the location of the gingival
margin due to inflammation or treatment will necessarily
influence relative probing depth or probing depth but not
necessarily influence the measurement of attachment level.
4.Errors associated with the fixed reference point:
Relatively stable landmarks which may be used for
attachment level measurements include the CEJ, occlusal
surfaces, restorations, markings bonded to tooth surfaces
and stents , and all may influence the reproducibility of
the measurements (Badersten,Nilveus and Egelberg,1984d).
Occlusal stents have been used to reduce the errors
associated with location of the CEJ (Isidor, Karring and
Attstrom, 1984; Badersten et al. , 1984d, Clark et al.,
1987; Magnusson et al. 1988). On the other hand, Jeffecot
et al.(1986) developed a controlled force probe which
electronically detected the CEJ and automatically recorded
probing depth and attachment level. Magnusson et al.(1988)
and Birek et al. (1987) employed a pressure-sensitive device
which electronically measured and recorded probing
attachment level using a stent or occlusal and incisal
surface as a fixed reference point.
Studies on the reproducibilty of probing attachment level
measurements have shown that the difference between
duplicate readings may occasionally be as much as 2 mm or
more. However, the vast majority of recordings can be
reproduced with a difference of not more than 1 mm (Glavind
and Loe 1967; Badersten et al., 1981; Cereck et al,.1983;
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Isidor et al.,1984; Badersten et al.,1984d; Harley et
al.1987).
The results of previous studies on the reproducibility of
attachment level measurements using onlay techniques are
shown in Table 1.1.
Isidor et al.(1984) used flexible splints to produce
readily identifiable reference points, and found a
compatibility of 60% for pocket depth and attachment level
measurements. A deviation of 1mm or less was found for 95%
of the surfaces. Badersten et al.(1984d) using an onlay
reference (occlusal stent) found that 90% of probing
attachment level measurements were reproducible within
+_1.0 mm difference. Measurement using onlay margins for
reference point demonstrated somewhat less variability than
the use of CEJ as a reference point. Harley et al.(1987)
using a stent technique and pressure controlled probe,
showed that 91% of probing depths and attachment levels
remained within +_lmm. Clark et al. (1987) using a stent
technique, concluded that measurements using the stent are
more reliable than using the CEJ.
The level of reproducibility varied notably between
patients, and between PD, tooth surfaces and types (Glavind
and Loe, 19 67; Loe et al. , 1978; van der Velden and de
Veries 1980; Goodson et al., 1982; Badersten et al.l984d;
Watts 1987).
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Table 1.1: The reproducibility of attachment level
measurements using onlay methods.
Reproducibility of attachment level
Reference measurements within +_lmm
Isidor et al.(1984) 95%
Badersten et al.(1984d) 90%
Harley et al. (1987) 91%
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1.5.1.3.5 Methods of statistical analysis for the
detection of attachment level changes
The introduction of reliable and reproducible methods that
can detect a change in attachment level which safely
exceeds measurement errors is of crucial value for the
measurement of periodontal disease activity, diagnosis and
treatment.
Specific amounts of probing attachment loss have been used
to define thresholds for periodontal disease activity
(Haffajee et al. , 1983a; Goodson et al. , 1982; Lindhe et
al., 1983; Harley et al., 1987; Muller et al., 1987). These
criteria were established to reduce the possibility of
false positive results due to probing errors.
To determine that loss of attachment has occurred at the
clinical level, it is important to take repeated
measurements of clinical attachment level over a separate
time. The methods used for the clinical detection of
disease progression and the analytic methods used to detect
changes in the data over time can influence the apparent
prevalence of periodontal disease activity. Thus the use of
different analytic methods or clinical assessments may
result in strikingly different prevalences of active
disease even in the same population being reported. The
interpretion of probing measurements must be carefully
handled.
Measurement error:
Since only a small proportion of sites are defined as
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experiencing disease activity in unit time, several authors
have suggested that a high percentage of these could be due
to measurement errors (Imrey 1986; Clark et al. , 1987;
Cohen and Ralls 1988, Blomqvist 1987). Differences between
duplicate attachment level measurements exceeding 3 times
the standard deviation have been used as the criterion for
disease activity, on the assumption that recorded
differences were normally distributed (Haffajee et al.,
1988; Haffajee et al., 1983a,b). However, Janssen et
al.(1987) warned that a normal distribution of errors
associated with duplicate measurement has never been proven
and other investigator have reported that differences
between attachment level measurements are not normally
distributed (Badersten et al. , 1984d; Glavind and Loe 1967;
Gonsollely and Best, 1988). Acceptance of the premise that
a normal distribution of errors is true underestimates
probing errors of reported proportions of sites that show
2mm gain or loss of attachment and the writers cautioned
that data derived from sites using this criterion weakly
corroborate the burst hypothesis.
Gunsolley and Best (1988) reported that only 70% of a
measured 3mm alterations might represent actual change and
30% could be accounted for by measurement error. Any
measurement alteration should include both measurement
error and actual change, and careful consideration should
be given to the technical problems associated with
detecting a small number of sites manifesting a variable
change in clinical attachment.
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Statistical Methods:
Various statistical methods have been used to test for the
significance of recorded changes in the attachment level.
These include linear regression analysis, running medians,
tolerance method, end-point analysis and other methods
which based on the specificity and sensitivity of
attachment level measurement to reduce both Type I and/or
Type II error rate as well as the false positive rate.
Iln general these statistical analyses have been used to
define and reduce the measurement errors, to detect minor
attachment level change as well as to test the
reproducibility of attachment level measurement. Each
method has strength and weakness.
Linear regression analysis method: in this method (Goodson
et al. , 1982; Badersten et al. , 1985b; Haffajee et al. ,
1983a) , the slope and the intercept of a regression line
are computed from a linear least squares fit of attachment
level measurements as a function of time, and the slope is
tested for a significant departure from zero while a
threshold of projected attachment level change per unit
time also has to be exceeded. This method is better suited
to assessing smooth alterations than bursts of disease
activity (Aeppli and Pihlstrom, 1989). Calculation of the
slope of the regression line determines the rate of loss
over time. Determination of the probability level for the
individual slope considers the variability of the
individual data points about the regression line,i.e. it
includes consideration of the level of reproducibility of
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the measurements at the specific site.
From a clinical point of view, the decision to classify a
given site as a site with probing attachment loss may need
to be based upon the magnitude of the projected difference
over the observation interval (for example change over a
year) in conjunction with the probability level.
Tolerance method: this designates locations manifesting
disease activity if they surpass each one of three
thresholds based on measurement error. These include 2
standard deviations (SD) in the population, 3 SD within the
individual subject and 3 SD at the specific site (Haffajee
et al., 1983a).
Running medians: this can detect abrupt shifts in
attachment level, but an arbitrary standard for change
needs to be selected (Haffajee et al., 1983a).
Regression analysis and tolerance methods are the most
commonly used in clinical trials. The tolerance method
requires measurements as few as 2 points in time and is
most suitable in detecting abrupt differences in a short
period of time (Haffajee et al.,1983a). The regression
analysis method is most suitable for assessing linear
changes in attachment level over a long period of time.
Haftajee et al. (1983a) evaluated the above statistical
methods in detecting periodontal disease activity in
individual sites. They found that regression analysis was
particularly sensitive to gradual changes whereas the
tolerance method was well suited to detecting changes over
a short period of time. However, the last technique has
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been criticized, because it uses standard deviations as its
basis and not actual differences between replicate
measurements (Janssen et al.1987). Regression analysis has
shown that the number of sites with periodontal breakdown
is twice that determined by the other two methods.
Haffajee et al.(1983b) suggested a criterion of 3 standard
deviations of the difference of replicate measurements,
which was equal to 2.46 mm (rounded to 3mm) in their study,
to reduce false positive detection of attachment level
change. This technique (3mm threshold) has been criticised
by Fleiss et al. (1991) as it has been applied to various
populations not having a similar precision of measurement.
Lindhe et al.(1983) used > 2mm as a threshold for
detecting attachment loss in their study, because they
considered that changes > 3 standard deviations (SD=0.83mm
reported by Haffajee et al.1983a) to be unlikely to be due
to measurement error.
Badersten et al.(1987) used a linear regression analysis
for the identification of sites with gain or loss of
probing attachment over 2 years, using significance level
of P<0.05. A minimum projected (change/year) of equal to or
>1.5mm (gain or loss) and a probability of p<0.05 were used
to classify a site as showing probing attachment gain or
loss .
Cohen and Ralls (1988) estimated the false positive rates
in the determination of changes in probing depth-related
periodontal measurements using computerized simulation.
They found that one third of sites detected by tolerance
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method (using threshold equal to or < 2.5mm) as showing
"bursts" of periodontal attachment change may be false
positives attributable to measurement error.
Goodson (1986) used computer simulation, he calculated the
expected Type-1 error and Type-II error rate for each
method and found them to be sufficiently low, while his
results for Type-II error suggests that a substantial
fraction of disease active sites was not detected by these
methods.
End-point analysis: this is used to compensate for the
inability of linear regression to detect rapid modulations
at the beginning and the end of observation periods.
However, this test is based on fewer probings and may
include more sites affected by probing error (Badersten et
al.1987). In this method the deeper of the pair of initial
measurements is compared against the shallower of the final
pair of measurements and if the change exceeds a specified
threshold, attachment level change is declared.
Evidence for rapid changes in periodontal attachment level
and pocket depth is based almost exclusively on differences
between sequential periodontal probing measurements. Real
attachment losses are postulated to have occurred if
changes at or beyond a specified magnitude are present at
frequencies substantially above those expected by chance.
Other methods:
Aeppli et al.(1985) used the estimating method of the false
positive rate and concluded that observing an increase of
probing depth greater than 1mm serves as a diagnostic test
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with high sensitivity and specificity.
The criteria adopted by Lindhe et al. (1989b) for
considering that a site has lost a significant additional
amount of attachment was an increase in probeable
attachment level of >2mm. The choice of this threshold was
based on estimates of Type 1 error rate and the false
positive rate for attachment losses for single measurements
presented by Glavind and Loe (1976) and replicate
measurements by Gunsollely and Best (1988).
Zappa et al.(1990) investigated the error for probing
measurements when assessed using all the sets of double
measurements. Clinical disease progression in their study
was defined as probing attachment loss reaching or
exceeding a fixed threshold of 2 mm.
Gunsolley and Best (1988) estimated the error rates
associated with pocket depth and attachment level
measurements by using a simulation method based on
resampling of replicated attachment level measurements.
They concluded that a large proportion of perceived changes
in attachment level or pocket depth can be attributed to
the false positive rate (the relative proportion of sites
with measured change in attachment level that occur in the
absence of real change in attachment level) . They also
concluded that replicating measurements of attachment level
reduce the rate of false positives, and found that with a
difference in the mean of replicated measurements greater
than or equal to 2mm, only 16% of changes were attributable
to error.
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Best et al.(1990) investigated the reliability of
attachment loss measurement in a longitudinal trial, and
found that attachment level measurements were in agreement
within 2mm on more than 95% of sites and detection of
attachment level change with a standard periodontal probe
in a longitudinal study can be reliable when 2 examiners
each detect a change of 2 mm or more at a subsequent
examination. They defined a reliable criterion for change
in attachment level which has less than 5% chance of
obtaining one false positive change in attachment level for
a mouth with 120 sites. Their results point out the lack of
sensitivity of standard periodontal probe measurements in
the detection of changes in periodontal attachment loss,
and 2-3 mm of change appears to be the limit of sensitivity
due to the high error inherited in the measuring method.
Lindhe et al. (1986) used a safety threshold of more than
2mm of probing attachment level difference to identify
sites with attachment loss. The reproducibility studies of
Badersten et al.(1984d) suggest a probing attachment loss
of more than 2mm occurs on the average in only 1-5% of
repeated measurements. On such a basis therefore Lindhe et
al.(1986) concluded that this threshold should provide
sufficient margin of safety. They used the frequency
distributions of the standard deviations of the repetitive
measurements at sites which showed no significant
attachment level change by regression analysis (change less
than 0.5mm at P<0.05) . They selected a cut off point of
>2mm as the safety threshold, based on the chance that
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false positive results would be less than 5%. The safety
requirement was 2 X SD of those stable sites, and which was
within less than 5% of the false positive.
1.5.1.4 Radiographs
In periodontology radiographs are used primarily to
estimate the severity and pattern of bone loss, to detect
pathological lesions and to study the effects of occlusion
(Lang and Hill, 1977) . Radiographs give information on hard
tissue changes but they are not able to provide information
on current disease status or predict future disease
activity. They are of no value in the diagnosis of
gingivitis and very early periodontitis.
1.5.1.5 The ability of the clinical parameters to
predict periodontal disease activity
The ability of clinical parameters (PI, GI, BOP, PD) to
predict periodontal disease activity as measured by the
loss of attachment level has been investigated in
longitudinal studies. However,investigations have failed to
report any significant relation between a subsequent
significant loss of probing attachment level used as an
indication of disease activity, and these clinical
parameters (Listgarten and Levin, 1981; Haffajee et al. ,
1983b; Badersten et al. , 1985a,1987, Fine and Mandel,1986) .
51
Haffajee et al. (1983b) assessed the diagnostic relationship
between certain clinical parameters (BOP, suppuration and
PI) measured before each 2-months time interval and future
disease activity in untreated periodontal disease patients
over a 2-year period, and found that none of the parameters
used either individually or in combination was useful in
predicting disease activity.
Badersten et al.(1985c,1987) and Vanooteghem et al.(1987)
reported the association of certain clinical parameters
with the incidence of breakdown sites monitored at three
month intervals during therapy and a follow-up observation
period of 24 months. They (Badersten et al., 1985c) found
that sites showing probing attachment loss were more
frequent among sites previously showing high scores for
plaque, bleeding on probing, and probing depth than in
sites with low scores. These clinical parameters were all
associated with probing attachment loss, but their
predictability value did not exceed 30-40%, and thus they
cannot be used to predict periodontal disease activity.
Badersten et al. (1987) found that the initial probing depth
could be related to subsequent change in probing attachment
level. Sites with deep initial probing depth subsequently
demonstrated a high incidence of gain and a low incidence
of loss of probing attachment. Probing attachment loss of
equal to or >1.5mm was more frequent in shallow sites than
deep sites. The PI and BOP showed a weak or no association
with probing attachment changes following therapy. Probing
attachment loss was more frequent at sites that exhibited
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bleeding on probing at the majority of the examinations
during 2 years.
Badersten et al.(1985c,1987) and Vanooteghem (1987) showed
that when the bleeding frequencies increased, the
corresponding predictive values also increased at < 26%.,
and as the plaque frequency increased, the positive
predictive value increased up to 25% (Badersten et al.1985c
,1987) .
Lang et al.(1986) in his retrospective study over 4 years
with examinations at 3-5 months intervals, found that as
the frequency of BOP increased, the positive predictive
value of breakdown increased (15% to 30%).
Lindhe et al.(1989) found that the relationship between PI
and changes with respect to probing depth and attachment
level were weak during a one year observation with
examinations at 2 months intervals.
Goodson (1986) found that the clinical measurements
(gingival redness,BOP ,suppuration, PI) and DFM bacterial
counts exhibited no association with episodic attachment
loss. Only the loss of alveolar bone and the presence of
specific bacterial species have been associated with
episodic attachment loss.
Haffajee et al.(1988) found that the severity of gingival
inflammation (GI, BOP, PI) related poorly to mean
attachment loss.
Claffey et al.(1990) investigated the diagnostic
predictability of scores for plaque, bleeding, suppuration
and probing depth for probing attachment loss over 3.5
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years following initial periodontal therapy. They found
that accumulated PI scores gave low predictability, while
accumulated BOP scores gave modest predictive values for
attachment loss. After a few years of maintenance, an
increase in probing depth, particularly if combined with a
high frequency of bleeding on probing, showed the highest
predictive value for probing attachment loss of the sites
examined.
Okamoto et al.(1988); Yoneyama et al.(1988); and Lindhe et
al.(1989a),all found a non-significant relationship between
changes in probing depth and probing attachment level.
Badersten et al.(1990) found a modest predictive value for
PI and BOP in predicting probing attachment loss . Increased
probing depth on the other hand showed high diagnostic
predictability, at least during the final years of a five
years observation period. Probing attachment loss was most
frequently found in sites with initial pocket depth (PD)
equal to or > 3.5mm and infrequently found in sites with
initial PD equal to or more than 7mm. However, Claffey et
al.(1990) found attachment loss was more frequent for sites
with PD initially equal to or > 7mm than in shallower
sites. In both studies PI and BOP frequencies had modest
predictive value for loss of attachment level, and also in
both studies residual probing depths had a modest
predictive value at 12 months but increased predictive
value at later yearly intervals. Increase in probing depth
compared to baseline seemed to be the criterion with best
predictive value, particularly if combined with bleeding
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frequencies equal to or > 75%. So it appears that
attachment loss is often associated with increased probing
depth.
Kaldahl et al. (1990) evaluated the relationship between the
presence of both gingival bleeding and supragingival
plaque, and probing attachment loss at sites demonstrating
> or equal to 2mm probing attachment loss during a 2-year
period of maintenance therapy. They found that gingival
bleeding and PI were not prognostic factors of attachment
loss .
Badersten et al.(1990) studied the diagnostic value of
clinical scoring of supragingival plaque, bleeding,
suppuration and probing depth to predict probing attachment
loss over 5 years of observation following nonsurgical
periodontal therapy. The results showed that all the
clinical parameters were associated with attachment loss.
The diagnostic predictability of either accumulated plaque
scores or accumulated bleeding scores reached a maximum of
about 30%. Residual probing depth equal to or > 7 mm
reached a predictability of about 50%. An increase in
probing depth equal to or > 1mm reached about 80%
predictability after 5 years, and thus the increase in
probing depth was found to be the most valuable method in
predicting probing attachment loss.
Jenkins et al.(1988) investigated the ability of certain
clinical parameters (pocket depth, PI and gingival redness)
and microbiological criteria to predict periodontal
breakdown during a one year period (with examinations at 2-
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month intervals) in 11 subjects with untreated advanced
periodontitis. They found that neither the PI scores, the
presence of gingival redness nor the pocket depth
measurements could be used in a predictive capacity for
attachment loss on either a site or patient basis.
Haffajee et al.(1991) investigated the association of
baseline clinical parameters (PD, baseline attachment
level, PI, GI, BOP) of periodontal disease with further
attachment loss in untreated periodontal disease patients
over the following year. They found that these clinical
parameters were strongly associated with risk of new
attachment loss (at 2 and 3mm thresholds) . Their study
demonstrated the strength of relation between prior
attachment loss and additional attachment loss, and
suggested that other clinical variables are less predictive
for additional attachment loss in a subject. Their results
and those of others (Albander et al. , 1986; Axelsson and
Lindhe 1978; Haffajee et al. , 1988) have indicated that
subjects with large numbers of sites of attachment loss or
alveolar bone loss are more likely to exhibit additional
attachment loss in the same sites or at new sites. So
patients already showing more periodontal destruction are
at higher risk for additional disease than those with
little or no evidence of destruction.
Concluding remarks:
The studies described above have assessed the ability of
clinical parameters to predict attachment loss in patients
monitored for 2 years or less, and this may have been too
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short period of time to properly study the diagnostic value
of clinical signs of disease. In general, as time
progressed these parameters provided improved diagnostic
predictability. Therefore, longer monitoring periods may
need to be used if clinical signs of disease are to reach
meaningful diagnostic values.
It can be concluded that the clinical parameters (PI, GI,
BOP, PD) used in the assessment of periodontal disease
cannot predict active periodontal destruction.
It also could be concluded that an improvement in the
reproducibility of attachment level measurements and the
detection of attachment level change as well as using
frequent attachment level measurements, will result in
reducing the false positive number of sites with attachment
loss. On the other hand, increasing the number of
periodontal sites and the length of studies will give a
better chance for detecting disease activity at more
periodontal sites. This in turn, with no doubt, will
improve the correlation between the disease activity,
measured by attachment level, and other clinical
parameters. So this may have an influence on the predictive
value of the clinical parameters in the assessment of
periodontal disease activity.
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1.5.2 Biochemical Methods and Gingival Crevicular
Fluid (GCF)
The examination of the host response in the periodontium by
analysis of GCF is an important approach to periodontal
diagnosis and the detection of destructive periodontal
disease.
Analysis of GCF constituents might provide an early,
biochemical indication of tissue changes that may
ultimately manifest clinically as destructive periodontal
disease. The analysis of GCF for biochemical markers of
disease is one of a battery of adjunctive diagnostic tests
used in identifying patients and/or sites at risk for
disease progression (Lamster et al. , 1989; Fine and Mandel,
1986; Offenbacher et al. , 1986, Lamster et al. , 1988a and
1988b).
Reliable biochemical methods of periodontal diagnosis must
show high sensitivity and specificity, and have a high
predictive value for the detection of future attachment
loss. These methods have two important aims; to identify
those patients at risk for breakdown, and to identify the
affected sites or regions in the susceptible individual.
The analysis of host response elements in GCF may provide
a noninvasive means of monitoring events occurring in
periodontal tissues.
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1.5.2.1 Gingival crevicular fluid; Definition,
Production, Sampling methods and volume
measurement
Definition:
The gingival crevicular fluid (GCF) in its most elementary
form could simply represent interstitial fluid, changing in
the presence of inflammation to inflammatory exudate
(Alfano, 1974; Pashley, 1976; Hattingh and Ho, 1980). It is
thought that interstitial fluid, even in the absence of
inflammation, can pass into the gingival sulcus because of
the nature of the dentogingival junction (Cimasoni, 1983) .
Thus GCF can be considered as an interstitial transudate
present within or at the orifice of the gingival crevice.
It contains various components derived mainly from four
sources, these being (1) Interstitial fluid; (2) products
of host cells; (3) plasma-derived molecules; (4) products
derived from the subgingival plaque (Cimasoni, 1983). Each
of these components contains a multitude of factors each of
which could be considered a possible candidate for
prediction of disease activity.
Production of GCF:
GCF production has been shown to be closely related to an
increase in vascular permeability of the gingival
crevicular plexuses underlying the sulcular and junctional
epithelium, during the early stage of inflammation (Brill,
1959; Brill and Krasse, 1958; Brill and Bjorn, 1959; and
Egelberg, 1966) .
Production of GCF in clinically healthy gingivae has been
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suggested to be controlled by different mechanisms which
have been postulated in two models:
1.Alfano (1974) model: this assumes that a very early or
preinflammatory flow of gingival fluid may be osmotically
mediated. Within the clinically healthy gingiva, the early
deposition of a small amount of subgingival plaque creates
limited quantities of macromolecules which may be absorbed
either on the surface of desquamating epithelial cells or
through phagocytosis. Further accumulation of molecules
occurs and they diffuse intercellularly between the
epithelial cells to the basement membrane which acts as a
major limiting barrier. Accumulation of the macromolecules
at the basement membrane create an osmotic gradient and
this results in the generation of gingival fluid flow. This
osmotically modulated gingival fluid is a transudate and
not an inflammatory exudate, but at various times it may
progress to a an exudate.
2.Pashley mathematical model(1976): this is based on
certain factors which govern fluid distribution across
capillary walls. The model implies that GCF production is
modulated both by the passage of fluid from capillaries
into the tissues (capillary filtration) and by its
subsequent removal via lymphatics. When the production of
fluid from capillaries is greater than the lymphatic
uptake, fluid accumulates as oedema or is removed as GCF.
The net flow of GCF depends not only upon the difference
between capillary filtration and lymphatic uptake, but also
on the filtration coefficients of the junctional and
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sulcular epithelia. It is suggested that the net GCF
production,in both health and disease, can be accounted for
by relative differences in the passage of fluid from
capillaries into the tissues, the uptake by lymphatics and
the filtration through junctional epithelium into the
gingival crevice. These differences are governed by
differences in the filtration coefficients of the membranes
delineating the different compartments as well as by the
differences in hydrostatic and osmotic pressure between
capllaries, lymphatics, tissue fluid and sulcular areas.
Both the Alfano and Pashley models of GCF production can be
postulated as follows: In the absence of inflammation,
macromolecules originating from accumulated plaque diffuse
intercellularly and reach the basement membrane where they
create an osmotic gradient and attract interstitial fluid
toward the sulcus. When more macromolecules reach the
basement membrane, an inflammatory reaction occurs. The
osmotic gradient is then greater but the fluid now
permeating the weakened basement membrane and the
junctional epithelium is a typical inflammatory exudate.
Many experiments on GCF production have been conducted.
Brill (1959) used histamine injection in dogs to increase
vascular permeability,and collected GCF by paper strips
from clinically healthy gingival sites.
Egelberg (1966) applied histamine topically to healthy
gingivae ,found increased permeability and large amounts of
GCF were collected. These experiments support the concept
that GCF is derived from plasma.
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Bickel, Cimasoni and Anderson (1985) did not report any
fluid recovery from healthy gingivae but they found a low
concentration of albumin in GCF during pre-inflammatory
plaque accumulation. Based on these experiments, it seems
that GCF is produced through leakage of plasma fluids and
proteins due to increased permeability of the vascular
plexus. The fluid passes through the connective tissue and
enters the gingival sulcus through the intercellular spaces
of the pocket epithelium.
Concentration of proteins in gingival fluid:
Controversial results have been obtained on the protein
concentration in GCF.
Brill and Bronnestam (1960) found that the total protein
content of GCF in unstimulated pockets was as low as 1:10
of that of serum, while in stimulated pockets it was only
slightly higher. Sueda et al.(1966) showed that GCF
contains proteins similar to those found in serum. Bang and
Cimasoni (1971) showed that periodontal inflammation is
accompanied by varying amounts of GCF according to the
severity of the inflammation. Their studies confirm that
GCF is an inflammatory exudate carrying high molecular
weight components such as proteins. Schenkine and Genco
(1977) concluded that the GCF from severely inflamed
periodontal tissue appears to represent a mild dilution of
serum and that less severe periodontal damage produces a
less dilute gingival fluid, while in another study they
concluded that the amount of protein increases with the
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severity of the inflammation.
Generally the protein concentration of GCF sampled from
sites with varying degrees of gingivitis and periodontitis
is equivalent to that of serum (Bang and Cimasoni 1971;
Biswas et al., 1977; Binder et al., 1987).
A number of studies confirm that GCF in cases of gingivitis
contains a similar concentration of total proteins as
present in serum (Hattingh and Ho, 1980; Bang and Cimasoni,
1971) and indicate also that the concentration of proteins
in GCF collected in the absence of clinical inflammation is
lower and similar to that of extracellular fluids. In
clinically healthy gingiva very little fluid can be
collected and GCF appears to contain a low concentration of
proteins. This could represent interstitial fluid generated
locally by an osmotic gradient and result from an increased
permeability of the gingival venules. This may then
progress to a classical inflammatory exudate,containing
higher amounts of total protein.
The protein concentration in GCF has been found to range
from 22-130 microgram/microliter (ug/uL) (Biswas et al.
(1977) .
Hattingh and Ho (1980) reported that the protein
concentration of GCF collected in the absence of clinically
visible signs of inflammation is 93 ug/uL, while its
concentration in inflamed gingiva is 69 ug/uL which
supports the results of Bang and Cimasoni (1971) who
reported a level of 68.3 ug/uL.
Novaes et al.(1980) demonstrated that GCF flow increased
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directly with the clinical inflammatory response. They
found the concentration of 64.1 ug/uL in their study. They
also found a higher total protein content in GCF from
severely inflamed pockets but lower protein concentration
compared to healthy gingiva, and this was due to a
significantly higher rate of GCF flow in clinically severe
periodontal disease. Their observations are consistent with
those of Schenkine and Genco (1977) . The protein probably
originates in part from the leakage of plasma proteins and
in part from the metabolism of various connective tissue
proteins.
Curtis et al. (1988) found that the concentration of protein
in GCF at an undisturbed healthy site is of the order of 22
ug/uL. They suggested that the variations in the
concentration of GCF protein reported in many studies are
due to the duration and method of collection and the
evaporative loss from the collection device prior to GCF
volume determination which causes a proportionately greater
underestimation of the total sample volumes when the
starting volume is low. Thus in health when the GCF volume
is invariably low, there is a tendency to overestimate the
concentration of GCF components.
Methods of collection of GCF:
Various methods have been used for GCF collection,and the
choice of a suitable technique depends on the type of
analysis required and the amount of GCF required. These
methods include:
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1.Absorbing paper strips: this is the most commonly used
method for measuring the flow of GCF and for the
quantitative analysis of GCF components (Golub et al.,1976;
Cimasoni and Giannopulo, 1988; Griffiths,Curtis and Wilton,
1988; Curtis et al. , 1990 ; Giannopoulp et al. , 1992 ;Lamster
et al., 1988a and 1988b) . This method was first used by
Brill and Krasse (1958) using both intracrevicular and
extracrevicular techniques.
2.Capillary tube or micropipette method: this is based on
the use of capillaries which allow the collection of 10-
40uL of fluid. Capillaries are used for the collection of
a large quantity of fluid (Ishikawa et al., 1972).
3.Gingival washing technique: this involves the ejection of
and reaspiration of a known volume of solution into the
gingival crevice. The method is used when cellular elements
of the fluid are studied (Skapski and Lehner, 1976) .
Standardisation and choice of the sampling methods:
Analysis of GCF should follow standardisation of the
sampling method, as different methods may influence the
amount and constituents of the GCF recovered. Also care
must be taken during collection to avoid possible
variations due to contamination, irritation and
evaporation. When microamounts of fluid are sufficient for
collection and analysis and when studying the healthy and
diseased crevice, the paper strip appears to be the method
of choice even though the insertion of a paper strip into
the crevice may cause gingival irritation which may lead to
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increased vascular permeability .
To avoid the variability associated with GCF collection by
paper strip, certain factors have to be considered. These
include sampling time and sampling repetition which have
been shown to influence the GCF flow rate and may lead to
reduction of GCF volume particularly during repeated
sampling (Binder,Goodson and Socransky, 1987; Curtis et
al. , 1988; Cao and Smith, 1989 ; Lamaster et al. , 1989) .
Variations in the fluid flow with time during the
collection procedure could significantly affect
quantitative observations on gingival fluid. Depending on
the collection procedure, it has been shown that the amount
of fluid production does indeed change in the minutes
following the contact of the paper strip with the marginal
gingiva. So the time factor has to be taken into in
consideration when collecting fluid and analyzing data
(Griffiths,Curtis and Wilton, 1988; Curtis et al., 1990).
Standardisation of the length of the strip to be inserted
in the crevice is necessary as the deeper the insertion
then the higher will be the recorded flow rate (Mann,1963) .
The sampling of GCF by standard paper strip using minimum
tissue irritation and the minimum adequate time to collect
sufficient fluid for analysis, was the method used in the
present study.
Measurement of volume of collected GCF:
Various methods have been used for measuring the volume of
collected GCF. These include:
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l.The wetted area of the filter paper can be viewed with a
microscope fitted with a graticule, directly or after
staining in an alcoholic solution of ninhydrin at a
concentration of 2% (Egelberg and Asstrom, 1973) . The
staining, however renders the sample unsuitable for future
analysis.
2 .Weighing the strip enables the flow of fluid to be
measured in milligrams per minute, and this is particularly
suitable for measuring large volumes of fluid (Cimasoni and
Giannopoulou, 1988) .
3.The Periotron: is the most suitable method for measuring
the volume of GCF absorbed on a paper strip and was
developed by Harco Electronics (Dental Products Division,
Winnipeg,Canada). The method is compatible with subsequent
chemical analysis (Hattingh and Ho 1980) and keeps
evaporation to a minimum. It does not suffer from the
disadvantages of the ninhydrin technique. The Periotron may
be considered an accurate instrument, provided that a daily
check of the reading accuracy is performed and paper strips
are placed in the machine in a standard position.
The Periotron reading represents the moistened area of the
strip rather than the amount of the fluid absorbed. The
reading is affected by many factors including the humidity,
temperature and most importantly the position of the strip
between the jaws of the Periotron. The instrument
functioned by measuring the reduction in capacitance
between sensors due to the wetting of a precut filter paper
strip. This activity was coupled to a digital readout on a
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scale of 0-200. The instrument allowed for rapid volume
determination, and the availability of the sample for
subsequent biochemical analysis. Recently, Periotron 6000
was introduced, with less variability than either the
Peroitron 600 or the ninhydrin staining method (Hinrich et
al.1984). The Periotron 6000 has been extensively used for
the investigation of GCF components and has shown
satisfactory results in the assessment of GCF volume
(Cimasoni, 1983). The only difficulty is the assessment of
minute amounts of GCF (volumes of less than 0.2uL) . The
measurement of these small volumes is necessary in certain
protocols, and be can be subject to uncontrolled errors
(Lamster et al., 1988a).
GCF volume flow rate in periodontal health and disease
activity:
Many studies have investigated the correlation between GCF
flow and the severity of gingival inflammation.
Brill and Bjorn (1959) concluded that inflamed pocket
epithelium yielded greater amounts of GCF than healthy
epithelium. Mann (1963) concluded that GCF flow correlated
with the severity of inflammation, and was able to find a
correlation between GCF flow and pocket depth. Egelberg
(1966) demonstrated that small amounts of GCF can be
recovered from clinically healthy gingiva. He found a
positive correlation between gingival indices and GCF flow.
Bjorn et al. (1965) found a positive correlation between GCF
flow and the gingival index scores.
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From the above studies it can be concluded that the volume
of GCF can be used as an accurate estimation of the
clinical degree of gingival inflammation.
Many differences in GCF quantity and composition from
'healthy' and diseased gingival sites have been identified
(Cimasoni, 1983; Fine and Mandel, 1986).
Smith et al.(1991) found striking differences in the volume
of GCF from different sites.
Determination of the volume of GCF collected on filter
paper strips represents an accurate assessment of early
inflammation and vascular permeability in a particular
patient. However, the interpatient variability is high, and
precludes the use of predetermined volume thresholds to
differentiate disease categories. Moreover,there are no
data to support the concept that GCF volume can be used to
predict future attachment loss.
1.5.2.2 Constituents of GCF and disease activity:
A limited number of markers in GCF associated with
progressive attachment loss such as PGE2 and B-glucuronidase
(neutrophil granule enzyme) have been identified (Fine and
Mandle,1986; Offenbacher et al.,1986). The evaluation of
PGF2 as a screening test for progressive attachment loss
indicated a high sensitivity, high specificity, and high
predictive value. Elevated levels prostaglandin E2 in GCF
has been found in patients with periodontitis compared to
those with gingivitis (Offenbacher and Goodson, 1984), and
deteriorating periodontal sites showed a five-fold
69
elevation PGE2 levels compared to stable sites (Offenbacher
et al., 1986).
B-glucuronidase was found to be an indicator and predicator
of localized and generalized clinical attachment loss with
high specificity and sensitivity (Fine and Mandel, 1986;
Offenbacher et al. , 1986) . In a study of patients with
periodontitis,B-glucuronidase levels in GCF were predictive
for patients and sites about to undergo significant probing
attachment loss, with a sensitivity and specificity of 89%
(Lamster et al., 1988a,b).
Host cells and their products, inflammatory cells (PMNs)
and their enzymes and other substances related to
inflammation and tissue destruction have been found in GCF
and associated with periodontal diseases (Cimasoni, 1983:
Fine and Mandle, 1986). Among those host factors that have
been identified in GCF are elastase, various cathepsins,
lactoferrin, and myeloperoxidase. Indicators of cell death
in GCF include aspartate aminotransferase and lactate
dehydrogenase. GCF collagenase activity was found to be
increased during active periodontitis in beagle dogs, and
was strongly correlated with attachment loss (Kryshtalskyj
et al., 1986). It was also found that collagenase activity
from periodontal pockets was positively related to GCF flow
and pocket depth (Golub et al., 197 6) .
Factors for complement pathways have also been identified
in GCF. The numbers of polymorphonuclear leukocytes in GCF
also increases during the development of experimental
gingivitis in man (Thurre et al., 1984) .
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1.5.3 Microbiological methods
Microorganisms are the primary aetiologic agents for the
periodontal diseases (Socransky, 1977; Socransky, 1970) and
there are hundreds of different species of bacteria present
in the oral cavity. Studies, using improved microbiological
methods, have confirmed that varying degrees of specificity
exist in the bacterial flora associated with health,
gingivitis and various forms of periodontitis (Listgarten,
1988; Slots, 1986a).
Microbiolgoical assessments for specific microorganisms in
individual periodontitis patients may be applied to
determine the causative agent; to assess disease activity;
to monitor the effect of treatment; and to decide on recall
intervals. It may also be helpful to identify those persons
at risk for either the initial episode or for recurrent
periodontal disease (Genco et al. , 1986) . Methods of
microbiological assessment include culturing, immunologic
assays,DNA probes,enzyme tests,and microscopic methods
(Slots, 1986b; Greensten, 1988).
1.5.3.1 Microscopic Methods:
Microscopic monitoring of the subgingival flora by either
phase-contrast microscopy (PCM) or differential dark-field
microscopy (DDFM) may help when used with other clinical
parameters in the diagnosis and management of chronic
periodontal disease and may enable the setting of
appropriate recall intervals for maintenance therapy. Both
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techniques are simple and allow the rapid classification
of bacterial samples on a percentage basis according to the
shape, size and motility of the bacteria.
Since bacteria can be visualized regardless of their
ability to grow in culture, darkfield or phase-contrast
microscopy provides a good means of determining both total
bacteria counts and counts of bacteria which have
characteristic morphotypes. Darkfield/phase-contrast
microscopy does not differentiate between microbial
species, nor between pathogens and non-pathogens for
bacteria with similar morphologies (Greensten and Poison,
1985) . For example bacteria such as actinobacillus
actinomyecetemcomitans (Aa) and P.qinqivalis, are neither
motile nor spirochaetal and cannot be specifically
identified using microscopic monitoring. Another
disadvantage of DDFM and PCM is that the samples must be
assessed immediately and cannot be stored for reassessment.
Problems due to sampling, specimen dispersion, morphotype
classification, and slide preparation have been found to be
associated with microscopic studies (Omar and Newman,1986).
It has been suggested that microscopic monitoring for
elevated levels of spirochaetes and/or motile rods may
identify sites of active periodontal breakdown but recent
finding do not support this hypothesis (Dunham et al.,
1985) . However subjects with treated periodontitis and
showing elevated levels of spirochaetes and/or motile rods,
have more frequent localized recurrences of periodontitis
than patients showing low proportions of these morphotypes
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(Listgarten and Hellden, 1978).
In subjects who discontinued professional maintenance, the
sensitivity and specificity of the microscopic test to
predict future breakdown in subjects was close to 80%.
However the test was not able to predict which particular
sites would be affected.
Microscopic monitoring of spirochaetes and motile forms has
been found to be an unreliable predictor of gingivitis
(Listgarten, 1985), and inflammatory exacerbations in
pockets (Listgarten and Hellden, 1978), and is inconsistent
in predicting increasing pocket depths (Listgarten et al.,
1984) . Microscopic monitoring is not suitable to monitor
disease activity (Dunham et al., 1985; Listgarten et al. ,
1986) .
It can be concluded that DDFM and PCM can identify
bacterial morphotypes but not specific bacteria, and may be
valuable diagnostic aids in the prevention of disease
recurrence, but not as predictors of the disease activity.
Microscopic studies of periodontal microbiota have
demonstrated the existence of distinctive microbial
populations in association with various stages of
periodontal disease and periodontal health. This was first
clearly established by Listgarten (1976) who on the basis
of electron microscopic studies reported many more
spirochaetes, Gram negative, and flagellated species in
periodontally diseased than in healthy sites. Most of the
microbial variance originated between subjects, rather than
between sampled sites within each subject (Evian et
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al. (1982)
1.5.3.2 Microscopic studies of subgingival microflora
in periodontal disease and their relation to
clinical parameters
A number of studies using DDFM and PCM have reported
distinct differences between the composition of the
microbiota at periodontally healthy sites and sites with
varying types of periodontal disease (Listgarten, 1986a,b;
Loe et al., 1965; Theilade et al., 1966; Listgarten et al.,
1975,1976; Listgarten and Hellden, 1978; Lindhe et al.,
1980; Keyes and Rams, 1983). Healthy sites were associated
with fewer bacteria, predominantly consisting of coccoid
forms and non-motile bacteria with greatly reduced numbers
of motile rods and spirochaetes (Listgarten and Hellden,
1978). Diseased sites were associated with increased
numbers of bacteria, with motile forms especially
spirochaetes, and with decreased numbers of coccoid forms (
Listgarten and Hellden 1978).
Several workers have shown a clear association between
changes in the proportions of the different morphologic
types and the disease activity, particularly the
correlation between increases in the proportions of
spirochaetes and other motile rods and increased disease
severity (Lindhe et al. , 1980; Listgarten and Levin, 1981) .
Spirochaetes and motile forms have been frequently found at
diseased sites (Listgarten and Hellden 1978; Armitage et
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al., 1982; Listgarten and Schifter 1982; Savitt and
Socransky 1984; Greenwell and Bisada 1984; Lindhe et al. ,
1980), but their proportions were best correlated to pocket
depths (Mousgues et al., 1980; Armitage et al., 1982; Evian
et al., 1982; Listgarten and Levin, 1981; and Savitt and
Socransky, 1984). Other have also demonstrated a
correlation between these forms (spirochaetes and motile
form) and pocket depth (Keyes et al., 1978; Listgareten and
Hellden 1978; Lindhe et al. , 1980; Listgarten and Levin,
1981; Armitage et al. , 1982; Savitt and Socransky 1984;
Green and Bissada, 1984). Evian et al.(1982) found a lack
of correlation between clinical parameters (PI, GI, PD) and
the proportions of spirochaetes and motile rods at
individual sites.
Listgarten and Hellden (1978) reported significant
differences in the microbial flora between clinically
normal and diseased sites within the same patient using
DDFM. They found that the proportions of cocci were higher
at normal sites (74.3%) than at disease sites (22.3%).
Motile rods were more numerous at diseased sites (12.7%)
than at normal sites (0.3%) and spirochaetes comprised
37.8% of the bacteria at diseased sites compared with 1.8%
at normal sites (relatively healthy sites with only mild
evidence of clinical inflammation). The ratio of motile to
non-motile bacteria in normal sites was found to be
1:49,whereas in diseased sites the ratio was in the
vicinity of 1:1. The findings indicated that diseased sites
were associated, with an increased number of motile rods
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and spirochaetes with a decrease in the number of coccoid
forms. These results have been supported by Lindhe et
al. (1980) who found an increase in motile forms and a
decrease in coccoid forms with increasing severity of
periodontal destruction.
Keyes and Rams (1983) monitored the composition of
subgingival flora by PCM and found that spirochaetes and
motile rods were highly associated with destructive
periodontal disease.
Mousques et al.(1980) using DDFM reported a moderately
strong correlation between the percentages of spirochaetes
and GI, PI, and PD.
Listgarten and Levian (1981) found a positive correlation
between the percentage of motile rods and GI and PI, and
between spirochaetes and PI and PD, with a negative
correlation between the percentage of cocci and PI when
sampled surfaces only were considered for analysis. They
concluded that there was a positive correlation between the
proportion of both subgingival spirochaetes and motile rods
with susceptibility to periodontal deterioration.
Evian et al. (1982) found no significant correlation between
clinical parameters (PI, GI, PD) and the proportions of
spirochaetes and motile rods at individual sites. They
suggested that bleeding on probing is positively correlated
with the proportion of subgingival spirochaetes.
Savitt and Socransky (1984) using DDFM found that
spirochaetes and other motile organisms were more
frequently present and in higher proportions in gingivitis
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and chronic periodontitis than in healthy subjects,and the
proportions of these bacteria were highly correlated with
pocket depth. Motile organisms were also found to be
positively correlated with PI and GI,in contrast to cocci
which showed a strong negative correlation with pocket
depth, PI and GI. Their results support the findings of
Armitage et al.(1982) that the percentages of spirochaetes
and motile rods may be related to the pocket depth.
Greenwell and Bissada (1984) reported the presence of
variations in the subgingival microflora from healthy and
intervention sites using DDFM and probing depth criteria.
Means from all sites indicated that deeper pockets were
associated with increased proportions of spirochaetes and
motile forms. They supported the concept of site-specific
variations in the subgingival microflora of patients
susceptible to periodontitis.
Wilson et al.(1985) using DDFM found a significant
relationships between the composition of the plaque and
probing depth and also with bleeding on probing at the
associated periodontal site. A close correlation between
clinical symptom "bleeding on probing" and the percentage
of motile microorganisms in the subgingival plaque was
evident. They confirmed that the proportion of motile rods
is not related to actual severity of disease as measured by
probing depth.
Bleeding upon probing has been shown to be a reliable
parameter for predicting a subgingival microflora with an
increased proportion of motile bacteria (Muller et al. ,
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1986). Similar observations were made by Armitage et
al.(1982) who showed that BOP correlated positively with a
subgingival microflora with increased proportions of motile
micro-organisms particularly the spirochaetes.
Wolff et al. (1985) using DDFM and PCM in a cross sectional
study supported the conclusion of other investigators
(Listgarten and Levin 1981, Armitage et al.1982) that
higher proportions of spirochaetes occur at deeper PD.
MacPhee and Muir (1986) found that deeper pockets tend to
contain higher percentages of spirochaetes and motile
organisms.
Abbas et al. (1986b) using PCM found that subgingival
samples from experimental gingivitis contained a high
proportion of spirochaetes. No differences in spirochaetes,
motile rods, and other forms could be demonstrated between
bleeding and non-bleeding pockets, and this is in agreement
with Evian et al. (1982) .
1.5.3.3 Microscopic assessment in prediction of
periodontal disease activity (Attachment Loss)
Many studies have been conducted to evaluate the role of
subgingival morphotypes particularly spirochaetes and
motiles in predicting the disease activity measured by
attachment level loss.
Studies on periodontal disease activity (PDA) and an
association with bacteria have found that microbial
determination has contributed limited information to
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facilitate PDA prognostication (Greenstein and Poison,
1985; Greenstein, 1988). Retrospective studies showed that
spirochaetes cannot forecast PDA (Listgarten et al., 1986;
Macfarlane et al., 1988).
Listgarten et al.(1978) suggested that spirochaete counts
may not be good predictors of attachment loss. Positive
correlations have been reported between the proportions of
spirochaetes and motile organisms in subgingival plaque and
susceptibility to periodontal deterioration.
Listgarten and Levin (1981) found that the presence of
elevated proportions of spirochaetes may predict further
periodontal breakdown. This was confirmed in part by Slots
et al.(1985) who found a significantly positive correlation
between spirochaetes and further loss of periodontal
attachment (equal or > 2mm) at 3-6 months and 12 months.
Claffey et al.(1985) showed that spirochaetes related
better to probing depth than to changes in probing
attachment level 12 months after therapy.
Baab and Opsving (1986) using PCM did not find a
significant differences in the percentages of cocci, motile
rods, or spirochaetes at bleeding and nonbleeding sites. In
contrast significant correlations were found between the
percentage of spirochaetes and PD, attachment level, and
gingival inflammation.
Necomb and Nexon (1989) found a significant negative
correlation between probing depth or attachment loss and
the proportion of cocci in the plaque, no significant
association being observed between clinical signs such as
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BOP and the microbiological assays. Their studies are in
agreement with those of Baab and Opsvig (1986) who found no
differences in the proportions of spirochaetes, motile
rods, and cocci between bleeding and non-bleeding sites of
similar probing depth.
MacFarlen et al.(1988) investigated the possible
correlations between attachment level change and
spirochaetes at baseline visit, at 2 months and after one
year in patients with untreated periodontitis. They
concluded that the quantification of neither spirochaetes
nor black-pigmented bacteroides species can be used
reliably to identify or predict disease-active sites.
Bacterial products, host cells and their derivatives were
found unable to forecast PDA (Fine and Mandel, 1986).
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1.5.4 Immunological methods:
Studies of immunological factors in periodontal diseases
have led to advances in understanding the pathogenesis of
these diseases. Immunological techniques may also help in
the identification of bacteria important in the aetiology
of periodontal disease. The immunologic methods of
diagnosis include assessment of immunoglobulins both in
serum and in GCF, assessment of peripheral blood and
gingival lymphocytes, and evaluation of phagocytes,
including monocytes and neutrophils. These studies have led
to recognition that the neutrophil phagocyte is a key
protective cell against periodontal infecting bacteria.
1.Antibodies: these include both serum and GCF
immunoglobulin levels to putative periodontal pathogens or
marker organisms. Elevated serum immunoglobulin titres to
A.actinomycetemcomitans have been reported for localized
juvenile periodontitis (Genco et al., 1985), and to B.
gingivalis for adult and rapidly progressive periodontitis
(Slots, 1979; Chung et al., 1983). Reasonable correlations
have been reported between elevated serum immunoglobulin
titres and specific organisms associated with active
lesions (Ebersole et al., 1987).
Studies of GCF antibodies have demonstrated that
immunoglobulin levels in GCF are generally lower than in
serum, but may be higher in about 27% of diseased sites
when antibody response to particular periodontopathic
organisms are assessed (Taubman et al.1982). This supports
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the concept of either local antibody production or the
existence of a concentration mechanism at diseased sites.
The antibody studies have helped in understanding the
infectious nature of periodontal disease. Antibacterial
immunoglobulins, especially those in GCF may be important
in controlling subgingival levels of periodontal bacteria,
localizing them to the periodontium. Specific
immunoglobulins are thought to exert their protective
effects by opsonising periodontal bacteria, preparing them
for phagocytosis and killing by neutrophils.
2.Neutrophils:
These include the defects in polymorphnuclear leukocytes
and/or monocyte function (chemotaxis, phagocytosis) as have
been found to be associated with chronic periodontitis
(Altman et al., 1985). In vivo crevicular leukocyte tests
involving a chemotactic challenge are apparently useful for
determining neutrophil function (Golub et al., 1981).
3.Lymphocytes:
Studies of lymphocyte function includes their involvement
in the production and activity of biologic response
mediators. Autologous mixed lymphocyte reaction (AMLR) was
found to be associated with early onset periodontal disease
(Ranney et al., 1981).
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1.6 Acute phase response
1.6.1 Introduction
The acute phase response is the response of the body to
injury or trauma. It consists of an orderly and
orchestrated series of reactions that normally result in
the arrest of the process of injury, in protection of the
organism against further injury, and the initiation of
repair and restorative processes aimed at returning the
organism to a homeostatic balance.
Immediate local responses to injury include the release of
potent components from activated and damaged cells such as
lysosomal enzymes and products of the arachidonic acid
pathway.
Systemic responses are slower and include activation of
phagocytic cells and the release of cytokines and hormones
from various cells. Also occurring are changes in the
metabolic activity of the liver which result in the
increasing synthesis and secretion by hepatocytes of a
number of plasma proteins termed "the acute phase
proteins"or "acute phase reactants".
Many of the acute phase proteins are present normally in
plasma and their levels only slightly increase during the
acute phase response. Examples of such proteins include
proteinase inhibitors particularly alpha-l-antitrypsin,
fibrinogen, complement (C1-C6 ,C9), alpha-l-macroglobulin,
alpha-2- macroglobulin. Other acute phase protein such as
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serum amyloid, and particularly C-reactive protein (CRP)
increase dramatically (100-1000 fold) within 24 to 48 hours
after the injury. The levels of other acute phase proteins
may even decrease, examples being albumin, lipoprotein and
transferrin, and these are termed "negative acute phase
proteins".
The term "Acute phase response" was first introduced by
Abernethy and his colleagues in 1941, to refer to the
changes in serum obtained from patients with infectious
diseases (Abernethy and Avery 1941).
The acute phase response is the response by an organism to
disturbance of its homeostasis. This may be due to diverse
stimuli such as tissue damage, trauma (physical and
chemical), infections (bacterial,viral, fungal, parasitic),
ischemic necrosis, neoplasms, immunologic disorders and
other insults. These stimuli are considered as having a
common denominator for production of cellular/tissue injury
or death.
The acute phase response is thought to be beneficial to the
injured organism with the aim of restoring the disturbed
physiological homeostasis. The increased levels of acute
phase proteins are an important component of the systemic
response to local ox general injury, which also includes
cellular, microbiological, biomedical, endocrine, and other
metabolic changes such as leukocytosis and fever.
The acute phase response is well preserved throughout
phylogeny and represents an important mechanism in
mammalian systems. The acute phase response often shows a
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striking species specificity, CRP for instance being an
acute phase protein in man but not in rats or mice, while
alpha 2-macroglobulin is an acute phase protein in rats but
not in man (Fey, 1987) .
The non-specific nature of the acute phase response is an
indication of its general activation and participation in
both innate and acquired immune reactions.
1.6.2 Induction and regulation of acute phase
response and protein synthesis
The acute phase response refers to changes in the
concentrations of a large number of plasma proteins which
reflect the re-orchestration of a pattern of gene
expression for secretory proteins in hepatocytes (Gauldie
et al. , 1989) . It is thought to be co-ordinated by signals
released at the site of injury which are able to circulate
through the blood stream to remote sites.
The increased levels of acute phase proteins are mainly due
to their increased synthesis, although in some cases there
may be a contribution from the release of preformed stocks
of protein (Koj, 1974). Most acute phases proteins are
synthesized by hepatocytes, and their increased production
results from an increased number of cells being recruited
to active synthesis. The acute phase response is mediated
by heterogeneous mechanisms (Kushner et al. , 1989).
The regulation of the synthesis of the acute phase response
appears to be highly complex and is widely modulated by
several specific cytokines. These cytokines are synthesised
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and released in response to an inflammatory stimulus by a
variety of cells which are present at the inflammatory
site, such as macrophages, fibroblasts, endothelial cells
and keratinocytes. The cytokines involved are interleukin-1
(IL-la and IL-lb), interleukin-6 (IL-6)/interferon B2
(INFB2), tumour necrosis factor-a(TNF-a), IFN-gamma,
transforming growth factor-B (TGF-B), and leukemic
inhibitory factors. These cytokines either alone or in
combination have been shown to be capable of influencing
plasma protein synthesis in human hepatocytes (Gauild et
al., 1987; Ramadori et al., 1985; Perimuter et al., 1986;
Mageiaiska-Zero et al., 1988; Baumann et al., 1989;
Mackiewicz et al., 1990).
Gauldie et al.(1989) demonstrated that the factors derived
from monocytes which stimulate hepatocytes can be accounted
for by three polypeptide cytokines; the major hepatocyte-
stimulating factor (HSF) activity is encompassed in the
molecule known as IFN-B2/BSF2/26KDa protein /HGF/HSF/IL-6
and minor HSF regulation or modulation is delivered by IL-1
and TNF. Each of these polypeptides has specific receptors
on the hepatocyte. The acute phase protein genes in the
hepatocytes can be separated into subsets that are
regulated by IL-6 alone or in combination with other
peptide hormones, and this is evidence of the additive or
negative effects of the "alarm cytokines" on IL-6 mediated
induction of genes expression.
IL-6/BSF2/INFB-2 has been implicated as a potent HSF that
drives the increased production of some acute phase
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proteins. IL-1B as well as TNF-a has no stimulatory effect
on human CRP expression while IL-6 stimulates the full
spectrum of acute phase proteins including CRP (Castell et
al. , 1988) . This implies that IL-6 has a key role in the
synthesis of human acute phase proteins.
Studies by Andus et al. (1987,1988) showed that recombinant
IL-6 (rIL-6/BSF2/IFN-B2) is the major regulator of in vitro
hepatic acute phase gene regulation. IL-6 in vivo should
cause an acute hepatic phase response similar to that in
vitro (Nijstan et al. , 1987; Vavoers et al. , 1988) .
Castell et al.(1989a,b) stated that activated monocytes
synthesise and release the cytokines IL-1, IL-6, and TNF-a,
with only IL-6 being able to induce the full spectrum of
acute phase proteins. They further stated that due to
induction and secretion of IL-6 in fibroblasts by TNF-a and
IL-1, a further amplication of acute phase proteins
induction is possible.
Factors other than cytokines (i.e. co-factors) such as
corticosteriods, may be required for optimal induction of
several acute phase proteins. As IL-1 and IL-6 stimulate
adrenocorticotrophic hormone (ACTH) synthesis (Wolski et
al., 1985), glucocorticoids are synthesized which in turn
stimulate acute phase proteins synthesis (Gross et al. ,
1984). Increased glucocorticoid concentrations inhibit the
production of IL-1, IL-6, and TNF-a (Lew et al. , 1988) .
Steel et al.(1991) found that acute phase proteins in vitro
differ in their responses to IL-1B and IL-6 alone, and in
combination. Dexamethasone enhanced the cytokine-driven
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induction of a subset of acute phase protein genes. Both
cytokines have an additive or synergistic effect on C-RP
and serum amyloid A (SAA) when added in combination with
dexamethasone.
1.6.3 Interleukin-6 and the acute phase response
Although several cytokines participate in the induction of
acute phase proteins synthesis, most of the studies carried
out in vitro and in vivo using either hepatoma cell lines
or human hepatocyte cultures point to the specific role of
IL-6 in the synthesis of the full spectrum of acute phase
proteins.
Interferon-B2 (INF-B2) has been shown to be identical with
B-cell stimulatory factor-2 (BSF-2). This is a 26kDa
protein and the name IL-6 was proposed for this molecule
which is identical to hepatocyte-stimulating factor (HSF)
(Gauldie et al., 1987.
IL-6 is synthesized by many different cells such as
fibroblasts and monocytes/ macrophages. Endothelial cells
are probably the major sources of IL-6 during systemic
inflammation. IL-6 acts on different target cells in vitro,
but in vivo the liver is the major target organ.
Studies on human cell lines show that IL-6 is an inducer of
the acute phase response, and stimulation of HepG2 cells
line by recombinant IL-6 resulting in an increase in the
synthesis of al-antitrypsin but not CRP or serum amyloid A.
The combination of IL-6 and IL-1 however, stimulate
production of CRP and serum amyloid A by Hep3B cells. Only
in NPLC/PRF/5 cells could an IL-6-dependent stimulation of
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CRP and SAA synthesis be detected (Ganapathi et al.,1988a) .
Studies using human hepatocyte primary culture showed that
IL-6 is the major inducer of acute phase protein synthesis,
and is capable of inducing CRP and SAA synthesis in a dose
and time-dependent manner(Castell et al. , 1988) . Studies by
Moshage et al.(1989), and Castell et al.(1989b) (Castell et
al., 1989a) showed that IL-6 stimulated the full spectrum
of acute phase proteins seen in inflammatory states in man,
while IL-1 and TNF-a had only a moderate effect on the
positive acute phase proteins and they failed to induce CRP
and SAA. This strongly suggests that IL-6 plays the key
role in human acute phase protein synthesis. Hinrich et
al. (1990) concluded that IL-6 is a major mediator in the
hepatic acute phase response.
Monocytes/macrophages when stimulated by bacteria,
lipopolysaccharides or viruses synthesise, secrete IL-1,
IL-6, and TNF-a which act via specific hepatic receptors.
IL-1 and TNF-a also stimulate fibroblasts, endothelial
cells and keratinocytes to synthesize IL-6 and thus amplify
the biological effects. IL-6 and TNF-a have been shown to
stimulate the release of ACTH from pituitary cells, leading
to increased secretion of glucocorticoids by adrenocortical
cells. The glucocorticoids on one hand increase the
stimulatory effect of monokines on the synthesis of acute
phase proteins by hepatocytes, while on the another hand
inhibit the synthesis of monokines.
It could be concluded that IL-6 is the most potent inducer
of acute phase protein synthesis in human hepatocytes.
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1.6.4 Regulation of C-reactive protein synthesis
CRP synthesis is regulated in a similar way to the other
acute phase proteins during the acute phase response.
Various experimental studies have been carried out in vivo
and in vitro using human hepatoma and hepatocyte cell line
cultures which strongly point to a key role of IL-6 in the
regulation of CRP synthesis.
Induction of CRP synthesis in a human hepatoma cell line
culture was reported by Darlington et al.(1986) and
Goldman et al.(1987), who showed that IL-1 and IL-6 are
able to stimulate CRP synthesis.
It has been found that CRP induction required cytokines
other than IL-1 or TNF-a and neither human rIL-1 nor human
rTNF-a caused induction of CRP in Hep3B cells (Taylar et
al. , 1989; Castell et al., 1989b; Ganapathi et al., 1988b) .
Castell et al.(1988), and Moshage et al.(1988) found that
IL-6 enhanced the synthesis of both CRP and SAA in human
primary hepatoma cultures, although Morrone et al. (1988)
demonstrated that IL-6 had only a minimal effect in
enhancing gene expression associated with CRP synthesis.
Studies by Ganapathi et al. (1988a) showed that partially
purified IL-6 and rIL 6 increased the synthesis of CRP in
the NPLC/PRF/5 cell line in a concentration-dependent
manner but not in the Hep3B cell line.
Studies of the effect of IL-1 in combination with IL-6 on
the induction of CRP revealed that the addition of either
IL-la or IL-lb did not further increase the response of CRP
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in the NPLC/PRF/5 cell line above that observed with IL-6
alone, but that in the Hep3B cell line the combination of
IL-la or IL-lb with IL-6 led to substantial induction of
CRP synthesis. Their findings demonstrated that CRP
induction in NCLP/PRF/5 cell line is not mediated by auto¬
crine secretion of IL-1, and they demonstrated that IL-6
plays an important role in regulating the synthesis of CRP
in human hepatoma cell lines.
Studies of Taylor et al.(1989) showed that the induction of
CRP synthesis, by both rIL-1 and rIL-6, is significantly
different in hepatoma cell line PLC/PRF/5 than in Hep3B-2
and HepG2 cell lines to the same range of concentrations of
each cytokine. They suggested that both IL-6 and IL-1
induce new CRP synthesis and may function via distinct
mechanisms.
Goldman et al. (198 9) showed that in vitro human hepatoma
cell system, the CRP de novo synthesis could be secreted
under the induction of certain factor. This factor could be
released from endotoxin-stimulated peripheral blood
monocytes or from human T-cell lines obtained from T-cell
lymphoma patients. This factor has been named hepatocyte
stimulating factor type 2 (HSF-2) and is known to be
synonymous with IFN-B2,BSF-2, and IL-6. Thus IL-6 plays a
major role in the tissue-specific induction of particular
acute phase proteins such as CRP.
The study of Moshage et al.(1988) indicated that rIL-1 and
rIL-6 both stimulate the secretion by liver of CRP in an
additive manner and that IL-1 exerts its action on enhanced
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synthesis of CRP at least in part via IL-6.
Castell et al. (1989b) showed that IL-6 stimulates the
synthesis of the full spectrum of acute phase proteins
including CRP.
It has been concluded from these studies that IL-6 plays
the key role in enhanced secretion and regulation of acute
phase proteins synthesis, including CRP by human
hepatocytes.
Castell et al.(1990) suggested that rIL-6 exerts its
regulatory effect on CRP synthesis at the pretranslation
level. IL-6 which is synthesized and secreted by human
monocytes, fibroblasts and endothelial cells on stimulation
by IL-lB and TNF-a, is capable of inducing CRP gene
expression and CRP synthesis.
Taylor et al. (1990) showed that transforming growth factor-
B (TGF-B) released by platelets early in the inflammatory
response modified the production of CRP induction by IL-lB
and IL-6, but it inhibits the IL-6 induced-synthesis of CRP
at a post-transcriptional level in hepatoma cell lines.
A2-Macroglobulin (A2-M) has been shown to bind IL-6,but the
bound IL-6 still retains its biological activity (Matsuda
et al.,1989). It binds transforming growth factor-B (TGF-B)
(Oconnor-McCourt et al. , 1987) which then becomes inactive,
regaining its activity only upon release from the complex.
Taylor et al. (1991) reported that A2-M can completely
neutralize the inhibitory effect exerted by TGF-B on the
IL-6-induced CRP production by human hepatoma cell line
PLC/PRF/5 without affecting the induction of CRP synthesis
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by IL-6. The interaction between A2-M and TGF-B may
influence the production of acute phase proteins by liver
hepatocytes. A2-M binds non-covalently with TGF-B to form
a complex which upon acidification releases TGF-B
inhibitory activity as detected by IL-6-induced CRP
production.
Certain studies have pointed to the presence of co-factors
such as corticosteroids which enhanced the induction of CRP
by cytokines in a dose-dependant fashion in Hep3B cell
cultures. Caffeine also acts as a co-factor in the
induction of CRP by IL-6 and IL-1 in Hep3B cells, and by
IL-6 alone in NLPC/PRF/5 cells (Kushner et al. , 1989).
Studies by Ganathapi et al. (1989) showed that the induction
of CRP in the Hep3B cell line required the combination of
dexamethasone and insulin while neither cytokine alone
induced a significant increase in the synthesis of CRP.
It has been shown that IL-6 alone is sufficient for CRP
production in the presence of dexamethasone in NPLC/PRF/5
(Ganapathi et al., 1988b).
Further studies by Ganapathi et al.(1991) in Hep3B cells,
showed that IL-6, IL-la and dexamethasone can influence CRP
synthesis, while TNF-a alone has no significant effect on
CRP. A detectable effect of IL-6 plus TNF-a was not
observed on CRP synthesis and an increase in the
concentrations of either IL-6 or IL-la lead to a dose-
related increase in CRP synthesis as long as a minimal
amount of the other cytokines was present. Dexamethasone
alone had no effect on CRP synthesis. These studies are in
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agreement with Ganter et al.(1989) studies which showed
that TNF-a acting alone or in combination with IL-6 has no
effect on CRP expression, and the main modulator of CRP
expression is IL-6. Ganter et al. (1989) also showed that
IL-6 action is not enhanced by IL-1B which is unable to
exert any relevant effect.
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1.7 C-reactive protein (CRP)
1.7.1 Historical review
Tillett and Francis (1930) observed that sera from patients
with acute febrile illness reacted with a C-polysaccharide
(CPS) known as fraction C or C-substance, extracted from
the cell wall of Streptococcus pneumonia. Their experiments
showed the early appearance of a precipitin for this C-
substance and that this precipitation reaction is not
limited to pneumococcal infections. The substance
responsible for this precipitation was termed C-precipitin
and was found to occur in a variety of febrile and non
febrile bacterial diseases as well as in non infectious
states.
Abernethy and Avery (1941) reported that this reactive
substance was a protein in nature and confirmed the
results of Tillett and Francis (1930) . They showed that
this reactive substance is capable of precipitating in the
presence of calcium the C-polysaccharide in the sera from
patients with a variety of diseases in the acute phase
stage and considered it as an abnormal protein present only
in the acute phase sera associated with a variety of
pathological conditions but not in healthy sera; their
reports led to its designation as "C-REACTIVE PROTEIN"
(CRP) .
Macleod and Avery( 1941) described an antibody to this CRP
raised in the rabbit called anti-rabbit CRP, and showed
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that sera from healthy subjects are free from CRP.
Anderson and McCarty (1951) confirmed the occurrence in the
rabbit of an acute phase protein analogous to human CRP
which reacts with Cx-polysaccharide in the same manner as
the CRP reaction with C-polysaccharide. They designated it
as Cx-reactive protein (CxRP).
CRP was first found in normal sera in a trace amounts by
Seligman et al.(1959) and this was confirmed by Goldwasser
and Rozansky (1951) . Nilsson (1968) showed that CRP is
present from trace amounts to 4mg/l in sera of healthy
subj ects.
C-reactive protein is a normal human plasma protein which
is present in the sera of healthy subjects, and in the
cerebrospinal fluid (CSF), while it has been reported to be
present also in oral fluids such saliva and gingival
crevicular fluid (Aziz et al., 1990) .
It is considered as a protype acute phase reactant as it is
the first protein that increases during the early stage of
the acute inflammatory response in most forms of injury,
infections, inflammation or tissue damage. It increases
dramatically and rapidly reaching 100-1000 folds of its
normal serum concentrations within 48 hours of an acute
stimulus such as serious trauma or severe inflammatory
conditions as in the case of significant bacterial
infections or active non-infective inflammatory diseases
(Kaplan, 1982; Pepys and Baltz, 1983).
Many diverse functional effects of CRP have been reported
in vitro and in vivo. The proposed immunomodulatory
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functions of CRP are derived from its interactions alone or
via its ligands such as C-polysaccharide (CPS), polyanions,
polycations, lipids and lipolipids with various elements
participating in the inflammatory response. These elements
include polymorphonuclear neutrophils(PMN), macrophages/
monocytes, lymphocytes, complement and finally platelets.
CRP is now a useful diagnostic aid in many diseases
particulary fetal diseases such as cystic fibrosis,
rheumatic fever, rheumatoid arthritis and myocardial
infarction (Kaplan, 1982; Pepys et al.,1981). The current
review of CRP will cover all its aspects with particular
consideration for its role in the inflammatory response and
subsequently with its specific relationship to current C-
reactive protein studies in periodontal diseases.
1.7.2 Biosynthesis of C-reactive protein
Experimental studies of CRP biosynthesis in the rabbit have
been pre-assumed to reflect CRP biosynthesis in man. Two
sites for CRP synthesis have been reported, and these are
hepatic and extra hepatic sites.
1.7.2.1 Hepatic origin of CRP synthesis
The only cells in the liver responsible for CRP synthesis
are the hepatocytes. This was first reported by Hurlimann
et al.(1966) who used isolated liver cell cultures, and has
been supported by Riley et al.(1969), Kushner and Feldman,
(1978), and also by Kushner et al.(1980) who used isolated
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perfused livers and identified the presence of CRP in the
cytoplasms of the hepatocytes of inflamed rabbits where
CRP-producing cells were recruited centripetally from the
portal zone. The recruitment starts in the periportal areas
and then spreads to involve all cells across the liver
lobule during the inflammatory process (Kushner and
Feldman, 1978) .
It has been shown by light microscopic studies that
hepatocytes contained CRP during the acute phase response
while ultrastructural studies confirmed that these cells
are the site of origin of this protein which is localised
to rough endoplasmic reticulum, Golgi apparatus and smooth
endoplasmic reticulum (Kushner and Feldman, 1978; Kushner
et al.,1980). Studies have indicated that, CRP which is
found in serum and in damaged tissue, is formed by
conversion of circulating precursors to pentameric CRP at
sites of tissue injury or at other sites distant from the
liver (Kushner and Kaplan, 1961; Kushner et al. , 1963).
All the above studies indicated that the liver is the
source of CRP in serum and in inflammatory lesions and that
tissue injury results in the induction of CRP synthesis in
hepatocytes. They also indicated that the capacity to
synthesize CRT does not appear to be limited to a
subpopulation of hepatocytes because when maximally
stimulated, virtually all hepatocytes appear capable of
synthesizing CRP.
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1.7.2.2 Extrahepatic origin of CRP synthesis
There is no evidence for CRP production by any organ other
than the liver except from a few investigators (Ikuta et
al. , 1986; Kuta and Baum, 1985,1986), who demonstrated that
a subset of peripheral blood lymphocytes (PBL) which
exhibit natural killer activity are able to synthesize CRP,
which apparently remains bound to the surface of these
cells and is called surface CRP(S-CRP). This S-CRP is not
acquired exogeneously. Kuta et al.(1986) and Baum et
al. (1983) studies showed that CRP expressed by PBL is a
membrane protein that does not appeared to be secreted.
Murphy et al.(1991) demonstrated that human peripheral
blood mononuclear cell (PBMC) express the CRP gene and
based on the studies by Kuta et al. (1986), concluded that
human PBMC can synthesized CRP. This is the first report on
the extrahepatic transcription of human CRP. They also
concluded that hepatocytes may synthesize and release
pentameric CRP which when protected from denaturation
remains inactive until it reaches the site of inflammation,
where the lymphocytes may synthesize and express the
conformating active form.
1.7.3 Secretion, metabolism and kinetics of CRP
synthesis
CRP dramatically increases in concentration in the blood of
many animals in response to inflammatory stimuli or tissue
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destruction and the termination of the process is followed
by a return of CRP levels to normal. CRP is produced by
progressively increasing numbers of hepatocytes after an
inflammatory response and secreted into the serum (Kushner
and Feldman, 1978). Continuous increase in the rate of CRP
synthesis appears to be dependent on continuing exposure to
extrahepatic factors (Kushner et al., 1980).
Rates of CRP synthesis in vitro are more directly related
to the duration of the inflammatory response in vivo and
the serum CRP level at the time that the liver was isolated
in the experimental animals. The post-inflammatory
elimination of CRP is equally rapid with the half life
estimated at approximally 8.9 hours (Kushner et al, 1980) .
The in vivo half life of CRP in the circulation of rabbits
is 4-6 hours and is the same in normal and stimulated
animals, the rapid rate of catabolism reflecting a rapid
rate of synthesis relative to blood levels (Chelladuria et
al. , 1982) .
The functional catabolic rate is the same in stimulated and
unstimulated animals and the amount of CRP catabolized per
day is thus proportional to the plasma concentration (Pepys
et al. , 1983). The kinetics of human CRP response are
compatible with a rate of synthesis and turnover comparable
to those seen with rabbit CRP (Pepys et al. , 1983) .
Studies of human CRP response showed that the peak level of
CRP which is attained, as in the case of myocardial
infarction, is correlated with the severity of tissue
damage (Kushner et and Feldman, 1978), and reaches its peak
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in 2 or 3 days and then comes down fairly quickly. The
level depends on the duration of increased CRP production
rather than upon the initial rate of rise (Kushner and
Feldman, 197 8) .
The experimental studies suggested that a great degree of
tissue injury results in more protracted formation of the
postulated CRP-inducing mediator. This leads to continued
maximal CRP synthesis by the liver for a longer period,
with consequent attainment of higher serum CRP levels. It
is inferred from these studies that the striking and rapid
changes in serum CRP concentration reflect a continuing
rise in the rate of hepatic CRP synthesis, and that CRP is
newly synthesized and rapidly secreted.
Once the induction of CRP synthesis by hepatocytes is
initiated the induction process involves the progressive
recruitment of increasing numbers of hepatocytes to CRP
synthesis. More extensive tissue damage results in
prolonging the induction of CRP synthesis and consequently
in higher serum CRP levels and this may be due to more
protracted activation of the mediator system. After a
variable period of time following stimulus, again related
to the extent of tissue injury, serum CRP levels usually
fall sharply, presumably reflecting sudden diminution in
hepatic synthesis of CRP (Kushner and Volanakis, 1982).
The secretion of CRP is increased during the course of the
acute phase response, and is regulated either by alteration
in the availability of specific receptors on the hepatocyte
membrane or by competition between different secretory
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proteins for common receptors. The secretion by the liver
varies over 1000-fold range depending on the presence and
severity of inflammatory stimuli (Macintyre et al. , 1985) .
Studies on rabbit CRP showed that the hepatocytes retard
the secretion of CRP and this inhibition diminishes as the
acute phase response progresses. The relationship between
the change in synthetic rate and efficiency of secretion is
not a causal one, but both synthesis and secretion are
regulated by independent intracellular mechanisms during
the acute phase response (Shou-Ih Hu et al., 1988).
1.7.4 CRP STRUCTURE
CRP belongs to a family of proteins known as pentraxins, a
name derived from their unique molecular configuration of
polypeptide subunits arranged in groups of five in a form
of disks with cyclic pentameric symmetry (Pepys et al. ,
1985). CRP, complement component Clt and serum amyloid P
component (SAP) are all related to the family of pentraxins
(Pepys et al. , 1985) . They are phylogenetically ancient,
have a unique structure and a calcium-dependent ligand
binding specificity for phosphorylcholine. CRP structure
resembles both the Clt component and SAP in amino acids
sequence homology and appearance under electron microscope
(Osmand et al. , 1977) . The pentameric form of the CRP
molecule has been confirmed by the rotation function
studies of two tetragonal crystal forms of human CRP (Myles
et al., 1991).
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Early studies by Gotschlich and Edelman (1967) showed that
the CRP molecule has a pentramic form consisting of an
aggregate of identical six subunits each having a m.w.of
21,000 daltons corresponding to a total m.w. of 129,000,
daltons held together by non-covalent interactions.
The primary structure of CRP has however been determined by
protein sequencing (Oliveira et al.1979), and consists of
five identical single polypeptide subunits with molecular
weight ranging from 21,000-23,000 daltons; each of these
subunits is noncovalently linked and assembled in annular
disk-like configuration with a cyclic pentameric symmetry
with m.w. ranging from 110,000-to 140,000 daltons for the
intact molecule. The subunit structure consists of a single
polypeptide chain of 187 a.a. with disulfide bounds. Each
subunit, within the intact molecule, binds one or two
calcium ions (Gotschlich and Eldman, 1967).
Robey et al. (1987) found that the primary structure of
human CRP revealed three regions evenly distributed through
out the protein. Each of these regions contains peptide
sequence closely resembling the amino acid sequence of the
immunomodulator peptide tuftsin that is found in the CH2
domain of the Fc segment of the immnoglobulin (Ig) heavy
chain. They concluded that human CRP contains three
peptides resembling tuftsin.
The human CRP gene together with serum amyloid P component
gene is located on the proximal long arm of chromosome 1
(Floyed-Smith et al., 1986; Sehgal et al., 1989).
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1.7.5 FORMS OF CRP
CRP has been reported to exist in two forms: native CRP
which electrophoreses as a gammaglobulin, and fast-CRP (F-
CRP) which electrophoreses as an alpha globulin and which
expresses, upon urea chelation and acid treatment or
heating, an antigenic reactivity form which is distinctive
from that of native CRP (Potempa et al. , 1983a) . The
antigen expressed on F-CRP could be expressed on free
subunits (pre-CRP) of human CRP (Mantzourians et al. ,
1983) .
Potempa et al.(1987) reported that F-CRP represents free
human CRP subunits, and they introduced the term "Neo-CRP"
to describe the antigenicity associated with free CRP
subunits. Potempa et al. (1983a,1987,1988) confirmed that
CRP can be structurally modified by heat, acid, or urea
chelation to express a neoantigen. Potempa et al.(1988)
confirmed that the neo-CRP antigen is not only expressed by
the modified CRP which remains soluble (free CRP subunits) ,
but it could be also expressed on the aggregated fractions.
CRP complexed with CPS in the fluid phase does not express
the neo-CRP antigen.
It has been found that under certain adsorption or
modification conditions, CRP undergoes conformational
alterations leading to the release of CRP subunits from the
pentamer, these subunits having unique surface
characteristics hallmarked by the appearance of neo-CRP
(Potempa et al. , 1983; Potempa et al.1987) .
104
Potempa et al.(1987) also reported that the neo-CRP
molecule has a m.w. of approximately 22,000 daltons, and
the CRP neo-antigen can be expressed on free CRP subunits
without proteolysis. They further reported that the
molecules expressing the neo-CRP antigens are present in
the acute phase plasma as in the case of rheumatoid
arthritis.
Neo-CRP has been reported to be naturally expressed in
tissues at sites of inflammation and necrosis (Zeller et
al. , 1986), and on the surfaces of a subpopulation of human
PBL expressing large-granular lymphocyte morphology and,
interestingly on B lymphocytes (Bray et al., 1988).
CRP subunits may arise in situ by de novo synthesis as well
as by native-CRP dissociation. The release of free subunits
in vivo may occur in the areas of acute inflammation where
hydrophobic sites become exposed on lipoproteins or
necrotic membranes. The forms of CRP expressing neo-CRP
epitope have the ability to activate and/or modulate the
functional responses of platelets, polymorphs and
monocytes(Potempa et al. , 1988) .
Studies by Shan-Ching et al.(1989) using monoclonal
antibodies, demonstrated five epitopes on the native CRP
molecule and three on neo-CRP, with one of the epitopes
expressed on native-CRP being retained on the modified
forms of the molecule.
Since CRP forms expressing the neo-CRP antigen binds to and
stimulate macrophage and neutrophil responses and are even
more protective than native CRP against lethal pneumococcal
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infections, this neo-antigen may well serve as an important
marker for relevant biological functions of CRP.
1.7.6 Serum CRP Levels
For a certain period, following its discovery in 1930 due
to the invalidity and insensitivity of the semiquantitative
techniques used in its detection in serum, CRP was
recognized as the protype acute phase protein associated
with pathological conditions only and not present in sera
from healthy subjects.
The methods used by early investigators (Wood et al. , 1951;
Nilsson et al., 1968) reported serum CRP simply as absent
or present or elevated. Such misinterpretation has limited
its clinical application as a disease marker. Now, due to
the development of reliable, valid and sensitive
quantitative techniques CRP has been appreciated as
normally present as a trace constituent of plasma in all
healthy subjects. The clinical measurement of serum CRP is
valuable as a screening test for a number of organic
diseases and as a sensitive objective index of disease
activity or response to therapy in some inflammatory,
infective and ischaemic conditions (Kaplan, 1982; Pepys et
al., 1981).
CRP is exceptional among human acute phase proteins to be
present at low level in normal healthy subjects (less than
0.1 mg/L),and in the rate and extent of its elevation (up to
3000-fold) in response to acute phase stimuli (Kushner and
106
Volanakis, 1982). CRP rises markedly in concentration in
association with inflammation and tissue necrosis, and it
has been found deposited at sites of cell injury (Kushner
and Volanakis, 1982).
1.7.6.1 CRP levels in healthy subjects
CRP was first reported to be present in sera from healthy
subjects by Seligman et al.(1959) in trace amounts, and
this was confirmed by Goldwasser et al.(1961). Clause et
al.(1976) and Kindmark (1972) demonstrated the presence of
CRP in all normal sera in very small amounts, and their
results indicate that CRP is a quantitative, and not a
qualitative phenomenon. Clause et al. (197 6) using sensitive
radioimmunoassays detected CRP to levels of 3 mg/1. They
also reported that the levels increase rapidly up to 1,000-
fold within 24-48 hours reaching concentrations as high as
300-500 mg/1 during intense inflammatory reactions. They
concluded that all individuals normally have small amounts
of serum CRP with a median level of approximately 0.6 mg/1
and a normal range of 0.07-8.20 mg/1.
Shine et al. (1981) confirmed CRP to be present in trace
amounts in the serum of healthy individuals with a median
value in healthy adults of 0.8 mg/1. They found that the
level of serum CRP in 90% of individuals was less than 3
mg/1 while 99% had less than 10 mg/1. They also reported
that CRP is universally present in serum.
Other studies found that most apparently healthy
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individuals have serum CRP levels less than 0.2 mg/1, but
levels as high as lmg/1 are not infrequently found
(Drahovsky et al., 1981). Levels below 1.0 mg/1 have being
considered as insignificant elevations.
Recently, Shapiro et al.(1989) have drawn a reference
range of 0.05-4.0 mg/1 at 95% confidence interval and up to
10.0 mg at 99% confidence interval,for serum CRP in healthy
adults.
1.7.6.2 Serum CRP levels in diseases
It is evident that a great range of elevated serum CRP
levels above those found in apparently healthy individuals
may be seen in disease. The sera with significant
elevations of CRP are divided arbitrarily into two groups,
moderate elevation (1-10 mg/1) or marked elevation (greater
than 10 mg/1) (Drohorsky et al 1981) . CRP levels rise in
serum within hours of the onset of inflammation, reaching
a peak during the acute stage and decreasing with the
resolution of inflammation or trauma (Pepys and Baltz,
1983) .
In response to most forms of injury, infection,inflammation
, or tissue damage the serum CRP level increases rapidly
and dramatically up to 1000-fold its normal level. It can
reach levels as high as 300-400 mg/1 within 48 hours of an
acute stimulus, and persist at high levels in individuals
with significant bacterial infection or active non-
infective inflammatory disease (Pepys and Baltz, 1983;
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Kushner and Volanakis, 1982).
CRP increases in serum in association with many different
types of inflammation and in response to a variety of
stimuli. Most commonly, it is related to bacterial
infections, ischaemic injury to tissue as in myocardial
infarction, malignant neoplasms associated with tissue
necrosis, physical or traumatic injury such as bone
fracture, surgery or burns, and inflammatory conditions
such as rheumatic fever, rheumatoid arthritis, vasculitis,
and ulcerative colitis (Kaplan 1982). It has been suggested
that the amount of CRP response varies directly with the
degree of tissue injury, with the type of inflammatory
response, and with the organ or tissue involved in the
inflammation. CRP responses occur more frequently in
bacterial than in viral infections (Kaplan 1982) .
Quantitative studies on human CRP responses have revealed
that there are highly significant differences between the
levels attained in response to different diseases (Pepys
1982) which may be due in part to the underlying
pathological process. Although the detection of elevated
levels of serum CRP is not specific for any particular
disease, it is a useful indicator of inflammation.
1.7.7 Binding specificities of CRP
1.7.7.1 Binding at the sites of inflammation
CRP has been detected on the surfaces of necrotic cells at
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sites of inflammation (Kushner and Kaplan, 1961; Kushner et
al. , 1963) and in tissue damaged in several naturally
occurring or experimentally-induced pathological
conditions. Kushner and Kaplan (1961) using direct
immunofluorescence reported CRP deposition in necrotic
skeletal muscle fibers of the rabbit, with a selective
localization to the inflammatory site and absence from
cells from non-inflamed tissues and organs. CRP was
detected in necrotic myofibers in rabbits after an
inflammatory stimulus, but not before its appearance in the
blood. Kushner et al.(1963) reported the deposition of CRP
in damaged myocardium. Tissue localization or deposition
of CRP is reported as selectively associated with acute but
not chronic inflammation (DuClose et al. , 1981) .
There are several reports of CRP deposition in vivo in
human inflammatory conditions. Parish (1977) found
deposition of CRP in cutaneous lesions of patients with
vasculitis. Gitlin et al.(1977) reported CRP localization
in rheumatoid arthritis patients. It has been suggested
that the binding of CRP to necrotic or altered cells may
reflect binding to altered membrane structures,in which
phosphotidylcholine, sphingomyelin, or both were exposed.
In this way it may activate the classical pathway of the
complement system, thus inducing cell lysis and releasing
complement mediators for chemotaxis and removal of necrotic
cell debris (Volanakis 1982; Kushner and Volanakis, 1982).
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1.7.7.2 CRP binding sites
Phosphorylcholine-containing ligands of CRP, polyanions and
polycations are all integral constituents of cells and
likely to be abnormally exposed in or released from damaged
tissues. CRP could function in plasma as a recognition
mechanism for abnormal materials of both extrinsic and
intrinsic origin via its interactions (Pepys, 1982). CRP
does not interact with the intact membranes of healthy
normal cells in vivo or in vitro.
CRP has two distinct but interactive ligand binding sites.
The first one is a calcium-dependent site which binds to
phosphorylcholine residues (Volanakis and Kaplan, 1971),
but can also bind other ligands which lack phosphoryl
choline such as certain bacterial polysaccharides
(Heidelberger et al.,1972) lipids, heparin, nucleic acids
and dextran sulphate (Gotschlich et al.,1982). This binding
specificity of CRP is directed toward phosphorylcholine
(pc) and choline phosphatides. The best ligand for the CRP
molecule is phosphorylcholine (Volanakis and Kaplan 1971)
but it also binds other phosphate mono-esters (Gostchlich,
, 1982) and non-phosphate or choline-containing
polysaccharides (Heidelberger et al. , 1972). CRP has a
capacity for calcium-dependent binding to phosphorylcholine
in C-polysaccharides of pneumococci (Kushner et al.1963;
Gostchlich 1982). The affinity of CRP for phosphorylcholine
is much greater than for other phosphate monoesters, and
choline itself cannot bind CRP (Gostchlich et al.1982).
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The second binding site for CRP does not require calcium
ions and forms complexes with polycations, including poly-
L-lysine, poly-L-arginine, lysine-and arginine-rich
histons, myelin basic protein and leukocyte cationic
protein (Siegal et al. , 1974; DiCamelli et al. , 1980;
Potempa et al., 1981), as well as with positively charged
non phosphorylcholine-containing liposomes (Tsujimoto et
al. 1980) . The poly cation-binding site may be a part of
the phosphorylcholine-binding site or at least be
allosterically modulated by it.
1.7.7.3 CRP binding reactivities
CRP has binding reactivities with various materials.
1.7.7.3.1 Calcium and non calcium-dependent binding
Generally two major groups of binding reactivities have
been reported for CRP.
A. The first group is a calcium-dependent reaction of CRP
with CPS, which has been found to be largely dependent on
specific reactivity with phosphorylcholine groups
(Volanakis and Kaplan, 1971), or as a calcium-dependent
binding with carbohydrate polymers of galactose (Gewurz,
1982) and galactosamine.
1.Calcium-dependent binding with carbohydrates:
CRP interacts in vitro with D-galactose-containing poly
saccharides, including polysaccharides containing
galactosamine (Higginbotham et al., 1970), and certain
polysaccharides similar to Nacetylgalactosamine (Oliveria
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et al., 1980).
2.Calcium-dependent binding with phosphorylcholine groups:
Studies by Volanakis et al.(1971) showed that CRP can bind
directly to phosphate monoesters in presence of calcium
ions, and they suggested that choline phosphate present in
CPS may provide the major reacting site of CPS with CRP.
The phosphorylcholines are found in cell walls of bacteria
as CPS in pneumococci and in other bacteria as well as on
the surfaces of fungi and parasites (Gewurz, 1982) . They
are also present but are not exposed in human cell
membranes as a part of phosphatidyl choline (Gewurz, 1982) .
When human cell membranes are disrupted through injury or
inflammation, their phosphorylcholine groups are exposed
and provide CRP with a potential binding site (Gewurz,
1982).
The functional effects of CRP binding reactivity with
phosphorylcholine-binding site are that in vitro it can
activate complement (Kaplan and Volanakis, 1974) and
enhance phagocytosis (Ganrot and Kindmark, 1969; Mortensen
et al, 1976) . In vivo it protects mice from lethal
infection with Streptococcus pneumoniae (Mold et al. ,
1982). Studies by Nakayama et al.(1984) showed that CRP has
a selectively inhibitory effect on the antibody response to
phosphorylcholines.
B.The second group of binding reactivities for CRP is
calcium-independent binding and involves polycations
including myelin basic protein and leukocyte cationic
proteins (Dicamelli et al., 1980; Siegel et al., 1975) . CRP
113
also shows binding specificity to certain polyanions
(heparin, hyaluronic acid), to other polycations (protamine
sulphate and histone,L-lysine,L-arginine), and to chromatin
and nucleic acids.
Certain polycations, including protamine sulfate, polymers
of L-lysine and leukocyte cationic proteins, could activate
the complement system via their reactivity with CRP (Siegel
et al. , 1975). The concept of a binding reactivity for
polycations is supported by the observations that CRP binds
and reacts with positively charged liposomes, causing
activation of the complement system (Richard et al. , 197 9) .
Studies by Potempa et al.(1981) showed that in the presence
of phosphorylcholine (PC), CRP rapidly precipitated and
formed complexes with polycationic polymers, suggesting a
relationship between CRP-polycation binding site and the
sites for calcium and PC. Their data are consistent with
Oliveira et al.(1980), who reported a 2-locus binding site
on CRP, one requiring calcium and is responsible for
phosphorylester binding, and the other not requiring
calcium and responsible for the binding of the cationic
group of phosphocholines.
Studies by Potempa et al.(1983) indicated that CRP-poly
cation interactions are significantly and selectively
influenced in the presence of small amounts of polyanions
such as heparin, chondroitin sulfate, and hyaluronic acid
but not DNA. Interactions of CRP with the above groups of
ligands may result in activation of the complement system,
and may have a physiologic significance during the acute
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inflammatory process.
1.7.7.3.2 Binding of CRP to Liposomes
Liposomes consist of concentric lamellae of lipid bilayer
membranes. Generally liposomes are composed of
phospholipids such as lecithin or sphingomyelin but they
also may have other lipid consistuents such as cholesterol,
charged lipids, and glycolipids. Liposomes can be prepared
with a marker such as glucose trapped in the aqueous
interspaces that separate the concentric membranes
(Richards et al. , 1977) . Studies of binding of CRP to
liposome model membranes have demonstrated the above two
categories of binding sites and have shown that complement
consumption and membrane lysis can result from these
reactions (Volanakis et al., 1979).
Studies by Richards et al.(1977,1979) indicated that CRP
interactions with liposomes in human serum result in
consumption of hemolytic complement,complement-dependent
membrane damage and release of trapped marker (glucose)
from the liposomes. This reaction requires a positively
charged membrane and is influenced by other variations in
membrane composition.
1.7.3.3 Antibodies
Studies by Ballou et al.(1990), using purified human CRP,
were unable to detect clinically important binding of CRP
to human IgG; monoclonal IgGl (monomeric IgG), polyclonal
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IgG, heat-aggregated IgG, experimentally prepared immune
complexes (ICs) or ICs from human serum samples. They
concluded that native human CRP does not have a clinically
significant binding capacity for immunoglobulin, and the
previously reported presence of CRP in ICs may result from,
or be facilitated by an association with components other
than immunoglobulin such as antigens or complement
components.
1.7.3.4 Fibronectin
Salonenee et al.(1984) reported that immobilized CRP binds
soluble plasma fibronectin, but not in the soluble phase.
Immobilized CRP also was found to bind effectively to
fibrinogen. Fibrinogen competes with fibronectin for CRP
binding sites. They suggest that the CRP deposits may trap
at the site of injury the circulating fibronectin, and
concluded that CRP possibly acts as a fibronectin receptor
in damaged cells. Their results provide a link between
acute phase response and tissue repair.
1.7.3.5 Chromatin (Cr) and Nuclei (Nucleic acids,
Nucleosome core particles)
Chromatin is composed of equal amounts of DNA and histons,
which are organized into repeating subunits known as
nucleosomes (Duclos et al.1991).
CRP binds to several nuclear constituents including small
nuclear ribonucleoproteins (snRNP) (Duclos et al.1990).
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Studies by Robey et el. (1984) showed that CRP binds to
chromatin and chromatin fragments which may be present in
the extracellular milieu at sites of tissue damage. This
binding in the presence of complement could lead to
chromatin degradation into nucleosome-sized fragments.
Shepherd et al.(1986) reported binding of human and rat CRP
to their respective autologous liver nuclei. This binding
is mediated by a CAP polycation site.
Studies by Duclos et al.(1991) reported CRP binding to
native sub-nucleosomal and chromatin fragments, and
demonstrated chromatin binding to histones H2A-H2B diamer
and (H3-H4) tetramer. They concluded that CRP binds to
nucleosome core particles, and their results indicate that
CRP binding sites include H: and part of other histons in
chromatin.
The functional effects of CRP binding to chromatin:
Binding causes chromatin solubilization and degradation
(Robey et al. , 1984). It enhances micrococcal nuclear
digestion when bound to nuclei, and this enhancement
indicates that CRP binding could alter the chromatin
structure and leads to increase in the rate of chromatin
digestion.
CRP may act as a scavenger of chromatin fragments released
from damaged cells, and may help mediate the removal of
chromatin and/or chromatin fragments from the body after
cell death provided the barriers separating CRP from
chromatin are destroyed (Robey et al., 1984). Thus CRP may
play an important role in the recognition and clearance of
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nuclear material from damaged cells (Robey et al., 1984).
Duclose et al.(1990) reported that CRP is rapidly and
effectively transported into the nucleolus of mammalian
cells. Their studies also showed significant similarities
between CRP and nucleoplasmin in nuclear localization
activity. They concluded that one possible effect of CRP
localization would be an alteration of RNA processing and
initiation of the degradation process of nuclear chromatin
of damaged cells to fragments resembling nucleosomes. Thus,
CRP may play a unique role in injured cells to alter
processing of damaged nuclei.
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1.7.8 CRP interactions with cellular elements of
immune system, and complement system
CRP interacts with the cellular elements of inflammation
, including neutrophils (polymorphs), monocytes /macrophages,
lymphocytes, and platelets, as well as with complement
system.
1.7.8.1 CRP interactions with Neutrophils (Polymorphs)
Many studies have been conducted on the interaction of CRP
with polymorphs (PMN). CRP interacts with neutrophils in
vivo and in vitro (Shephard et al. , 1986; Zeller et al. ,
1986; Muller et al., 1986; Butch a et al., 1987a).
In general native CRP alone is ineffective in stimulating
human PMN (Shephard et al., 1986; Zeller et al.,1986) .
However under certain conditions, some forms of complexed
or aggregated CRP both bind to and modify biological
activities of human PMN (Shephard et al., 1986; Kilpatric
and Volanakis, 1985; Muller et a., 1986).
The biological activities modified, include stimulation of
motility (Wood, 1951; Butcha et al. ; 1987b), enhancement of
attachment to endothelium (Muller et al.1986), phagocytosis
(Kindmark,1971;Morstein et al., 1977; Garnot and Kindmark
1969), and superoxide anion production (Dobrinch and
Spagnulo, 1991).
a.Binding:
Several studies have shown that PMN possess a specific cell
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surface receptor for CRP, which may be either associated
with, or identical with, IgG Fc gamma receptor, in as much
as aggregated IgG can act as a competitive inhibitor of CRP
binding (Muller et al. , 1986; Shephard et al. , 1986;
Kilpatrick and Volanakis, 1985; Zeller et al.1986,Butcha et
al.1987b Shaphard et al., 1986; Dobrinch and Spagnuolo
1991; Ballou et al. , 1989). The presence of specific
binding sites for CRP on neutrophils supports the concept
of CRP acting as a nonspecific opsonin,
b.Phagocytosis:
CRP has been shown in vitro to have an influence on PMN
phagocytosis. Aggregated CRP at high concentrations
activates complement, thereby attracting PMN and inducing
release of lysosomal enzymes (Parish, 1977).
Studies have reported that native CRP complexed with
pneumococcal C-polysaccharide (Pn-CPS) has an opsonic
activity for human PMN phagocytosis. In these studies it
was found that the opsonic activity is dependent on both
the ability of CRP to activate complement and the presence
of phosphorylcholine in the bacterial capsule [Mold et al. ,
19 82; Edwards et al. , 1982; Kindmark, 1971; Garnot and
Kindmark, 1969 ; Mortensen et al., 1976) .
Kilpatrick and Volanakis (1985) showed that stimulated
neutrophils can be induced to phagocytose Pn-CPS-CRP
complex, and that both Pn-CPS and CRP-mediated interactions
with the neutrophils are necessary for generation of the
phagocytic signal. They concluded that native CRP function
is to variously enhance phagocytosis by acting as an
120
opsonin. Shephard et al.(1986) concluded that the uptake
of CRP and CRP-CPS complexes into neutrophils appears to be
via a specific CRP-dependent mechanism, independent of
complement activation.
Klipatrick et al.(1987) demonstrated that lymphocytes
release a low m.w.soluble factor(s) or a modulator(s) that
induce(s) phagocytosis of CRP-coated cells by activated
PMN. This phenomenon occurred under conditions similar to
those in vivo.
The above studies and those which demonstrated binding of
soluble CRP to PMN (Muller et al. , 1986; Butcha et al. ,
1987b; Bullou et al. , 1989) support the primary opsonic
role for CRP and suggest that the major immuno-modulatory
function of CRP is enhancement of phagocyte clearance
mechanisms. So it could be concluded that CRP acts as an
opsonin for PMN and has a biological property in its
ability to recognize foreign pathogens and initiate their
elimination by interaction with the complement system and
stimulated PMNLs.
C.PMN response to CRP:
Migration, adherence and chemotaxis:
Muller et al. (1986) showed that CRP interaction with PMN
IgG Fc receptors mediates the adherence of the PMN and this
may be important in the localization of the inflammatory
focus.
Wood (1951) showed that soluble CRP stimulates the directed
migration of PMN. Native CRP has been shown either to
inhibit chemotaxis (Butcha et al. , 1987a),or to have an
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influence on chemotaxis (Robey et al. , 1987; Shephard et
al., 1986) .
CRP can inhibit neutrophil chemotaxis in vitro at high
concentrations when it may control the inflammatory
response by down-regulating neutrophil migration(Kew et
al., 1988,1990).
Chemiluminescence (CL):
Zeller et al.(1986) found that aggregated CRP (but not
native CRP) binds to and selectively modulates the response
of PMN to IgG Fc receptor-induced respiratory burst
activity measured by chemiluminescence.
The studies by Potempa et al.(1988) showed that neo-CRP
consistently, and in a dose-dependent manner, potentiated
the respiratory burst response of human PMN to heat-
modified IgG. Conversely Tatsumi et al.(1988) found that
platelet activating factor (PAF)-induced chemiluminescence
of neutrophils was suppressed by native CRP.
Superoxide anion production:
Dobrinch and Spagnuolo (1991) demonstrated that purified
human CRP impairs the oxidative capacity of neutrophils
(PMN) by two mechanisms. One mechanism is through
interaction with receptors on neutrophils causing direct
cell inhibition, while the other is by direct antioxidant
activity causing scavenging of superoxide anion. CRP may
thus have a regulatory role in oxygen-radical production
during the inflammatory response in a dose dependent
manner.
Relatively high levels of purified native CRP can inhibit
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superoxide anion generation in vitro (Kew et al. , 1986) .
Butcha et al. (1987a) reported a dose dependence of
neutrophil response to CRP. An initial stimulation of PMN
function at low CRP concentrations, which includes
enhancement of directed migration of PMN with maximal
effects at lmg/1 has been found, with slightly potentiated
activation of oxygen generation and secretion by certain
agents at concentrations up to 5 mg/1. With increasing
concentrations of CRP (above 10 mg/1) an inhibition of
superoxide anion production, chemotaxis and vitamin B12-
binding protein secretion was observed.
The kinetics and dose dependence of the neutrophil response
to CRP appear to be ideal for a physiological inhibitor of
the potential tissue toxicity resulting from neutrophil
functions. A low level of CRP could allow full expression
of such functions with maximum damage to the infecting
agent but with increasing CRP levels,'super-activation' of
phagocytes would be prevented, thereby minimizing damage to
the host. Thus CRP may function as a negative feedback
mechanism for the potentially cytotoxic neutrophil
functions, limiting phagocytic oxidative mechanisms, and
down-regulating the inflammation.
Butcha et al. (1988) found that human CRP causes a dose-
dependent decrease in the extent of activation of
superoxide production, granule secretion, and protein
phosphorylation in stimulated neutrophils. Binding of CRP
to PMN appears to play a dual role. At concentrations of
lmg/1 or less CRP elicits PMN chemotaxis and phagocytosis.
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At higher concentrations (>10mg/l) it may inhibit oxygen
radical generation, superoxide production and secretion,
chemotaxis, and protein phosphorylation (Butcha et al.1988;
Butcha et al.1987a].
Neutrophil (polymorphs) response to the peptides of
degraded CRP:
Degradation of CRP by neutrophils may result in release of
peptide fragments, whose effect may be different to that of
native CRP (Robey et al., 1986) .
Robey et al.(1987) found that in vitro native CRP did not
induce phagocytic leukocytes either to chemotax or to
produce superoxide. Proteolysis or degradation of purified
CRP in vitro by human neutrophil-derived acid proteases
produced peptides with potent immunoregulatory properties
on leukocyte function, similar to those of tuftsin
molecules. These properties include stimulating phagocytic
cells to chemotax, the production of superoxide, and
induction of mononuclear cells to produce IL-1 at
concentrations similar to those required for tuftsin to
also induce these phenomena.
Shephard et al.(1988) found that CRP intralysosomally
processed by enzymes, resulted in soluble peptides of m.w.
<14000 dalton which at a concentration of 2mg/l modulate
neutrophil functions, including inhibition of chemotaxis,
superoxide production, degranulation and phagocytosis.
The studies of Shephard et al. (1989) indicated that CRP-
derived peptides at an inflammatory site resulted from CRP
degradation by neutral serine protease of the membranes of
124
PMA-stimulated neutrophils. These peptides can inhibit many
of the proinflammatory functions of PMN such as superoxide
production,and can oppose the tissue destructive potential
of these cells. They concluded that CRP functions as an up
regulatable substrate for membrane-associated neutrophil
serine protease(s).
Shephard et al.(1990) reported that small soluble peptides
are produced in vitro when CRP is degraded with non-
stimulated or PMA-stimulated PMN and purified neutrophil
membranes. They demonstrated that three of these peptides
(CRP-III,CRP-IV,CRP-V) significantly inhibit chemotaxis,
and superoxide production from activated neutrophils at
high concentration. They concluded that CRP serves as a
dramatic upregulatable substrate yielding bioactive
peptides on degradation that oppose the tissue destructive
potential of activated PMN.
The above studies together with those of Dobrinch and
Spagnuolo (1991) support the notion that CRP may have a
regulatory role in oxygen-radical production during acute
inflammation in a dose dependent manner.
CRP peptides: based on the observation that the primary
structure of human CRP contained three regions with peptide
sequences closely resembling the amino acid sequence of the
phagocytic stimulator tuftsin (Robey et al.1987), it was
proposed that CRP acts as a substrate for phagocyte derived
enzymes which liberate bioactive peptides at the sites of
inflammation(Robey et al. , 1987; Shephard et al. , 1988) .
Peptides generated when CRP is degraded by neutrophil
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lysosomal enzymes (Robey et al. , 1987; Shephard et al. ,
1988), modulate certain aspects of the acute phase
response. Peptides generated in this way were shown to
inhibit various classical neutrophil functions (Shephard et
al., 1989; Robey et al., 1987; Shephard et al., 1988) and
inhibit platelet aggregation (Fiedal et al. , 1988) . Cleaved
forms of CRP, containing the tuftsin sequence Thr-Lys-Pro-
Arg, either enhance (Robey et al. , 1987), or inhibit
(Butcha et al. , 1986) PMN chemotaxis, lysosomal enzyme
release, and superoxide anion generation.
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1.7.8.2 CRP interactions with Monocytes/Macrophages
a.Binding:
Several investigations in vitro have showed that CRP has a
specific binding site on monocytes/macrophages (Kearney et
al. , 1982; Whisler et al. , 1983; Mortensen, 1982; Zeller et
al. , 1986; Honda et al. , 1987) . Murine and human monocytes/
macrophages also express membrane CRP (MCRP) receptors
(Zahedi et al., 1988; Zeller et al., 1989). The MCRP occurs
as a membrane-associated protein expressed on liver when it
helps in galactose-specific binding of certain ligands
(Kempaka et al., 1990).
Studies indicate that CRP binds to human monocytes at a
site physically associated with but distinct from IgG Fc
receptors, and CRP-reactivity may be influenced by an
association with this receptor (Zahedi et al. , 1988; Zeller
et al. , 1989; Ballou et al. , 1989; Tebo and Moretensen ,
1990; Ballou and Cleveland, 1990). CRP is generally assumed
to be produced and secreted by hepatocytes and presumably
the liver macrophages acquire CRP as secondary phenomenon.
b.Phagocytosis:
CRP has been shown to have an influence on phagocytic
activity of monocytes/macrophages. The presence of CRP on
particle surfaces has been reported to facilitate their
ingestion by human monocytes(Mortensen et al, 1976), and
mouse macrophages (Mortensen and Duszkiewicz, 1977).
Mortensen et al.(1977) showed that the presence of both CRP
and cleaved-complement components (C3b,C4b) on the
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particles as erythrocyte membranes was necessary for the
efficient attachment and uptake by the macrophages. CRP
complexes bind to murine human macrophages and in the
presence of complement can be ingested by these cells in
vitro.
c.Monocytes/Macrophages response to CRP:
Aggregated or complexed CRP with its ligand can interact
with human monocytes (Zeller et al., 1986b; Zeller et al.,
1986a; Janco et al.,1983).
Inhibition of precursor cell recruitment:
Marcelletti et al.(1982) reported that high CRP
concentrations specifically inhibited the in vitro clonal
proliferation of normal granulocyte-macrophage precursors
which possess IgG Fc-receptors and are committed to the
mononuclear phagocyte lineage. CRP has no effect on
macrophage progenitor cells stimulated by an inflammatory
response.
Mortensen (1983) reported that CRP selectively inhibited in
vitro normal monocyte colony formation of granulocyte-
monocyte colony forming cells derived from bone marrow .
The results are consistent with a regulatory role for CRP
during monocytopoiesis induced by inflammation.
The above studies suggest that CRP functions as a negative
feedback regulator of the cellular composition of the acute
phase of an inflammatory response.
Immunomodulatory effect of CRP on monocytes/macrophages:
CRP in a monomeric form, complexed with its ligands or
aggregated has been shown to act as a immunomodulator of
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macrophage/monocyte function.
PAF-induced activation of monocytes has been shown to be
inhibited by CRP in vitro (Tatsumi et al., 1988). CRP has
also been shown to have migration inhibition factor (MIF)-
like activity (Whisler et al. , 1986). Barna et al.(1984)
demonstrated that liposome-associated CRP is readily
endocytosed by macrophages and enhances both superoxide
anion production and tumoricidal activity of macrophages.
Zahedi and Mortensen (1986) found that purified CRP
activated inflammatory mouse macrophages to a tumoricidal
state independently of both lipopolysaccharides and
lymphocytes.
Barbara et al. (1987) found that purified human CRP
activated monocyte-mediated cytotoxicity and oxidative
metabolism,in a dose-dependent manner when exposed to acute
phase serum levels of CRP in vitro. So CRP may serve as a
biologically relevant macrophage activator/ monocyte
modulator contributing to the nonspecific host response
associated with the early stage of the acute inflammatory
response.
Zeller et al. (1986a) demonstrated that aggregated-CRP
selectively augments Fc receptor-mediated stimulation of
monocyte oxidative metabolism, the respiratory burst
activity being measured by chemiluminescence. They
suggested a significant role for CRP in the modulation of
monocyte activity at the site of inflammation.
Honda et al. (1987) suggested that the initial CRP binding
to monocytes and the subsequent internalization initiate
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the synthesis of IL-1.
Whisler et al.(1986) showed that low concentrations (but
not high) of CRP (2.5-10 mg/1) increased monocyte
chemotaxis. CRP alone is sufficient to result in some
increase in procoagulant activity (PCA), and causes further
increase in PCA in the presence of CPS and immune
complexes. CRP plays a role in modulating the chemotaxis
and (PCA) of monocytes during the early stages of
inflammation.
Barna et al.(1988) found that CRP at high level induced a
dose-dependent cytotoxicity in human alveolar macrophages
in vitro. This supports the previous studies by Barna et
al.(1984), which showed an enhancement of tumoricidal
activity in macrophages in experimental animals in vivo and
in vitro, and in human monocytes exposed to CRP in vitro.
Robey et al. (1987) found that in vitro native CRP did not
induce macrophages/monocytes to chemotax or to produce
superoxide. Proteolysis or degradation in vitro of purified
CRP by human neutrophil-derived acid proteases resulted in
peptides with potent immunoregulatory effects, similar to
those of tuftsin molecules. The effects include stimulating
monocytes to chemotax, production of superoxide, and
induction of mononuclear cells to produce IL-1 at
concentrations similar to those required for tuftsin to
induce similar phenomena.
Activation of monocytes/macrophages significantly augmented
by proteolytic fragments of CRP (Robey et al. , 1987;
Shephard et al., 1988, 1989, 1990) . The proteolytic
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fragments activate macrophages in a similar way to tuftsin
or substance P (Robey et al., 1987; Shephard et al., 1988,
1989,1990) with stimulation of monocyte phagocytosis,
chemotaxis, superoxide and IL-1 production (Garnot and
Kindmark, 1968). Such activating fragments may be generated
early in infective diseases by proteases released from
necrotic cells including granulocytes or from the
infective agents. The fragments could also be generated
within macrophages during endocytosis or phagocytosis of
ligands opsonized either by S-CRP or by their MCRP, thereby
connecting the opsonic activity with activation of the
immune system.
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1.7.8.3 CRP interactions with Lymphocytes
a.Binding:
Interaction of CRP with lymphoid cells:
Purified CRP alone does not detectably bind to lymphocytes
(James et al.1981a), but in the presence of an appropriate
ligand such as pneumococcal CPS or phosphocholine it can
bind to normal lymphocytes, particularly those with the IgG
Fc receptor. Binding is increased in the presence of acute
phase sera such as occurs in rheumatoid arthritis and
streptococcal infections (William et al., 1980). The
studies of James et al.(1981b) indicated that CRP-binding
occurs with T cells, B cells, and null cells. The studies
also indicated that CRP-binding cells predominantly
represent a subset of cells bearing Fc receptor, and these
cells have the morphological characteristics of large
granular lymphocytes. Subsequently James et al.(1983)
demonstrated the presence of S-CRP on the surfaces of
lymphocytes. Studies have indicated the presence of CRP
antigenicity on the surface of lymphocytes involved in the
mediation of natural killer activity ((Kushner and
Volanakis, 1982) .
Kuta and Baum (1986) suggest that some lymphocytes, the
large granulated lymphocytes (LGL), produce small amounts
of CRP themselves and express it on their cell surfaces,
the surface CRP (S-CRP) not being acquired exogenously from
trace levels of CRP in normal serum. The lymphocytes that
produce S-CRP in this way apparently do not secrete CRP
into serum or tissue fluids.
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Ikuta et al.(1986) reported the synthesis and secretion of
CRP by peripheral mononuclear cells in culture, under the
stimulation of a factor derived from activated monocytes.
They suggest that this factor is relevant to metabolites of
an arachidonate cascade.
The findings of Samberg et al. (1988) indicate that a
molecule identical to a neo-ant igenic form of CRP is
present on the surface of a significant proportion of
normal human lymphocytes. They also demonstrated the
preferential expression of neo-CRP, and not native-
CRP,epitopes on these cells.
Bray et al.(1988) demonstrated that a neo-antigenic form of
CRP, or a cross-reactive molecule, is present on the
surface of natural killer cells and B cells, and suggest
that this molecule (neo-CRP) may be physically associated
with Fc gamma receptors present on these cells.
CRP effects on Lymphocytes:
Binding of CRP to T-lymphocytes can result in modulation of
their functional characteristics in vitro. Hornung et al.
(1971) showed that low levels of purified CRP stimulated
lymphocyte blastogenesis, while Hokama et al.(1973) found
inhibition of phytohaemagglutinin (PHA)-stimulated
blastogenesis. They suggest that serum CRP is responsible
for the depression of the lymphoblastogenic response to
mitogens that is observed in many disease processes.
Mortensen (1975) reported that CRP binds selectively to T-
lymphocytes (TL), inhibits their ability to form
spontaneous rosettes with sheep erythrocytes, and also
133
inhibits their response to allogenic cells in mixed
lymphocyte culture (MLC) reactions. CRP was effective in
inhibition of blastogenesis in undirectional MLC reactions.
CRP failed to inhibit phytohaemagglutinin (PHA) or
concavalin A (Con-A)-induced mitogenesis.
Mortensen (1975) also reported that CRP does not bind to B
lymphocytes (BL) nor does it alter their functions such as
their ability to activate complement components (C3b),
binding to a portion of Ig (IgG), or the mediation of
antibody-dependent cytotoxicity (ABDC) reactions.
Mortensen and Gewurz (1976) reported that CRP bound to
murine T lymphocytes, inhibited mixed lymphocyte reaction
and the generation in vitro of cytotoxic T-cells.
Mortensen et al. (197 9) reported that human CRP, added to
murine cultures, inhibited in vitro induction of T
lymphocyte-dependent IgM and IgG antibody formation, by a
CRP-mediated generation of a suppressive T-cell population.
CRP may thus have an immunoregulatory function that limits
the cellular response during inflammation.
Crofts et al. (197 6) found that CRP binds to lymphoblasts
formed upon stimulation with antigens but not with
mitogens. Collectively CRP reacted selectively with a
subpopulation of T-lymphocytes and influenced certain T-
cell-dependent functions.
Mortensen (1976) showed that purified human CRP inhibits
antigen-induced lymphocyte proliferation, chemotactic
factor (lymphokine) production and both antigen- and
mitogen (PHA, Concavalin A)-induced MIF (macrophage
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inhibition factor) formation. CRP decreased the production
of MIF and Migration chemotactic factor (MCF) from both
antigen and mitogen-stimulated lymphocytes (Mortensen et
al. , 1977) . The studies of Mortensen (1977) indicated that
CRP mediates the suppression of antibody induction to T-
dependent, but not T cell-independent, antigens by
interaction with T cells and thus generating the suppressor
T-cell population. The results demonstrated CRP-mediated
inhibition of the antibody plaque forming cells response to
T-dependent but not T-independent antigens.This inhibition
required the presence of CRP-binding T-cells.
Mortensen (1982) found that the pokeweed mitogen (PWM)-
induced generation of polyclonal-secreting cells was
inhibited,in a dose-dependent manner by both purified human
CRP and CRP-CPS complexes. CRP and CRP-CPS complexes
mediated suppression by binding and activating monocytes
and T cells with IgG Fc receptor. These findings indicate
that CRP has the potential to modulate antibody response
during the course of an inflammatory response.
CRP enhances cell-mediated cytotoxicity at pathological
concentrations in a dose-dependent manner (Veter et al. ,
1983) , and in vitro CRP and CRP-CPS complexes significantly
enhance cell-mediated cytotoxicity, minimally enhanced the
mixed lymphocyte reaction, and induce a small but regularly
detectable blastogenic response in resting PBL.
The studies of Whisler et al.(1983) showed that CRP
considerably augments the early development of B-cell
colonies.This augmentation is maximal during the initial
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stages of colony formation. Thus relatively modest
concentrations of CRP can promote focal B cell
proliferative responses, and so one of the biological
functions of CRP is the ability to modulate the activities
of the B cell system.
Wangel and Kontiainen (1983) suggested that high levels of
CRP induce human peripheral blood mononuclear cells to
elaborate a suppressor factors(s) with an effect in vitro
on polyclonal B cell activation. The factor suppresses the
plaque forming cell response in three major Ig classes in
a similar manner to that of Concavalin A generated
suppressor factor in respect to its time of action, its
effect on the Ig classes M, G and A, its lack of
cytotoxicity and some structural aspects.
Whilser et al.(1986) found that CRP inhibited the promotion
of B-cell colony formation by autoactivated T cells. CRP
directly reduced T4 helper cell promotion of colony
formation rather than inducing T8-mediated suppression of
the T4 cells. Their studies demonstrated that CRP can
directly reduce the ability of autoreactive T4 cells to
expand the B-cell compartment, and block T-cell activation
events proximal to proliferation.
Vetter et al.(1986) concluded that the most significant
effect of CRP on lymphocytes is a substantial increase in
cell-mediated cytotoxicity. CRP enhancement of the killing
generated in a mixed lymphocyte culture is due to
enhancement of the cytotoxic T-cell response. This
enhancement may serve both to increase the specific
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cytotoxic T-lymphocyte (CTL) response and to broaden the
specificity of the in vivo cell-mediated cytotoxicity
response, since physiological concentrations of CRP are
elevated 24-48 hours after infection.
CRP and Natural Killer (NK) Activity:
The results of Baum et al. (1983) demonstrated that CRP is
present on certain NK effectors, and that the cell-surface
CRP and not the fluid-phase CRP is involved in the
mediation of NK activity, suggesting that the involvement
is at the level of the effector cell.
Baum et al. (1987) suggest that although CRP appears to be
involved in NK-mediated killing, it is not involved in
effector target cell-mediated recognition. Their studies
confirmed the previous studies that S-CRP is involved in NK
responses.
Hamoudi and Baum (1991) provided evidence which indicates
that anti-CRP blocks NK-mediated lysis at the calcium
dependent stage of lysis. Events that follow this stage in
the lytic process are also inhibited. They reported that
this inhibition occurs during a calcium-dependent stage
that immediately follows conjugate formation. This provides
direct evidence that CRP involvement is a post-binding
event.
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1.7.8.4 CRP interactions with the complement system
Activation of the complement (C) system by CRP was first
demonstrated by Kaplan and Volanakis (1974), who reported
complement interaction with CRP complexes such as those
with pneumococcal C-polysaccharide, choline phosphatides,
lecithin and sphingomyelin. This activation induced
complement consumption with marked depletion of the early
acting complement components CI, C2, C4, and to a lesser
degree complement components C3-C9 via the classical
pathway independent of the presence of specific Ig. The
reaction resulted in electrophoretic conversion of
complement component C3, indicating that an effective C3-
convertase had been formed. Interaction of CRP with lipid
emulsions containing cholesterol and other phospholipids
also resulted in classical pathway activation of
complement.
Segial et al.(1974) found that the polycation protamine
sulphate induces consumption of complement in acute phase
serum by interaction with CRP, and this interaction
involves activation of the primary classical pathway at the
level of complement component CI.
Volanakis and Kaplan(1974) reported that the presence of
complement Clq is a selective requirement for complement
activation by CRP complexes.
Claus et al.(1977a) reported interaction of CRP with
complement Cb at the level of complement Cql in a similar
way to immunoglobulin. Studies by Jaing et al.(1991)
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indicate that a conformation-determined region on CRP binds
to a sequence-determined region on the collagen-like region
(CLR) of Clq leading to complement activation.
Segial et al.(1975) reported that CRP interaction with
polycations such as poly-L-lysine polymers and other
naturally occurring polycations such as leukocyte cationic
protein, arginin-rich histones, and myelin basic protein
resulted in complement activation with depletion of
complement components CI to C5 as well as early complement
components. Osmand et al.(1975) found that CRP initiated
complement-dependent passive haemolysis of cell coated C-
polysaccharides. It was subsequently shown that CRP
interaction with erythrocyte-pneumococcal-CPS and serum or
complement components resulted in the deposition of
fragments of C3b and C4b on the cells which could mediate
the adherence of such cells to both B lymphocytes and
monocytes expressing receptors for complement components.
This resulted in enhanced phagocytosis by monocytes
(Mortensen et al., 197 6) . This mediation by CRP of
reaction, adherence and phagocytosis by monocytes and B-
cells points to the significant role of CRP in host
defence.
CRP may augment phagocytosis by two distinct routes,
serving as an opsonin and possibly increasing the
activation of phagocytic cells (Mortensen et al. , 1976) .
Claus et al. (1977b) reported that CRP significantly
enhanced the activation of complement by salt-like
polyanion-polycation complexes. Examples of polyanions are
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heparin, DNA, hyaluronic acid, chromatin sulfate, and
dextran sulfate while examples of polycations are
protamine sulfate and poly-L-lysine.
Volanakis and Narkates (1981) reported that liposomes with
a particular lipid composition bind CRP in the membrane
leading to classical complement pathway activation, and the
lipsome-bound CRP could then bind human Clq,the recognition
protein of the classical pathway.
Miyazawa and Inoue (1990) found that even in the absence of
phosphocholine-containing or polycation-containing ligands,
CRP can cause complement activation in mildly acidic
conditions, which are within the physiological range
normally found at an inflammatory locus.
The previous studies indicated that CRP-initiated
complement activation can proceed to opsonization, and
suggested that these reactions may occur in vivo since CRP
has been demonstrated to be deposited on damaged tissue at
sites of inflammation. CRP may thus cause complement
cleavage product generation at inflammatory sites and also
mediate the subsequent clearance of damaged cells or
cellular constituents from these sites.
Volanakis.(1982) showed that CRP-C-polysaccharide
precipitates can be solubilized by the action of human
complement, the reaction resulting in the deposition of
complement proteins on both CRP and pneumococci. Their
studies presented preliminary evidence for covalent binding
of C3 fragments to CRP and pneumococci.
Edwards et al. (1982) reported that CRP greatly enhanced the
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complement-mediated chemiluminescence (CL) response of PMN
to pneumococci type 27 in normal serum and in serum lacking
Ig. These findings support the concept that CRP plays a
protective role in bacterial infection.
Berman et al.(1986) showed that CRP-complement classical
pathway activation is restricted to the early parts of
complement activation (CI, C4, C2, and to lesser extent C3)
but does not involve significant consumption of complement
components C5-C9 (membrane complex attack) and so
complement-mediated lysis does not occur. They concluded
that CRP binding to nucleated cells leads to complement
activation without cytolysis as no activation of membrane
complex attack occurs.
Mold and Gewurz (1981) showed that CRP in contrast to Ig,
inhibits alternative pathway activation by either
pneumococci, streptococci or liposomes. CRP binding to
membrane or bacterial surfaces can convert them from
alternative pathway activation to classical pathway
mechanisms. Mold et al.(1984) showed that CRP inhibition of
the pneumococcal activation of complement alternative
pathway is due to increasing the interaction between factor
H and C3b on pneumococcal surfaces, which causes inhibition
of C5 converatase activity of both classical and
alternative pathways. This phenomenon may limit the
complement reaction beyond C3, and may prevent damage by
C3-C9 at the sites of inflammation while at the same time
allowing effective opsonization. Either type of CRP
binding,i.e.calcium-dependent binding to phosphocholine-
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containing pneumococci, and calcium-independent binding to
polycation liposomes, could result in both classical
pathway activation and alternative pathway inhibition.
Generally once CRP bound to phosphocholine-containing cell
walls (necrotic or damaged but not normal cells),
aggregated by heat and has reacted with phosphorylcholine
-containing or cation-containing ligands or reacted with
polycation-polyanion complexes, it can activate the
classical complement pathway effectively (Kaplan and
Volanakis, 1974; Volanakis and Kaplan, 1974; Siegel et al. ,
1975, Osmand et al., 1975; Claus et al., 1977a,1977b) . This
activation occurs by Clq and CI activation, and does so as
effectively as IgG antibody.
All the functional and biological effects of complement
activation are generated by CRP, including opsonization by
fixation of C4b and C3b and by lysis (Mortensen et al. ,
1976; Mold et al., 1982, Osmand et al.1976). When CRP binds
to some of its ligands, including positively charged
liposomes and whole pneumococci, it inhibits activation of
the complement alternative pathway and initiates instead
activation by the classical pathway (Mold and Gewurz, 1981;
Mold et al., 1984), which involves the attachment of CRP to
the activating surface.
CRP reactivity with complement and effects on phagocytosis:
CRP may function in host defence. In the presence of
complement, CRP appears to have opsonic properties. The
reactivity of CRP with a variety of substances ( e.g.
microbial products, damaged tissues) released or exposed as
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a result of inflammation, or in association with model
membranes, and cationic molecules, has been shown to result
in activation of the classical pathway (Edwards et al.,
1982) . Thi3 leads to complement-dependent phagocytosis by
a process for which the presence of CRP is required. In the
case of human CRP, there is no doubt that complement
activation can then generate chemotactic factors and the
opsonic fragments of fixed complement proteins. CRP and
complement were found to stimulate ingestion of
erythrocytes by human monocytes or mouse macrophages in
vitro (Mortensen et al. , 1976, Mortensen et al. , 1977),and
to alter clearance patterns in vivo (Nakayama et al. ,
1982).
The biological importance of CRP interaction with
complement indicates the importance of complement
activation products in the elimination of foreign antigens.
The functions of CRP may relate to its ability to
specifically recognize cellular elements carrying
phosphocholine which is available for reaction and this may
then initiate their elimination by interaction with
complement system.
Studies in vivo have demonstrated that CRP can activate the
classical pathway of complement after complexing with
certain polyanions or pneumococcal capsular C-
polysaccharide antigen (Kaplan and Volanakis, 1976), which
then enhances opsonization (Edwards et al. , 1982).
There is evidence from in vitro studies with monocytes
that, following complement fixation by CRP binding to a
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particular ligand, the presence of both CRP and fixed
complement is required for internalization (Mortensen et
al. , 1976; Mortensen and Duskiewicz, 1977) . Mortensen et al
(1977) found that enhanced phagocytosis was dependent on
both the presence of CRP and the deposition of fragments of
C3 and C4 on the indicator cells. Mortensen et al.(1977,
1976), Claus et al. (1977a,b) and Edwards et al.(1982)
reported that enhancement of phagocytosis by mouse
macrophages was mediated through a direct interaction of
CRP with macrophage Fc receptors which activate the
classical complement pathway and enhance opsonization.
Comparable results have been obtained in vivo in mice (Mold
et al., 1982).
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1.7.8.5 CRP interactions with Platelets
Many investigations have been carried out on CRP
interaction with platelets, and controversial results
obtained.
Fiedal and Gewurz (1976a) found that CRP, in a dose-
dependent relation, causes inhibition of the aggregation
of human platelets stimulated by modified human Ig (heat-
aggregated) or thrombin. It also inhibits the activation
of platelet factor 3 by the same stimulants.
Fiedal and Gewurz (1976b) found that CRP causes inhibition
of platelet reactivities stimulated by poly-L-lysine,
adenosine diphosphate (ADP) and epinephrine in platelet-
rich plasma (PRP) . It also inhibits the platelet
aggregation stimulated by collagen in PRP. CRP inhibits the
activation of platelet factor 3 (PF3) and the release of
serotonin during stimulation of platelets by ADP, and
arachidonate.
Marder et al. (1977) demonstrated that higher concentrations
of both rabbit and human CRP are capable of inhibiting the
aggregation of rabbit platelets and the retraction of a
fibrin clot.
Fiedal et al.(1977) reported that CRP inhibits the release
of platelet adenosine diphosphate (ADP) and/or serotonin at
the same time as inhibition of platelet aggregation
stimulated by aggregated human IgG occur.
Simpson et al.(1982) reported that activation of platelets
by modified heated-CRP (H-CRP) results in the secretion of
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both platelet dense bodies and an alpha-granule
constituent. The results also showed the formation of
thromboxane B2.
Fiedal et al.(1982a) reported that the platelet inhibitory
effects of CRP preparations, previously reported as
inhibition of platelet activation resulted from association
with low molecular weight factor.
Fiedal et al. (1982b) reported that modified CRP (H-CRP),and
CRP when complexed with polycations (poly-L-lysine, and
protamine) but not with C-polysaccharides, induced the
reactions of aggregation and secretion from isolated
platelets. This generated a platelet release reaction with
aggregation and secretion occurring coincidentally. Pure
isolated, native CRP does not affect platelet function
(Fiedel et al., 1982a,b). The results of Fiedal et
al(1982c) indicate that the platelet receptors for the
modified forms of CRP and IgG are distinct.
Fiedal (1985) reported that the reversible aggregation and
secretion of ATP by platelet-rich plasma activated by ATP,
became irreversible due to the presence of H-CRP.
Aggregated CRP appears not to be an agonist in PRP but only
a strong synergist, synergizing with known platelet
agonists in plasma, and not acting as a direct platelet
activator itself. The studies indicated that the platelet-
directed activity associated with CRP is not utilized
unless platelets are otherwise challenged.
Fiedal et al. (1986) reported that cleaved forms of
pentameric CRP resulting in certain CRP peptide fragments
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can inhibit platelet activation and aggregation. CRP in a
degradative environment, such as at sites of inflammation
/tissue damage or through the action of serum protease, may
thus temporarily down-regulate the platelet function.
Vigo (1985) reported that CRP inhibits platelet aggregation
induced by PAF and can stabilize platelet membranes against
the lytic effects of lysophosphatidyl choline. Inhibition
of platelet aggregation is accompanied by an inhibition of
arachidonic acid release from both phosphatidylcholine and
phosphotidylinostitol. CRP binding to membranes can protect
them against the detergent-like effects of lysolipids and
from the action of phospholipases.
Inhibition of phospholipases by CRP results in an
inhibition of arachidonic acid release, thereby blocking
the production of inflammatory mediators. CRP might thus
act as an early protective recognition mechanism in acute
inflammation. By binding to membranes, CRP prevents further
tissue destruction and stabilizes cellular membranes
against detergent-like effects.
The study by Fiedal (1988) suggests that aggregated CRP
initially stimulates platelet activation independent of
fibrinogen but in doing so activates a fibrinogen-dependent
mechanism capable of augmenting the overall extent of
platelet stimulation.
Fiedal and Gamble (1988) concluded that aggregated CRP and
ligand-complexed forms of CRP initiate the activation of
platelets, whereas naturally occurring CRP peptides inhibit
platelet activation. Their studies reported that neutral
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proteases of PMN cleave CRP into reactive products
(peptides) with the potential to inhibit platelet
activation. They found that a minimum of two linear
functional domains exist in the CRP molecule located in the
mid-portion and C-terminus, and which influence platelet
activation. The mid-portion domain inhibits platelet
activation stimulated by ADP or acid-soluble collagen,
whereas the C-terminal domain initiates platelet
activation. Both the CRP domains contain a homologue of the
immunoregulatory signal peptide tuftsin.
Janos et al.(1991) reported that CRP (l-20mg/l) inhibited
PAF-induced aggregation of human platelets in a time and
dose-dependent manner.
So CRP may be an important modulator of platelet activation
during the acute inflammatory reaction. In general many of
the reports on the effect of CRP on platelets are
controversial. A self-complexed form of CRP and CRP
aggregated with heat or modified with oxygen species were
shown to amplify platelet activation by ADP, epinephrine,
thrombin and collagen (Fiedal, 1985; Miyazawa et al. ,
1988) . Augmentation of PAF-induced aggregation also has
been reported (Kohakayama et al.1986). In contrast, native
pentameric CRP has been found to inhibit platelet
activation (Fiedal et al., 1976a,b).
The elevation of CRP levels during inflammation and tissue
destruction thus may serve to limit platelet functions.
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1.7.9 Biological functions of C-reactive protein
CRP provides one of the several signals that trigger and/or
regulate immune surveillance by augmentation or inhibition
of various components of the immune response. This is an
essential and beneficial function of CRP.
CRP provides a synergistically acting signal only, a help
which often facilitates homeostasis and which appears in
some instances to be an essential factor for homeostasis to
occur. Measurement of CRP may be used as an indicator of
the acute phase response. The measurement of levels of CRP
in serum, cerebrospinal fluid or urine are widely used for
rapid and early diagnosis of various inflammatory
conditions and to monitor the course of inflammation.
Elevation of plasma levels of CRP during the acute phase of
an infection is generally regarded as a favorable
prognostic indicator.
Despite a large number of investigations, the biological
function (s) of CRP and its role in the inflammatory
response are still not fully clear, in vitro studies have
shown that CRP potentially has both pro- and anti¬
inflammatory properties. The precise in vivo function of
CRP has not been elucidated even though its remarkable
phylogenetic conservation suggests an important beneficial
role during inflammation.
The stable conservation of the existence of CRP throughout
vertebrate evolution, including its molecular structure and
ligand-binding specificity suggest that it has an important
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biological role which is presumably beneficial to the
organism.
The main role of CRP may be to provide for enhanced
clearance of inappropriate materials from the plasma
whether these are of extrinsic origin, such as
microorganisms and their products, or of intrinsic origin
such as autologous products of cell damage and death.
In general the biological functions of CRP include the
following:
l.Ligand binding:
The specific and broad spectrum ligand-binding reactivity
of CRP in all species enables it to recognize products of
a wide range of different microorganisms. Binding to these
products may reduce their toxicity or role in pathogenicity
while involvement of secondary processes such as
complement activation and phagocytosis may also contribute
to protection against infection. The efficacy of this
function, at least for human CRP in mice infected with
pneumococci, has been clearly demonstrated (Mold et al. ,
1981; Mold et al., 1982a). Patterson et al.(1968) concluded
that CRP participitates in non specific resistance to
bacterial infection in mice and rabbits, and thus it may
function as an opsonin or bacteriolytic agent. This
supports the concept that CRP may function both in lower
animals, which have not evolved specific antibody
mechanisms, as well as in higher animals when it may
function at an early stage of infection before production
of specific antibody gets underway.
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2.Opsonization:
A potent opsonic role has been proposed as a major CRP
function in man (Kilpatric and Volanakis, 1985; Mortensen
et al. , 1977), and this is supported by evidence of
specific binding receptors for CRP on human phagocytic
cells, including neutrophils and monocytes.
Investigations of opsonic properties of CRP resulted from
the initial finding of CRP binding to Streptococcus
pneumoniae and a number of other bacteria (Kindmark, 1971;
Mold et al.1982). Kindmark (1971) reported that CRP
stimulates the phagocytosis of various species of
pathogenic bacteria, including Gram-positive and Gram-
negative pathogens. CRP may combine with bacteria to act as
an opsonin with consequent promotion of non-specific
resistance to infection.
Human CRP which has been aggregated or complexed with
multivalent ligand is a potent activator of the classical
complement pathway (Volanakis, 1982; Volanakis and Narkates
, 1983), and by virtue of this effect it can act as a
complement-dependent opsonin in vitro (Mortensen et al. ,
197 6) . Many investigators have speculated that CRP may
function in vivo by opsonizing damaged and necrotic tissue
for subsequent phagocytosis (Pepys, 1981; Pepys and Baltz,
1983; Pepys et al., 1985).
3.Resolution and repair of damaged tissue:
CRP has been demonstrated in rabbits in association with
necrotic muscle fibers in induced ischaemic lesions of the
myocardium (kushner and Kaplan, 1961; kushner et al. ,
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1963), and in man CRP has been reported in the lesions of
cutaneous vasculitis (Parish, 1977) and in association with
synovial cell nuclei in biopsies from patients with
rheumatoid arthritis (Gitlin et al. , 1977) .
Human CRP does not bind to the intact membranes of healthy
living cells, or to artificial membranes which mimic their
composition or structure. It does however bind to damaged
or altered cell walls and to artificial phospholipid
membranes, and having done so it then activates complement
(Volanakis , 1982). It has been therefore suggested by
Volanakis that the role of CRP may be to recognize damaged
cells and their products. It is thought that CRP regularly
binds to damaged cells in vivo , and by then activating
complement to generate the chemotactic and opsonic
activities required to promote phagocytosis, leads to
resolution and repair of the lesion (Kushner and volanakis,
1982) .
4.Clearance of abnormal materials from the circulation:
It has been suggested that a function of CRP is to promote
the clearance of abnormal materials from the circulation
and/or contribute to their detoxification (Pepys, 1981,
Lancet). Experiments have shown that CRP does indeed
mediate or enhance blood clearance of pneumococcal C-
polysaccharide-coated erythrocytes (Kilpatrick et al.,
1987; Kilpatrick and Volanakis, 1985; Mold et al., 1981) .
, and this also requires an intact complement system.
Increased production of CRP is stimulated as effectively by
autologous damage in the absence of infection as it is by
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infection. During the course of tissue damage a variety of
cellular constituents may get access to the plasma.
If an abnormal material of extrinsic origin,such as a
microorganism or microbial product, is in the plasma it too
may have its clearance enhanced by CRP provided that it
bears appropriate ligand(s). This function of CRP has been
demonstrated with pneumococci and with C polysaccharide-
coated erythrocytes. Human CRP is able to activate a normal
mouse complement system, and initiate opsonization and
phagocytosis in a similar manner to immunoglobulin. CRP may
therefore have a role in organ sequestration if CRP binds
to the component cells (Nakayama et al., 1982).
The interaction between aggregated CRP and plasma low
density lipoproteins (LDLP) may result in the clearance of
LDLP from the circulation and so have a role in the
pathogenesis of atherosclerosis (Pepys and Baltz, 1983) .
5.Inflammation:
Intradermal or intracutaneous injection of C-
polysaccharides in patients with acute pneumococcal
pneumonia or with rheumatic fever, elicits an immediate
wheal and flare reaction which resolves over an hour or so
and which is then followed by a delayed reaction (Francis
and Abernethy, 1934; Finland and Dowing, 1935) . The lesion
is oedematous and erythematous,and may have a central
haemorrhagic area. In normal healthy subjects, or
convalescent patients whose serum CRP levels have fallen
toward normal, injection of C-polysaccharides has no
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effect. Injection in experimental animals of aggregated CRP
which had previously been incubated with human complement
and had fixed Clq, elicited similar lesions with neutrophil
infiltration and fibrinoid necrosis (Parish, 1977). These
findings suggest the possibility of this mechanism
initiating inflammation or tissue-damaging process when
circulating CRP levels are high. In vivo CRP has been shown
to be deposited at sites of ischemia and necrosis (Kushner
et al. , 1961; kushner et al. , 1963), and several studies
have shown that CRP is deposited almost exclusively in
neutrophil-rich inflammatory lesions, whereas little or no
CRP is observed in lesions composed primarily of
mononuclear cells (Duclos et al. , 1981; Parish , 1977;
Gitlin et al.,1977).
CRP may be particularly important during the early periods
of inflammation when the antibody titres are low. CRP meets
the criteria of a physiological response modifier since its
concentration in blood, as well as in tissues, changes
dramatically during the early course of the inflammatory
response.
One function of CRP within an inflammatory site is to clear
the inflammatory focus, including bacterial clearance and
allow tissue repair to proceed (Nakayama et ai. , 1983) .
Since CRP is known to be deposited at the site of tissue
destruction, it may be expected to exert its influence on
the macrophages infiltrating these sites.
While it is possible that CRP may be enhancing inflammation
and contributing to the chronicity of the lesions, it may
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also be promoting healing. Yoshinori et al.(1989) concluded
that CRP may play a critical role in the response to injury
by serving as an opsonin for dead cells, in turn amplifying
and focusing the inflammatory response on dead and damaged
tissue, with both potential beneficial and pathological
consequences. Monocyte ingestion of CRP-opsonized cells
stimulates TNF-a secretion, which will further elevate CRP
level. Thus, with tissue injury, cytokine generation and
acute phase protein synthesis result in a system enhancing
cellular debridement and promoting repair, perpetuated by
the persistence of damaged tissue.
6.Interaction of CRP with cells from immune system
Many studies have been conducted on CRP-mediated effects on
various inflammatory cells and immunocytes, notably the
monocyte/macrophage and its precursor cell, the neutrophil
polymorphonuclear leukocyte, the NK-cell and other
lymphocyte subpopulation, and platelets.
CRP or CRP-derived peptides modify the behavior of all
these types of cells. Studies on CRP interaction with these
cells has resulted in a wide range of conflicting ideas ,
some of which are due to CRP existing in two different
forms; the native pentameric molecule which is the major
circulating form, and the neo-CRP which is a free CRP
subunit exposing antigenic epitopes (Potempa et al. , 1987) .
The activity of CRP may also depend on whether it is
aggregated, complexed or cleaved.
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Potempa et al.(1988) found Neo-CRP induces aggregation and
secretions from platelets, and also potentiated platelet
activation stimulated by ADP in platelet-rich plasma.
Native CRP alone or when complexed with CPS does not cause
induction. Forms of CRP expressing neo-CRP are not able to
activate the C system, unlike CRP-CPS complexes.
In general native CRP alone is ineffective in stimulating
human PMNL (Zeller et al. , 1986; Shephard et al. ,1986),
monocytes (Zeller et al., 1986; Potempa et al., 1988),
platelets (Fiedal et al. , 1982,1985), and lymphocytes
(James et al. , 1981,1982; Vetter et al. , 1983). However
under certain conditions, some forms of complexed or
aggregated CRP both bind to and modify biological
activities of human lymphocytes (James et al., 1981,1982;
Vetter et al. , 1983), and platelets (Fiedal et al., 1982).
Platelets: platelets have specific receptors for CRP
(Fiedal et al. , 1982c), which inhibit aggregation (Fiedal
and Gewurz , 1976a,b), but augment activation (Miyazawa et
al.,1988) . Aggregated CRP or complexed with its ligands
stimulates platelet aggregation and release reactions
(Fiedal et al., 1982).
Heated-CRP has been shown to induce aggregation and
secretion in isolated platelets and to synergize with
platelet activators to induce similar reactions in
platelet-rich plasma (Fiedal et al., 1982; Fiedal et al.,
1985)) . CRP inhibits PAF-induced aggregation of platelets
by inhibiting phospholipase activity and blocking the
release of inflammatory mediators (Vigo, 1985; Fiedal et al
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1982; Fiedal et al.,1985).
Neutrophils:
CRP binds to neutrophils (Shephard et al. , 1986; Kilpatrick
and Volanakis, 1985; Muller et a., 1986) . Native CRP has
been shown variously to enhance phagocytosis by acting as
an opsonin (Kilpatrick and Volanakis, 1985), to inhibit
superoxide anion generation, lysosomal release (Butcha et
al. , 1987), and chemiluminescence (Tatsumi et al, 1988;
Zeller et al., 1986), and to influence on chemotaxis (Robey
et al.,1987; Shephard et al, 1986). Heated-CRP has been
shown to potentiate the aggregated IgG-induced respiratory
burst activity of human neutrophils as measured by
chemiluminescence (Zeller et al., 1986a,b).
Lymphocytes:
CRP augments T lymphocyte cell-mediated cytotoxicity (James
et al., 1981,1982; Vetter et al., 1983,1986). It can both
augment (Mortensen et al., 1982) and inhibits (Whilter et
al., 1983,1986) B lymphocyte colony formation and inhibit
B lymphocyte plaque formation (Vetter et al., 1986,
Mortensen et al., 1982) . CRP binds to natural killer (NK)
cells as neo-CRP ( Baum et al., 1983; Samberg et al., 1988)
and is involved in NK cell activity at effector cell level
but not at target recognition (Kempka et al., 1990) .
Monocytes: CRP binds to human macrophages enhancing their
respiratory burst response to aggregated IgG (Mortensen et
al. , 197 6; Zeller et al., 1984) and mouse macrophages show
a similar response (Zeller et al.;,1983 ; Potempa et al. ,
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1986; Mortensen et al. , 197 6) . CRP augments monocyte
activation and superoxide release (Zeller et al.,
1986,1988; Potempa et al., 1988; Barna et al., 1988), but
inhibits PAF-induced activation (Tatsumi et al. ,1986) . It
also inhibits MIF-like activity (Whiser et al., 1986), and
precursor cell recruitment (Marcelletti et al. , 1982;
Mortensen et al. , 1983), but it augments tumor cytotoxicity
(Barna et al., 1984; Zahedi et al., 1986) . Activation of
monocytes/macrophages by proteolytic fragments of CRP is
significantly augmented (Robey et al. , 1987; Shephard et
al. , 1988,1989,1990). The proteolytic fragments activate
macrophages in a similar way to tuftsin (Robey et al.,
1987; Shephard et al., 1988,1989,1990). Such activating
fragments may be generated early in infectious diseases by
proteases released from dead cells or granulocytes or by
the infective agents. They could also be generated within
macrophages during endocytosis or phagocytosis of ligands
opsonized by surface-CRP or via their membrane CRP. This
connects the opsonic activity with activation of the immune
system.
7.Phagocytosis and Complement Activation;
CRP complexed with CPS is a potent in vitro activator of
the classical complement pathway (Gewurz et al., 1983;27;
Kaplan and volanakis , 1974; Claus et al. , 1977; Volanakis,
1982; Volanakis et al., 1983; Mold et al., 1982; Claus et
al. , 1977), and enhances opsonization (Mortensen et al. ,
1976; Edward et al., 1982; Holzer et al., 1984).
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Studies in vivo have demonstrated that CRP can activate the
classical pathway of complement after complexing with
certain polyanions or capsular CPS antigen of pneumococcus
(Kaplan and Volanakis, 197 6; Edwards et al.,1982) .
The reactivity of CRP with a variety of substances
(microbial products, damaged tissues) released or exposed
as a result of inflammation or the reaction with model
membranes and cationic molecules, has been shown to result
in activation of the classical pathway of complement
(Edwards et al., 1982),and to complement-dependent
phagocytosis.
In the case of human CRP, there is no doubt that this
complement activation can then generate chemotactic factors
and opsonic fragments of fixed complement proteins. There
is evidence from in vitro studies with monocytes that,
following complement fixation by CRP binding to a
particular ligand, the presence of both the CRP and the
fixed complement is required for internalization to occur
(Mortensen et al., 1976; Mortensen and Duskiewicz, 1977).
Mortensen et al.(1977) found that enhanced phagocytosis is
dependent on both the presence of CRP and the deposition of
fragments of C3 and C4 on the indicator cells, and the
enhancement of phagocytosis by mouse macrophages was
mediated through a direct interaction of CRP with
macorphage Fc receptors.
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1.7.10 CRP and Oral Diseases
There are few reports on the relation of CRP and oral
diseases.
Adam and Christide (1962) reported a preliminary study of
serum and saliva CRP levels and periodontal diseases, using
a semiquantitative method (capillary precipitation test).
They found that 50% of the patients were positive for both
serum and saliva samples, primarily from cases of marginal
periodontitis or periodontal abscesses.
Boucher et al.(1967) using a capillary precipitation
procedure, tested sera for CRP from patients with various
forms of inflammatory oral diseases (acute alveolar
abscess, acute periodontitis, acute necrotizing ulcerative
gingivitis, chronic marginal gingivitis) and from controls.
The highest incidence of positive CRP tests and the
strongest CRP reactions were observed in patients with
acute alveolar abscesses. The CRP test became negative
after antibiotic treatment and tooth extraction in two
patients with acute alveolar abscess.
Shklair et al.(1968) used the slide-latex agglutination
test to study the relation between the presence of serum
CRP and periodontal diseases (severe and moderate cases of
necrotizing ulcerative gingivitis (NUG) , gingivitis, and
periodontitis). The periodontitis group consisted of 10
cases of severe periodontitis which had generalized acute
inflammation with much bone loss and pocket formation, and
8 cases of moderate periodontitis with only localized areas
of bone loss and inflammation. They found that the presence
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of CRP in the serum was more common in the severe than in
the moderate periodontal group. When CRP was found to be
initially positive, the CRP test became negative 3-7 days
after the initiation of treatment in severe cases and a
week following the initiation of treatment in moderate
cases. This coincided with the elimination of the
inflammatory stage. In the control group, 33 were negative
for CRP. So in general patients with severe forms of
periodontal disease usually develop CRP in their serum. The
patients in the severe NUG group had the highest percentage
of CRP production, followed by those with severe
periodontitis, and then by severe gingivitis. The patients
with moderate infections had a significantly lower
incidence of CRP production. They concluded that a positive
serum CRP test may be due to the presence of enough
necrotic or injured tissue that can enter the blood stream
to elicit a CRP reaction.
Iwamoto et al.(1979) using a latex particles agglutination
test for the detection of CRP in human saliva, found that
human whole saliva and sublingual-submandibular saliva was
positive but parotid saliva was negative. The titre of
salivary (supernatant) CRP showed a positive correlation
with oral hygiene index of Green and Vermillion (1960), the
debris index, the calculus index and the viscosity of
saliva. Titres of CRP were significantly higher in whole
saliva than in supernatant saliva. They concluded that the
source of CRP in whole saliva is the sublingual-
submandibular salivary glands and not the blood.
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Adinolfi and Lehner (1976) studied the concentration of CRP
and other acute phase proteins in sera from 40 patients
with Behcet's syndrome and recurrent oral ulceration (ROU)
using a single radial immunodiffusion technique. Their
results showed significantly increased amounts of CRP in
Behcet's syndrome. They concluded that CRP might be useful
in the differential diagnosis of Behcet's syndrome,
especially from recurrent oral ulceration. They suggested
that during inflammation in recurrent oral ulceration, some
of the acute phase proteins including CRP are increased.
This increased CRP in some patients may modulate the
immunological mechanism in such way, as by their binding to
T lymphocytes, to promote phagocytosis and to activate
complement. This induces a transition from focal oral
ulceration to multifocal Behcet's syndrome. Lehner (1978)
in his review stated that CRP could be involved in
modulating the cell-mediated immune response by its effect
on T lymphocytes. He concluded that at least two types of
damaging immune mechanisms could be involved, the cell-
mediated and the immune complex induced reactions, and
these might account for the association between ROU and
Behcets syndrome. Lehner and Adinolfi (1980) using radial
immunodiffusion technique, showed that serum CRP increases
significantly in all groups of Behcet's syndrome except the
arthritis group, and does not increase significantly in
cases of recurrent oral ulceration.
Martin et al. (1988) studied the levels of serum CRP and
other acute phase proteins in sera of 36 patients with
162
chronic periapical granulomas before and after surgical
treatment, using the rate nephelometry method. Mean serum
concentrations of CRP were slightly increased at diagnosis,
but had decreased significantly 3 months after apicectomy.
The slight elevation of serum CRP may be due to the limited
extent of the inflammation. The decrease of CRP levels
reflect the complete recovery after elimination of local
inflammation by apicectomy.
Aziz et al. (1990) carried out the first study of CRP in
gingival crevicular fluid in a group of patients with
chronic periodontitis and healthy control subjects using an
ELISA technique. They also measured the level of CRP in
saliva and serum in a cross sectional study. They were the
first to report the presence of CRP in gingival crevicular
fluid, and quantified its level in both the GCF and saliva.
They concluded that CRP is present in the gingival ,
crevicular fluid in both the patient and control groups.
Aziz et al. (1991) measured the level of CRP in serum and
saliva in a group of patients with oral candidosis (denture
stomatitis) before and after treatment using an ELISA
technique, and found that both serum and salivary CRP
levels were increased in oral candidosis and the levels
fell in response to treatment.
Sibraa et al.(1991) used direct and indirect immunodot
techniques in quantifying acute phase proteins including
CRP in gingival crevicular fluid from periodontally
diseased and healthy sites. Indirect immunodots were used
to identify and establish relative amounts of CRP in two
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diseased and two healthy sites in 24 periodontal disease
patients. They found that CRP levels did not vary
significantly between healthy and diseased sites. Their
detection of CRP via indirect immunodot systems indicate
its presence in both healthy and diseased sites, and their
results supported the results of Aziz et al.(1990) on the
presence of CRP in the gingival crevicular fluid.
Wannfors and Hansson (1991) studied the relation between
serum CRP and other acute phase proteins in patients with
acute osteomyelitis using electroimmunoassay. They found
that CRP was markedly raised in four samples from three
cases. The serum level also decreased rapidly when the
initiating stimulus stopped. They suggested that the raised
serum levels of CRP may be due to sample collection either
during an intense initial phase or coincident with
exacerbations. They concluded that a certain "mass of
inflammation" seemed to be necessary before raised values
of CRP were detected.
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CHAPTER TWO
Clinical Materials and Methods
Aims, Subjects, Experimental Design, Clinical Methods
and Data Analysis
2.1 Subjects
Two groups of subjects were selected for the study.
A.Cont ro1 group:
This group consisted of twenty-five subjects with a mean
age of 22.4+_1.5 years and a range of 20-26 years. The
group contained 9 females with mean age of 22.7+_1.3 years,
and 16 males with mean age of 22.2+_ 1.6 years. The
subjects in this group were dental students in their final
year at Edinburgh Dental Hospital. The selection criteria
for this group were:
1.Each subject should be healthy with no history of any
systemic disease or chronic infection at the time of the
experimental study.
2.Each subject must not have been on steroids in the last
six months before the start of the clinical study.
3.Each subject should have no history of periodontal
disease, nor undergo any periodontal treatment before or
during the study. He/she should have a healthy periodontal
condition, with good oral hygiene and be on standard home
mouth care.
B.Patient group:
This group consisted of 54 patients with a mean age
41.1+_9.2 years and a range of 20-60 years. Thirty five
were females with a mean age of 37.5+_7.6 years, and 19
were males with a mean age of 47.7+_8.3 years. These were





The subjects were selected on the basis that each of them
should have a history of chronic periodontitis for at least
one year before the start of the study. The history should
include a presence of periodontal problems, including
pockets of more than 4 mm already recorded with a PC12
probe (Prisma, UK) and kept in their standard periodontal
pocket charts. Most of these patients were on maintenance
therapy at one to three months recall, receiving normal
prophylaxis which included scaling and polishing at most of
their visits, and root planing on some visits. Treatment as
described was continued for ethical reasons.
b.Exclusion criteria:
1.No history of serious systemic disease or recurrent
chronic infection except periodontal disease.
2.No history of using steroids in the last six months
before the study.
2.2 Selection of sites
Sites for both control and patient groups were selected
according to the Technical clinical report series number
621 (Geneva WHO 1979). WHO (CPITN index system) teeth and
sites were selected from each subject's dentition for this
study. These included, mesiobuccal sites for teeth number
16 (maxillary left first molar), 21 (maxillary left central
incisor) and 24 (maxillary right first premolar). They also
included the mesiolingual sites for teeth number 36
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(mandibular left first molar), 41 (mandibular right central
incisor) and 44 (mandibular right first premolar). If one
of these sites was missing in the subject the next distal
site was used or the next tooth in the dentition would be
selected.
2 . 3 Aims of the study
2.3.1 General Aims
A.The development of a reproducible method of measuring the
attachment level change. This aim was to measure small
changes and reproduce accurate results. This measurement
gave changes in the attachment levels (loss, gain or no
change) among the sites and in both groups over one year.
B.Development of a reliable and valid method for the
calibration of the Periotron 6000 to measure the volume of
gingival crevicular fluid. This would be applicable to the
wide range of the collected volumes of gingival crevicular
fluid.
C.Development of a reproducible and sensitive technique to
measure the levels of the acute phase protein, C-reactive
protein (CRP) in serum, saliva and in particular in the
small volumes of gingival crevicular fluid. This would be
either by developing a new technique or establishing or
modifying an existing technique.
2.3.2 Specific Aims
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A.To investigate the presence of C-reactive protein in the
saliva and gingival crevicular fluid from the selected
sites in both control and patient groups, using the enzyme-
linked immunoabsorbant assay (ELISA).
B. To investigate the possible association of C-reactive
protein with the activity of periodontal disease measured
by periodontal attachment loss, and also the possible
predictive value of C-reactive protein in the destructive
process of chronic periodontitis. This investigation
includes the following objectives:
Bl.The main objective is to correlate the clinical status
of the subject using in particular the changes in
attachment levels, with the levels of C-reactive protein
particularly in gingival crevicular fluid collected from
the related sites. This correlation is to be found
sequentially at 2-monthly intervals over the observation
period, and the over the one year period.
The objective is to detect clinically the disease activity
indicated by loss of attachment " at individual site or
within each subject, with corresponding values of C-
reactive protein.
B2.To seek any possible correlation between C-reactive
protein and the following data:
a.Gingival inflammation using gingival index and bleeding
on probing scores.
b.Pocket depth.
c.Oral hygiene using plaque index.
d.Microbiological composition of subgingival plaque using
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the percentages of spirochaetes, motile rods,coccoid cells
and other.
C.To seek any possible correlation between the clinical
parameters and the disease activity as measured by
attachment level loss.
D. To seek any possible correlation between subgingival
flora, in particular spirochaetes and motile rods, with
clinical parameters particularly with attachment level
changes. The objective is to seek a possible correlation
between loss of attachment and spirochaetes as well as
motile rods.
2.4 Experimental design
1.A signed informal consent was taken voluntarily from each
subject after a full explanation of the aims and methods of
the clinical study.
2.Following their agreement to participate, an upper and
lower rubber base impression was taken and from the
resulting casts, a soft polythene stent for attachment
level measurements was constructed for each arch.
Subsequently, each subject was examined on six occasions
over one year at 2 monthly intervals on average. No subject
should have taken antibiotics for at least 72 hours before
any examination date, otherwise the visit was postponed.
3.The following clinical data, measured as described
subsequently were recorded at each visit for each subject
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at the selected sites, and in the following order:
a.Unstimulated whole mixed saliva (at least 1ml) was
collected at each visit by expectoration.
b.Plaque index scores were taken.
c.Gingival crevicular fluid from the selected sites at each
visit, using a filter paper strip technique. The volumes
were then measured using a Periotron 6000.
c.Gingival index scores were taken.
d.Probing pocket depth and attachment level measurements:
These measurements were recorded twice at each visit. The
first set of both pocket depth and attachment level
measurements were recorded after the sites were sampled for
GCF. During this period bleeding on probing (BOP) was also
recorded. The second set of both pocket depth and
attachment level measurements for all the sites were
recorded after collection of the other clinical data in
upper and lower jaw, starting again with the sites that
were first sampled.
e.Subgingival plaque from the selected sites at each visit
was collected immediately after the recording of the first
set of attachment level measurements and the recording of
BOP at each site.
f .Venous blood up to a volume of 10 mis was collected at
each visit.
2.5 Clinical Methods
Only one examiner (SA), was used throughout these studies
to record all the clinical parameters.
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2.5.1 Plaque index (PI)
Plaque accumulation was measured according to plaque index
of Silness and Loe (1964) which scored plaque accumulation
on a scale 0 to 3 as follows:
Score 0 = tooth surface is clean, no plaque in the gingival
area.
Score 1 = a film of plaque adhering to the free gingival
margin and adjacent area of the tooth surface. The plaque
can be removed only by running a sharp explorer across the
tooth surface.
Score 2 = visible plaque on the tooth surface. Moderate
accumulation of soft deposits within the gingival crevice
,on the gingival margin and/or adjacent tooth surface,
which can be seen by naked eye.
Score 3 = abundant plaque within the gingival crevice
and/or the gingival margin and adjacent tooth surface.
PI gave a separate recording for each of the selected sites
and was called site PI scores, or the mean of the scores of
all selected sites within each selected subject and this
was called a subject mean for PI. The mean of the total
scores for a group of teeth (sites) has been called mean
site PI scores, and was used for the assessment.
2.5.2 Gingival index (GI)
The Gingival Index by Loe and Silness (1963) and Loe (1967)
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has been used to assess gingival inflammation on each of
the selected sites within each subject at each visit.
The following criteria have been used:
0 = absence of inflammation: clinically healthy gingiva.
1 = mild inflammation: there is a slight change in colour
and little change in texture; no bleeding on pressure.
2 = moderate inflammation: there was moderate glazing,
redness, Oedema, and hypertrophy; bleeding on pressure.
3 = severe inflammation: there was marked redness and
hypertrophy; tendency to spontaneous bleeding; and
ulceration.
GI gave a separate recording for each of the selected sites
and was called single site GI scores, the mean of the
scores of all selected sites within each selected subject
has been used as a subject mean for GI. The mean of the
total scores for a group of teeth (sites) was called mean
site GI scores and was used for the assessment.
2.5.3 Bleeding on probing (BOP)
Bleeding on probing was used to detect the presence of
gingival inflammation in particular at the base of the
crevice or periodontal pocket. A pressure-sensitive probe
(WHO pressure-controlled probe) set at 3 0 gram, with a
blind ball point was inserted gently into the crevice at
each selected site. Scoring was performed within 30 seconds
of probing. Bleeding upon probing was scored dichotomously.
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A score of 1 was given if there was bleeding while a score
of 0 was given if there was no bleeding on probing.
2.5.4 Pocket depth (PD) and Attachment level
measurement
A pressure-sensitive periodontal probe was made according
to our instruction and need (Prima Instrument Company,U.K).
The probe tip had a diameter of 0.6mm, with l-13mm
gradutions at 1mm increments, and deep marks at 4mm,7mm and
10mm depth. It is a modified type of hinge-controlled
probe. The probe was calibrated by a calibrated screw to
receive only 0.2 5N to 0.3ON.
2.5.4.1 Development of a reproducible method for
measuring attachment level changes and pocket
depth (Modified stent technique)
A calibration trial was carried to develop a method for
reproducibly measuring pocket depth (PD) and attachment
level changes associated with periodontal disease, using a
modified stent technique (Figure 2.1). This study compared
the new technique with the conventional stent technique
developed primarily by Isidor et al. (1984) in the measuring
the pocket depth and attachment level changes.
Eight subjects (3 males and 5 females, mean age = 25.5+_5
years) voluntarily participated in this trial. Ten sites
were used in each subject, these were WHO sites (16, 21,
24, 36, 41, 44) and 4 random sites.
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After subject selection an impression was taken for both
lower and upper jaw using rubber base material, and a model
poured. The position of the selected sites were marked on
the model to determine the position of the orthodontic
tubes in the stent. A polyethylene plastic (Bioplast) stent
of 4mm thickness was constructed on individually cast
models using a vacuum forming machine. The stent was then
trimmed approximately 2-3 mm coronally to the gingival
margin. Two types of stent were constructed on each model,
one was made according to the method used by Isidor et
al. (1984) with grooves cut on the stent at the selected
sites and this was called the stent without tubing. The
second stent was made with orthodontic stainless steel
tubing of 1.25mm internal diameter fixed into the stent as
a guiding pathway for the insertion and angulation of the
constant pressure probe to the selected sites, and as a
fixed reference point for attachment level measurements.
The same probe (constant pressure probe) was used with both
stents. The measurements for both pocket depth and
attachment level were repeated on 2 occasions at 2 weekly
intervals. The probe was set at 0.30N probing force.
Measurements were read to the nearest 0.5mm. With the stent
in place, the distance was measured from the end of the
tube which was the reference point to the base of the
pocket and this represented the attachment level
measurement with regard to the stent. The pocket depth (PD)
was measured as the distance from the base of the pocket to
the gingival margin, and this was taken at the same time as
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attachment level measurement.
Results indicated that this modified technique using
orthodontic tubing reproducibly measures pocket depth and
attachment level with a compatibility between readings of
60% and 57.5% for pocket depth and attachment level
respectively, while the stent without tubing showed
compatibility of 43% and 50% for attachment level
measurement and pocket depth respectively. Using the stent
with tubing a deviation of +_lmm or less was obtained for
98% of sites and of +_2 mm for 2% of sites for attachment
level measurements, as well as a deviation of 1 mm or less
for 100% of sites was obtained for pocket depth
measurements. Using the conventional stent without tubing,
a deviation at +_lmm or less at 85% and 95% was obtained
for attachment level and pocket depth measurements
respectively, and a deviation at +_2mm was found in 5% of
the sites for pocket depth measurement as well as a
deviation equal to or more than +_ 2mm was obtained at 15%
of the sites for attachment level measurements. For the
stent with tubing, the mean +_SD for the differences of
the replicated reading for attachment level and pocket
depth was equal to - 0 . 07 5+_0 . 65mm, and - 0 . 087+_0 . 66mm
respectively, while for the stent without tubing it was
found to be 0.075+_l.07mm, and 0.25+_0.77mm for attachment
level measurement and pocket depth respectively. The
results indicated that splints with tubing were more
accurate than the conventional onlay splints, and are
suitable for longitudinal studies measuring attachment
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level changes and pocket depth.
2.5.4.2 Measurement of pocket depth and attachment level
changes during the longitudinal studies of
untreated periodontal disease
A stent with tubing was constructed (2.5.4.1) for the upper
and lower arch for each of the selected subjects. A
constant-pressure probe was used to record the pocket depth
and attachment level changes (2.5.4.1).
Duplicated measurements were taken for both PD and
attachment level measurements at each of the selected sites
for the longitudinal studies (2.2) which included the
mesiobuccal site for 16, 21, 24 and the mesiolingual site
at 36, 41, 44. Pocket depth measurements were taken at the
same sites, as it's attachment level recordings. These
duplicated measurements were repeated at each visit
bimonthly during the period of the study. The mean of each
pair of the duplicated measurements was used for the
calculation.
In this method attachment level measurements do not rely on
the location of the cemento-enamel junction (CEJ) as its
identification is often complicated by its subgingival
location or the presence of restorations or subgingival
calculus.
2.5.4.3 Detection of attachment level changes
The change in the attachment level between each successive
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visits at 2 monthly intervals, between the baseline and
final visit, and over the period of observation (one year)
was detected using certain methods (2.7) . Significant
attachment level changes were assessed retrospectively on
completion of the study as described latter.
2.5.4.4 Classification of attachment level changes
(attachment level grading)
A classification system for attachment level changes at the
selected sites was produced. This represents the direction
and the extent of attachment level change at specific sites
during the longitudinal study of both periodontitis
patients and the control group. Individual sites were
classified according to the attachment level changes during
each prescribed period into three categories:
a.Improved sites (gain in attachment level).
b.Loser sites (loss of attachment level).
c.Stable sites (no change in attachment level).
This classification was dependent on the direction and
extent of the change detected according to the analytical
method described below (2.7) .
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2.6 Collection of samples
2.6.1 Collection of the saliva
Unstimulated whole mixed saliva (at least 1 ml) was
collected in a plastic 50 ml tube at each visit. The sample
was then transferred to the laboratory and stored at 4 C°
overnight. The clear solution carefully separated from the
lower part without centrifuging and then stored at -20 C°
for CRP analysis.
2.6.2 Gingival crevicular fluid (GCF) collection
Supragingival plaque was first removed from the tooth
surface with a periodontal probe, during recording of the
plaque index scores. This was an essential requirement
prior to the collection of GCF samples in order to prevent
contamination. Where the plaque was abundant (score 2 or 3)
it was carefully removed using a sickle scaler with the tip
kept slightly above the gingival margin in an effort to
minimis the stimulation of GCF flow. GCF sampling was
carried out before any other clinical recordings which
could cause irritation to the tissue and serum
contamination of the sample. These include pocket depth,
attachment level measurements, GI, BOP and subgingival
plaque sampling.
The individual site was isolated carefully with cotton wool
rolls and gently air-dried in an apico-coronal direction
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using a chip syringe. The area was carefully isolated and
a saliva ejector was used to avoid saliva contaminating the
samples. A sterile paper strip (periopaper, IDE Interstate,
Amityville, NY, U.S.A) was gently inserted into the sulcus
in a direction parallel to the long axis of the tooth and
until mild resistance was felt, whilst care was taken to
avoid mechanical trauma to the crevice. The strips were
left in the crevice for one minute and then transferred to
a chairside located Periotron 6000 (IDE, Amityville,
NY,U.S.A) for volume determination. The sampling was
repeated within three minutes after the first collection.
Each periostrip was then placed in a labelled individual
sterile polyethylene microcentrifuge tubes (BioRad
Laboratories) into which a small, perforated inner tube had
been positioned halfway down the tube. Fifty microlitres
(uL) of sterile phosphate-buffered saline (0.02 M phosphate
, PH 7.4) containing 0.05% Tween 2 0 (PBST 20) was then
applied to the periostrip.
The periostrips were subsequently transported to the
laboratory and stored at -40 C° prior to the elution of GCF.
2.6.3 Subgingival plaque
Bacterial samples were obtained as follows:
Supragingival plaque or debris was removed before sampling
from each of the selected sites during measuring the
supragingival plaque, using a clean curette followed by
gingival crevicular fluid collection, then another clean
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periodontal curette was introduced through the sulcus or
pocket orifice as far apically as possible and the
bacterial contents removed. If necessary the process was
repeated several times to obtain enough material. The
sample was suspended by vigorously agitating the tip of the
instrument in a small screw cap vial containing 0.2-0.3 ml
of sterile 0.85% sodium chloride solution containing 1%
gelatin. The sampling was taken at each selected site and
at each visit.
2.6.4 Detection of subgingival microorganisms using
phase-contrast microscopy (PCM)
Morphological studies of the subgingival flora at each
selected site for both periodontitis and control subjects
were carried out using phase contrast microscopy.
The bacterial suspension was dispersed just prior to the
examination by aspirating and expelling the fluid seven
times through a disposable tuberculin syringe equipped with
a 23 gauge needle. Special care was taken to avoid
excessive air bubbles during the dispersion. In order to
minimize clumping and the loss of bacterial motility,
samples were prepared and the examination completed within
one hour of the collection. One drop of suspension was
applied to a microscopic slide and a cover slip placed over
the solution. Excess fluid was removed by inverting the
slide over an absorbent surface and applying moderate
pressure. The slide was examined by phase-contrast
microscopy at a magnification of xl200 using a 10x10 grid
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eyepiece graticule during counting of the bacteria. This
lens contained equal divided squares through which the
bacteria could be morphologically recognized and counted.
Generally from 100-200 bacteria from fields selected at
random were classified into four morphological categories
as follows: coccoid cells; other (curved rods with no
flagella, fusiforms, straight rods, and filaments),
spirochaetes (small, medium and large), and motiles. The
last group included all cell types, other than spirochaetes
, which exhibited motility under the microscope. This group
generally comprised either straight or curved rods and on
occasion fusiform and coccoid cells). Cell motility which
could exhibit several characteristic patterns had to be
distinguished from brownian movement or motion imparted by
streaming of fluid between the slide and coverslip. All the
cells exhibiting distinct flagella were also included in
this group even though they were not actually moving at the
time they were observed. The motiles were counted only if
they were within the area which was being scanned within
the field, an organism moving back and forth through the
area was only counted once. Clumps of cells in which all
cells could not be clearly distinguished were not included
in the counts, in such cases fewer cells had to be counted
than the usual minimum number of 100 cells.
The percentage of each morphotype was calculated from the
absolute numbers and was used for calculation.
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2.6.5 Blood sampling
Venous blood from the antecubital fossa, up to a volume of
10 mis ,was collected in glass bottles at each visit. Blood
samples were transferred to the laboratory and kept at 4 C°
overnight until centrifuging at 3500 rpm for 15 minutes.
The serum was removed and stored at -20 C° for CRP analysis.
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2.7 Data Analysis
2.7.1 Identification of attachment level change at
each periodontal site
Two methods were used to identify the changes in the
attachment level. These included a linear regression
analysis (Goodson et al.,1982, Badersten et al.,1985d,
Haffajee et al., 1983a,1986b), and a safety threshold
method.
Linear regression analysis method:
By this method the slope and the intercept of a regression
line were computed from a linear least squares fit of
attachment level measurements as a function of time, and
the slope was tested for a significant departure from zero
while a threshold of projected attachment level change per
unit time also had to be exceeded. Calculation of the slope
of the regression line determines the rate of change over
time. Determination of the probability level for the
individual slope considers the variability of the
individual data points about the regression line, i.e.it
includes consideration of the level of reproducibility of
the measurements at the specific site.
Duplicated measurements from each site were taken using the
stent method described earlier (2.5.4.2) at the first visit
and each bimonthly visit during the period of the study
(one year). The mean of each replicate of measurements was
used for data analysis. This was carried out to reduce the
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probability of an error associated with these measurements.
A total of 900 replicates of attachment level measurements
for all the sites (150) in the control group (25 subjects)
were recorded for all the visits during the study period.
For the patient group (54 patients) 1920 replicated
attachment level measurements were recorded for all the
sites (324) for six visits during the period of study. Five
sequential measurements in each group resulted from the
replicated attachment level measurements between each two
visits for all the sites. The sequential measurements in
each group were individually subjected to regression
analysis, and the extent and direction of attachment level
change was determined as represented by the regression
coefficient (the slope) for each site.
In order to consider that a real change occur at each
individual site, the regression coefficient of the site had
to departure from zero at significance level of P<0.05. On
the basis of that a significant change in attachment level
measurement per site occurred over the study period of one
year, which was detected by regression analysis at
probability (P)<0.05, three group of sites emerged. These
included sites which became significantly deeper, sites
which became significantly shallower, and the "not
changing" sites which did not change according to trends
revealed by regression analysis of probing measurements
taken bimonthly on each patient (or control) for the period
of the year. The criterion for "not changing" site was that
a trend toward deepening or becoming shallower at P<0.05
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significant level was not detected over the monitoring
period. The number and percentages of each group of these
sites is shown in Table 2.1.
Using a significance value of P<0.05, it was found that in
the patient group, 50(15.3%) of the total sites became
significantly deeper in probing attachment level, 8(2.7%)
became significantly shallower, while 266(82.1%) sites
showed no significant change at P<0.05 during the period of
study (one year). In the control group, only 2(1.4%) sites
become significantly deeper in their probing attachment,
3(92%) sites became significantly shallower in their
probing attachment, while 145 (96.6%) sites showed no
significant change over the period of study.
The standard deviations of the repeated measurements, at
each visit, of all "not changing" sites were averaged and
their mean was used in deciding a cut off point which was
used in determining the real change for each site at each
bimonthly visit and over one year. The number of "not
changing" sites and the average of their standard
deviations in each group was shown in table 2.2.
A cut off point which was more than three times the average
of the standard deviations of the "not changing" sites was
selected for both patient and control groups. For the
periodontal sites in patient group, the cut off point was
>1.92 mm (3x 0.64)), and later rounded up to 2mm, while for
the periodontal sites in the control group this was >1.32mm
(3x 0.44mm) rounded up to 1.5mm.
From the above results, a change equal to or more than 2mm
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was taken as a threshold level for attachment measurement
change at each periodontal site in the patient group. In
order to consider that a real change of attachment level
had occurred at a periodontal site, the site had to show a
change which was equal to this threshold over two months
between each pair of successive visits or over one year
between the first and the final visit.
In the control group, a change equal to or more than 1.5mm,
was taken as the threshold level for attachment measurement
change at each periodontal site. In order to consider a
periodontal site showed real attachment level change, it
must have shown a change which was equal to this threshold
over 2 months between each successive visits, or over one
year between the first and sixth visit.
Another less stringent criterion was used (in our study) in
detecting a real change at each periodontal site in the
patient group. This included the use of a cut off point
which was more than twice the averaged standard deviations
of the "not changing" sites, and this was more than 1.28mm
(2x0.64) rounded up to 1.5 mm.
Safety threshold method:
This is based on a reducing the false positive rate of
attachment level measurements using the frequency
distribution of the standard deviations of the repetitive
measurements at sites which showed no significant
attachment level change (the "not changing" sites) by
regression analysis at P<0.05 (Tables 2.2, 2.3a, 2.3b).
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This method was used to test the validity of the 2mm cut
off point which was mentioned before.
In this method, a cut off point of 2mm for the patient
group and of 1.5 mm for control group, was selected as a
safety threshold in determining a real change in attachment
level at each site. The 2mm safety threshold for the
patient group was at least twice the standard deviations of
more than 95% of the "not changing sites" determined by
regression analysis. This selection was based on the chance
that a false positive rate for attachment level
measurements would be less than 5%, i.e. only less than 5%
of attachment level changes using this threshold would be
due to measurement error and this was considered the false
positive rate (the number of sites which did not show a
real attachment level change but they were recorded as if
they did show the change). The selected safety threshold of
2mm was at least twice the standard deviations of more than
95% of the "not changing" sites and its occurrence was
within less than 5% of the false positive rate.
The safety threshold for the control group was selected to
be 1.5mm which was at least twice the standard deviations
of more than 97% of "not changing" sites in this group, and
this was also within less than 5% of the false positive
rate.
This method of selecting the safety threshold was used by
Lindhe et al. (1986) who used a safety threshold of more
than 2mm of probing attachment level difference to identify
sites with attachment loss. A cut off point of 2mm in our
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study which was selected originally on the basis of
averaged standard deviations of "not changing" sites
determined basically by regression analysis, was confirmed
when the frequency distribution of the range of standard
deviations of those sites was used to determine a cut off
point or safety threshold. In both methods, the safety
threshold was equal to 2mm for the patient group and to
1.5mm in the control group. This difference in threshold
level between patient and control groups could be due to
subject variation and/or site variation (Badersten et
al.l984d), as for example the mean pocket depth in the
control group was significantly less than in patient group
(P< 0.05) . It has been found that probing measurements
become more deep and reproducible in the deep pockets than
shallow pockets (Janssen et al.1987).
2.7.2 Classification of periodontal sites according to
attachment level change in the longitudinal
study
A safety threshold or cut off point of 2mm and 1.5 mm was
first used to classify the change in attachment level at
each periodontal sites in the patient and control groups
respectively, between each successive visit and between the
first visit and sixth visit (over one year). On this basis,
the periodontal sites were classified into three categories
which are:
1.Loser sites: these were the sites that have lost
189
attachment level equal to or more than 2mm between each two
successive visits,or over one year.
2.Stable sites: these are the sites which showed change in
their attachment level at less than 2mm gain or loss
between each successive visits or over one year.
3.Improved sites: these are the sites which have gained
equal to or more than 2mm in their attachment level between
each successive visits or over one year.
The same classification was used for the periodontal sites
in the patient group when a less stringent cut off point of
1.28mm rounded up to 1.5 mm was used. The loser sites were
those sites that lost equal to or more than 1.5mm
attachment level, the improved sites were those which
gained equal to or more than 1.5mm attachment level, while
the stable sites were those which did not show a change of
1.5mm or more in their attachment level.
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TABLE 2.1: The number and percentage of periodontal sites which did not
change, became significantly deeper or became significantly
shallower according to trends revealed by regression analysis
(at P<0.05) of attachment level measurement taken bimonthly in
all subjects within each group for the period of one year.
Subject No. of Not Becoming Becoming
Group Sites Changing Deeper Shallower
Controls 150 115(96.61) 2(1.11) 3(21)
Patients 321 266(32 . 1 1) 50( 15.31) 8(2.71)
TABLE 2.2 Means of standard deviations (SD) of repeated measurements at
sites showing no significant attachment level change detected by
regression analysis at P<0.05. The safety threshold equal to
more than 3 mean of standard deviations was rounded up to the
nearest mm.
Subject Number Mean SDs (mm) Safety
Group of Sites Threshold (mm)
Patients 266 0.64 2.00
Controls 145 0.44 1.50
TABLE 2.3a: Frequency distribution of standard deviations (SD) of the
repeated probing attachment level measurements at sites showing
no significant attachment level change determined by regression
analysis at P<0.05.
Patient Croup
Total sites = 266
SD Range (mm) Number of Sites Percentage Accumulative
Percentage
0.00-0.49 115 43.23 43.23
0.50-0.99 128 48.12 91 .35
1 .00-1.124 10 3.76 95.11
1 .125-1.249 6 2.26 97.36
1 .25-1.99 5 1 .88 99.24
2.00 2 0.75 99.99
TABLE2.3b: Frequency distribution of standard deviations (5D) of the
repeated probing attachment level measurements at sites showing
no significant attachment level change determined by regression
analysis at P <0.05.
Control Group
Total Sites = 142
SD Range (mm) Number of Sites Percentage Accumulative
Percentage
o • o o o ID 112 77.2 77.2
0.50-0.749 23 15.8 93.0
0.75-0.99 7 4.8 97.8
1.00-1.125 3 2.2 100
2.7.3 Statistical Analysis
All statistical analyses were performed on the mainframe
UNIX computing system at Edinburgh university, using the
General Statistic (Genstat) package.
Various statistical analyses were used according to the
requirement.
Analysis of clinical findings and microbiological data was
performed using both subject and site as an experimental
unit. Statistical analysis for CRP results was performed
using the site as experimental unit except for saliva and
serum CRP where the subject only was used for analysis.
In the case of using the subject as an experimental unit,
the values of the clinical indices (PD, GCF volume and
attachment level change) and microbiological data using the
percentage of each bacterial morphotype (coccoid cells,
other, motile rods and spirochaetes) were averaged from all
the selected sites within each subject and that produced a
subject mean for the variable. Data on serum C-reactive
protein (CRP) and salivary CRP results were only used on a
subject basis.
When the site was used as an experimental unit,the values
of each of the clinical parameters, the microbiological
variables (using percentages of bacterial morphotypes) and
the gingival crevicular CRP results for both concentration
and secretion) , were averaged for all the sites in each
group of subjects, and that was considered a site mean for
that variable. The site mean for each subgroup of sites
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(loser, stable and improved) for each variable was
calculated in the similar way.
Regression analysis using Pearson correlation coefficient,
Spearman rank correlation test, Chi-Square, and the
analysis of variance (ANOVA) including the t-test, Fisher
test (F-test) and paired-t-test, were used in current
studies. These were used to seek any correlation between
the changes in attachment level and each of the clinical,
microbiological variable as well as CRP results. This was
done using either the site or the subject (when suitable)
as an experimental unit of analysis. These methods were
also used to compare the differences in the clinical,
microbiological and CRP results, between the classified
site groups of attachment level changes (loser,stable and
improved sites) .
Fisher-test was used to search for any difference in the
clinical, microbiological variables and GCF CRP results,
among site groups at the same visit. In case the F-test
showed a significance value of F< 0.05, the differences for
any variable between the loser and stable site groups or
between the loser and improved site groups of sites were
tested using t-test.
Both parametric and non-parametric statistical methods
(when suitable) were used to seek any possible correlation
between the clinical parameters and change in attachment
level for both subject and site as experimental units.
For discrete variables (plaque index, gingival index and
bleeding on probing), non-parametric statistical method
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were used when either subject or site was used as an
experimental unit. Chi-square was used to test the
correlation of these discrete variables to the attachment
level change, and to compare their difference among
classified groups of sites. Fisher test was used to find
the correlation of these discrete variables with GCF CRP
concentration and secretion.
When the site was used as an independent unit, regression
analysis and Spearman rank correlation test were used to
test for an association between attachment level change for
each site group and the clinical, and the microbiological
variables as well as GCF CRP results. The loser site group
was compared with stable and improved site groups for its
clinical variables, microbiological variables and GCF CRP
results using a t-test.
When the subject was used as a unit of analysis, the change
of attachment level between each two successive visits at
2 months intervals, and over the one year period was
averaged from the selected sites within each subject, and
the resultant subject mean for attachment level change was
used for ranking these subjects. The values of each
clinical variables (PD, GCF volume) or microbiological
variable using percentage (coccoid cells, other, motile
rods and spirochaetes) at the initial visit of each
successive visits were averaged from the selected sites
within each subject. The average was used for ranking the
subject for that variable. Spearman rank correlation was
used to assess the association between each of these
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variables and attachment level change.
For GCF CRP results, both concentration (ng/ml) and
secretion (ng/minute) were used for analysis on a site
basis only, and normal logarithms for the concentration was
used only when it was necessary.
For normalisation of GCF data, any negative value for the
GCF volume was adjusted to 0 value for volume calculation
only. Any negative value of transformed GCF volume was
ignored and not used for GCF CRP level calculations for
both concentration and secretion, while a 0 value of GCF
volume was used for GCF CRP secretion results but not for
CRP concentration results.
For GCF CRP results, when the CRP test was positive for
each of the duplicated GCF samples the values were
averaged, and when the test was negative for both samples
the result was considered negative and was give a value of
zero. In case of one GCF sample being positive and the
other negative, the negative value was considered equal to
35ng/ml which was half of detectable limit (70 ng/ml) by
ELISA for CRP. The value of CRP for the positive sample and
the 35 were averaged to produce a mean for that sample.
GCF CRP levels were compared between loser sites and stable
sites (loser versus stable sites) within each subject at
initial visit and at the subsequent visit of each pair of
successive visits, and also for their difference between
the initial and subsequent visits. CRP levels were also
compared for each site group (loser versus loser and stable
versus stable), between the initial and the subsequent
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visit of each pair successive visits and for the one year
period. The above comparisons were carried out using ANOVA.
Further more, GCF CRP levels were compared in a similar way
as above using the matched pairs of loser and stable sites
within each subject using paired-t-test.
A null hypothesis was suggested that there would be no
association between GCF CRP levels for both secretion and
concentration with attachment level change over each
prescribed period. This was required to test the GCF CRP
level differences between loser and stable sites recorded
for pairs of successive visits or for the period of one
year. The null hypothesis required that there would be no
difference in GCF CRP level between loser and stable sites
at the subsequent visit (where the attachment level loss
could have occurred) of each paired successive visits at 2-
months intervals. It also included the fact that there
would be no significant difference in the CRP levels over
two months (or one year) recorded for each of the loser and
stable site groups.In addition, the difference in CRP
levels over each paired successive visits (or over one
year) should not significantly vary between the loser and
stable site groups. This is the most important effect as it
compares the change between the initial visit and
subsequent visit at loser versus stable sites. So if these
hypotheses were null particularly the last one, then CRP
levels would not show any association with attachment level
change, and its level would not be significantly different
between the sites showing attachment level loss (loser
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sites) and the non changing sites (stable sites).
The change in CRP levels, was calculated by subtracting CRP
level at the subsequent visit from that at the initial
visit of each pair of successive visits.
In order to investigate the possible diagnostic potential
of GCF CRP levels as a test, a contingency 2x2 table (Table
2.4) was formulated based on the data of GCF CRP recorded
at the subsequent visit of each pair of successive visits.
The mean GCF CRP concentration (ng/ml) or secretion
(ng/minute) for the loser sites at this subsequent visit
was used as a threshold value for the CRP level test. In
the case of using CRP concentration as a threshold value,
the test was considered positive when the site demonstrated
a CRP level above this designated threshold value, where if
the concentration was equal to or below this threshold
value the test was considered negative. The same conditions
were applied when CRP secretion was used to test its use as
a diagnostic aid. Specificity and sensitivity values and
positive and negative predictive values were calculated
using standard methods as shown in table 2.4.
Further to the above statistical methods, logistic
discriminant analysis was used to find the ability of the
clinical parameters, the microbiological variables, and GCF
CRP levels individually or collectively to discriminate
between the loser (active) and stable (inactive) site
groups over each prescribed period including the one year
period. This analysis was also used to find the ability of
the above variables individually or collectively to predict
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periodontal disease activity in the patient group over each
prescribed period. In other words, to investigate their
possible role, and in particular GCF CRP levels for both
concentration and secretion as diagnostic predictors for
the periodontal breakdown as measured by attachment level
loss in our study.
Throughout this thesis, the term 'paired successive visits' is
used to describe any pair of the consecutive visits which took
place at intervals of two months during the course of the
study. For example Visit 1 and Visit 2 (two months apart) are
considered 'paired successive visits', where Visit 1 is the
initial visit of the pair and Visit 2 is the subsequent visit.
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TABLE 2.4 2x 2 table for CRP diagnostic test and
characteristics.
Disease Present Disease Absent
Positive CRP True positive (a) False positive (b)
test
Negative CRP False negative (c) True negative (d)
test
Positive predictive value = a/ (a + b)
Negative predictive value = d/ (c + d)
Sensitivity = a/(a + c)
Specificity = d/(b + d)
CHAPTER THREE
Laboratory Materials and Methods
3.1 Materials
All chemicals were analytical grade and obtained from BDH




Carbonate-bicarbonate buffer (pH 9.6) : this was prepared by
dissolving 1.59g Na2C03, 2 . 93g NaHC03, and 0.2g of NaN3, made
up to 1 litre with distilled water, and the pH was adjusted
to 9.6. This buffer was then stored at 4 C° and used for two
weeks only .
3.1.1.2 Phosphate buffered saline (PBS)
This was prepared by dissolving 8. Og of NaCl, 0.2g of
KH2P04, 2 . 9g of Na2HP04.12H20, 0.2g of KC1 made up in 1 litre
of distilled water, and the pH was adjusted to 7.4.
3.1.1.3 Washing and diluting Buffer (PBST-20)
This is a phosphate buffered saline plus 0.05% w/v tween,
prepared by dissolving 8. Og of NaCl, 0.2g of KH2P04, 2.9 of
Na2HP04.12H20, 0.2g of KC1, 0.5ml of tween 2 0 (Sigma Chemical
Company Ltd, Poole, Dorset),made up to 1 litre of distilled
water. The pH was adjusted to 7.4.
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3.1.1.4 Phosphate citric buffer
This was prepared by adding 25.7mls of 0.2 M dibasic sodium
phosphate, and 24.3mls of 0.1 M citric acid to 50 ml of
deionized water made up to 100 mis. The pH was adjusted to
5.0.
3.1.1.5 Fetal Bovine serum
This was bought from Boehring (Boehringer Mannheim,
Diagnostics and Biochemical Co.Ltd, Lewes, East Sussex,
U.K) .
3.1.2 Purified standard C-reactive protein and antisera
for enzyme-linked immunosorbent assay (ELISA)
3.1.2.1 Rabbit Anti-Human C-Reacive Protein (IgG Fraction
of Antiserum Developed in Rabbit
This was bought from Sigma (Sigma Chemical Company Ltd,
Poole, Dorset, UK).
3.1.2.2 Goat Anti-Rabbit IgG (Whole Molecule) Horse
Raddish Peroxidase Conjugate (affinity isolated
antigen specific antibody developed in goat)
This was bought from Sigma (Sigma Chemical Company Ltd,
Poole Dorset, UK) . It had an enzymatic activity of 35
purpurogallin units/ml.
204
3.1.2.3 Goat Anti-Human C-Reactive Protein developed in
goat
This had a concentration of 6.3mg/ml and was bought from
Sigma (Sigma Chemical Company Ltd, Poole, Dorset, UK).
3.1.2.4 Substrate
Each tablet contained 4mg of o-Phenylenediamine
dihydrochloride (OPD). This was bought from Sigma (Sigma
Chemical Company Ltd, Poole, Dorset, UK).
3.1.2.5 Substrate buffer solution
This was made by dissolving 1 tablet of the substrate (OPD)
in each 20 mis of phosphate citric buffer at pH 5.0. Four
microlitres of 100% volumes hydrogen peroxide were
immediately added to each 20 mis of phosphate citric buffer
prior to addition of the substrate.
3.1.2.6 Standard C-Reactive Protein (STD CRP)
This was bought Boehring (Boehringer Mannheim, Diagnostics
and Biochemical Co.Ltd, Lewes, East Sussex, U.K). It a had
concentration of 79 mg/L.
All the standards and antisera for ELISA assays came in
liquid form except Rabbit anti-human CRP which came in the
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form of lyophilised powder and was reconstituted according
to the manufacurer's instructions. All reagents, after
reconstitution if required,were aliquoted and stored at -20
C° until used. Reagents were replaced regularly to avoid
expiration.
3.1.3 Microtitration plates
These were microtitre plates bought from Dynatech
Laboratories Ltd.Sussex, UK.
3.1.4. Multiskan Reader II




3.2.1 Calibration of Periotron 6000
The Periotron was calibrated on a bimonthly basis by
duplicate measurements of volumes using normal blood serum
from 0.05 to 1.OuL on periopaper strips (periopaper, IDE
Interstate, Amityville, NJ,U.S.A.) . At the time of each
patient sampling additional duplicate determinations of 0.3
and 0.5uL were also made.
The reciprocal jaws were cleaned with 95% methanol and
allowed to air dry before the filter paper strip was
inserted between its jaws. Prior to application of a sample
a dry clean periopaper was placed between the electrodes of
the Periotron was then adjusted to zero. The paper was then
removed and a measured volume of serum was placed on the
end of the strip using a one microlitre Hamilton syringe
(Hamliton Bonaduz, AG, CH-7402, Switzerland). This syringe
was used to deliver to the filter-paper strips volumes
ranging from 0.05 to 1.35uL at 0.05 increments. The paper
was replaced in the Periotron 6000 (IDE, Amityville, New
York, U.S.A.) and the scale value read after 16 seconds.
This was repeated ten times for each volume. The Periotron
readings for all volumes were expressed as the mean +_
standard deviation of all ten measurements. Linear
regression analysis was used to generate lines representing
the relationship of volumes to readings on the Periotron
6000 (Figure 3.1).
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Using linear regression analysis, the points plotted for
serum were resolved into two lines. The first line being
determined by fluid volumes from 0.05 to 0.4uL, and the
second line by fluid volumes from 0.4 to 1.35uL. The slope,
intercept, and the coefficient of correlation for each line
in both scales were provided in Figure 3.1. The slope of
the lines determined by volumes below 0.4 was significantly
(P< 0.01) less than the slope of the line determined by
volumes greater than 0.4. An important consideration is the
volume of fluid corresponding to each unit reading on the
periotron 6000. Using the slope of the line determined by
smaller volumes of fluid (0.05- 0.4uL), each periotron unit
was equal to 0.00484 uL for serum (r= 0.9979) while for the
line determined by volumes above 0.4uL, the slope was
corresponded to 0.00923 (r= 0.9962) uL per unit of reading.
The study showed a reasonably accurate assessment of GCF
volume from 0.05 to 0 . 4uL as each unit reading corresponded
to approximately 0.005uL, was consistent with that of the
manufacture, but not for volumes above 0.4. Our results for
those volumes (0.05-0.4uL) are also consistent with those
by Lamster (1985b) and Hinrich et al.(1984).
3.2.2 Determination of GCF volumes
Conversion of a specific number of units on the Periotron
to an actual GCF volume requires consideration of both the
slope and the intercept.
208
A calibrated curve was constructed for the Periotron 6000
to determine the actual volume of GCF on each filter strip
(Fig.3.1). The graph is based on the relationship of unit
readings on the Periotron to known volumes of serum
delivered onto the strip. This calibration graph indicated
that each periotron unit from 0 to less than 75 units
corresponded to 0.00484uL, and each periotron unit above 75
was corresponded to 0.00923uL.
The conversion of specific unit readings on the periotron
6000 to the actual volume of GCF sampled on a filter strip
was made by using the equation for that section of
calibrated graph. The following equation was used for the
calculation:
Y = AB + C. where:
Y = The actual volume sampled on periostrip to be
determined.
B = the slope of the line relating fluid measurements to
fluid volumes.
A = the Periotron reading.
C = the measurement intercept when the Periotron reading is
0 .
When calculating the actual volumes of GCF, the slope, and
the intercept of the calibration graph were used for each
cut off volume.
Fig.3.1 showed the relationship of unit readings on the
Periotron 6000 to actual volume of fluid which was drawn by
the graph. Linear regression analysis was used to fit
lines to the data. The data were resolved into two lines
209
(0.05 to approximately 0.4uL, 0.4 to 1.35uL), and the slope
, intercept and correlation coefficient (r) were provided.
The boundaries of these lines as based on the abscissa
(unit readings on the Periotron) for serum were 0-75, and
75-175. Based on these cut off points related to the
boundaries of these two lines, the following mathematical
equations which are consistent with above equation, were
used to convert the periotron reading in the actual volumes
which used calculations:
I. If the reading was equal or below 75, the following
equation was used:
Y = (A x 0.00484) + ( -0.005).
II. if the reading was above 75, the following equation was
used:































































3.2.3 Elution of GCF from periopaper
A method for elution of static GCF was developed and was
shown to provide nearly total recovery of CRP activity from
the filter papers. The GCF samples after collection (2.6.2)
were recovered from the strips via a centrifugal elution
technique. The 50 uL of PBST used for storage of periostrip
was removed from the inner tube inside the microcentrifuge
tube and relayered on the filter strip. The tubes were
centrifuged at 13,000xg for 30 seconds, followed by three
additional extractions with 50 uL of PBST. The strip, which
was still retained in the perforated inner tube, was then
discarded and the eluted 200 microlitre, in the lower part
of the tube, transferred to a fresh vial and stored frozen
at -40 C° until required for subsequent analysis of CRP
which was normally performed within two months of
collection. The volume on the strips was estimated by means
of Periotron 6000 units and reference to the calibration
curve.
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3.3 Development of a modified ELISA technique for
quantification of CRP in Serum, Saliva and
Gingival Crevicular Fluid
A double sandwich solid phase enzyme-linked immunosorbent
assay (ELISA) was developed to detect and measure CRP in
GCF,saliva and serum. This is a modified technique of the
ELISA used by Salonen (1982) for measuring serum CRP, with
an improvement to increase its sensitivity limits and this
could be used for measuring CRP in small volumes such as
0.1-0.2uL of GCF samples.
3.3.1 Sandwich ELISA methodology
Method:
First step:
This included coating the microtitre plate with the first
antibody, the goat antihuman CRP antiserum which is
specific to the antigen (CRP).
Microtitre plate (Dynatech Laboratories, Sussex, U.K) was
coated with 50 microlitre/well of goat antihuman CRP
antiserum at 1/5000 in coating buffer (carbonate
bicarbonate buffer) at pH 9.6. The plate then incubated
overnight at 4 C°.
Second step:
This included the addition of the test sample (serum, GCF,
saliva), and purified standard serum CRP to the plate where
any antigen (CRP) present in the sample was captured by the
immoblised antibody. In this step, the plate was washed
with washing buffer (PBST 20) three times with 30 seconds
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intervals, and dried in the air. 50uL of diluted antigen
(standard serum CRP) or diluted test sample in PBST 20 were
added per well and incubated for 90 minutes at 37 C°.
The test sample for GCF, serum, and saliva were diluted at
1/200, 1/2000, and 1/2 respectively. The first vertical
column of the plate was used for 8 controls which were antigen-
free. The vertical second and final columns were used for
serial two-fold dilutions of the purified standard CRP,
resulting in a total of 8 standard solutions within the
working range for the CRP assay from 8.976 to 0.070 ng/ml.
This allowed the construction of a standard curve from
which sample antigen quantities could be found. The
standards were run in duplicate,and a total of 24 samples
of antigen were run in triplicate horizontally in each
plate.
Third step:
This included incubation with the second specific
antiserum, the rabbit anti-human CRP antiserum. In this
step, the plate was washed three times with PBST 20, and
dried. 50uL of rabbit anti-human CRP at dilution
1/20000 in PBST 20, was added for each well, incubated for
90 minutes at 37 C°.
Fourth step:
This included the incubation with horse radish peroxidase
(HRP) conjugated goat anti-rabbit IgG. In this step, the
plate was washed three times by PBST 20, dried in the air,
and 50uL of horse radish peroxidase (HRP) conjugated goat
anti-rabbit IgG at dilution of 1/500 in PBST 20 was added
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to each well. The plate was incubated for 120 minutes at 37
C°.
Fifth step:
This included addition of the substrate (OPD) to the plate,
stopping the reaction and the plate reading. The plate was
washed three times with PBST 20, dried in the air, and
lOOuL of the substrate (OPD) solution was added to each
well. The reaction was stopped within 25 minutes using 50
uL/well of 0. 2M H2S04. The plate was then read at 492nm
blanked on the first column (the controls), and the optic
densities obtained using a Multiscan II reader which
connected directly to the an IBM PC computer with a
computing ELISA programme to give absolute reading of CRP
as ng/ml.
In all steps the incubating buffer (PBST 20) contained
fetal bovine serum (FBS) at 5% w/v and 0.05% w/v of Tween
20, except the substrate solution and the coating antibody
step.
3.3.2 Establishment of CRP sandwich ELISA
A series of experiments were conducted in order to
establish conditions for the ELISA. The standard chess
(check)-board type dilutions were used for defining the
optimal condition for goat, rabbit and HRP conjugated
antiserum dilutions.
Serial Chess-board type dilutions of goat antihuman CRP
antibody (1/100, 1/1000, 1/3000, 1/5000, 1/10000) in
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coating buffer (carbonate bicarbonate buffer), Rabbit
antihuman CRP antibody (1/5000, 1/10000, 1/20000, 1/40000),
and HRP conjugate (goat anti rabbit IgG conjugate) at
1/100, 1/250, 1/500, 1/1000) in PBST 20 incubating buffer
were used. The optimal conditions for each of these
reagents were obtained where the specific antisera were not
in excess of the antigen (CRP), where there was a minimum
background (non-specific binding). These included 1/5000
dilution in coating buffer for goat anti-human CRP
antiserum, 1/20000 dilution in PBST 20 for rabbit anti-
human CRP antiserum, and 1/500 dilution in PBST 20 for HRP
conjugate goat anti-rabbit IgG antiserum , and all (except
goat) antiserum gave best results with incubation
temperature at 37 C°. Incubation with goat anti-CRP antibody
overnight at 4 C°, was used because this gave more uniform
results. Incubation for 90 and 120 minutes with the
standard CRP or specific rabbit antiserum gave a similar
standard curve resolution. 120 minutes for incubation with
HRP conjugate gave better standard curve resolutions and
better results for the test samples than 90 minutes
particularly when the conjugate at 1/500 in diluting buffer
was used. These conditions gave low non-specific binding
(optic density < 0.01) in the controls and maximum optic
density (OD) in the lowest standards 25 minutes after
adding the substrate. So incubation for 90 minutes with
standard/ specific antisera, and incubation for 120 minutes
with HRP conjugated serum was selected for the ELISA.
The best results were based on the best curve resolutions
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and the very low non-specific binding in the controls. Also
the optimal conditions included maximum OD in the presence
of the antigen (Standard CRP).
Various percentages of the blocking agent, the fetal bovine
serum (FBS) at 10% w/v, 5% w/v and 1% w/v were tested in
their ability to block the non-specific binding and reduce
the background. The 5% FBS was found to give the optimal
results for ELISA with minimal background and high
sensitivity. Blocking with FBS at 5% w/v in all reagents,
with exception of coating antibody and substrate solution,
during incubation was judged to be sufficient.
The detectability limit of the assay, was defined as the
lowest concentration of the standard antigen (CRP) which
gave optic densities significantly different from that of
the controls. In order to make the assay more accurate and
precise, the best concentration of standard CRP was
selected, on the basis that the lowest standards or those
values of the linear portion of the standard curve gave an
optic density significantly higher than that of the
controls.
Various working ranges of purified CRP (standard CRP) were
tested to construct the reference curve. These included
18.0-0.14ng/ml, 9.00-U.077ng/ml, 8.977-0.070 ng/ml and
4.488-0.350ng/ml) of purified STD CRP. The last working
range resulted in less significant differences at the
lowest portion of the curve from that of controls when
compared to the standard CRP concentration range of 8.977
to 0.07 ng/ml and thus the second one was selected for the
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construction of the curve. This range gave best resolution
for the standard curve, and significantly higher optic
densities for the lowest standards than those of the
controls. The working range of the standard antigen was
produced by serial two fold dilutions of the standard
antigen in PBST 20, resulting in 8 standard dilutions for
the construction of a standard curve (Figure 3.2) . The
resolution of the curve drawn from standard CRP
concentrations plotted against their ODs were improved when
the working range of 4.488-0.035ng/ml was increased to the
range of 8.977-0.070ng/ml. This was carried out to make the
difference between the OD of the lowest standards of the
linear portion (precision part) of the standard CRP curve
at the second working range different significantly from
that of the controls, in comparison with the first working
range. This working range had a significantly different
optic density for the last two values when compared with
ODs of the controls which have very low non-specific
binding (background) < 0.1 with H2S04 and < 0.01 before
stopping the reaction 25 minutes after the addition of
substrate.
Figure 3.2 showed the typical calibration curve for
standard CRP at concentrations ranging from 8.977-
0.070ng/ml, plotted against their corresponding optic
densities. The least squares method was used to plot the
line of best fit and the correlation coefficient (r > 0.99
was obtained for the assay. Linear function of the
concentration C = A + B X OD, where OD= optic density, C=
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the concentration, A= the intercept and B= the slope (the
best fitted line of concentration against the OD) was used
for the determination of sample antigen quantities. A
similar standard curve was generated automatically by the
computerised ELISA programme, and a new line fitted each
time an assay was run. The sample antigen was quantified
















































3.3.3 Pilot study in the quantification of C-reactive
protein (CRP) in serum, saliva and GCF using
double sandwich ELISA
3.3.3.1 Preliminary experiments to detect and quantify
CRP in GCF
Studies were conducted to find if CRP was present in GCF or
not. Small volumes of GCF were collected from healthy sites
(less than O.luL for most of them), and the minimum amount
of fluid required to run ELISA assays for antigen
determination in triplicate is 150uL (50uL per well). Thus
eluting sampled GCF in 1/200 of PBST 20 was tried first.
In order to test for the presence of CRP in GCF and to
establish an elution volume and working dilution of the
sampled GCF for quantification of CRP by ELISA, 100 samples
of GCF were tested with various volumes (Table 3.1)
randomly collected from periodontal sites from both healthy
controls and patients with periodontal disease. These
samples were tested for the presence of CRP, and the
elution/dilution procedure for GCF was established. All the
samples were eluted first in 200 uL of PBST 20 as described
earlier (3.2.3), and further diluted to 1/600 in PBST 20.
The GCF samples were tested for CRP using ELISA for both at
1/200 and 1/600 dilutions in PBST 20.
The results (Table 3.1) showed that CRP is present in GCF
and this is supported by the finding of Sibbera et al.
(1991) who detected CRP by an immunodot method in GCF from
both healthy sites and from sites with periodontal disease.
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The results also showed that an increase in the elution
factor from 1/200 to dilution of 1/600, will result in
decreasing the incidence of CRP detection in GCF samples
from 37% to 20%. It was also found that the range and the
mean of the volumes which gave a positive test for CRP were
increased from the range of 0.12-1.0 uL and mean of 0.317
uL for the positive samples at elution of 1/200 to the
range of 0.305-1.0 uL and mean of 0.40uL for the positive
samples at dilution of 1/600. CRP at elution of 1/200
could not be detected in volumes below 0.121 uL, with a
mean of 0.317 uL, while at dilution 1/600 CRP could not be
detected at volumes up to 0.305uL and at mean volumes of
0.40 uL.
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TABLE 3.1. Gingival crevicular fluid CRP levels (ng/ml) as determined
by ELISA in the original GCF eluate at 1 /200 in PBST 20 and
1 /600 in PBST 20. Incidence of CRP positive test is shown.
Negative results indicate that CRP levels cannot be detected
by ELISA.
GCF elution at 1 /200
in PBST 20
(total sample = 100)
(range of volume =
0.02-1.0 uL)
GCF dilution at 1/600
in PBST 20
(total samples = 100)
(range of volume =
0.02-1 .0 uL)
CRP test Positive Negative Positive Negative
Number of
samples
37 63 20 80
GCF volume
range (uL)
0.121-1.00 0.020-0.350 0.305-1.00 0.020-0.52
GCF volume
mean (uL)





In order to confirm the presence of CRP in GCF and to find
if the elution of 200uL is better than 250uL, another 100
samples of GCF were eluted (3.2.3) in 250uL and were also
further diluted to 1/500 in PBST 20. These samples were
tested for the presence of CRP by ELISA. These samples had
various volumes (Table 3.2) and had been randomly collected
from various sites from both healthy subjects and
periodontally diseased patients. The results confirmed the
presence of CRP in GCF, and indicated that increasing the
dilution of GCF resulted in decreasing of the incidence of
CRP in GCF from 20% at elution 1/250 to 11% at dilution of
1/500. A positive CRP test was only found at volumes equal
to or more than 0.213 uL with elution of 1/250, and at
volumes equal to or more than 0.37uL when GCF were diluted
up to 1/500.
The results from both experiments using elution at 1/200,
1/250 and dilution at 1/600, 1/500 in PBST 20, confirmed
CRP presence in GCF, and that the developed ELISA could be
used to detect its presence. These data also indicated that
elution of GCF samples in 2 00 uL was most suitable for
detection of GCF CRP, if present, in all the volumes as
both the lowest and highest concentrations of samples
tested were found to be within the working range of the
standard CRP. On the other hand, it seems that 1/200
elution would avoid further dilution of volumes
particularly at 0.1-0.2uL and would avoid the chance of
missing the CRP, if present. It would however, help to
detect the CRP, if being present in small volumes
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particularly at healthy sites or those with early
inflammation. This was later proved when no volume below
0.luL showed the presence of CRP, and no volume even more
than luL showed CRP concentration outside the working range
of the standard CRP using elution of GCF at 1/200 uL with
PBST 20.
The volume (elution) to 1/200 from the technical point of
view is the lowest volume that is reguired for the assay
(ELISA).
The experiments also indicated that the developed ELISA can
only detect CRP, if present, in any volume egual to or more
than 0.luL. Any volume below that showed no CRP present,
and this either was due to the dilution factor and limited
sensitivity of ELISA or more likely the concentration was
too small to be detected or there was no CRP.
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TABLE 3.2. Gingival crevicular fluid CRP levels (ng/ml) as determined by
ELISA in the original GCF eluate of 1 /250 in PBST 20, and at
dilution of 1 /500 in PBST 20. Incidence of CRP positive tests
was shown. Negative results indicate that CRP levels at that
volume cannot be detected by ELISA.
CCF elution at 1 / 2 5 0 GCF dilution at 1/500
in PBST 20 in PBST 20
(total samples = 100) (total samples = 100)
(volume range = (volume range =
0.035-1 .05 uL) 0.035-1 .05 uL)
CRP test Positive Negative Positive Negative
Number 20 80 11 89
CCF voiume 0.213-1 .05 0.035-0.420 0.370-1.05 0.035-0.530
range (uL)





In order to find if CRP in GCF responds in the same way as
the standard CRP, five samples (sample 1 to 5) of GCF were
collected and eluted (3.2.3) originally in 200uL of PBST
20, and were further diluted in 1/600,1/1800 of PBST 20.
Another six samples (sample 6 to 11) were collected and
eluted (3.2.3) originally in l/250uL of PBST 20, and were
further diluted at 1/500, 1/1000 in PBST 20.
As shown in Table 3.3 acceptable dilution profiles were
obtained for CRP in all the samples. This indicated that
CRP in GCF responds in a similar way to the highly purified
standard CRP and all the concentrations were within the
working range when elution 1/200 was used. This also
indicated that the developed assay (ELISA) could be used
for GCF CRP quantification.
3.3.3.2 Assessment of the recovery of CRP protein from
periopaper in vitro
In order to assess the suitability of periopaper as a means
of collecting GCF for subsequent CRP analysis, the recovery
of CRP applied to this strip was investigated. Serum
samples containing known concentrations of CRP were used
for this investigation. Using a one uL Hamilton syringe,
one uL of the serum was applied to each periopaper (10
strips) . Each strip was then transferred to a plastic
micro-centrifuge tube and the collected fluid was eluted
into 200uL of PBST 20 (3.2.3) . The eluted samples were then













Gingival crevicular fluid CRP levels (ng/ml) as determined by
ELISA in serial dilutions of the original GCF eluates at 1/200
and 1 /250 uL in PBST 20. Results 'below' indicate that the CRP
level cannot be detected by ELISA at that dilution.
GCF Volume (uL) Dilution Factor CRP Concentration
(ng/ml)
0.787 1 / 2 0 0 238
1 /600 90.3
1/1800 49.6
0.208 1 / 2 0 0 277.5
1 / 6 0 0 98.3
1/1800 below
0.365 1 / 2 0 0 713
1 / 6 0 0 241.2
1/1800 80.23
0.529 1 / 2 0 0 333.78
1 / 6 0 0 132.4
1/1800 below
0.252 1 / 2 0 0 55.55
1 / 6 0 0 below
1/1800 below
0.126 1 / 250 115.8
1 / 5 0 0 below
1/1000 below
0.279 1 / 2 5 0 66.7
1 / 5 0 0 below
1/1000 below
0.213 1 / 2 5 0 274
1 / 5 0 0 147.6
1 /1000 below
0.373 1 / 2 5 0 554.3
1 / 5 0 0 286.2
1/1000 94
0.252 1 / 2 5 0 141
1 / 5 0 0 82.2
1/1000 below
0.210 1 / 2 5 0 49.3
1 / 5 0 0 below
1/1000 below
concentrations in the eluate within the working ranges of
the sandwich ELISA. The concentrations of CRP in the serum
in the original 200uL eluate for each of the strips was
compared against that in the 200uL (10 samples) of PBST 20
directly delivered to the plate after dilution in 1/2000 uL
of PBST, and the percentage of the efficiency of recovered
CRP was calculated. The results showed that 96.2% of CRP in
the eluted serum applied to periostrips was recovered.The
mean +_SD of CRP concentration for eluted serum was
19.3+_0.8 ug/ml, and for non eluted serum sample was
20.1+_0.7 ug/ ml. The results indicated that this method of
elution and recovery was sufficient to recover almost all
of the CRP from periopaper, and that the periostrip is
suitable for collecting GCF for CRP analysis.
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3.3.3.3 Quantification of serum CRP
In order to find if the developed ELISA could be used for
determination of serum CRP, the following experiments were
conducted.
In the first experiment, 50 samples of serum were used to
find the working dilution of serum for CRP determination.
The samples were diluted at 1/1000, 1/2000, and 1/4000 in
PBST 20, and tested for CRP by ELISA. The results (Table
3.4) indicated that dilution at 1/2000 is the best one for
the determination of CRP in serum as it is the lowest
dilution that gives a high incidence of positive tests
within the working range of standard CRP. During subsequent
experiments when the test serum CRP was detected above the
working range, the next serial two-fold dilution of the
sample was rerun to detect the CRP.
In the second experiment, five samples of serum were
collected and tested for CRP by ELISA. Serial dilutions of
these sera were tested at 1/2000, 1/4000, 1/8000, and
1/16000 in PBST 20 (Table 3.5).
It was found that the concentrations of CRP in serum
responded in a similar way to CRP standards in ELISA. This
indicated that the developed ELISA was suitable for
measuring serum CRP.
3.3.3.4 Comparison of ELISA with Laser nephelometry in
CRP determination
The developed ELISA was compared with Laser nephelometry
(LN) for the detection of CRP.
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Thirty sera from cystic fibrosis patients were kindly
granted to me from Edinburgh Royal Infirmary. These
contained CRP at concentrations of 10.5-45.5 mg/L with a
mean of 28.5mg/L. Their concentrations were already
determined by the LN technique. All 30 sera were diluted at
1/8000 in PBST 20, and subjected to CRP determination using
ELISA. It was found (Table 3.6) that their concentrations
ranged from 8.5 to 41.2mg/L and had a mean of 2 6.3mg/L.
Using percentage efficiency calculations, it was found that
ELISA can quantify up to 92.2% of the total amount of CRP
detected by LN. The correlation between both methods in
quantifying CRP was high (r= 0.93). It could be concluded
that the developed ELISA was valid and suitable for
determination of CRP, even at high concentrations.
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TABLE 3.4. CRP levels as determined by ELISA in sera at serial dilutions in
PBST 20. The result 'below' or 'above' indicates that CRP
levels cannot be detected at that dilution as it was outside the




CRP test Pos. Neg. Pos. Neg. Pos. Neg,
Number 45 50 39 1 1





TABLE 3.5 CRP concentrations (mg/L) in sera as determined by ELISA at two¬
fold serial dilutions ( 1 /2000-1 /15000) in PBST 20. Results
'below' or 'above' indicate that CRP levels cannot be detected
by ELISA as they were outside working range of standard CRP.
Sample Dilution Factor Serum CRP concentration
(mg/L)
1 1 / 2 0 0 0 1 1 .122
1 / 4000 5.661
1 /8000 2.790
1/15000 1.410
2 1 / 2 0 0 0 9.144
1/4000 4.680
1 / 8 0 0 0 2.395
1/16000 1 .205
3 1 / 2 0 0 0 0.258
1/4000 0.146
1 / 8 0 0 0 below
1/16000 below
4 1 / 2 0 0 0 above
1/4000 8.65
1 / 8 0 0 0 4.390
1/16000 2.200
5 1 / 2 0 0 0 0.144
1 /40 0 0 below
1 / 8 0 0 0 below
1/16000 below
TABLE 3.6. Serum CRP concentrations as determined by both ELISA and Laser
Nephelometry (LN) method. A dilution of 1 /8000 in PBST 20 for
each sample was used for ELISA. Percentage of efficiency of
ELISA in measuring CRP was 92.2%.
Method of CRP Detection
ELISA Laser Nephelometry
CRP Levels (number = 30) (number = 30)






3.3.3.5 Quantification of CRP in saliva
Saliva samples were used to test for the presence of CRP.
Fifty samples of unstimulated whole saliva were randomly
collected and used for CRP analysis by ELISA. Up to 2mls
were collected for each sample from controls and patients
with periodontal disease. Samples were left overnight at 4
C°, and then the clear solution removed and transferred to
another clean tube for CRP analysis. The samples were then
diluted in serial dilutions at 1/2, 1/4, and 1/8 in PBST
20, and tested for CRP using ELISA.
The results (Table 3.7) indicated that CRP was present in
the saliva. The data also showed that a dilution at 1/2 was
found to give the best results, and showed a high incidence
of positive CRP tests which was 53% (28) of the total
samples. The incidence of positive CRP was found to be
decreased with increasing dilution factors (Table 3.7) .
In order to find if the CRP in saliva responded in a
similar way to that for standard CRP using ELISA, five
positive samples were selected and retested for CRP at
dilutions of 1/2, 1/4, 1/8 in PBST 20. It was found (Table
3.8) that salivary CRP responded in a similar way as
standard CRP, within the working range, and as the dilution
factor increased the concentration decreased. These results
indicate that the developed ELISA is suitable for detecting
of CRP in the saliva.
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TABLE 3.7 CRP concentration (ng/ml) in saliva samples as determined by
ELISA at double serial dilutions (1/2, 1/4, 1/8) in PBST 20.
The 'negative' result indicates that CRP level cannot be




CRP test Pos. Neg. Pos. Neg. Pos. Neg,
Number 28 22 1 8 32 8 42
Mean CRP 0.382 - 0 .290 - 0.221
concentration
(ng /ml)





TABLE 3.8. CRP levels (ng/ml) in saliva samples as determined by ELISA at
serial dilutions (1/2, 1/4, 1/8) in PBST 20. The result 'below'
indicates that the CRP level cannot be detected at that
dilution as it was below the working range of standard CRP.









1 / 8 0.512
4 1 12 0.142
1/4 below
1 IS below
5 1 /2 0.152
1 / 4 below
1 / 8 below
CHAPTER FOUR
RESULTS
4.1 Attachment level changes in both periodontal
patient and healthy control groups during the
longitudinal study
4.1.1 Incidence of attachment level change over one
year determined by linear regression analysis
method
Fifty four periodontal patients on maintenance therapy at
1-3 months recall and 25 healthy control dental students
with no evidence of periodontal diseases were involved in
present study. Six sites within each subject was selected
(2.2) and these resulted in 324 sites for the patient group
and 150 sites for the control group which were studied over
one year.
Attachment level measurements were taken in duplicate at
each of these sites, at each bimonthly visit, and at the
baseline visit (first visit) using the stent method which
was described earlier (2.5.4.2) . A total of 1920 and 900
replicated measurements were recorded for all the sites at
all visits in patient and control group respectively. These
replicated measurements at each visit for each site were
averaged, and the site mean was used for data analysis. The
replicated measurements resulted in five paired sequential
measurements for each group during the whole year.
The five sequential attachment level measurements were
subjected to linear regression analysis (2.7.1) and the
direction and extent of attachment level change over the
study period (one year) was determined. The projected
change which was the rate of change over one year was
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determined by the regression coefficient (the slope) for
each site, and this coefficient departed from zero at a
significance value of P<0.05.
On the basis of a significant change in attachment level
measurement per site occurring over the study period of one
year, which was detected by regression analysis at
probability (P< 0.05), three group of sites emerged. These
included sites which became significantly deeper, sites
which became significantly shallower,and the "not changing"
sites which did not change according to trends revealed by
regression analysis of probing measurements taken bimonthly
for each patient (or control) for the period of the year.
The criterion for a "not changing" site was that a trend
toward deepening or becoming shallower at P<0.05
significance level was not detected over the monitoring
period. The results of regression analysis for attachment
level changes are shown in Table 4.1.
It was found that in the patient group 50(15.3%) of the
total sites in 25 subjects became significantly deeper
(mean change was -0.42 mm) in probing attachment level, 8
(2.7%) of sites in 7 subjects became significantly
shallower (mean change was +0.39 mm), while 266(82.1%) of
the sites showed no significant change at P<0.05 during the
period of one year study. In the control group, only two
subjects showed attachment level loss over one year and
2(1.4%) of total sites become significantly deeper (mean
change was -0.2mm) in their probing attachment level, 3(2%)
sites became significantly shallower in their probing
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TABLE 4.1: Regression analysis of the attachment level measurements taken
at each bimonthly visit at each site in patient and control
groups. Sites were classified according to trends revealed by
regression analysis of these measurements into: sites becoming
significantly deeper, becoming significantly shallower, and "not
changing" sites. The criterion for "not changing" sites was
that a trend toward deepening or becoming shallower at that site
was not detected over one year at P<0.05..
Site Subject No. of No. of Percentage Attachment
























attachment and these were occurred in three subjects, while
145(96.6%) sites showed no significant change over the
period of study.
4.1.2 Incidence of attachment level change during two
months intervals between each successive visits
determined by a safety threshold method
A safety threshold method described earlier (2.7.1) using
a cut off point of equal to or >2mm and equal to or >1.5mm
was used to determine the change in attachment level at
each periodontal site in the patient and control groups
respectively, between each pair of successive visits and
between the first visit and the final visit (over one
year) . Another less stringent criterion using a safety
threshold of 1.5mm was used to determine the attachment
level change at each periodontal sites in patient group
only.
On the basis of these safety thresholds, the periodontal
sites were classified into three categories which were
loser, stable and improved sites (2.7.2). The number and
percentage, mean and standard error (SE) of attachment
level change for each category for patient and control
groups is shown in Table 4.2 and Table 4.3.
In the patient group, when a safety threshold of 2mm was
used, The percentage of loser sites which lost attachment
level equal to or >2mm over each pair of successive visits
ranged from 3.2%-7.4%, while 22.4% of the total sites
studied became losers during one year. The percentage of
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improved sites which gained equal to or >2mm ranged from
1.9-2.9% over each pair of successive visits while it was
0.7% for all the sites studied over one year. The number of
subjects who showed attachment loss equal to or > 2mm over
each pair of successive visits ranged from 10(18.5%) to 20
subjects(37%), while 36 subjects (66.7%) showed loser sites
in their attachment level at this threshold over one year.
The mean attachment loss for loser sites between each pair
of successive visits ranged from 2.04-2.48mm, while the
mean attachment loss for all the loser sites over one year
was 2.5mm.
When a less stringent criterion (1.5mm) to determine
attachment level change was used, the incidence of loser
sites for each pair of successive visits became higher
approximately at 30%, while only two more sites classified
as loser over a one year period (Table 4.3).
In the control group, using a safety threshold of 1.5mm to
determine attachment level change, the percentage for loser
sites was very small ranging from 0-2% with a mean
attachment loss ranged from 1.5-2mm. The percentage of
improved sites was very small ranged from 0-1.33% with a
mean of attachment gain ranged from 1.50-2mm. It was
obvious from the results (Table 4.3) that in the control
group only very few sites for each pair of successive
visits and over one year showed attachment level change at
this threshold. Thus no further analysis of the data was
worth carrying out on the control group using site as an
experimental anaylsis.
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TABLE 4.2: Classification of attachment level changes per site in patient
group between each two successive visits and over one year (visit
1 —visit 6), using a safety threshold of 2 mm. The sites were
classified into loser, stable and improved sites, and their
numbers, percentage as well as mean attachment level change, are
shown.
No. of
Classified No. of Attachment Level Loser
Visits Sites Sites Percentage Change Subjects
Mean + SE
Visit 1 Loser 24 7.4 -2.04+0.13 17
-Visit 2 Stable 293 90.4 -0.01+0.04
Improved 7 2.2 +2.24+0.13
Visit 2 Loser 14 4.3 -2.23+0.10 1 1
-Visit 3 Stable 301 92.9 -0.09-^0.04
Improved 9 2.8 +2.28+0.21
Visit 3 Loser 16 4.9 -2.39+0.10 16
-Visit 4 Stable 302 93.20 -0.09+0.04
Improved 6 1.9 +2.47+0.20
Visit 4 Loser 10





Visit 5 Loser 23





Visit 1 Loser 70





TABLE 4.3: Classification of attachment level change per site in both
patient and control groups for each two successive visits,
using a safety threshold of 1.5mm. The sites were classified
into loser, stable and improved sites. The number, percentage
as well as mean attachment level change for each site group are
shown.
Loser Sites Stable Sites Improved Sites
Visit Group N Oo Mean+SE N Oo Mean+SE N Oo Mean+SE
1-2 Control 0 0 0 150 100 0.1+0.04 0 0 0
Patient 37 11.4 -2.10+0.1 279 86.1 -0.3+0.04 8 2.5 2.2+0.1
2-3 Control 2 1.3 -2.00+0.3 148 98.7 -0.6+0.05 0 0 0
Patient 26 8.0 -1.91+0.1 287 88.6 -0.4+0.04 1 1 3.4 2.4+0.2
3-4 Control 3 2.0 -1 .75+0.3 146 97.3 -0.3+0.04 1 0.7 1.7+0.0
Patient 27 8.3 -2.07+0.1 288 88.9 -0.6+0.04 9 2.8 2.2+0.2
4-5 Control 3 2.0 -1.75+0.1 145 96.7 -0.2+0.04 2 1 .3 2.0+0.0
Patient 18 5.5 -2.10+0.1 283 90.7 -0.4+0.04 1 1 3.4 2.2+0.1
5-6 Control 1 0.7 -1.50+0.0 149 99.3 -0.3+0.04 0 0 0
Patient 32 9.9 -2.22+0.1 271 86.7 -0.1+0.04 9 2.8 2.2+0.2
1-6 Control 3 2.0 -1.67+0.1 145 96.7 0.2+0.03 2 1 .3 1.5+0.0
Patient 73 23.4 -2.45+0.1 237 76.0 -0.3+0.40 2 0.7 3.0+0.3
4.2 Clinical, microbiological and laboratory-
findings using the subject as an experimental
unit of analysis
Two groups of subjects were used in our study, these were
the patient group and the control group.
The patient group consisted of 54 patients who were on
maintenance periodontal therapy at 1-3 months recall
system. Six sites were selected from each patient (2.2). A
total of 324 sites from all patients were studied. The
control group consisted of 25 healthy dental students with
no history of periodontal disease at selection time and
they had good oral hygiene and a healthy periodontium. A
total of 150 sites from all the controls were selected for
our study. The purpose for selecting these two groups, was
to investigate the clinical parameters and CRP levels and
their association with attachment level change among these
two groups.
In this study, the clinical parameters (PI, GI, BOP, PD,
GCF volume), microbiological data (percentages of coccoid
cells, other, motile rods and spirochaetes) and serum and
saliva CRP were investigated using subject as an
experimental unit. The mean of attachment level
measurements for each subject at each visit, was calculated
by averaging all the values at all six sites within each
subject. This was the subject mean for attachment level
measurement. In a similar way, the subject mean for pocket
depth, GCF volume, and each of bacterial morphotypes at the
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initial visit of each pair of successive visits was
calculated. The subject mean of each variable at the
initial visit was used as a baseline subject mean for the
subsequent (recall) visit for each pair of successive
visits. For the study over one year, the recorded data at
first visit was considered the baseline to the final visit
(sixth visit).
The mean attachment level change for each subject over each
pair of the successive visits (and over one year) was
calculated by subtracting the subject mean of attachment
level measurement at the subsequent visit from the
attachment level measurement at the initial visit.
Subjects were ranked for their mean attachment level
changes over each pair of successive visits (and over one
year, between first and sixth visit).
The subject mean for each variable (except PI, GI and BOP)
at the initial visit of each pair of successive visits (and
at the first visit with relation to sixth visit) was also
ranked. Spearman rank correlations using the ranked subject
mean for attachment level change and each of the above
variables was mainly used in our study when subject was
considered as an experimental unit of analysis.
The exception to this, was the study on serum and salivary
CRP and their association with attachment level change
where no rank system was used.
For discrete variables, PI , GI and BOP, their scores were
compared with attachment level change using a Chi-square
test.
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4.2.1 Clinical findings in the patient and control
groups
The clinical parameters for patient and control groups are
shown in Table 4.4. This included the mean +_ standard error
of pocket depth and attachment level measurements recorded
using the stent technique (2.2) at each visit in both the
control group and patient group. The data showed that both
pocket depth and probing attachment level measurements are
higher for the patient group than the control group at all
visits. The mean pocket depth for patient group was >3.5mm
at all the visits, and did not significantly change during
the whole period.
The differences in attachment level for all the subjects
(in each group) was averaged, and this produced a mean
attachment level change per subject in each group, and this
is shown in Table 4.5. It was found that the probing
attachment level in the patient group was deeper than in
the control group at each visit. The mean attachment level
loss during one year (annual attachment level loss) in the
patient group was 0.42mm and was higher than in the control
group (0.08mm).
The attachment level change per subject over each pair of
successive visits, and over one year was investigated for
their correlation later on (4.2.4.3) with the change in
serum and salivary C-reactive protein (CRP).
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TABLE 4.4: Mean and standard deviation (SD) of pocket depth (PD) andattachment level measurement (ALM) per subject at each visit inpatient and control groups.






















































TABLE 4.5: Mean difference in attachment level measurement per subject
between each two successive visits and over one year in control
and patient groups.
Mean difference in
Visits Subject Group Number in attachment level
(mm)
Visit 1- Control 25 0 .008
Visit 2 Patient 54 -0.211
Visit 2- Control 25 -0 .087
Visit 3 Patient 54 -0.105
Visit 3- Control 25 -0.055
Visit 4 Patient 54 -0.160
Visit 4- Control 25 0.009
Visit 5 Patient 52 -0.111
Visit 5- Control 25 -0.039
Visit 6 Patient 52 -0.244
Visit 1- Control 25 -0.080
Visit 6 Patient 52 -0.420
4.2.2 Association of attachment level change with
clinical parameters (PI, GI, BOP, PD) and GCF
volume in patient and control groups
The purpose of this study was to find if there was any
correlation between attachment level change over each pair
of successive visits (and over one year), with the clinical
parameters (PI, GI, BOP, PD) and GCF volume. In other words
to find if any of these parameters could be associated with
or predict disease activity as measured by attachment loss
per subject. This study was based on using the subject as
an experimental unit (2.7.3).
The subject mean for the attachment level change over each
pair of successive visits, and for pocket depth and GCF
volume, recorded at the initial visit of each two
successive visits, was ranked. Spearman rank correlation
was used to test the association of attachment level change
with these two clinical parameters in each group, and the
results are shown in Table 4.6. No significant correlation
was found between either the pocket depth or GCF volume
with the attachment level change over any pair of
successive visits or over one year in control group. In the
patient group, a significant correlation (r = 0.363 at
P<0.05) was found between GCF volume and attachment level
change only over one year. For pocket depth, a positive
significant correlation (r=0.290 at P<0.05) was only found














Spearman rank correlation test between attachment level change
over each two successive visits (and over one year) with pocket
depth (PD) and gingival crevicular fluid (CCF) volume at the
initial visit in both patient and control groups.
Spearman rank correlation
coefficient (r)


















































* = statistically significant at P <0.05
In the other study, a Chi-square test was used to find if
there was any association between the scores of PI, GI, BOP
and attachment level change in each group over each
prescribed period. As is shown in Table 4.7, no significant
association was found between attachment level change and
PI and between attachment level change and GI in both the
control and patient groups. No significant association was
found for attachment level change with BOP in the control
group, while BOP was significantly (P<0.05) associated with
attachment level change for the successive visits 3-4 and
4-5, as well as over one year.
4.2.3 Association of attachment level change with
bacterial morphotypes (coccoid, other, motile
rods, spirochaetes) in the patient and control
groups
The purpose of this study is to find if there was any
association between subgingival bacterial morphotypes
(coccoid cells, other, motile rods and spirochaetes) with
the attachment level changes per subject in each of the
patient and control groups over each pair of successive
visils and during one year. Most interesting is to find if
the motile bacteria (motile rods and spirochaetes) are
associated with or predict attachment level loss in
periodontal patients.
Phase contrast microscopy was used to detect the presence














Chi-square analysis for the association between the attachment
level change over each two successive visits (and over one
year) with plaque index, gingival index and bleeding on probing
at the initial visit in both patient and control groups.
Chi-square analysis and x value
Group Number Plaque index Gingival index Bleeding on
probing





























































* = statistically significant at P<0.05
periodontal site at each visit as early described (2.6.4) .
The mean percentage of each morphotype was calculated and
used for data analysis.
The mean percentage of each morphotype at the initial visit
of each pair of successive visits, was ranked for each
subject. The attachment level change over each paired
successive visits was also ranked for each subject.
Spearman rank correlation test (2.7.3) was used to test the
association between attachment level change per subject and
the subject mean percentage of each bacterial morphotype
recorded at the initial visit of each two successive
visits. As is shown in Table 4.8,no significant correlation
was found between attachment level change and each of these
bacterial morphotype in both the patient and control group
over any pair of successive visits, and over one year.
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TABLE 4.8: Spearman rank correlation test between attachment level change
over each two successive visits (and over one year) with coccoid
cells, other, motile rods and spirochaetes at the initial visit
in both patient and control groups.
Spearman correlation coefficient (r)
























































































4.2.4 Laboratory Findings on serum C-reactive protein
(CRP) and salivary CRP in the patient and
control groups
The purpose of this study was to find the level of serum
and salivary C-reactive protein in both patient and control
groups. Serum and saliva samples were collected at each
visit from each subject in each group (2.6.1, 2.6.5). The
levels of CRP in serum and saliva were determined using the
ELISA technique described earlier (3.3.2).
The mean and standard error (SE) of the serum concentration
(mg/1) and salivary CRP concentration (ng/ml) for each
group at each visit was shown in Table 4.9.
It was found that salivary CRP levels were higher in the
patient group compared to control group. The mean salivary
CRP concentration at all visits, was 1.045 and 0.175 ng/ml
for the patient and control groups respectively. The range
of salivary CRP was found to be 0.0-11.97 ng/ml and 0.0-
1.89 ng/ml for the patient and control groups respectively.
The mean serum CRP concentration at all visits, was 1.752
mg/1 and 0.969 mg/1 for the patient and control groups
respectively. The range for serum CRP was 0.145-20.0 mg/1
and 0.140-8.0 mg/1 for the patient and control groups
respectively.
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TABLE 4.9: Levels of serum CRP and saliva CRP in each of the patient and
control groups at each visit, and over all visits. The mean

























































150 0.969+0.11 150 0.175-0.031
307 1.752+0.650 313 1.045-0.107
4.2.4.1 Correlation of serum and saliva CRP levels in
each subject group
The aim of this study was to find if there is a correlation
between the level of serum and salivary CRP in each group
at each visit.
Pearson correlation analysis was applied to test this
correlation, and the result are shown in Table 4.10.
At most visits, no significant correlation was found
between the levels of serum CRP and saliva CRP in each
subject group.
4.2.4.2 Comparison between control and patient groups
for their serum and salivary CRP levels
The aim of this study was to compare the patient group and
the control group for their levels of salivary CRP and
serum CRP. Using analysis of variance, the levels of
salivary CRP and also the levels of serum CRP, between
patient and control groups at each visit was compared.
As shown in Table 4.11, the serum CRP level was found to be
significantly higher (P<0.05) in the patient group compared
to its level in control group at only two visits. It was
also found that the levels of salivary CRP in the patient
group were significantly higher (P<0.01) than in the
control group at each visit.
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TABLE 4.10: Pearson correlation test between serum CRP concentration (mg/L)
and saliva CRP concentration (ng/ml) in each of the patient and
control group at each visit. Pearson correlation coefficient
(r) and P-value are shown.
Pearson Correlation Test between Serum CRP
and Saliva CRP



















































TABLED.11: t-test analysis of the differences in serum CRP levels and
saliva CRP levels between patient and control groups at each
visit.













4.2.4.3 Association of serum CRP and saliva CRP with
attachment level changes in each group
In this study, the levels of serum and salivary CRP was
tested for their association with attachment level changes
per subject (in each group) over each two successive visits
and over one year.
Regression analysis using Pearson correlation coefficient
was used to test if there is an association between the
attachment level change per subject with the change in
salivary and serum CRP, over each pair of successive visits
and over one year in each subject group.
As shown in Table 4.12, no significant correlation was
found between attachment level change and the change in
serum or salivary CRP in each group at any occasion.
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TABLE 4.12 Regression analysis for attachment level change and the change
in the saliva CRP concentration and serum CRP concentration in
each group over each two successive visits, and over one year.
Pearson correlation coefficient and P value are shown.
Pearson correlation (r) between Pearson correlation (r) between
attachment level change and attachment level change and
salliva CRP change serum CRP change
Visit Group Number r P-value Number r P--va lu
1-2 Control 25 0.065 NS 25 -0.236 NS
Patient 54 0.015 NS 54 -0.146 NS
2-3 Control 25 0.131 NS 25 0.031 NS
Patient 53 •0.011 NS 53 -0.129 NS
3-4 Control 25 0.229 NS 25 -0.164 NS
Patient 50 0.066 NS 50 -0.190 NS
4-5 Control 25 0.041 NS 25 0.22 NS
Patient 52 0.161 NS 52 -0.133 NS
5-6 Control 25 0.200 NS 25 0.155 NS
Patient 52 0.067 NS 52 0.169 NS
1-6 Control 25 •0.20 NS 25 -0.2 NS
Patient 50 •0.42 NS 50 -0.14 NS
NS = not significant at P<0.05
4.3 Clinical, microbiologic and laboratory findings
in the patient and control groups using the site
as an experimental unit of analysis
In this study, the site was used as an experimental unit of
analysis in each of patient and control groups as follows.
4.3.1 Clinical findings (PI, GI, BOP, PD, attachment
level measurement) and GCF volume for periodontal
sites in patient and control groups
The clinical data for PI, GI, BOP, PD and attachment level
measurement as well as GCF was collected as described
earlier for each site in each group at each visit. A total
of 324 sites and 150 sites were used at each visit in this
study for the patient and control groups respectively. The
details including mean and standard error of each variable
for all periodontal sites in each group and each visit are
shown in Tables 4.13, 4.14, and Table 4.20 for GCF volume.
The attachment level was measured relatively to the fixed
reference point on the stent and it was considered as a
relative attachment level measurement. The BOP was
expressed as a percentage of sites that bled on probing at
each visit.
As shown from the results, the mean PD was ranged from 3.53
to 4.04mm for periodontal sites in the patient group while
it was ranged from 1.98 to 2.15mm for all the periodontal
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sites in the control group. The mean pocket depth for all
the sites for all the visits in the patient group was
3.72mm and higher than the control group which was 2mm.
The mean GCF volume (Table 4.20) for all sites ranged from
0.07 to O.lOuL and from 0.242 to 0.31 uL for all
periodontal sites in the control and patient group
respectively. The mean GCF volume for all sites at all
visits in the patient group was 0.279uL and higher than in
the control group which was 0.081uL.
The frequency of BOP ranged from 41-49% and from 4-8% for
all the sites in the patient and control groups
respectively. The mean scores of both PI and GI for all
periodontal sites in the patient group for all visits was
2.28 and 0.30 respectively.
The frequency distributions of bleeding sites, plaque index
and gingival index scores at the initial visit of each pair
of successive visits for the patient group are shown in
Figure 4.1 for bleeding sites; Figures 4.2a,b,c,d,e,f for
plaque index scores, and Figures 4.3a,b,c,d,e,f for
gingival index scores. As is shown higher frequency of
bleeding sites were found for loser sites than stable sites
on all occasions except for the successive visits 5-6. It
was also found that high plaque scores (2-3) were found for
both loser and stable site on most occasions. Low gingival
scores were found for both loser and stable site groups as
well as for all sites together on all occasions.
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TABLE 4.13: Clinical data of ail sites in the patient group at each visit.
The mean and standard error (SE) of the plaque index (PI),
gingival index (GI), pocket depth (PD) and attachment level
measurement (ALM) are shown. Bleeding on probing (BOP) is
expressed in frequency percentage.
Mean + SE of Clinical Data
Visit No. of PI Gl BOP PD(mm) ALM (mm)
Sites Mean + SE Mean + SE % Mean + SE Mean + SE
1 324 2.33+0.05 0.50+0.05 43 3.53-0.33 6.1+0.79
2 324 2 .24+0 .05 0.23-0 .04 41 3.61+0.94 5.4-20.36
3 324 2.29-0.05 0.32-0.05 44 3.50-0.91 6.5-0.36
4 324 2.60+0.05 0.23-0.04 44 3.70-0.92 5.7-0.90
5 312 2.26-0.04 0.20-0.04 44 3.7820.93 6.8-0.97
6 312 2.30+0.04 0.25-0.05 49 4.04-0.97 7.2-0.98
All 1920 2.23+0.01 0.30+0.02 44 3.72-0.36 6.5-0.45
Visits
TABLE 4.14: Mean and standard error (SE) of pocket depth (PD) and attachment
level measurement (ALM) for all the sites in the control group
at each visit. The frequency of BOP was also shown in frequency
percentage.
Visit No. of PD ALM BOP
Sites Mean + SE Mean + SE
1 150 1.80+0.59 4.51-0.70 3%
2 150 1 .98+0.59 4.51+0.68 4°,
3 150 1.97+0.59 4.59+0.53 3%
4 150 2.04+0.53 4.65^0.63 4°,
5 150 2.13+0.60 4.54+0.64 3%
6 150 2.15-0.62 4.68-0.54 4%































































































































































































































































































































































































































































































































































4.3.2 Microbiologic findings (coccoid cells, other,
motile rods and spirochaetes) in the patient
and control groups
The subgingival plaque sampled at each site as described
earlier (2.6.3) was analysed individually using phase-
contrast microscopy. The mean percentages and standard
error (SE) of each bacterial morphotype (coccoid cell,
other, motile rods and spirochaetes) for all sites in each
group at each visit is shown in Table 4.15. The range of
the mean percentage of motile rods for all sites was 2.09-
2.97% in the patient group and was higher than that for all
the sites in control group (0.05 -0.26%) .
The mean percentage of motile rods for all visits was 0.13%
and 2.04% for the control and patient groups respectively.
The range of mean percentages of spirochaetes for all the
sites in patient group was 5.57-6.70% and was higher than
that of all the sites in control group (0.23-0.54%). The
mean percentage of spirochaetes for all the sites at all
visits was 0.40% and 5.77% in the control and patient
groups respectively.
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TABLE 4.15: Mean + standard error (SE) of the percentage for coccoid cells,
others, motile rods and spirochaetes for all sites in the
control and patient groups at each visit.
Visit Subject No of Mean + Standard Error (SE)
Group Sites Coccoid Other Motile rods Spirochaetes
cells
Visit 1 Control 150 85.2+1.6 11.5+2.3 0.26+0.06 0.36^0.13
Patient 324 56.3+1.4 32.4+1.0 2.97+0.33 5.57-^0.56
Visit 2 Control 150 73.8+2.8 9.3+1.9 0.09+0.02 0.23+0.09
Patient 324 54.6+1.5 32.6+1.1 2.49+0.32 5.70+0.51
Visit 3 Control 150 68.3+3.2 9.11+4.1 0.05+0.02 0.54+0.12
Patient 324 56.0+1.4 34.6+1.0 2.09+0.22 6.10+0.54
Visit 4 Control 150 66.9+3.1 10.1+3.1 0.13+0.07 0.30+0.12
Patient 324 53.0+1.4 34.1+1.1 2.28+0.25 5.38+0.48
Visit 5 Control 150 59.8+3.1 12.3+1.9 0.04+0.03 0.45+0.13
Patient 312 51.2+1.6 31.6+1.2 2.16+0.25 6.19+0.63






















4.3.3 Association of attachment level change per site
with clinical and microbiological variables in
each site group in the periodontal patients
The aim of this study was to find if there was any
association between attachment level change over each two
successive visits and over one year with the initial value
of each of the clinical and microbiological variables
measured at the initial visit of each pair of successive
visits. In other words to find if any of these variables at
their initial measurement would be associated with
attachment level breakdown or predict disease activity over
each prescribed period.
All the sites studied in the patient group were classified
into the three categories previously mentioned (2.7.2).
These were loser, stable and improved sites. The mean and
standard error of their attachment level change over each
prescribed period, and their number and percentage was
already been shown in Table 4.2. Regression analysis using
Pearson correlation coefficient and the Spearman rank
correlation test using Spearman correlation coefficient
were used to test the association between attachment level
change over each prescribed period and the clinical
variables (pocket depth, GCF volume) and for microbiologic
variables (coccoid cells, other, motile rods and
spirochaetes) recorded at the initial visit of each pair of
successive visits and at the first visit which corresponded
to the change over one year.
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Chi-square analysis was used to test the association of
attachment level change over each prescribed period with
the scores of plaque index (PI), gingival index (GI) and
bleeding on probing (BOP).
The results for these associations are shown in Tables
4.16-19, where the mean and standard error of the initial
value of each variable at each previous visit, the Pearson
correlation coefficient and Spearman correlation
coefficient are shown.
As was shown from the results (Table 4.16) no significant
correlation between attachment level change and pocket
depth, was found at almost all occasions for all three
groups of sites using both regression analysis and Spearman
correlation tests. The only significant (P<0.05)
correlation for pocket depth with attachment level change
found was over the successive visits 4-5 for stable sites.
No significant association was found between attachment
level change and GCF volume for any site group at most
occasions except for loser sites for the successive visits
5-6 .
No significant correlation was found between attachment
level change and each of the subgingival bacteria (coccoid
cells, other, motile rods) for each site group on any
occasion (Table 4.18,19). A significant correlation (r=
0.464, at P < 0.05) was found with spirochaetes for the
loser sites for the successive visits 1-2 only.
No significant correlation was found between attachment
level change and plaque index for any site group on any
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occasion except the successive visits 5-6 for loser sites
(X2 value= 7.34) (Table 4.17).
For gingival index, it was found that attachment level
change associated with significantly low scores of GI for
both loser and stable sites at most occasions.
With respect to bleeding on probing and its association
with attachment level change, the only significant
correlation was found with loser sites over one year,while
for stable sites a significant correlation was found for
the successive visits 1-2, and 2-3 (Table 4.17).
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TABLE4.16: Regression analysis and Spearman correlation analysis of the
association of attachment level change over each successive
visits (and over one year) with initial values of pocket depth
and GCF volume at the previous visit in each site group.
Pearson and Spearman correlation coefficients are shown.
Initial Correlation Initial Correlation
PD (mm) Coefficient CCF Volume Co-efficient
Site (uL)
















































0.139 0.423-0.064 0.123 0.044
0.173 0.250+0.013 -0.003 -0.005
0.700 0.572-0.030 0.313 0.413
0.029 0.263-0.052 0.084 0.102
0.05 2 0 .240-0 .01 2 0.022 -0.0 04
0 .000 0 .236-0 . 035 -0 .496 0 .478
-0.232 0.309+0.079 0.057 -0.355
0,213* 0.273-0.014 0.109 0.116
-0.133 0.237-0.083 -0.323 -0.534
-0.176 0.33+0.050 -0.466* -0.064
0.099 0.269-0.014 -0.033 -0.089
0.516 0.290-0.099 0.772 0.154
-0.030 0.339+0.031 -0.175 -0.125
0.133 0.249-0.016 0.059 0.027
0.000 0.632-0.133 0.000 0.000
* = statistically significant at P<0.05
TABLE 4.17: Chi-square analysis of the association of attachment level
change over each two successive visits (and over one year) with




Visit Site Group Mean+SE Value
Chi Square Analysis
Initial Initial
Gl X2 BOP X2
Mean+SE Value Frequency Value
Visit 1- Loser 2.58+0.15 1.5 0.58+0.20 4.2* 50 Oo
Visit 2 Stable 2.30+0.05 0.35 0.50+0.06 68.0* 42 6.3
Improved 2.14+0.38 0.00 0.25+0.20 0.0 10 0.0
Visit 2- Loser 2.28+0.24 0.00 0.29+0.22 7.2* 57 0.3
Visit 3 Stable 2.23+0.06 1 .38 0.32+0.04 70.0* 70 1 1 .2*
Improved 2.61+0.23 0.00 0.67+0.40 0.0 10 0.0
Visit 3- Loser 2.56+0.17 2.00 0.40+0.25 5.1* 50 0.0
Visit 4 Stable 2.26+0.05 0.03 0.28+0.04 30.0* 43 3.7
Improved 2.56+0.24 0.00 0.67+0.46 0.0 1 2 0.0
Visit 4- Loser 2.00+0.32 0.40 0.40+0.25 1.6 50 0.0
Visit 5 Stable 2.26+0.05 0.61 0.28+0.04 35.0* 44 3.8
Improved 2.26+0.24 0.00 0.40+0.35 0.0 17 0.0
Visit 5- Loser 2.04+0.17 7.34* 0.17+0.16 15.7* 35 2.1
Visit 6 Stable 2.27+0.05 0.05 0.20+0.04 86.0* 46 2.7
Improved 2.26+0.20 0.00 0.35+0.27 0.0 1 7 0.0
Visit 1- Loser 2.46+0.10 2.05 0.41+0.71 20.6* 30 25.0*
Visit 6 Stable 2.54+0.05 3.75 0.20+0.40 33.0* 37 3.2
Improved 2.50+0.05 0.25 0.0 i 0.00 0.0 0 0.0
* = statistically significant at P<0.05
TABLE4.18: Regression analysis and Spearman correlation test for the
association of attachment level change over each two successive
visits (and over one year), with the initial value of coccoid
cells and others at the previous visit in each site group.
Pearson and Spearman correlation coefficients are shown.
Visit Site
Group (N)
Initial Correlation Initial Correlation
Coccoid Coefficient Other Coefficient
Cells (%) (%)









































































TABLE4.19: Regression analysis and Spearman correlation test for the
association of attachment level change over each two successive
visits (and over one year) with motile rods and spirochaetes at
the initial visit for each site group. Pearson and Spearman
correlation coefficients are shown.
Initial Correlation Initial Correlation
Motile Rods Coefficient Spirochaetes Coefficient
Site (1) (?,)
Visit Group(N) Mean+SE Pearson Spearman Mean+SE Pearson Spearman
1-2 Loser 4.61+1.21 0.072 -0.026 5.35^2.05 -0.464* 0.075
Stable 2.39-0.35 -0.037 -0.002 5.52-0.59 -0.031 0.047
Improved 0.31+2.23 -0.337 -0.31 4 4.48-3 .30 0 .257 -0 .1 60





















3-4 Loser 2.98+0.99 0.144 0.056 4,23-2.45 -0.009 0.040
Stable 2.05-0.23 -0.016 -0.077 5.21-0.56 0.000 -0.004
Improved 1 .50+1 .61 0 .540 0 .598 5 .71 -4.0 1 -0.31 3 -0.359
4-5 Loser 1.70+1.42 -0.164 -0.263 3.72-2.74 -0.013 0.022
Stable 2.39-0.26 -0.005 0.093 5.30+0.51 -0.005 0.073



















1-5 Loser 4.20+0.72 0.127
Stable 2.71+0.39 -0.004
lmproved 6 . 93-4. 23 0 .000
0.121 6.43-1.22 0.023 0.050
0 .043 5 .57-0.66 -0.003 0 . 025
0.000 3.56-7.21 0.000 0.000
* = statistically significant at P'0.05
4.3.4 Laboratory findings of GCF CRP (GCF CRP
concentration, GCF CRP secretion)
4.3.4.1 Reporting of GCF CRP results
GCF CRP analysis was reported using the concentration (the
amount of CRP in a given volume), and the total CRP in the
sample (activity/sample). Sites with converted volumes of
equal to or < 0 uL were not included in the calculation of
concentration as this made evaluation of the concentration
data difficult. All sites with a converted GCF volume equal
to 0 were included for secretion calculation. All sites
were included when GCF volumes were calculated, and GCF
volumes which converted to < 0 were adjusted to 0 uL.
4.3.4.2 GCF CRP levels for all periodontal sites in
the patient and control groups
The sampled gingival crevicular fluid for each periodontal
site at each visit in each group was tested for CRP level
using ELISA technique described earlier (3.3.1). The
results of GCF CRP were reported as the amount of CRP
(nanogramm) per unit of GCF volume (uL). This was
considered the concentration of GCF CRP, and expressed as
ng/ml for data normalisation and analysis. The results were
also reported as the total amount of CRP (ng) in the sample
of GCF (activity/sample) collected over one minute, and
this was the secretion of GCF CRP (ng/minute) . The mean
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levels of GCF CRP both for concentration and secretion for
all sites for each subject group at each visit was shown in
Table 4.20. Both GCF CRP concentration and secretion were
significantly higher for periodontal sites in the patient
group than those for the control group at each visit. The
range of concentration was 0.0-1227.8 ng/ml and 0.0-118.5
ng/ml for all sites in the patient and control groups
respectively. The mean GCF CRP concentration per site in
the control group was 6.24ng/ml, while for the patient
group was 60.0ng/ml for all visits.
The GCF CRP secretion per site ranged from 0.0-1.89 ng/
minute and 0.0-233.7ng/minute in the control and patient
groups respectively. The mean CRP secretion for all
periodontal sites for all visits was 1.23ng/minute and
18.8ng/minute in control and patient groups respectively.
The range of means of GCF CRP concentration for all the
sites was 53.87-63.52 ng/ml and 4.06-10.5 ng/ml in the
patient and control groups respectively. The range of means
of GCF CRP secretion was 16.19-20.82 ng/minute and 0.92-
1.92ng/ minute for the patient and control groups
respectively.
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TABLE4.20: Mean and Standard Error (SE) for gingival crevicular fluid (GCF)
volume, GCF, CRP concentration (ng/ml) and GCF secretion























Control 150 0.071+0.007 4.06-1.23 0.95-0.29





















































4.3.4.3 GCF CRP levels for each group of sites in
periodontal patients during a longitudinal
study-
In this study, the periodontal sites for all patients were
classified into three groups in the same way as mentioned
before (2.7.2) using a safety threshold of 2mm. The levels
of GCF CRP for both concentration and secretion are shown
in Table 4.21. The results show the mean and standard error
(SE) of GCF CRP levels for each site group, and these are
CRP levels at the initial visit of each pair of successive
visits for each site group. The loser sites were those
sites which lost attachment level at the subsequent visit
of each pair of successive visit, and each had GCF CRP
levels which were measured at the initial visit of the same
pair of successive visits. For visit 1-6, the loser sites
were those sites which lost attachment level over one year,
and their initial GCF CRP measurement was that found at the
first visit corresponded to those sites designated as loser
sites over the one year period. The same measurements were
applied to both stable and improved sites for their initial
GCF CRP levels.
As shown in Table 4.21, the GCF CRP levels were close for
both loser and stable sites at the initial visits on most
occasions. The mean GCF CRP concentration ranged from 26.5
to 68.4ng/ml, and from 52.6 to 64.0ng/ml in the loser and
stable sites respectively. For the whole study (over one
year), GCF CRP concentration was 57.2ng/ml and 65.5ng /ml
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for loser and stable sites respectively.
For GCF CRP secretion which was reported as ng/minute (ng/
sample), the range was 15.5-25.4 and 16.6-19.4ng/minute for
loser and stable sites respectively. For the whole study,
the GCF CRP secretion was 20.8 and 19.3 ng/minute for loser
and stable sites respectively.
Comparisons in GCF CRP levels between loser and stable
sites at the initial visit of each pair of successive
visits were done and are shown later on in subsequent
results.
The level of GCF CRP at the initial visit was considered as
the initial GCF CRP level for each pair of successive
visits in the following studies of its association with
periodontal disease activity and in particular the
attachment level loss which occurred at the subsequent
visit.
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TABLE 4.21: Mean and Standard Error (SE) of the gingival crevicular fluid
(GCF) CRP concentration (ng/ml) and secretion (ng/minute) for
each site group at the initial visit of each pair of successive
visits (and for the period of one year) .
'GCF' CRP Levels at Initial Visit
CRP Concentration CRP Secretion
Site (ng/ml) (ng/minute)
Visit Group Number Mean+SE Mean+SE
1-2 Loser 2 4 SO.1+18.3 13.1+5.9
Stable 293 64.0+5.2 19.4+1.7
Improved 7 55.0+33.3 28.2+10.9
2-3 Loser 14 26.5+23.6 15.5+7.2
Stable 301 61.2+6.1 19.0+1.6
Improved 9 76.3+35.0 51.4-8.9
3-4 Loser 16 62.5+17.6 16.6-5.9
Stable 302 52.6+4.1 16.0+1.4
Improved 6 95.4+23.7 26.3-9.7
4-5 Loser 10 68.4+24.2 25.4+8.0
Stable 293 59.7+4.4 19.1+1.5







1-6 Loser 70 57.2+10.3 20.3+3.5
Stable 240 65.5+5.8 19.3-1.9
Improved 2 135.4-63.7 62.3+20.5
4.4 Association of GCF CRP levels with microbiologic
findings, clinical parameters and GCF volume at
each site group
4.4.1 Association of GCF CRP levels with subgingival
bacterial morphotypes
In this study the GCF CRP levels (concentration and
secretion) were tested for their association with
subgingival bacteria including motile rods and
spirochaetes. This study was carried out for each site
group and for all sites collectively. Means of GCF CRP
levels and mean percentages of motile rods and spirochaetes
for each site group (and all sites together) at the initial
visit of each pair of successive visits and of the whole
period, were ranked. Spearman rank correlation test was
used to test the correlation of GCF CRP levels with motile
rods and spirochaetes. The results including Spearman
correlation coefficients are shown in Table 4.22.
GCF CRP secretion had a, significant positive correlation
(P<0.05) with the percentage of motiles rods and
spirochaetes for all sites together at the initial visit of
most occasions, while it had a significant correlation with
motile rods for the stable site group on most occasions and
with spirochaetes on all occasions. CRP secretion had also
a significant correlation with these bacteria for loser
site group at the initial visit of the successive visits 4-
5, 5-6 and for the one year period.
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With regard to GCF CRP concentration, a significant
positive correlation with motile rods,and with spirochaetes
was found for each of loser and stable or site group as
well as for all sites together on few occasions only.
For improved sites no significant correlation was found
between GCF CRP levels and either of motile rods or
spirochaetes on any occasion.
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TABLE4.22: Spearman rank correlation test between gingival crevicular fluid
CRP levels and motile rods and spirochaetes for each site group
in the periodontal patients at the initial visit of each pair of
successive visits.
Spearman Rank Correlation Coefficient










































































4-5 Loser(10) 0.693* 0.571* 0.423 0.359
Stabie(293) 0.246* 0.216* 0.119 0.143
lmproved(9) 0.233 0.700 0.306 0.010





































* = statistically significant at P<0.05
4.4.2 Association of GCF CRP levels with PI, GI, BOP
The purpose of this study was to find if GCF CRP levels
were associated with the indices of inflammation, GI and
BOP, and also with plaque index.
The association of GCF CRP levels including concentration
and secretion with each of those indices for each site
group and all sites together at the initial visit of each
pair of successive visits and of the whole study over one
year were tested using Fisher-test. The results were shown
in Table 4.23. It was found that both GCF CRP secretion and
concentration were significantly (F< 0.05) associated with
plaque index, gingival index and bleeding on probing for
the stable site group and for all sites together on most
occasions.
For the loser site group, no significant correlation was
found for CRP concentration with PI and GI or BOP, except
on one occasion for GI (visits 1-6), and on one occasion
for BOP (visits 5-6).
With regard to GCF CRP secretion in the loser sites, a
significant positive correlation (F< 0.05) was found for
visits 3-4 and 1-6 for PI, for visits 5-6 and 1-6 for GI,
while for BOP on most occasions.
No significant correlation was found between CRP
concentration and secretion with PI, GI and BOP for the
improved site group on any occasion.
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TABLE 4.23: Fisher test analysis for the association of gingival crevicular
fluid CRP levels with plaque index (PI), gingival index (Gl) and
bleeding on probing (SOP) for each site group at the initial
visit of each pair of successive visits.
Fisher test analysis and F-value
CRP concentration and:
Site PI Gl BOP




Loser(24) 0.111 0.536 0.355 0.476 0.964 0.015
Stable(293) 0.012 <0.001 <0.001 <0.001 <0.001 <0.001
lmproved(7) 0.371 None 0.120 0.542 None 0.111
A! I (324) 0.017 <0.001 <0.001 <0.001 <0.001 <0.001
Loser(14) 0.433 0.537 0.039 0.725 0.556 0.023
Stable(301) 0.019 <0.001 <0.001 <0.001 <0.001 <0.001
lmproved( 9) 0.424 0.51 5 0.424 0 .049 0.099 0.049
All (324) 0.01 4 <0.001 <0.001 <0.001 <0.001 <0.001
Loser(16) 0.109 0.520 0.104 0.049 0.930 0.199
Stabl'e(302) 0.002 0.01 6 <0.001 <0.001 <0.001 <0.001
Improved(S) 0.270 0.230 0.804 0.361 0.201 0.427
All (324) <0.001 0.014 <0.001 <0 .000 <0.001 <0.001
Loser(10) 0.133 0.396 0.055 0.080 0.715 0.046
Stable(293) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
lmproved(9) 0.391 None 0.544 0 .420 None 0.145
Al I (312) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Loser(23) 0.560 0.523 0.029 0.153 0.003 <0.001
Stable(283) <0.001 0.213 <0.001 <0.001 <0.001 <0.001
Improved(S) 0.923 0.490 0.313 0.951 0.550 0.950
All (312) <0.00 1 0 .259 <0.001 <0.001 <0.001 <0.001
Loser(70) 0.533 0.046 0.531 0.044 <0.001 0.023
Stable(240) <0.001 0.023 <0.001 <0.001 <0.001 <0.001
Improved(2) None None None None None None
Al I (312) <0.001 <0.001 <0.001 <"0.001 <0.001 <0.001
4.4.3 Association of GCF CRP levels with PD and GCF
volume
In this study, GCF CRP levels were tested for their
association with pocket depth and gingival crevicular fluid
volume for all sites and for each of the site groups which
are loser, stable and improved sites.
The GCF volume and pocket depth for all sites and for each
site group at the initial visit of each pair of successive
visits and for the period of one year, was ranked. The GCF
CRP level for each concentration and secretion at the same
initial visit was also ranked. Spearman rank correlation
was used to test the association of GCF CRP with each of
these two variables. The results were shown in Table 4.24.
For pocket depth, it was found that GCF CRP levels for both
secretion and concentration showed a positive significant
correlation (P<0.05) with pocket depth for loser site
group, stable site group and all sites together on most
occasions.
For GCF volume, a significant positive correlation was
found with CRP concentration on one occasion only for each
of loser and stable site group and for all the sites
together. Interestingly GCF CRP secretion was significantly
associated with GCF volume on all occasions for each site
group and for the total sites together. On other hand, no
correlation was found for GCF CRP concentration for each of
pocket depth and GCF volume for improved sites on any
occasion.
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It was obvious that GCF CRP levels (secretion and
concentration) were significantly associated with both
pocket depth and GCF volume for loser, stable and all sites
together at the initial visit of the successive visits 1-6
(over one year).
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TABLE 4.24: Spearman correlation test between gingival crevicular fluid
(GCF) CRP levels, pocket depth and GCF volume for each site
group in periodontal patients at the initial visit of each pair
of successive visits.
Spearman Correlation Coefficient Between
CRP concentration and: CRP secretion and:
Pocket CCF Pocket GCF
Site Depth Volume Depth Volume
Visit Croup Number (r) (r) (r) (r)
1-2 Loser 24 0.392* -0.226 0.279 0.472*
Stable 293 0.247* 0.169 0.267* 0.600*
Improved 7 0.699 0.431 0.272 0.881*










































































































* = statistically significant at P<0.05
4.4.4 Association of GCF CRP levels with attachment
level
4.4.4.1 Association of the change in GCF CRP level with
attachment level change for all sites in the
control and patient groups
The purpose of this study was to find if the response in
GCF CRP levels was associated with attachment level change
over each paired successive visits and over one year for
all sites in both patient and control groups. It was also
the aim to find if there was any difference between the
control and patient groups for this response.
The change in attachment level for all the periodontal
sites in each group over each prescribed period, and the
change in GCF CRP levels for secretion and the logarithmic
transformation for CRP concentration change for the same
sites were subjected to regression analysis and Pearson
correlation coefficient was produced. The results of this
analysis and Pearson correlation coefficients are shown in
Table 4.25.
As can be seen from the results, a significant positive
correlation (P<0.05) was found between attachment level
change over each pair of successive visits and over one
year with the change in GCF CRP levels both for secretion
and concentration for all the sites in the patient group.
The correlations are illustrated in figures 4.4-9,and it
was found that as the probing attachment level increased
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between each two successive visits (and over one year), the
GCF CRP levels increased over the same period. This means
that GCF CRP was present in high levels when there was
increasing probing attachment level at subsequent visit of
each pair of successive visits and after one year. It was
also found that when the probing attachment level
decreased, the GCF CRP level decreased over the same
period. So high levels of GCF CRP were associated with
increasing probing attachment level, while low levels of
GCF CRP were associated with decreasing probing attachment
levels.
A significant correlation was also found between attachment
level change and the change in GCF CRP levels for
periodontal sites in the patient group for all visits
together (Table 4.25, and Figures 4.8-9) .
For the control group, no significant correlation was found
between attachment level change and the change in GCF CRP
levels for either secretion or concentration for all sites
on any occasion.
The results of above studies led to further investigation
of GCF CRP levels and clinical parameters used in measuring
periodontal breakdown and in particular the attachment
level loss.
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TABLE 4.25: Regression analysis and Pearson correlation coefficient (r) for
the change in attachment level and gingival crevicular fluid
(GCF) CRP levels (concentration and secretion) between each pair
of successive visits, and over one year, for all periodontal
sites in the patient and control groups.
Pearson Correlation Coefficient (r)
between Attachment Level Change
and CRP Level Change


























































































































































































































































































































































































































































































































































4.4.4.2 Association of GCF CRP levels with attachment
level change at each site group in periodontal
patients
The purpose of this study was to find if GCF CRP levels,
for both secretion and concentration, were associated with
or could predict periodontal disease activity measured by
attachment level loss. The three groups of sites; loser,
stable and improved sites were used for this study. The
attachment level change per each site group over each two
successive visits, and over one year and GCF CRP levels
(concentration and secretion) measured at the initial visit
of each pair of successive visits, and at the initial visit
related to attachment level change over one year, were all
subjected to regression analysis. The results of this
analysis using Pearson correlation coefficient and Spearman
rank correlation coefficient for both CRP secretion and
concentration with attachment level change, are shown in
Table 4.26.
It was obvious that no significant correlation was found
between GCF CRP levels, for both concentration and




TABLE 4.26: Regression analysis using Pearson correlation coefficient (r 1)
and Spearman rank correlation coefficient (r2) for the
association of attachment level change for each site group over
each pair of successive visits (and over one year) with gingival
crevicular fluid (GCF) CRP measured at the initial visit of each
pair of sucessive visits in the patient group.
Correlation test between attachment level
change and GCF CRP levels
Concentration Secretion Concentration Secretion
Site
Visit Group r1 P r2 P r1 P r2 P
1-2 Loser (24) 0.029 NS 0.077 NS -0.038 NS 0.046 NS
Stable(293) 0.143 NS 0.033 NS 0.114 NS 0.071 NS
lmproved(7) -0.114 NS -0.251 NS -0.238 NS -0.315 NS
2-3 Loser(14) -0.060 NS 0.120 NS 0.136 NS 0.097 NS
S tab 1 e (3 01) 0.078 NS 0.040 NS 0.050 NS 0.028 NS
lmproved( 9) 0.563 NS 0.296 NS 0.516 NS 0.230 NS
3-4 Loser(16) 0.238 NS 0.372 NS 0.216 NS 0.332 NS
Stable(302) 0.082 NS 0.048 NS 0.013 NS 0.008 NS
lmproved(6) -0.443 NS -0.527 NS -0.239 NS -0.598 NS
4-5 Loser(10) 0.133 NS 0.254 NS -0.098 NS -0.118 NS
Stable(293) 0.082 NS 0.179 NS 0.089 NS -0.144 NS
lmproved(9) 0.680 NS 0.097 NS 0.694 NS 0.073 NS
5-6 Loser(23) 0.223 NS 0.076 NS 0.194 NS 0.042 NS
Stable(283) 0.007 NS -0.042 NS -0.076 NS -0.092 NS
Improved(6) -0.033 NS 0.853 NS 0.030 NS 0.698 NS
1-6 Loser(70) 0.015 NS -0.156 NS -0.061 NS -0.106 NS
Stable(240) 0.135 NS 0.078 NS 0.118 NS 0.112 NS
lmproved( 2) 0.000 NS 0.000
NS = not significant at P<0.05
4.5 Differences in clinical parameters, subgingival
bacteria and GCF CRP levels among site groups
The purpose of this study was to investigate the
differences between site groups (loser versus stable and
loser versus improved) for their clinical parameters (PI,
GI, BOP and PD) , GCF volume, GCF CRP concentration and
secretion, and subgingival bacteria (coccoid cells,other,
motile rods and spirochaetes) at the initial visit of each
pair of successive visits and the initial visit for one
year period. Fisher-test was used to test the differences
among all site groups together for all these variables
except for GI,PI and BOP. When F-value was significant,
analysis of variance (t-test) was used to test the
difference between each two group of sites.
For PI, GI and BOP, Chi-square was applied to test the
difference between loser versus stable sites for these
clinical indices.
The results for these analyses are shown in Tables 4.27-
4.29.
For both CRP secretion and concentration (Table 4.27), no
significant differences was found between loser and stable
sites, and between loser and improved sites at the initial
visit on almost all occasions.
For GCF volume (Table 4.27), a significant difference
(F<0.05) was found among site groups for visits 1-2, 2-3
and 1-6. ANOVA was used to test the difference between each
two site groups, and it was found that GCF volume was
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significantly (P<0.05) higher in loser sites than for
stable sites.
For pocket depth (Table 4.27), a significant difference
(F<0.05) was found among the site groups together on all
occasions. ANOVA again was used to test the difference
between loser and stable sites and between loser and
improved sites. No significant difference was found between
loser and stable sites on all occasions.
For PI and GI (Table 4.28), no significant difference was
found between loser and stable sites on any occasion.
For BOP, the frequency of bleeding sites was significantly
higher for loser site group than for stable site group (X2
value =39.9) only for visits 1-6.
For subgingival bacteria (Table 4.29), no significant
difference was found among all site groups for all
bacterial morphotypes (coccoid cells, other, motile rods
and spirochaetes) on any occasion.
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TABLE 4.27: F-test for the differences between ail site groups for their
gingival crevicular fluid (CCF) CRP concentration, GCF CRP
secretion, GCF volume and pocket depth (PD) recorded at the
initial visit of each pair of successive visits. When the F-
value was significant, ANOVA was used to test the difference in
that variable between loser and stable sites, and between loser
and improved sites.
F-test Analysis of Variance (ANOVA)
All Site Loser Versus Loser Versus
Groups Stable Improved
Visit Variable F-Value T-Value T-Value













3-4 CRP Concentration 0.297
CRP Secretion 0.570
GCF Volume 0.763
Pocket Depth <0.001 0.17 -8.81*
4-5 CRP Concentration 0.589
CRP Secretion 0.604
GCF Volume 0.923
Pocket Depth 0.003 1.03 -7.30*












* = statistically significant at P<0.05 for t-value
STABLE4.28: Chi-square analysis of the difference between loser and stable
sites for their plaque index (PI), gingival index (Gl) and
bleeding on probing (BOP) recorded at the initial visit of each
pair of successive visits and the baseline visit for a one-year
period. values are shown.
Chi-square Analysis
Loser Sites Versus Stable Sites
Visit Clinical Index Value
1-2 PI 1 .26

















* = statistically significant at P<0.05
TABLE 4.29: F-test for the differences between all site groups for their
percentages of coccoid cells, other motile rods and spirochaetes
recorded at the initial visit of each pair of successive visits.
When the F-value was significance, ANOVA was used to test the
differences in that variable between loser and stable sites, and
between loser and improved sites.
F- test Analysis of Variance (ANOVA)
All Site Groups Loser Versus Loser Versus
Stable Improved
Visit Variable F-value T-Value T-Value
1-2 Coccoid Cells 0.748 _ _
Other 0.294 - -
Motile Rods 0.244 - -
Spirochaetes 0.951 — -
2-3 Coccoid Cells 0.453 - -
Others 0.551 - -
Motile Rods 0.033 0.10 0.30
Spirochaetes 0.359 - -




Coccoid Cells 0 .546
Others 0 .347
Motile Rods 0 .820
Spirochaetes 0 .466
Coccoid Cells 0 .339
Others 0 .327
Motile Rods 0 .461
Spirochaetes 0 .265




4.6 GCF CRP levels for loser and stable periodontal
sites at the initial visit, at the subsequent
visit of each pair of successive visits, and
their differences over the visits
4.6.1 GCF CRP levels for all loser and all stable
periodontal sites for all patients
The purpose of this study was to find the level of GCF CRP
for concentration (ng/ml) and secretion (ng/minute or
ng/sample) for all the sites in the loser group and for the
stable group, at the initial visit and subsequent visit of
each pair of successive visits . It was also the aim to find
if there was a significant difference between loser versus
stable sites at the initial and at the subsequent visit,
and if there was a significant difference in their CRP
level responses (change) over each two successive visits
for 2-months interval and over one year. Furthermore, it
was also aimed to study the difference in GCF CRP levels
for each site group (loser or stable) between the initial
and subsequent visits. In this study all the loser sites
and all the stable sites had already been identified over
each two successive visits using safety threshold of 2mm.
The number and mean +_ standard error of each group of
these sites for each pair of successive visits and over one
year have already been shown in Table 4.2.
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4.6.1.1 The levels of GCF CRP concentration and secretion
The level of GCF CRP for concentration and secretion for
each site was determined using ELISA technique was
described earlier (3.3.1). The mean GCF CRP concentration
and secretion for all loser sites and for all stable sites
at the initial visit, subsequent visit and their difference
between these two visits are shown in Tables 4.30 and 4.31.
As is shown in Table 4.30, the mean CRP concentration at
the initial visit was ranged from 26.5 to 68.4 ng/ml and
from 42.6 to 65.0 ng/ml for the loser and stable site
respectively. The mean CRP concentration at the subsequent
visit had a range of 109.3-177.9 ng/ml and of 42.8-61.1
ng/ml for the loser and stable sites respectively.
For CRP secretion, as is shown in Table 4.31, the mean CRP
secretion at the initial visit had a range of 15.5-25.4
ng/ml and of 16.0-19.4 ng/ml, while the means at subsequent
visit ranged 30.6-51.0 ng/ml and 14.4-19.7 ng/ml for loser
and stable sites respectively.
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TABLE 1.30: Gingival crevicular fluid CRP concentration (ng/ml) for loser
and stable sites for the patient group at the initial visit,
subsequent visit, and their difference for each pair of

































































TABLE 4.31: Gingival crevicular flud CRP secretion (ng/minute) for loser
and stable sites for the patient group at initial visit,
subsequent visit, and their difference over each pair of
successive visits (and over one year) .
Visit Site Group Number
Mean CRP Secretion (ng/minute)





























































4.6.1.2 Comparison of GCF CRP levels at all loser and all
stable sites
In this study, the levels for CRP secretion and
concentration were compared between loser and stable sites
(loser versus stable) at the initial visit, subsequent
visit and the difference between these two visits. The
concentration and secretion levels were also compared for
the same site group (loser versus loser, and stable versus
stable) between the initial and subsequent visits. ANOVA
(t-test) was used to compare all these data, and the
results are shown in Tables 4.32 and 4.33.
For CRP concentration, as is shown in Table 4.32, no
significant difference was found between loser and stable
sites (loser versus stable) for their CRP concentration at
the initial visits for all occasions, while a highly
significant (P<0.05) difference was found in their CRP
concentrations at the subsequent visit for all occasions.
The CRP concentration for all loser sites was significantly
higher than that for all stable sites at the subsequent
visit on all occasions.
It was also found that the response (change) of CRP
concentration for each site group between these two visits
(initial and subsequent) was significantly different
(P<0.05) between loser and stable sites (loser versus
stable) at all occasions, with significantly higher
responses at loser sites than at stable sites. On the other
hand, it was found that CRP concentration was significantly
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higher (P<0.05) for loser sites at the subsequent visit
than at initial visits (loser versus loser) on all
occasions, while no significant difference was found in CRP
concentration for stable sites between initial and
subsequent visits (stable versus stable) on most occasions
(except visits 2-3 and 1-6).
For CRP secretion, as is shown in Table 4.33, there was a
significant (P<0.05) difference in its level between loser
and stable sites (loser versus stable) at the subsequent
visit but not at the initial visit. A significantly higher
CRP secretion was found for loser sites than for stable
sites at subsequent visits, and a significantly higher
response in CRP secretion was found for loser sites
compared to stable sites (loser versus stable) between
these two visits (initial and subsequent) . It was also
found that there was a significantly higher level of CRP
secretion for loser sites at the subsequent visit when
compared with the level at the initial visit (loser versus
loser between visits), while no significant difference in
CRP secretion was found for stable versus stable site
between these two visits except on one occasion.
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TABLE 4.32: Analysis of variance (ANOVA) for gingival crevicular fluid CRP
concentration between the loser and stable site groups, at the
initial visit, subsequent visit, and between their
differences over each pair of successive visits (and over one
year). ANOVA for CRP concentration for each site group between
each two successive visits is also shown.
Analysis of Variance and T-Value
At the Same Visit Between Two visits
Loser Versus Stable Loser
Successive Site Initial Subsequent Versus









1 .20 7.20' -5.70* -5.36* 2.17*
3-4 Loser 16
Stable 302
0.54 3.53' -2.53' -2.32* -0.75
4-5 Loser 10
Stable 293
0.34 2.73' -2.00= -2.03* -0.30
5-5 Loser 23
Stable 233
0.95 4.13* -3.93' -3.53* 1 .41
1-6 Loser 70
Stable 240
0.67 10.23* -5.79* -4.75* 3.41'
* = statistically significant at P<0.05
TABLE 4.33: Analysis of variance (ANOVA) of gingival crevicular fluid CRP
secretion between loser and stable sites in patient group at
initial visit, subsequent visit, and between their difference
between these successive visits (and over one year) . ANOVA of
the GCF CRP level difference for each site group (loser versus
loser, stable versus stable) between each pair of successive
visits is also shown.
Analysis of Variance and T-Value
At the Same Visit Between Initial and
Subsequent Visits
Loser Versus Stable Loser Loser Stable
Successive Site Initial Subsequent Versus Versus Versus
Visits Group Number Visit Visit Stable Loser Stable
!-2 Loser 24 0.20 3-23* -3.62* -3.62* 0.53
Stable 293
2-3 Loser 14 0.50 5.33* -5.53* -4.98* 3.00*
Stable 301
3_4 Loser 16 0.10 2.75* -2.50* -2.95* -1.51
Stable 302
4-5 Loser 10 0.73 2.06* -1.98* -3.06* 1.25
Stable 293
5-5 Loser 23 0.14 3.17* -3.33* -3.96* -1.36
Stable 283
1-6 Loser 70 0.34 7.95* -5.309* -2.71* 0.26
Stable 240
* = statistically significant at P<0.05
4.6.2 GCF CRP levels for matched pairs of the most
loser site and the most stable periodontal site
in the patient group
In this study, a matched pair of loser and stable sites
within each patient was selected. This selection was based
on the worst site (the most loser) and the most stable
site. One loser site and one stable site within the loser
patient were selected, and whenever there was more than one
stable site, a random selection was used. The mean and
standard deviation (SD) of the attachment level change for
the matched pairs of the selected sites over each pair of
successive visits (and for the one year period), are shown
in Table 4.34.
4.6.2.1 The level of GCF CRP secretion and concentration
The levels of GCF CRP for concentration and secretion for
matched pairs of sites, at the initial visit and subsequent
visit of each pair of successive visits (and over one
year),and their CRP level difference between these visits
are shown in Table 4.35 and Table 4.36.
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TABLE 4.34 Mean and Standard Deviation (SD) of attachment level change for
matched pairs of loser and stable sites within each patient,
over each pair of successive visits, and over one year.







































TABLE 4.35: Mean and Standard Deviation (5D) of gingival crevicular fluid
CRP concentration (ng/ml) for matched pairs of loser and stable
sites within each patient at the initial visit, subsequent visit










1-2 Loser 17 70.8+64.9 118.8+63.0
Stable 17 73.7+98.5 43.0+48.9
-48.9+66.0
31.0+111.6
2-3 Loser 11 27.3+28.0 148.7+117.0 -121.0+109.2
Stable 11 62.7+87.8 49.2+51.6 13.0+54.0
3-4 Loser 16 62.5+58.0 128.9+91.6
Stable 16 49.3+84.0 64.0+74.0
-66.5+97.6
-15.6-64.6
4-5 Loser 10 82.9+77.0 102.0+166.0























TABLE 4.36: Mean + Standard Deviation (SD) of gingival crevicular fluid CRP
secretion (ng/minute) for matched pairs of loser and stable
sites at initial visit, subsequent visit and between each pair





































































4.6.2.2 Comparison of GCF CRP levels for matched pairs of
loser and stable sites
In this study the levels of GCF CRP concentration and
secretion for matched pairs of loser and stable sites
within each patient were compared (loser versus stable) at
the initial visit, the subsequent visit and for the
differences between these visits using a paired t-test. The
levels of CRP for each site group (loser and stable) at
initial visit and at the subsequent visit were compared
(stable versus stable, and loser versus loser) using the
same statistical test. The results of the comparisons of
CRP concentration and secretion are shown in Table 4.37 and
Table 4.38 respectively.
For CRP concentration, no significant difference was found
between loser and stable sites (loser versus stable) at
each initial visits except for the successive visit 2-3
where CRP levels was significantly (P< 0.05) higher at
stable sites than loser sites. CRP concentration was
significantly (P<0.01) higher for loser sites than stable
sites (loser versus stable) at each subsequent visit for
all occasions. CRP concentration was significantly higher
(P<0.01) for loser sites when it compared between initial
and subsequent visits (loser versus loser) on all
occasions, while for stable sites (stable versus stable) a
significant (P<0.05) difference was found only for visits
1-2 and 1-6 (over one year). The difference (the response)
in CRP concentration for loser sites over each pair of
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successive visits (and over one year) was significantly
higher (P<0.01) when it was compared with the response for
the stable sites (difference at loser versus difference at
stable sites).
For CRP secretion, no significant difference was found at
each initial visit between loser and stable sites (loser
versus stable sites) for most occasions except for visits
4-5 and 1-6 where CRP secretion was significantly (P<0.05)
higher at loser sites than at stable sites. At the
subsequent (recall) visit of each pair of successive visits
and over one year, CRP secretion was significantly higher
for loser sites than for stable sites (loser versus
stable). A significant (PcO.Ol) difference was found for
loser sites between the initial and subsequent visits
(loser versus loser) on all occasions, while for stable
sites (stable versus stable) CRP concentration was
significantly different (P<0.05) for visits 1-2. The
difference (response) in CRP secretion between the initial
and the subsequent visit was significantly higher for loser
sites than for stable sites (difference for loser versus
difference for stable) on all occasions.
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TABLE 4.27: Paired t-test analysis for CP? concentration (ng.'ml) between
matched pairs of loser and stacle sites at the initial visit,
the subsequent visit, and their difference between these
successive visits (and over one year), as well as within each
site group between the initial and subsequent visits.
Paired T-Test
P-Value







1-2 Laser 17 > 0.05 <0.01
Stable 17
^•01 <0.01 <0.05
2-3 Loser 11 <0.01 <0.01 <0.01 <0.01 >0.05
Stacie 11
3-4 Loser 15 >0.05 <0.01
Stable 15
<0.01 <0.01 >0.3:
4-5 Loser 10 > 0.05 <0.01
Stable 10
<0.01 <0.05 >0.05
5-5 Loser 19 > 0.05 <0.01
Stable 19
<3.01 <0.01 >0.05
1-5 Loser 35 > 0.35 <0.31 <0.31 <0.01 >0.05
Stable 35
TABLE 4.33: Paired t-test analysis for CRP secretion (ng/minute) between
matched pairs of loser and stable sites at the initial visit,
the subsequent visit and between these successive visits (and
over one year), as well as within each site group between the
initial and subsequent visits.
Paired T-Test
P-Value
Loser Versus Stable Between Successive Visits
Initial Subsequent Loser Loser Stable
Site Visit Visit Versus Versus Versus
Visits Group Number Stable Loser Stable
1-2 Loser 17 >0.35 <0.01 <0.05 <0.01 <0.05
Stable 17
2-3 Loser 11 >0.03 <0.01 <0.05 <0.01 >0.05
Stable 11
3-4 Loser 16 >0.05 <0.35 <0.05 <0.01 >0.05
Stable 16
4-5 Loser 10 <0.35 <3.31 <0.35 <0.05 >0.35
Stable 10
5-6 Loser 19 - >0.35 <3.35 <0.05 <0.01 >0.05
Stable 19
1-6 Loser 36 <o.0 5 <3.01 <0.01 <0.01 >0.05
Stable 36
4.7 Predictability of GCF CRP for periodontal
disease activity in periodontal patients
The main aim for this study was to investigate the role of
GCF CRP levels for both secretion and concentration in
predicting periodontal breakdown measured by attachment
level loss in the patient group over each pair of
successive visits at two monthly intervals. The aim was to
investigate its predictability for periodontal breakdown
over one year. The object was to investigate the role GCF
CRP as either a predictive tool for periodontal destruction
or as a diagnostic aid by which it could be decided that
periodontal breakdown had occurred at the periodontal site.
So diagnostic predictability was also investigated.
In this study, the predictability of GCF CRP levels was
investigated using all loser sites where disease activity
had occurred, and all stable sites where no significant
breakdown had occurred as described earlier (2.7.2).
The predictability of GCF CRP was also investigated on a
more stringent basis which was a selective method. In this
method a matched pair of the worst loser site and the most
stable site allocated according to the method described
earlier (2.7.2) was used to investigate GCF CRP
predictability for periodontal disease activity.
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4.7.1 Predictability of GCF CRP for periodontal disease
activity using all loser and stable sites
In this study the CRP predictability for periodontal
disease activity determined by attachment level loss was
investigated using all the loser and stable sites in the
periodontal patients in whom the attachment level changes
was reported earlier (Table 4.2). This method was used on
the basis that disease activity could occur at any site
throughout the mouth in "random bursts".
This method would give weight to the patient and site
together, as a unit of experimental analysis, for disease
activity.
In this study, the GCF CRP levels at a certain threshold
for both concentration and secretion was used to
investigate their predictability. These thresholds (Table
4.39) were based on the data of GCF CRP concentration and
secretion at the subsequent visit of each two successive
visit for each occasion. For each occasion, there was a
certain threshold level for positive and negative CRP tests
for concentration and secretion. The threshold level for
positive CRP tests was that level of GCF CRP which exceeded
the mean CRP level of all the loser sites at the subsequent
visit for that occasion, while the threshold for a negative
CRP test was that level of CRP which was equal to or < the
mean CRP level for all the loser sites at the subsequent
visit. In other words a test for CRP was considered a true
positive test for any site which showed a CRP secretion or
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concentration level higher than the mean CRP level of all
the loser sites at the subsequent visit of the two
successive visits at that occasion. In the same way, a test
for CRP (secretion or concentration) for any site was
considered a true negative test when its CRP level was
equal to or < the mean level of CRP for all the loser sites
at the subsequent visits of each two successive visits for
that occasion. Any stable site with CRP level exceeding the
positive CRP threshold was considered as being a false
positive test for CRP, while any loser site with a CRP
level below the positive CRP threshold was considered as
being a false negative test. The positive and negative
predictive value, the sensitivity and specificity of the
CRP test (for both concentration and secretion) for
periodontal disease activity occurring over each two
successive visits and over one year (visits 1-6), were
calculated using the contingency table and equations
mentioned earlier in Table 2.4, and the results are shown
in Table 4.39.
As shown from the results, the positive predictive value
for CRP was very low and has a range of 10.8%-40% and of
10.9%-28% over each two successive visits for both
concentration and secretion respectively, while the
negative predictive value for CRP was very high and has
range of 94.4-97.7% and of 94.6-98.0% for CRP concentration
and secretion respectively for each two successive visits.
So in a high percentage of cases, a positive CRP test using
concentration and secretion individually would have
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misclassified a stable (inactive) site a being a loser
(active) site, while in about 5% of cases a negative CRP
test for both concentration and secretion individually
would have misclassified an active (loser) site as being
inactive (stable) site. The sensitivity of the CRP test was
low and had a range of 31.2-47.6% and of 37.5-50.0% for
concentration and secretion respectively for each two
successive visits, while a high specificity was found for
the CRP test with a range of 83.3-97.0% and of 84.6-94.0%
for concentration and secretion respectively for each two
successive visits.
The predictability of CRP over one year was also studied,
using the threshold level for positive and negative CRP
tests for both concentration and secretion, which was based
on the data for CRP levels recorded for all loser sites
after one year. In the same way as mentioned above, the
true positive and true negative as well as the false
positive and false negative test was decided, and the
results are shown in Table 4.39. It was found that the
positive predictive value was 60% and 57.8% for
concentration and secretion respectively. A high negative
predictive value was found at 83.8% and 83.4% for
concentration and secretion respectively. A low sensitivity
of 38.6% and 37.2% was found for concentration and
secretion respectively, while a very high specificity was
found at 92.5% and 92% for concentration and secretion
respectively. So over one year period, a positive CRP test
for both concentration and secretion would have
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misclassified about 40% of stable (inactive) sites as being
loser sites, while 17% of loser (active) sites would have
been misclassified as being stable (inactive) sites by the
negative test.
339
TABLE 4.39: Diagnostic predictive value of gingival crevicular fluid CRP
levels for periodontal disease activity measured by attachment
level loss over each two successive visits (and over one year).
CRP threshold levels (ng/ml), based on the data from the
subsequent visits for all the loser sites at each prescribed




Threshold Predictive Predictive Sensitivity Specificity
Level Value(%) Value(%) (%) (%)
1-2 ^Concentration >124.7 18.4







2-3 Concentration > 177.9 40.0







3-4 Concentration >127.3 13.5







4-5 Concentration >128.1 10.8







5-6 Concentration > 1 09.3 20.0







1-6 Concentration > 1 17.2 60.0







* = concentration (ng/ml)
** = secretion (ng/minute)
4.7.2 Predictability of GCF CRP for periodontal disease
activity using matched pairs of loser and stable
sites within each patient
In this study the CRP predictability for periodontal
disease activity as determined by attachment level loss,
was investigated using matched pairs of loser and stable
sites in periodontal patients of whose attachment level
change was determined as reported earlier (Table 4.34) .
This is a selective method and was used to find if there
was any difference in the predictability level of GCF CRP
from that method in which all loser and stable sites were
included, and also to find if the predictability level was
masked by the large number of stable sites.
In this study, the GCF CRP levels at a certain thresholds
for both concentration and secretion was used to
investigate its predictability. These thresholds (Table
4.40) were based on the data of GCF CRP concentration and
secretion related to the loser sites of matched pairs only
at the subsequent visit of each pair of successive visits
for each occasion. For each occasion, there was a certain
threshold level for a positive and negative CRP test for
concentration and secretion.
The same rules which were used for selecting CRP level
thresholds, true positive and negative CRP tests and the
false positive and negative tests for all the loser and
stable sites (4.7.1), were used in this study for selecting
the thresholds for positive and negative CRP tests.
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The only exception, was that the thresholds were based on
the data from the loser sites of the selected matched pairs
for each prescribed period.
The positive and negative predictable values, the
sensitivity and specificity of CRP test (for both
concentration and secretion) for periodontal disease
activity which occurred over each pair of successive visits
and over one year (visits 1-6), were calculated using the
contingency table and equations mentioned earlier in Table
2.4, and the results are shown in Table 4.40.
As is shown from the results, the positive predictive value
for CRP concentration was reasonably high on most
occasions. The positive predictive value ranged from 62.5%
at visits 3-4 to the highest level (100%) at visits 2-3.
The negative predictive value for CRP concentration was low
and ranged from 53% at visits 4-5 to the highest level of
63.5% at visits 1-6. The sensitivity for CRP concentration
was also low and ranged from 31.2% at visits 3-4 to the
highest level (50%) at visits 4-5. The specificity was very
high for all occasions and ranged from 80% at visits 4-5 to
100% at visits 2-3.
For CRP secretion, the positive predictive value was high
on all occasions and ranged from 70% to 100%, while the
negative predictive value was low and ranged from 50 to
62.5%. The sensitivity was low on all occasions and ranged
from 31.5 to 50%, while the specificity was high on all
occasion and was ranged from 81.3 to 100%. So a positive
CRP test using concentration and secretion would have
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misclassified a stable (inactive) site a being a loser
(active) site in between 25 to 38% of cases for CRP
concentration and in between 15 to 3 0% of cases for CRP
secretion on most occasions. A negative CRP test would have
misclassified an active (loser) site as being inactive
(stable) site in 38-47% of cases for CRP concentration and
in between 38-42% of cases for CRP secretion.
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TABLE 4.40: Diagnostic predictive value of gingival crevicular fluid CRP
levels for periodontal disease activity as measured by
attachment level loss over each two successive visits (and over
one year) . CRP threshold levels, based on the data from the
subsequent visits for matched numbers of loser sites and stable




























































































































4.8 The ability of clinical parameters, GCF CRP
levels, and microbiological variables
individually or collectively to discriminate
between loser and stable sites.
The purpose of this study was to find if any of the
clinical parameters (PI, BOP, GI, PD), microbiological
variables (motile rods and spirochaetes), GCF volume and
CRP levels (concentration and secretion), alone or in
combination would be able to discriminate between loser and
stable sites over each pair of successive visits and over
one year. The values of these variables recorded at the
initial visit of each pair of successive visits, and for
the whole study period of one year alone and in combination
were subject to logistic discriminant analysis. The results
are shown in Table 4.41, Table 4.42 and Table 4.43.
As is shown in Table 4.41, none of PI, GI, BOP, PD, motile
rods or spirochaetes individually or in combination with
each other could discriminate between loser and stable
sites for each pair of successive visits. While GCF volume
significantly (P<0.05) discriminated between loser and
stable sites only for visits 1-2 and 2-3 when it was used
alone and when used in combination with BOP.
For visits 1-6 (over one year period) as it was shown in
Table 4.41, GCF volume, BOP, PD, and spirochaetes
individually successfully discriminated between loser and
stable sites (significance level at P<0.05). When BOP was
used in combination (two factors) with GCF volume, with
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motile rods, and with spirochaetes, it retained its ability
to significantly discriminate between loser and stable
sites. It was also found that both BOP and pocket depth
(two factors) significantly discriminated between loser and
stable sites when they were used in combination for visits
1-6 (over one year period).
In the other study, GCF CRP secretion and concentration
failed to discriminate between loser and stable sites for
each pair of successive visits when they were used
individually but they did so for visits 1-6 (over one year
period) (Table 4.42,4.43).
When CRP secretion, GCF volume, PD, BOP, GI, motile rods
and spirochaetes were tested in combination for each pair
of successive visits, CRP secretion and GCF volume (two
factors) in combination discriminated (P<0.05) between
loser and stable sites only at visits 2-3 and both had a
significant effect for discrimination when they were
combined with BOP (three factors) for this pair of visits
(Table 4 .42) .
For visits 1-6 (over one year period), as it is shown in
Table 4.42, CRP secretion alone or in combination with
other variables was able to significantly discriminate
between the loser and stable sites. CRP secretion and
pocket depth (two factors) in combination significantly
discriminated between loser and stable sites. It was also
found that both CRP secretion and BOP (two factors) were
significant (P<0.05) alone for this discrimination when
they were combined with each of spirochaetes, GCF volume
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and GI, while both these two variables (secretion and BOP)
together with PD (three factors) significantly
discriminated between loser and stable sites. This last
finding is the most interesting one as it is for three
factors.
When CRP concentration alone or in combination with other
variables (GCF volume, PD, BOP, GI, motile rods and
spirochaetes) was tested for this discrimination, the
following was found (Table 4.43):
CRP concentration alone or in combination with other
factors failed to discriminate between loser and stable
sites for each pair of successive visits, and only GCF
volume had a significant effect alone when it was tested in
combination with concentration and both with BOP for visits
1-2 and 2-3 only.
For the visits 1-6 (over one year period) , it was found
that CRP concentration significantly (P<0.05) discriminated
between loser and stable sites when it was tested alone or
in combination with other variables (GCF volume, PD, BOP,
GI, motile rods and spirochaetes). CRP concentration in
combination with GCF volume (two factors) and in
combination with pocket depth (two factors) as well as in
combination with both GCF volume and BOP (three factors),
significantly (P<0.05), together with these factors,
discriminated between loser and stable sites. CRP
concentration and BOP had a significant effect for this
discrimination when they were tested together (three
factors) with spirochaetes and GI. On the other hand, with
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the combination of three factors (GCF CRP concentration, PD
and BOP), both CRP concentration and PD had a significant
effect of discrimination. The finding of a three factor
effect (CRP concentration, BOP and GCF volume) for visits
1-6 in discriminating loser and stable sites was an
interesting one.
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TABLE 4.41: The ability of gingiva! crevicular fluid volume (GCF), plaque
index (PI), gingival index (Gl), bleeding on probing (BOP),
pocket depth (PD), motile rods and spirochaetes at the
initial visit of each pair of successive visits (and over one
year) to discriminate individually or collectively between
loser and stable sites, using logistic discriminant analysis.
Discriminant Analysis Between Loser and Stable Sites
T-Value
Variable V1-V2 V2-V3 V3-V4 V4-V5 V5-V5 Vl-Vi
GCF Volume 2.30* 2.60* 0.58 0.39 1 .22 3.93*
PI 1 .60 0.25 1 .36 -1.35 -1.33 1 .90
Gl 0.45 0.44 -1 .34 0.32 -0.17 1 .97
BOP 0.72 0.19 0.56 0.37 -1 .01 5.92*
PD 1 .83 0.63 0.69 1 .07 -0.79 6.13*
Motile Rods 1 .37 -0.25 0.90 -0.49 0.27 0.83
Spirochaetes -0.13 0.92 0.30 1 .22 0.25 2.18*
BOP 0.27 -1.13 0.33 0.19 -1.71 5.03*
GCF Volume 2.16* 2.34* 0.44 0.20 1 .96 0.31
BOP 0.34 0.30 0.25 0.69 -1 .21 6.11*
Motile Rods 1.16 -0.33 0.70 -0.73 0.77 -1 .46
BOP 0.35 -0.19 1 .08 1.17 -1 .24 5 .73*
Spi rochaetes 0.45 0.92 -1.14 -0.29 0.31 -0.42
BOP -0.02 -0.12 0.26 -0.22 -0.68 3.52*
PD 1 .69 0.66 0.47 1 .02 -0.24 3.77*
v = visit
* = statistically significant at P<0.05
TABLE4.42: The ability of GCF CRP secretion, bleeding on probing (BOP),
gingival index (Gl), pocket depth (PD), gingival crevicular
fluid (GCF) volume, motile rods and spirochaetes at the initial
visit of each pair of successive visits (and over one year) to
discriminate collectively between loser and stable sites, using
logistic discriminant analysis.
Discriminant Analysis Between Loser and Stable Sites
T-value
Variable V1-V2 V2-V3 V3-V4 V4-V5 V5-V6 Vl-Vi
Secretion -0.21 -0.48 0.13 0.76 -0.14 5.74*
Secretion -0.43 -0.44 -0.20 0.95 -0.20 5.77*
Motile Rods 1 .43 -0.16 0.89 0.68 0.32 -1.18
Secretion -0.18 -0.73 0.35 0.54 -0.22 5.45*
Spirochaetes -0.08 1.13 -0.84 1 .08 0.31 0.07
Secretion -1 .70 -2.16* -0.29 0.65 -0.97 4.66*
GCF Volume 2.89* 3.51* 0.64 -0.09 1.63 -0.63
Secretion -0.65 -0.78 -0.09 0.39 -0.24 4.03*
Pocket Depth 1 .96 0.95 0.68 0.86 -0.81 4.14*
Secretion -0.56 -0.74 -0.19 0.76 0.39 3.55*
BOP 1 .02 0.22 1 .05 -0.54 -1 .28 3.50*
Spirochaetes -0.42 0.98 -1.15 1 .21 0.77 -0.82
Secretion -1 .70 -2.00* -0.40 0.61 -0.42 3.52*
BOP 0.22 -0.04 0.44 -0.01 -1 .49 3.60*
GCF 2.76* 3.49* 0.51 -0.08 1 .96 -1 .34
Secretion -0.70 -0.81 -0.21 0.55 0.52 3.02*
BOP 0.26 0.82 0.32 -0.43 -0.81 2.09*
Pocket Depth 1 .74 0.27 0.48 0.97 -0.33 3.18*
Secretion -0.62 -0.78 0.13 0.5 0.46 3.60*
BOP 0.78 0.46 0.86 -0.09 -1.09 3.52*
Gi 0.25 0.58 -1 .47 0.31 -0.06 -1 .03
V - Visit
* = statistically significant at P<0.05
TABLE 4.43: The ability of GCF CRP concentration, bleeding on probing
(BOP), gingival index (CI), pocket depth, motile rods and
spirochaetes and gingival crevicular flud (GCF) volume at the
initial visit of each pair of successive visits (and over one
year) to disciminate collectively between loser and stables
sites, using logistic discriminant analysis.
Discriminant Analysis Between Loser and Stable Sites
T-value
Variable V1-V2 V2-V3 V3-V4 V4-V5 V5-V6 V1-V6
Concentration -0.21 -1 .35 0.55 0.36 -1 .02 7.14*
Concentration -0.31 -1 .32 0.35 0.45 -1 .04 7.17*
Motile Rods 1 .39 -0.08 0.77 -0.55 0.51 -0.87
Concentration -0.19 -1.56 0.79 0.24 -1 .08 7.05*
Spirochaetes -0.09 1 .22 -0.93 1.18 0.61 1 .67
Concentration -0.44 -1 .82 0.44 0.32 -1.07 6.87*
GCF Volume 2.35* 2.87* . 0.47 0.35 1.33 3.93*
Concentration -0.29 -1 .67 0.37 0.14 -0.79 6.32*
Pocket Depth -0.76 1.14 0.56 1 .02 -0.43 4.98*
Concentration -0.48 -1.58 0.32 0.34 -0.76 6.05*
BOP 0.99 0.27 0.83 -0.29 -0.90 3.25*
Spirochaetes -0.44 0.99 -1.14 1.17 -0.93 0.40
Concentration -0.38 -1 .54 0.32 0.26 -0.54 5.95*
BOP -0.13 -0.71 0.17 0.07 -1 .43 2.17*
CCF Volume 2.13* 2.82* 0.35 0.25 1 .90 2.52*
Concentration -0.64 -1 .69 0.29 0.23 0.66 5.93*
BOP 0.16 0.25 0.13 0.28 -0.51 1 .56
Pocket Depth 1 .75 0.94 0.45 1 .02 -0.10 4.08*
Concentration -0.49 -1 .57 0.26 0.17 -0.69 6.09*
BOP 0.72 0.51 0.79 0.15 -0.66 3.61*
G1 0.16 0.55 -1 .46 0.40 -0.05 0.68
V = visit
* = statistically significant at <0.05
4.9 The ability of clinical parameters, microbiologic
variables and GCF CRP levels recorded at the
initial visits individually or collectively to
predict periodontal disease activity at the
subsequent visits.
The purpose of this study was to find if any clinical
parameter (PI, GI, BOP, PD and GCF volume), microbiological
variables (motile rods and spirochaetes) and GCF CRP levels
(CRP concentration and secretion) recorded at the initial
visit of each pair of successive visits (and over one year)
could predict periodontal disease activity measured by
attachment loss at the recall visits on each occasion.
Logistic discriminant analysis was used to investigate this
predictability either individually for each variable or
collectively for two or more variables on each occasion.
The results are shown in Tables 4.44, 4.45 and 4.46.
The overall agreement (the percentage of sites which are
diagnosed by the predictor as being loser sites when a real
attachment loss had occurred, and of sites which are
diagnosed as stable site when no real attachment level
change has occurred), the percentages of misclassified
sites (the percentage of sites which are diagnosed by the
predictor as being loser sites but no real change in
attachment level was occurred, and for the sites
misclassified as being stable when a real change had been
occurred), the sensitivity and specificity were used to
describe the predictability of each variable. Whenever the
sensitivity was 10% or less it was adjusted to 10% for
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normalisation of the data in the tables. For the
predictability on an individual basis, the following were
found:
For CRP concentration for all pairs of successive visits,
the overall agreement range was 43-60%, the misclassified
percentage range was 40-57%, the sensitivity range was 10-
13%, the specificity was very high and ranged from 93-97%.
For the one year period, the predictability was better than
for any pair of successive visits; it had an overall
agreement of 76%, the misclassified percentage was 24%,
while the sensitivity and specificity were 47% and 93%
respectively.
For CRP secretion for all pairs of successive visits,the
overall agreement range was 33-67%, the misclassified
percentage range was 33-67%, the sensitivity was 10%, the
specificity was very high and ranged from 90-97%. For the
one year period, the predictability was better than for any
pair of successive visits; it had an overall agreement of
71%, the misclassified percentage was 29%, while the
sensitivity and specificity was 41% and 90% respectively.
For GCF volume for all pairs of successive visits, the
overall agreement range was 62-72%, the misclassified
percentage range was low and had range of 28-38%, the
sensitivity range was 10-13%, the specificity was very high
and ranged from 93-97%. For the one year period, there was
an overall agreement of 68%, the misclassified percentage
was 32%, while the sensitivity and specificity were 34% and
83% respectively.
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For BOP for all pairs of successive visits,the overall
agreement range was 47-58%, the misclassified percentage
range was 42-52%, the sensitivity was 10%, the specificity
was very high and ranged from 94-97%. For the one year
period, the predictability was better than for any pair of
successive visits; it had an overall agreement of 67%, the
misclassified percentage was 33%, while the sensitivity and
specificity was 38% and 92% respectively.
For PD for all pairs of successive visits, the overall
agreement range was 50-59%, the misclassified percentage
range was 41-50%,the sensitivity range was 10-11%, the
specificity was very high and ranged from 93-97%. For the
one year period, the predictability was better than for any
pair of successive visits; it had an overall agreement of
58%, the misclassified percentage was 42%, while the
sensitivity and specificity was 30% and 85% respectively.
No interesting results were found for spirochaetes, motile
rods, PI or GI on individual basis for their
predictability, as the misclassified percentages were still
around 30% or more with a low sensitivity (10%) . The
results over the one year period were better than most of
the paired successive visits for most of these four
variables.
For the predictability of the above variables when they
were used in combination, the followings results were found
(Tables:4.45,4 . 46) :
For CRP concentration when it was used in combination with
the other variables, the predictors failed to give good
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results at the initial visit for each pair of successive
visits. As in most occasions the overall agreement did not
exceed 77%, and the sensitivity did not exceed 25% except
on one occasion, the misclassified percentage did not get
below 33% except on one occasion. Over the one year period,
the predictability improved particularly for concentration,
BOP and spirochaetes (three factors) where the overall
agreement was 74%, the sensitivity was 52% the specificity
was 94%, and 25% were misclassified.
The overall agreement for CRP concentration, BOP with
either of GCF volume, PD or GI (three factors) was
relatively high (the range was 75-77%), with sensitivity of
46-46%, a specificity of 94-95%, and a low percentage of
misclassified ranged at 23-26%. For CRP concentration
with either PD, GCF volume, motile rods or spirochaetes
(two factors), the overall agreement was 74-76%, the
sensitivity was 47-49%,the specificity was 91-94% and the
misclassified percentage was 23-26%. When CRP secretion was
used in combination with other variables (Table 4.46),
there was no improvement in the predictability either for
two factors or for three factors from that for combining
concentration with other variables for all paired
successive visits and even for the one year period.
However, it seems from the results that better
predictability was found for long term over one year and
when there was a high percentage of loser sites. In other
wards, a high percentage of stable sites could mask or
reduce the predictability level.
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TABLE 4.44: The predictability of CCF CRP concentration (Concen.), CRP
secretion (Sec.), gingival crevicular fluid (GCF) volume,
plaque index (PI), gingival index (Gl), bleeding on probing
(BOP), pocket depth (PD), motile rods (MR), and spirochaetes
(Spiro.) at the initial visit of each pair of successive visits
(and for a one year period) in predicting periodontal disease
activity individually, using logistic discriminant analysis.
The percentages of overall agreement (Agr.), sensitivity,
specificity and misclassified for each variable are shown.
Predictability of Variable (%}
CRP CRP GCF Motile
Visits Concen. Sec. Volume Rods Spiro. PI Gl BOP PD
V1-V2 Overall Agr. 43 33 72 74 30 47 71 58 59
Sensitivity 10 1 0 13 11 1 1 10 10 10 10
Specificity 94 90 95 93 89 94 93 94 95
Misclassified 57 67 28 26 70 53 29 42 41
V2-V3 Overall Agr. 51 40 72 28 71 52 84 55 59
Sensitivity 10 10 10 10 10 10 10 10 10
Specificity 97 95 97 85 95 96 96 96 96
Misclassified 49 60 28 72 29 48 16 45 41
V3-V4 Overall Agr. 60 63 65 74 33 50 22 57 52
Sensitivity 10 10 10 10 10 10 10 10 10
Specificity 96 96 95 95 97 95 98 96 96
Misclassified 40 37 35 26 67 50 78 43 48
V4-V5 Overall Agr. 60 67 62 30 76 47 82 56 58
Sensitivity 10 10 10 10 10 10 10 10 10
Specificity 97 97 96 95 98 97 97 97 97
Misclassified 40 33 38 70 24 53 18 44 42
V5-V6 Overall Agr. 44 44 66 71 70 48 18 47 50
Sensitivity 10 10 10 10 10 10 10 10 10
Specificity 93 93 93 93 92 96 94 94 93
Misclassified 56 56 34 29 30 52 82 53 50
V1-V6 Overall Agr. 76 71 68 71 68 56 73 67 58
Sensitivity 47 41 34 36 33 27 34 38 30
Specificity 93 90 83 83 83 83 89 92 85
Misclassified 24 29 32 29 32 44 27 33 42
TABLE 4.45 The predictability of GCF CRP concentration (Cone.), gingival
crevicular fluid (GCF) volume, plaque index (PI), gingival
index (Gl), bleeding on probing (BOP), pocket depth (PD),
motile rods (MR), and spirochaetes (Spiro.) at the initial
visit of each pair of successive visits (and for the one year
period) in predicting periodontal disease activity in
combination, using logistic discriminant analysis. The
percentages of overall agreement (Agr.), sensitivity,
specificity and misclassified for each variable are shown.
Predictability of Combined Variables (%)
Visits
Cone Cone Cone Cone







V1-V2 Overall Agr. 45 46 43 44 72 64 61 65
Sensitivity 1 0 10 1 0 10 15 12 10 1 1
Specificity 95 95 94 95 95 95 94 95
Misclassified 55 54 57 56 28 36 39 35
V2-V3 Overall Agr. 51 52 50 50 61 77 70 74
Sensitivity 1 0 1 2 1 0 10 10 1 1 10 10
Specificity 97 97 93 97 97 97 97 97
Misclassified 49 48 50 50 39 23 30 26
V3-V4 Overall Agr. 60 62 53 58 58 56 67 68
Sensitivity 10 12 10 1 1 10 1 0 10 10
Specificity 96 97 94 95 96 96 96 96
Misclassified 40 48 47 42 42 44 33 32
V4-V5 Overall Agr. 60 60 52 57 52 60 67 75
Sensitivity 10 1 0 11 10 10 33 60 10
Specificity 97 97 96 95 97 97 98 97
Misclassified 40 40 48 43 48 40 33 25
V5-V6 Overall Aqr. 52 53 52 53 54 55 53 52
Sensitivity 11 1 2 1 1 1 0 12 10 10 10
Specificity 96 97 96 96 97 95 94 95
Misclassified 48 47 48 47 46 45 47 48
V1-V6 Overall Agr. 76 77 74 75 75 77 75 74
Sensitivity 47 49 48 48 46 48 46 52
Specificity 93 92 91 94 95 95 94 94
Misclassified 24 23 26 25 25 23 25 26
TABLE 4.46: The predictability of GCF secretion, gingival crevicular fluid
(GCF) volume, plaque index (PI), gingival index (Gl), bleeding
on probing (BOP), pocket depth (PD), motile rods (MR), and
spirochaetes (Spiro.) at the initial visit of each pair of
successive visits (and for over the one year period) in
predicting periodontal disease activity in combination, using
logistic discriminant analysis. The percentages of overall
agreement (Agr.), sensitivity, specificity and misclassified
are shown.
Predictability of Combined Variables (%)
Sec. Sec. Sec. Sec.
CRP Sec. Sec. Sec. Sec. BOP BOP BOP BOP
PD Volume MR Spiro PD Volume Spiro Gl
Visit
V1-2 Overall Agr. 32 36 33 34 62 72 66 62
Sensitivity 1 0 10 10 10 1 1 15 11 1 0
Specificity 90 90 90 90 95 96 94 95
Misclassified 68 64 67 64 38 28 34 38
V2-V3 Overall Agr. 40 41 40 39 54 75 64 37
Sensitivity 1 0 10 10 10 10 10 10 10
Specificity 95 95 94 94 97 97 96 97
Misclassified 60 59 60 61 46 25 34 63
V3-V4 Overall Agr. 63 63 62 59 59 53 72 70
Sensitivity 10 10 10 10 10 10 10 10
Specificity 96 96 96 96 95 96 96 96
Misclassified 37 37 48 41 41 42 23 30
V4-V5 Overall Agr. 67 67 60 59 70 61 74 71
Sensitivity 1 0 10 10 10 10 10 10 10
Specificity 97 97 95 95 97 97 98 97
Misclassified 33 33 40 41 30 39 26 29
V5-V6 Overall Agr. 44 42 40 41 46 54 42 46
Sensitivity 1 0 10 10 10 10 . 10 10 10
Specificity 93 92 92 92 95 96 95 95
Misclassified 46 58 60 59 54 46 48 54
V1-V6 Overall Agr. 73 78 73 73 73 69 67 70
Sensitivity 50 50 50 50 44 39 40 41
Specificity 91 91 92 93 92 90 92 92
Misclassified 22 22 27 27 27 31 33 30
CHAPTER FIVE
DISCUSSION
5.1 Considerations on clinical and laboratory data
5.1.1 Identification of attachment level changes
It has been found that only a small proportion of
periodontal sites are defined as experiencing disease
activity, and several authors have suggested that a high
percentage of these could be due to measurement errors
(Imrey 1986, Clark et al. , 1987, Cohen and Ralls 1986) .
Differences between duplicate attachment level measurements
exceeding 3 times the standard deviation have been used as
the criterion for disease activity, assuming that recorded
differences were normally distributed (Haffajee et
al.,1988; Haffajee et al. , 1983a,b). However, Janssen et
al.(1987) have warned that a normal distribution of errors
associated with duplicate measurement has never been proven
and other papers have reported that differences between
attachment level measurements are not normally distributed
(Badersten et al. , 1984d, Glavind and Loe, 1967; Consollely
and Best ,1988). Acceptance of the premise that a normal
distribution of errors is true underestimates probing
errors of reported proportions of sites that show a 2mm
gain or loss of attachment and the writers cautioned that
data derived from sites using this criterion only weakly
corroborate the burst hypothesis.
Many periodontologists have used > or equal to 2mm loss
(Muller et.al, 1987; Harley et al., 1987) or > or equal to
3 mm loss (Lindhe et al., 1983; Haffajee et al., 1983a,b)
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in clinical attachment level to determine whether or not a
real change has taken place.
In the present study, attachment level measurements were
taken in duplicate for each site within each patient at
each visit using a pressure-controlled probe and a modified
stent method described earlier (2.5.4.1). This method of
attachment level measurement was found to be a reproducible
one in our studies in a similar way to the onlay method
used by other authors (Badersten et al., 1984d ; Isidor et
al., 1984).
Our modified stent method of probing attachment level
measurements showed that the differences between the
duplicate readings of measurements may occasionally be as
much as 2mm or more. The replicated measurements in our
studies resulted in five paired sequential measurements for
each group during the whole year. These sequential
measurements were subjected to the linear regression
analysis method described earlier (2.7.1), and the
direction and extent of attachment level change over the
one year period was determined using a significance level
of P<0.05.
The most important purpose of using regression analysis,
was to find the sites which were significantly not changed
(the "not changing" sites). These are the sites which did
not change according to trends revealed by regression
analysis of probing measurements taken bimonthly for each
patient (or control) for the period of the year.
The average of the standard deviations of "not changing"
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sites was used to find a significantly acceptable cut off
point, which was three times more than the mean of the
standard deviations of all these sites. This was 2mm for
the patient group, and 1.5mm for the control group, and
used in determining a real change in attachment level over
each prescribed period at each site.
The safety threshold method which was described earlier
(2.7.1) using a certain cut off point of attachment level
was used to detect significant attachment level change.
This method was based on a reducing the false positive rate
of attachment level measurements, by using the frequency
distribution of the standard deviations of all "not
changing" sites determined by regression analysis.
It was basically used to test the selected cut off point
which was mentioned above. The 2mm safety threshold for
the patient group was twice the standard deviations of more
than 95% of "not changing" sites determined by regression
anaylsis, and its occurrence was within less than 5% of the
false positive rate. This means that the chance was that
the false positive results for attachment level change
would be less than 5%. In other words, only less than 5% of
the change in attachment level using this threshold would
be due to measurement error and this was considered the
false positive rate (the relative portion of sites with
measured change in attachment level that occurred in the
absence of real change in attachment level). The safety
threshold for the control group was selected at 1.5 mm
which was at least twice the standard deviations of more
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than 97% of "not changing" sites in this group,and this was
within less than 5% of the false positive rate.
The reasons for selecting this method was that it would
give reduced false positive rates, as basically the average
of the standard deviations of "not changing" sites was used
to find the significantly acceptable cut off point.
This method of selecting a cut off point has already been
used by Goodson et al. (1982) who used the mean of the
standard deviations of the repeated attachment level
measurements of all "not changing" sites determined by
regression analysis (at significance level of P<0.05) .
Their selected cut off point was > three times the mean of
the standard deviations of those sites (2.5mm).
Our method of identifying the attachment level changes
using these cut off points (1.5 and 2mm) was confirmed when
tested by using the frequency distribution of the standard
deviations of all the "not changing" sites. In both
methods, the safety threshold was equal to 2mm for the
patient group and to 1.5mm for the control group. This
difference in threshold level between the patient and
control group could be due to the subject variation and/or
the site variation (Badersten et al.,1984d). For example
the mean pocket depth in the control group was
significantly less than in the patient group (P< 0.05). It
was found that the probing measurements became deeper and
more reproducible in the deep pockets than in the shallow
pockets (Janssen et al., 1987).
This method of selecting safety threshold was introduced
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by Lindhe et al.(1986) who used a safety threshold of more
than 2mm of probing attachment level difference to identify
sites with attachment loss. They selected their safety
threshold on the basis of the findings by Badersten et
al.(1984d), who suggested that a probing attachment loss of
more than 2mm would occur on average in only 1-5% of
repeated measurements. On this basis, therefore Lindhe et
al.(1986) concluded that this threshold should provide a
sufficient margin of safety.
They used the frequency distribution of the standard
deviations of the repetitive measurements at sites which
showed no significant attachment level change by regression
analysis (at P<0.05) . They selected a cut off point of >
2mm as the safety threshold, based on the chance that false
positive results would be less than 5% and the frequency of
the cut off point must be less than 5% of the false
positive rate.
The views of Gunsolley and Best (1988); Best et al.(1990)
, and Lindhe et al.(1991) on attachment level measurement
errors, appear to support this method.
Gunsolley and Best (1988) estimated the error rates
associated with attachment level measurements, and
concluded that a large portion of perceived changes in
attachment level can be attributed to false positive rates.
They found that with a difference in the mean of replicated
measurements greater or equal to 2mm only 16% of changes
were attributable to error.
Best et al.(1990) investigated the reliability of
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attachment level measurement in a longitudinal trial, and
found that attachment level measurements were in agreement
within 2mm in more than 95% of sites. They defined a
reliable criterion for change in attachment level which was
having less than a 5% chance of obtaining one false
positive change in attachment level for a mouth with 120
sites. Their results point out the lack of sensitivity of
standard periodontal probe measurements and that 2-3mm of
change appears to be the limit of sensitivity due to the
high error inherited in the measuring method.
The criteria adopted by Lindhe et al. (1989b) for
considering that a site has lost significant additional
amounts of attachment was an increase in the probeable
attachment level of > 2mm. The choice of this threshold was
based on estimate of the false positive rate for attachment
losses for single measurements presented by Glavind and Loe
(1976) and replicate measurements by Cunsollely and Best
(1988).
Although Haffajee et al.(1983a,b) suggested a criterion of
3 standard deviations of the difference of replicate
measurements, which was equal to 2.5mm rounded up to 3mm,
in their study to reduce false positive detection of
attachment level change, this technique (3mm threshold) has
been criticised by Fleiss et al. (1991) as it has been
applied to various populations not having a similar
precision of measurement.
It could be concluded that our selection of a safety
threshold of 2mm would be acceptable to be used for
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identification of attachment level in our study as it was
based on a reducing the false positive rate, and would seem
to be within the limit of sensitivity of attachment level
measurement (2-3mm). It could be suggested, that using a
cut off point of >2mm would not necessarily be appropriate
for every study to identify a real attachment level change.
5.1.2 Incidence of attachment level change
Longitudinal studies of untreated periodontal patients have
indicated that attachment loss occurs at relatively few
sites over the observation periods (Goodson et al. , 1982;
Lindhe et al. , 1983; Haffajee et al. , 1983a,b; Harley and
Watts 1987; Muller and Flores, 1987; Okamoto et al., 1988;
Papapanou, et al.1989).
In our study, the incidence of attachment level change over
one year determined by the linear regression analysis
method at a significance level of P<0.05, was shown earlier
in Table 4.1. In the patient group, 15.3% of the total
sites became significantly deeper in probing attachment
level, while 2.7% of the sites became significantly
shallower during the one year period. When a significance
level of P<0.01 was used, 4% of sites showed significant
attachment loss in the patient group, while only 2% of
sites showed significant attachment gain.
The results for attachment level change over one year using
regression analysis (at PcO.Ol) were similar to those
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reported by Haffajee et al. (1983a) and Goodson et
al.(1982). Haffajee et al.(1983a) found that 5.1% of sites
showed significant loss of attachment and 2.3% of sites
showed significant attachment gain (at P< 0.01) over one
year. Goodson et al. (1982) found that sequential attachment
level measurements made at monthly intervals for a year,
when analyzed by regression analysis at P<0.01,
demonstrated a significant increase in probeable attachment
level in 5.7% of all sites monitored in 22 subjects.
Our results showed that at a significance level of P<0.05,
the incidence of attachment loss (15.3%) was higher than
that found by Jenkins et al. (1988) in their longitudinal
studies on 11 patients with untreated chronic adult
periodontitis during a one year period. Using regression
analysis (P< 0.05), they found that 9.8% of sites showed
attachment loss of equal to or > 2mm per year,and only 6%
of sites studied showed gain in attachment level.
When a safety threshold method using a cut off point of
equal to or > 2mm was used to determine the change in
attachment level at each periodontal site in our patient
group, the percentage of loser sites over each pair of
successive visits ranged from 3.2-7.4%, while 22.4% of the
total sites studied became losers during the one year
period. The percentage of improved sites which gained equal
to or > 2mm ranged from 1.9-2.8% over each pair of
successive visits while it was 0.7% for all the sites
studied over one year. The results over each paired
successive visits are relatively small, and close to those
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reported by Harley et al. , 1987, who found that 3.7% of
sites became deeper and 4.5% of sites became shallower by
2mm or more over a three month period in patients with
untreated periodontal disease.
With regard to the incidence of attachment loss over a one
year period (22%), this was a relatively higher percentage
compared to previous studies. For example studies by Lindhe
et al. (1983) in their longitudinal studies on Swedish
patients with untreated periodontitis over a 6 year period,
found that 37% of sites lost 2 mm or more, and only 0.2% of
sites showed gain of > 2mm in attachment level. An observed
attachment loss of equal to or > 2mm was found in 6.2% of
Swedish subjects and in 9.1% of American subjects over one
year. This maybe due to method they used in measuring and
identifying the attachment level change.
5.1.2 Reporting of GCF CRP data
GCF volumes are usually below luL, and if small errors
occur in the estimation of GCF volumes, it would result in
disproportionally large alterations in the concentrations
of GCF constituents (Lamster et al., 1988a). These errors
are more likely to happen particularly in the ultra low
range of GCF volumes, as losses from evaporation could
easily occur both during sampling and transfer of the
sample to the Periotron. It has been agreed that expression
of GCF constituent data as a total amount is preferable
(Lamaster et al. , 1986 and 1988a; Wolff et al. , 1988),
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while other investigators seems to have their reservations
and usually report results both as concentration and total
amounts (Giannopoulou et al. , 1992 ; Eley and Cox et
al.1992) . hamster et al. (1986) concluded that reporting of
GCF constituents using activity/ collected sample could be
a more sensitive indicator of periodontal pathology than
standard clinical parameters. He found a disassociation
between clinical parameters and the data for GCF analysis
of its content when reporting it as concentration. Lamster
et al. (1989) concluded that the expression of the data as
total activity per sample or concentration provided a very
different relationship to periodontal disease activity.
Since the GCF volume in any disturbed crevicular location
is generally less than 1 uL, even small errors in the
measurement of sample volume or constituent content can be
grossly magnified during subsequent calculation. So using
the second approach of reporting GCF CRP analysis as a
total CRP amount in crevicular location/GCF sample becomes
more meaningful.
In our studies, GCF CRP analysis was carried on the basis
of data reported using both the concentration (the amount
of CRP per unit of volume),and the total CRP amount in the
sample (activity/sample). The first approach assumes that
the results obtained from a small sample of the fluid will
be representive of the total fluid volume. Since the volume
of GCF at any site is both small and extremely variable, it
is not possible to collect a standard volume of GCF from
every site. Calculation of the concentration of the
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constituents in GCF could be complicated by site as, when
converted, it would have a GCF volume equal to or < 0 uL.
Thus, sites with converted volumes of equal to or < 0 uL
would not be considered in the calculation of concentration
, which makes evaluation of the concentration data
difficult. All sites were considered when mean GCF volume
or total CRP activity were calculated. For GCF volume,
samples which converted to equal or < 0 were adjusted to 0
uL.
However, in our studies on GCF CRP, it was found that there
was no improvement in the associations of attachment level
change or other clinical parameters with the GCF CRP when
the data was analysed on the basis of either concentration
and secretion. Not, even the logarithmic transformation of
concentration or secretion (data not shown) made any
improvement in these associations.
It could be concluded that reporting the GCF constituent
data by either concentration or secretion or both may
depend on the constituent to be studied.
5.2 Longitudinal study of healthy controls and
chronic periodontitis patients on maintenance
therapy
5.2.1 Clinical, microbiological and laboratory findings
using the subject as an experimental unit of
analysis
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The clinical findings in the patient and control groups
using the subject as an experimental unit of analysis,
demonstrated that the patient group had periodontal disease
as they had pocket depths > 3.5mm (Table 4.4) and a low to
moderate frequency of BOP (Table 4.13) and also the data
reflected that they were on maintenance therapy throughout
the study period as no significant change in their pocket
depth was found over each pair of successive visits and
over one year. In contrast, the clinical findings
demonstrated that the control group were did not have
periodontal disease or gingivitis as they had a shallow
pocket depth over the study period (Table 4.4) and a very
low frequency of bleeding on probing throughout the study
period (Table 4.14) . On the other hand no change in the
attachment level was reported over the study period in this
group.
The association of clinical parameters (PI, GI, BOP, PD)
and GCF volume with attachment level change over each pair
of successive visits and over one year was studied in both
groups using the subject as an experimental unit of
analysis. It was found that both PI and GI had no
association with attachment level change in both groups on
all occasions, while BOP was significantly associated with
attachment level change in the patient group on a few
occasions (Table 4.7). Both pocket depth and GCF volume had
no significant correlation with attachment level change in
both patient and control groups except on one occasion for
the patient group.
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The microbiological data including the percentages of each
of coccoid cells, other, motile rods and spirochaetes
failed to demonstrate any association with attachment level
change in both patient and control groups on any occasion
(Table 4.8).
It could be concluded that the above clinical parameters
and microbiological variables had no association with
periodontal disease activity on subject basis. So we are
not able to determine the subjects at risk of periodontal
disease activity using these clinical parameters.
The studies on serum and salivary CRP levels in both
patient and control groups demonstrated no association with
attachment level change on any occasion (Table 4.12),and
thus none of these variables could be used to diagnose
subjects with periodontal disease nor determine subjects at
risk of periodontal disease.
For serum CRP, as it was found to be within normal limits
for the patient group, this may indicate that periodontal
disease activity is not generalised enough to produce
systemic changes in serum CRP.
A significantly higher salivary CRP was found in the
patient group compared to the control group, and this may
be due to the presence of periodontal disease within the
patient group. A speculation on that increased level of
salivary CRP in the patient group suggest it could be due
to the GCF source, and this should not be excluded. The
level of salivary CRP was found to be 1:1000 of GCF CRP,
and this may support this speculation. No significant
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association was found between serum and salivary CRP on
most occasions, and thus the direct contribution of serum
to salivary CRP may be minimal. However, further studies
using salivary samples from parotid, submandibular or
sublingual glands or mucosal saliva, are required to
investigate its source. The previous studies (Adam and
Christids, 1962; Boucher et al., 1967; and Iwamoto et al.,
1979) on salivary CRP are not reliable as they used
semiquantitative methods to measure its level, although no
study mentioned its arbitrary level. These studies
confirmed the presence of CRP in whole saliva, and showed
that its incidence in the whole saliva was higher in
patients with periodontal disease than in healthy control
subjects, as well as they showed its absence in saliva
sampled from the parotid gland.
5.2.2 Clinical, microbiological and laboratory findings
using the site as an experimental unit of
analysis
The associations of periodontal disease activity measured
by attachment level loss with clinical, microbiological and
laboratory findings was also investigated using the site as
a unit of experimental analysis. The periodontal sites
either collectively or in groups were studied. These
included loser sites, stable sites and improved sites. The
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most interesting is the studies on either of the loser and
stable site groups, and the differences in their clinical,
microbiological and GCF CRP levels.
This investigation was mainly carried out because the
disease activity occurred at loser sites as assessed
retrospectively while no significant attachment level
changes was recorded for the stable sites. It was also
hoped to find if each of the variables could discriminate
between disease presence (at loser site) and disease
absence (at stable site).
5.2.2.1 Clinical findings
The clinical parameters including PI, GI, BOP, PD and GCF
volume for the each site group in the periodontal patients,
and their association with attachment level change was
studied for each pair of successive visits and over the one
year period (visits 1-6) .
The results as reported earlier (Tables 4.13-20) showed
that all the clinical parameters including PI, BOP, PD, and
GCF volume had no significant association with attachment
level change for each pair of successive visits and over
one year at each site group on most occasions.
For GI, attachment level change was found to be associated
with low GI scores at each site group, and this may
indicate that marginal gingivitis was well controlled
throughout the study as the patient group were receiving
maintenance therapy.
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BOP showed no significant association with attachment level
change on most occasions except for the stable site group
for visits 2-3, and for loser sites over the one year
period.
Our results on attachment loss association with these
clinical parameters were simliar to the previous reports
(Listgarten and Levin, 1981; Haffajee et al., 1983b;
Badersten et al. , 1985c and 1987; Fine and Mandel 1986) .
These studies were failed to report any significant
relation between the subsequent significant loss of probing
attachment level used as an indication of disease activity,
and these clinical parameters. Our studies also agreed with
the results of Goodson (1986), Haffajee et al.(1988), and
Lindhe et al.(1989a). Goodson 1986 found that GI, BOP , PI,
exhibited no association with episodic attachment loss.
Haffajee et al.(1988) found that the severity of gingival
inflammation measured by GI, BOP, and PI related poorly to
mean attachment loss. Okamoto et al.(1988); Yoneyama et
al.(1988); and Lindhe et al. (1989a) found no significant
relationship between changes in probing depth and probing
attachment level.
Our findings that BOP showed an association with attachment
level change, specifically attachment loss at the loser
sites suggests this parameter may be useful to monitor the
periodontal disease during maintenance therapy over one
year period, or maybe of diagnostic help for periodontal
disease activity particularly if long term studies were
carried out. However, although there was an association
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with BOP over the one year period, the predictive value of
this parameter was found to be low in our study as it will
be discussed later on.
Generally, it could be concluded that none of these
clinical parameters recorded at the initial visit of each
paired successive visits and over the one year period could
predict future attachment level loss when the site or
subject were used as the experimental unit. In other words,
none of them would be useful as a diagnostic aid for
periodontal disease activity.
5.2.2.2 Microbiological findings
The association of subgingival bacteria including coccoid
cells, other, motile rods and spirochaetes with attachment
level change at each site group was investigated, and the
results indicated that all these bacterial morphotypes
failed to predict the disease activity identified by
attachment loss at loser site group over any prescribed
period including the one year period. So phase-contrast
microscopy failed to predict periodontal disease activity
and can not be useful. Our studies confirm the previous
observations of Listgarten et al.(1986), Harley et
al.(1987), Goodson 1986, and Macfarlen et al.(1988). These
investigators found that dark field microscopy of




It was mentioned earlier (3.3.3.1), that CRP was present in
GCF from healthy and diseased periodontal sites in the
patients, and healthy controls. These results support the
earlier reports by Aziz et al. (1990) on CRP presence in
GCF. They also support the results of studies by Sibraa et
al.(1991).
In the Sibbra study, no quantitative determination of GCF
CRP levels was carried out as it was only a pilot study on
the presence of CRP at the diseased and healthy periodontal
sites. They found no difference in the incidence of CRP
presence among diseased and healthy sites. With exception
of the above mentioned report, no study have ever been
reported on GCF CRP. So our study in 1990 was the first
report on GCF CRP, and has already been supported by the
results of Sibraa et al. (1991) .
The levels of GCF CRP for both concentration (ng/ml) and
secretion (ng/sample or ng/minute) for all the periodontal
sites in the patient and control groups were studied, and
their association with clinical parameters particularly
attachment level measurements as well as with
microbiological variables were investigated.
As shown earlier (Table 4.20) there are higher CRP levels
for both concentration and secretion for all periodontal
sites in the patient group compared to the control group at
each visit. This might reflect the presence of periodontal
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disease in the patient group, and might be due to higher
GCF volumes or deeper pockets in patient group. These two
speculations were investigated and are discussed later on.
When the association between the change (response) in
attachment level and the change (response) of CRP levels on
logarithmic transformed data for both concentration and
secretion over each pair of successive visits (and over one
year) for all sites in the patient and control groups was
investigated, CRP response was significantly associated
with attachment level change in the patient group but not
in the control group. This is an interesting finding where
a positive significant correlation was found between
attachment level change and GCF CRP levels for both
concentration and secretion. In this correlation as was
illustrated earlier in figures (4.4-4.9), as probing
attachment level increased at the subsequent visit of each
pair of successive visits (and over one year) , the CRP
level increased at the same visit. It was also found that
as probing attachment level decreased at the subsequent
visit on each occasion, the CRP level decreased. So the
deeper the probing attachment level, indicated with a large
difference between the initial and subsequent visit of each
pair of successive visits, became, the higher the level of
CRP at the subsequent visit became. These results indicated
a decisive parallel association between the change in
attachment level and the CRP response.
As periodontal disease activity is determined by increasing
probing attachment level, which in our study was supposed
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to have occurred at the subsequent visit of each occasion,
and higher CRP levels were found at this visit, It could be
suggested that higher CRP levels may be associated with the
occurrence of periodontal disease activity retrospectively.
This is the first study carried out on GCF CRP levels and
attachment level change. It could be also suggested that
GCF CRP may act as a supportive diagnostic tool for
attachment level measurements to determine periodontal
disease activity. However, this suggestion was further
studied and is discussed later on.
5.3 Differences in the clinical parameters,
microbiological variables and GCF CRP levels
among site groups
The studies showed earlier (4.5) that there was no
significant difference between the loser and stable sites
for Pi, GI, and PD recorded at the initial visits on all
occasions. BOP was more frequent at loser sites than stable
sites over the period of one year. GCF volume was
significantly higher at loser sites on three occasions.
All the subgingival bacterial morphotypes studied (coccoid
cells, others, motile rods and spirochaetes) were not
significantly different between loser and stable sites.
CRP secretion and concentration showed no significant
differences between the loser and stable sites on all
occasions.
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So from the above results it seems that loser and stable
sites have no significant difference in their initial
clinical parameters,microbiological variables and CRP
levels on most occasions.
It could be suggested that these factors would seem to have
no effect on the response on CRP levels in the gingival
crevice. Although GCF volume was significantly different on
three occasions, no significant difference was found in CRP
levels between loser and stable sites at the initial visits
of all occasions. So this suggests that it had no effect on
CRP levels for both concentration and secretion at the
initial visits in the crevice. However, this was further
confirmed when GCF volume showed no significant effect on
CRP levels even at subsequent visits (data was not shown).
In separate studies (data was not shown) it was found that
the clinical parameters (PD and GCF volume) recorded at the
subsequent visits was not significantly different between
loser and stable sites on most occasions. These results
also cast doubt about the effect of these two factors on
the response of CRP levels over each paired successive
visits. It could be suggested that these factors would not
govern CRP levels in the gingival crevice.
In general the above clinical, microbiological factors have
no effect on CRP levels or responses in the gingival
crevice at least in the short term of two months.
The effect of GCF volume and BOP on CRP levels at the
initial visit for the one year period may be limited or not
significant as there was no significant difference for both
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CRP levels at the same initial visits between loser and
stable sites on all occasions. This means that higher
volume of GCF (as for loser sites) do not necessary mean
higher CRP levels than in small volumes.
It may be possible to suggest that the inflammatory
condition of the gingival margin or the inflammation at the
base of the pocket, which lead to increased vascular
permeability and increasing GCF flow (volume), will not be
enough to affect CRP response in the gingival crevice. In
contrast a strong episode resulting in attachment level
breakdown might have this effect. So it could be concluded
that the response in GCF CRP levels was not governed by
either of these factors or variables. It could also be
concluded that the association between attachment level
change and CRP response could not be affected by any of
these variables. It could be suggested at this stage that
attachment level loss may govern CRP level changes in the
gingival crevicular fluid at the subsequent visit.
5.4 GCF CRP level associations with clinical
parameters and microbiological variables
The studies on the associations of GCF CRP levels with
clinical parameters (PI, GI, BOP, PD) recorded at the
initial visits for all site groups, as mentioned earlier
(4.4.2), showed a significant positive association for CRP
concentration with all of these variables at stable sites
on all occasions, while for loser sites only CRP
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concentration was significantly associated with PD on most
occasions. These associations could be due to the presence
of a limited inflammatory condition at the gingival margin
or at the base of the pocket resulting in a limited
increase of GCF CRP concentration at the time of collecting
the data, as GI and BOP represent the present status of the
inflammatory process in the gingival tissue or the gingival
crevice. Although the pocket depth represents the past
history, like the loss of attachment level, it is possible
for the inflammatory process to reoccur, particularly in
deep pockets as in the case of both loser and stable sites,
at any time resulting in increased gingival crevicular
fluid which may affect CRP concentration. So it could be
concluded that the association between CRP concentration
and each of GI and BOP and PD and GCF volume may be mainly
due to the limited inflammatory process occurring in deeper
pockets. It could also be suggested that this inflammatory
process may be not strong enough to result in attachment
level loss or such limited inflammation may have occurred
before or after the strong episode resulted in attachment
level loss.
Most interesting was the association between CRP secretion
with pocket depth for loser and stable sites, and with GCF
volume for all the site groups on all occasions.
Again the association between CRP secretion and pocket
depth could be incidently due to the presence of deep
pocket depth which did not change on most occasions, and
that may participate in increased gingival crevicular fluid
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flow on all occasions. Thus, a positive correlation between
secretion and GCF volume which resulted for all site groups
may be due to the residual pocket depth, and /or to the
presence of limited inflammatory processes resulting in
increased vascular permeability and increased GCF flow.
Such inflammatory processes may not be strong enough to
cause attachment loss.
No significant association was found between CRP levels for
both concentration and secretion measured at the initial
visit of each paired successive visits and for the one year
period with attachment level change over each prescribed
period. These indicate that CRP levels at the initial
visits may not be useful predictors of periodontal disease
activity.
In general, it could be concluded that the associations of
CRP secretion and concentration with the inflammatory
indicators such as GI, BOP and GCF volume could be due to
a limited inflammatory condition occurring at either loser
or stable site groups, but usually in residual deep
pockets.
As no association between CRP levels at the initial visit,
was found for attachment level change. This may indicate
that such inflammatory processes would either not be strong
enough to produce significant increased CRP levels and
attachment level change, or it could be that a strong
episode occurred at any time before recording of these
clinical parameters and measuring the CRP levels.
The association of CRP levels with motile rods and
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spirochaetes could be due to the presence of residual deep
pockets in both loser and stable sites, with the main
effect on stable sites due to their large number.
5.5 GCF CRP and periodontal disease activity
The initial finding of a GCF CRP change association with
attachment level change at the periodontal sites in the
patient group led to further investigation for the possible
role of GCF CRP in predicting or diagnosing periodontal
disease activity at specific sites within an individual.
No studies have been reported in the literature on the
ability of GCF CRP to differentiate between periodontally
active (loser) versus stable sites (inactive). Two
investigations were carried out in this thesis to assess
this role for GCF CRP.
In the first investigation, all the loser sites and stable
sites as designated earlier (4.2) were included. In this
investigation, both the patient and the site had been
considered as this gave more chance for the periodontal
disease to be expected at any site within any subject, than
if paired sites were selected within each subject as it
would be in the second investigation.
The clinical data of these two site groups (all loser and
all stable sites) and the their differences were already
shown earlier (Tables 4 . 2,4.16.,4.17,4.27,4.28), and
discussed earlier (5.2.2.1). A highly significant
difference in attachment level change was found between
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these groups on all occasions.
Three studies, during the first investigation, were
conducted to investigate this possible role of GCF CRP.
The first study was carried out to investigate the site
effect on CRP levels. The difference in GCF CRP levels
between loser and stable site groups at the initial visit
and at the subsequent visit of each pair of successive
visits (and over one year) was compared (loser versus
stable at the same visit).
In the second study, the appointment (visit) effect on CRP
levels was investigated. CRP level for each of loser and
stable site group at the initial visit was compared with
corresponding level at the subsequent visit (loser versus
loser or stable versus stable) between initial and
subsequent visits.
In a third study, the effect of site by appointment (visit)
on CRP levels was investigated. The differences in CRP
levels over each pair of successive visits, were compared
between loser and stable site groups.
As mentioned earlier about the hypotheses with regard to
the GCF CRP association with attachment level change and
periodontal disease activity (2.7), the results of the
above studies on GCF CRP were shown earlier (Tables 4.3 0-
33), and the possible CRP role in the diagnosis of
periodontal disease is discussed as fellows:
The results of the first study demonstrated no significant
difference in CRP levels (concentration and secretion)
between loser and stable sites (loser versus stable) at the
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initial visit of each pair of successive visits (and over
one year). This might suggest that it is more likely that
GCF CRP at the initial visit may be at its normal level at
those sites which later on were designated as loser and
stable sites in the subsequent visits. Alternatively, it
may be that this level (at the initial visit) had already
declined from high levels during the period preceding the
sampling time of GCF for the initial visit, as disease
could be having a burst of disease activity at any site for
short periods (days or weeks), and then the site may go in
remission for long periods and stay stable. On the other
hand, none of the clinical parameters (PI, GI, BOP, PD) and
GCF volume showed any effect on CRP levels both for
concentration and secretion (5.3). So the effect of
inflammation either in the gingival margin (GI) or at the
base of the pocket (BOP), which could increase vascular
permeability and eventually lead to increase GCF flow (the
volume), might be not strong enough to increase GCF CRP. In
contrast a strong episode resulting in attachment level
breakdown would have this effect. This may explain a
possible mechanism of catabolism and metabolism or
production of CRP within the periodontal tissues. For
example, tissue destruction means cellular change in the
periodontal unit, the predominant presence of lymphocytes,
which are the only extrahepatic source of CRP known at the
present time (Murphy et al., 1991; Kuta and Baum, 1986) . It
also means the initiation of all the steps involved in
immune response actively within the periodontal tissues
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which results in bringing most of the acute phase proteins
to this area. The most likely is CRP, and an increase in
its accumulation in the gingival crevice as it was already
been confirmed that CRP is present in the crevice (Aziz et
al.1990) . It could be suggested that CRP increasingly
accumulated in the area in order to participate in the
defence system by expressing its various biological
effects. These functions have already been mentioned in the
review of literature on CRP (section 1.8) . The acute
inflammatory process (episode) resulting in attachment
level loss would seem tohave its effect on CRP levels, and
may govern its presence in the gingival crevice.
In the first study, it was also found that CRP levels for
both concentration and secretion for the loser site group
were significantly higher than for stable site group at the
subsequent visit. So,it could be concluded that higher CRP
(concentration and secretion) was associated with the
presence of disease activity identified, retrospectively,
at the loser site at the subsequent visit. It may be
suggested that the stability of the periodontal site would
be associated with low levels of GCF CRP or at least no
dramatic change would occur in GCF CRP during the period of
remission at specific periodontal site. So the results of
the first study indicated that the site had an effect on
GCF CRP levels, as CRP levels are significantly higher at
loser sites (where disease activity was retrospectively
recorded) than at stable site (where no significant
attachment loss was recorded).
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In the second study, the results showed that both CRP
concentration and secretion for the loser site group at the
subsequent visit were significantly higher than their
corresponding levels at the initial visit on all occasions
(loser versus loser between visits). While for the stable
site group, a significant difference was found only at the
subsequent visit of the successive visits 2-3 and one year
period for concentration, and only for successive visits 2-
3 for secretion. So it is obvious that a dramatic change in
CRP levels was occurring at recall visits for each pair of
successive visits (and over one year) for loser sites where
the periodontal breakdown was occurring at the same time.
This could lead to the conclusion that CRP levels
significantly increased with the presence of disease
activity. These findings support our early results
(5.2.2.3) which showed that CRP levels significantly
increased with increasing probing attachment level. It
could be concluded that CRP levels can significantly change
in response to attachment level change over a two month
interval, and this explained the appointment (visit) effect
on CRP levels.
In the third study, the results confirmed those of the
second study, and furthermore indicated that the change in
CRP levels (for both secretion and concentration) over each
paired successive visits and over the one year period was
significantly higher for loser sites than stable sites.
This change represented the response in CRP levels
according to the change in the circumstances of crevice or
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attachment level apparatus and this was most likely the
response to the change in attachment level as the other
factors (GI,BOP,PD,and GCF volume) were found to have no
effect on its levels.
The response in CRP secretion over one occasion and for two
occasions for CRP concentration, was significant for stable
sites. However, this response was significantly lower when
compared with that of loser sites on the same occasions. In
other words, we can say that the appointment (visit) by
site effect for the stable site group was limited. In
contrast, the appointment by site effect on CRP levels was
obvious for loser sites on all occasions. So the site
effect, appointment effect and site by appointment effect
on CRP levels were confirmed either for the short term over
each paired successive visits, or for the long term (over
one year).
Thus, the conclusion can be drawn, that the dramatic
response in GCF CRP levels was due to the strong
inflammatory condition which occurred at the crevice and
led to periodontal tissue breakdown represented by
attachment level loss.
In conclusion, and on the basis of these studies using all
loser and stable sites within the patient group, CRP levels
for both concentration and secretion were significantly
associated with periodontal disease activity occurrence
either for the short term over each paired successive
visits or over the long term over one year. This means that
all the hypotheses proposed on CRP levels with regard to
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attachment level change and in particular the periodontal
breakdown measured by attachment loss (2.7.3) were
significantly rejected.
It could be suggested at this stage that CRP levels,
although not useful as predictors of disease activity, may
be useful aids in the diagnostic predictability of
periodontal breakdown at any site in periodontal patients
including healthy and disease sites.
In the second investigation, similar studies were carried
out but on the basis of selecting matched paired sites
within each patient as described earlier (4.7.2). In this
investigation, the patient variance was ignored, and a
weight was given to the site only.
This was carried out to find if the CRP level effect and
its predictability for periodontal disease activity were
masked by the large number of stable sites included in the
first investigation. This could have a more powerful
predictability but at the expense of patient weight and it
may not be clinically acceptable as paired sites within
each individual do not properly represent all the sites. In
contrast, six sites selected in the first investigation,
was suggested to represent all teeth in the mouth (Ramjford
et al. , 1956) . The matched paired sites were significantly
different in their attachment level change (Table 4.34)
The levels of CRP for both concentration and secretion for
the groups of paired sites and their difference at the same
visits and between visits were mentioned earlier (4.6.2)
and shown in Tables (4.35,4.36).
389
Paired t-tests were carried to test the site effect,
appointment effect and site by appointment effect on CRP
levels for these matched pairs of loser and stable sites.
In other words, to test the hypotheses proposed earlier
(2.7.1) . The results have already been mentioned in Tables
4.37 and 4.38.
The results indicated that there was a site effect on CRP
levels for both concentration and secretion as it was found
that CRP levels were significantly higher for the loser
sites when compared with that of the stable sites at the
subsequent visits on all occasions, but no significant
difference was found at the initial visits of each paired
successive visits except on one occasion. The results also
indicated that the appointment had an effect on CRP levels,
as it was found that CRP levels for loser sites (and not
for stable sites) at the subsequent visits were higher than
at the initial visits on all occasions. Moreover,the
results also indicated that there was an appointment by
site effect on CRP levels, as the response (difference) in
CRP levels for both secretion and concentration over each
pair of successive visits and over one year was
significantly higher for loser sites than for stable sites
on all occasions.
The results of the second investigation,indicated that CRP
levels for both secretion and concentration at the
subsequent (recall) visits were significantly associated
with attachment level changes which occurred over each
paired successive visits and the one year period.
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From the results of the second investigation it could be
concluded that although CRP levels at the initial visits
have no association with attachment level loss and thus
could not be used as prospective predictors of periodontal
breakdown, its levels at the subsequent visits may be
useful as supportive diagnostic aids to attachment level
measurement in determining the occurrence of disease
activity retrospectively. In other words,CRP levels may act
as a diagnostic indicators for periodontal disease activity
retrospectively. This speculation was further investigated
and is discussed later on.
So from the results of both investigations, it could be
concluded that CRP levels measured at the subsequent visits
for both secretion and concentration were significantly
associated with periodontal disease activity occurring over
each paired successive visits and over one year. It could
also be concluded that CRP levels may act as a diagnostic
indicator retrospectively, but not prospectively, for
attachment level loss at any site.
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5.6 Predictability of clinical parameters,
microbiological and GCF CRP for periodontal
disease activity
The ability of clinical parameters (PI,GI,BOP,PD) and GCF
volume, the subgingival bacteria including motile rods and
spirochaetes, and GCF CRP levels ( concentration and
secretion) recorded at the initial visits of each paired
successive visits (and over one year period) to predict
periodontal disease activity as measured by the loss of
attachment level has been investigated in our studies. Two
investigations were carried out to study the predictability
of these parameters.
In the first investigation the ability of the above
variables to discriminate between the presence of disease
activity as represented by loser sites and the absence of
disease activity as represented by stable sites, either
individually or in combination on each occasion, was
carried out. The values of each variable recorded at the
initial visit of each paired successive visits and over one
year were used in this investigation to find if these
variable could discriminate between loser and stable sites
using logistic discriminant analysis. As shown from Tables
4.41,4.42 and 4.43, all these variables failed individually
or collectively to discriminate between loser and stable
sites for each paired visit. The only exceptions were for
GCF volume for the successive visits 1-2 and visits 2-3,
either alone or with BOP or with CRP secretion or
392
concentration (two factors) or with BOP and CRP secretion
or concentration (three factors). However, the effect of
the combined factors for these two paired visits was
related to GCF volume as on visits 1-2, and to GCF volume
and CRP secretion on visits 2-3.
For the one year period, CRP secretion and concentration ,
GCF volume, PD, BOP and spirochaetes were able to
discriminate significantly between loser and stable sites
when they had been used individually. In combination, PD
with each of BOP, CRP secretion and CRP concentration (two
factors) significantly discriminated between loser and
stable site. In a combination of three factors secretion,
PD and BOP; the concentration, BOP and GCF volume, these
factors retained their effect and all three factors
significantly discriminate between loser and stable sites.
Each of these factors retained their effect when used in
combination with other variables (for example with GI,
spirochaetes or motile rods).
It can be concluded from that all the above variables
either individually or in combination would not be able to
discriminate between the active and inactive periodontal
sites at least for short periods of time (for example two
months) and thus doubt is cast over their use as predictors
of disease activity for the short term. On other hand, over
a one year period, some of these predictors seemed to be
able to discriminate between active and inactive
periodontal sites either individually or collectively. The
most useful would be BOP and PD and GCF volume as clinical
393
parameters, and CRP concentration and secretion as
laboratory markers to discriminate between the disease
presence and disease absence, and may be useful to monitor
the periodontal disease over a long term period.
However, from a clinical point it seems that these
variables (CRP secretion and concentration, PD and BOP and
maybe GCF volume would not be useful as reliable
discriminants as they failed in the short term and
succeeded in the long term. In this situation, the
assessment of the cause of the periodontal disease is more
important in very short term (even less than two months) in
order for the clinician to be able to take the necessary
therapeutic or preventive measures rather than waiting for
one year when the condition may be worse and this would
unacceptable.
However, the predictability of the clinical parameters (PI,
GI, BOP, PD, and GCF volume), microbiological variables
(spirochaetes and motile rods) and GCF CRP levels
(concentration and secretion) at the initial visits of each
paired successive visits and over one year period, for
periodontal disease activity was studied using logistic
discriminant analysis. In this study,the overall agreement,
sensitivity, specificity, and the misclassified percentages
were used to assess this the predictability.
The objective was to find if any of these variables
individually or collectively was able to predict the
periodontal breakdown before its occurrence so that
necessary preventive measures could be taken. In other
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words, to test these variables for their ability to
determine periodontal sites at high risk of periodontal
breakdown.
As mentioned previously (4.9), all of these variables
either individually or collectively failed to predict
periodontal disease activity over each paired successive
visits due to their low sensitivity and high percentage of
misclassified cases. Although, an improvement appeared for
most of these variables over a one year period, they are
still considered unreliable predictors due to their low
sensitivity and unacceptable percentage of misclassified
sites which were classified as being loser (active ) while
they were stable sites. On other hand, The small size of
the loser sites and the large size of stable sites on
predictability of these parameters should not be excluded.
In conclusion, none of these variables was useful in
predicting attachment level loss at any site either for the
short or long term.
Our results do confirm previous reports which demonstrated
the inability of clinical criteria to predict periodontal
disease activity (Haffajee et al. , 1983b; Badersten et al. ,
1985c; Jenkins et al., 1989; Kaldahl et al., 1990;
Baderstent et al.,1990).
Haffajee et al. (1983b) assessed the diagnostic relationship
of certain clinical parameters (BOP,PI) at each 2-months
time interval to future disease activity in untreated
periodontal disease patients over a 2-year period, and
found that none of the parameters used either individually
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or in combination was useful in predicting disease
activity. Badersten et al. (1985c) found that sites with
probing attachment loss were more frequent as sites with
high scores for bleeding on probing. They found that the
predictability value of PI, GI, BOP did not exceed 30-40%,
and thus cannot be used to predict periodontal disease
activity. Kaldahl et al. (1990) found that gingival bleeding
and PI were not prognostic factor of attachment loss.
Claffey et al.(1990) investigated the diagnostic
predictability of scores for plaque, bleeding, and probing
depth for probing attachment loss over 3.5 years following
initial periodontal therapy. They found that accumulated PI
scores gave low predictability, while accumulated BOP
scores gave modest predictive values for attachment loss.
Badersten et al.(1990) studied the diagnostic value of
clinical scores of supragingival plaque, bleeding, and
probing depth to predict probing attachment loss over 5
years of observation following nonsurgical periodontal
therapy. In their study, the diagnostic predictability of
either accumulated plaque scores or accumulated bleeding
scores reached a maximum of about 30%, while the residual
probing depth equal or > 7 mm reached a predictability of
around 50%.
Jenkins et al.(1988) investigated the ability of certain
clinical parameters (pocket depth, PI and gingival redness)
and microbiological criteria to predict periodontal
breakdown during the one year period (with examination at
2-monthly intervals) in 11 subjects with untreated advanced
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periodontitis. They found that neither the PI scores,the
presence of gingival redness nor the pocket depth
measurements could be used in a predictive capacity for
attachment loss on either site or patient basis.
Our studies on the predictability of motile rods and
spirochaetes for attachment level loss, confirmed previous
investigations which have been conducted to evaluate the
role of subgingival bacterial morphotypes particularly
spirochaetes and motiles in predicting the disease activity
measured by attachment level loss. Previous retrospective
studies showed that spirochaetes cannot predict periodontal
disease activity measured by attachment loss (Listgarten et
al.,1978; Listgarten et al.,1986; Harley et al.1987;
MacFarlane et al.1988). Harley et al.1987 monitored the
clinical attachment levels over 12 weeks in patients with
untreated periodontal disease every four weeks. Their study
showed that none of PD, bleeding on probing or subgingival
bacterial morphotypes, indicated which sites would lose
attachment over a 12 weeks period. They concluded that
retrospective darkfield examination of sites where apparent
loss of 2mm or more had occurred, failed to predict the
periodontal disease activity. MacFarlen et al.(1988)
investigated the possible correlations between attachment
level change and spirochaetes at the baseline visit,at 2
months intervals and after one year in patients with
untreated periodontitis. They concluded that the
quantification of spirochaetes cannot be used reliably to
identify or predict disease-active sites.
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5.7 Diagnostic Predictability of GCF CRP levels at
the subsequent visits for periodontal disease
activity
The predictability of both CRP concentration and secretion
measured at the subsequent visits of each paired successive
visits and over one year for the occurrence of periodontal
breakdown determined by attachment level loss at the same
visit (subsequent visits) was investigated by two different
studies. In the first study, all the loser and stable sites
determined by the safety threshold method and classified
earlier (2.7.2,2.7.3,4.2), were used. While in the second
method, matched pairs of loser and stable sites within each
patient were used (Table 4.35).
As was discussed earlier (5.5,5.6), CRP levels measured at
the initial visits would not be useful predictors of
periodontal disease activity prospectively, but they may be
a useful aid for diagnostic assessment of this activity. In
other words, they maybe able to determine the occurrence of
periodontal disease activity measured by attachment loss
retrospectively. So this suggestion was investigated and
the results were mentioned earlier (Tables 4.39,and 4.40).
The thresholds used for these two studies, as mentioned
earlier (Tables 4.39, 4.40) were based on the data of CRP
levels recorded at the subsequent visits for each
prescribed period. This was because CRP levels were
significantly higher for loser sites at these visits
compared with their levels at the initial visits of each
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prescribed period. Secondly, the response for CRP levels
over each paired successive visits (and over one year) for
loser sites was significantly higher than those levels for
stable sites on all occasions. The selection of these
thresholds was also based on the findings that CRP levels
were significantly associated with increasing probing
attachment loss recorded at the subsequent visits, and as
no significant association was found for attachment level
change and CRP levels at the initial visits and due to
their failure to predict periodontal disease activity at
the initial visits. So this selection method of thresholds
would give a powerful positive CRP test and negative CRP
test as well as a powerful sensitivity and specificity.
In the first study, when all loser and stable sites were
used, CRP concentration and secretion failed to predict
periodontal disease activity retrospectively either for the
short term (over each paired successive visits) or over the
long term (one year period). Although there was an
improvement in their predictability over the one year
period, but this improvement was not enough to make these
variables (CRP concentration and secretion) useful
diagnostic aids for periodontal disease activity. This was
because of the low positive predictive values for both CRP
secretion and concentration, which resulted in
misclassifying a reasonable number of stable sites as being
loser sites on all occasions despite their high
specificity.
In the second study, when matched pairs of loser and stable
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sites within each patient were used, there was a limited
improvement in the predictability for both CRP
concentration and secretion on all occasion, despite the
fact there was no significant difference in thresholds used
for positive and negative CRP tests in both studies. The
positive predictive value was significantly higher while
the negative predictive value was significantly lower and
no significant difference could be found for either
sensitivity or specificity on all occasions. No significant
improvement in predictability was found between the one
year period and the paired successive visits.
The improvement in positive predictive value may be due to
the decrease in the stable sites used in matched pairs
compared to the first method.
However, using the second method, the results again
indicated that both CRP concentration and secretion are not
good predictors of the occurrence of disease activity
recorded at the subsequent visits (retrospectively), and
thus may be not useful as a diagnostic aid in determining
the presence of disease activity. The sensitivity of the
test was still low and the negative predictive value still
not high enough, despite the high positive predictive
value. So the positive test would have misclassified the
stable sites as being loser sites in between 15-40% of
cases on most occasions for both concentration and
secretion, although it was reasonable for one occasion
only. The negative test would have misclassified the loser
sites as being stable in about 40% of cases on all
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occasions. However, from a clinical point of view CRP
concentration and secretion could still not be considered
good predictors and not useful as diagnostic aids in
periodontal disease activity or course.
In general, the sensitivity of CRP tests was very low
demonstrating a very high rate of false negatives. The
relatively higher specificity value is probably due to the
low overall number of positive tests.
The reason for the low predictive value for CRP
concentration and secretion could be due to the large
number of stable sites involved in the study and the small
number of loser sites due to the specific method of
attachment level detection.
The Periodontal destruction may, however, occur during
exacerbation episodes of short duration accompanied by
changes in CRP levels. The duration of such episodes may be
much shorter than the intervals at which attachment level
measurements were taken in the present study, and therefore
the disease activity episode could have occurred at any
point in time during each prescribed period (two months
observation period, and over one year). It may be possible
that the periodontal episodes, which resulted in attachment
level loss, would either have accompanied or preceded the
change in CRP levels. CRP level change could have occurred
in very short periods during any exacerbation of any
inflammatory condition, and then the level could have
returned back to normal after the healing process or when
the stimulus was removed. This is more likely as CRP is an
401
acute phase protein whose levels in serum have been shown
(Kaplan, 1982; Pepys and Baltz, 1983) to increase rapidly
during severe inflammatory processes within 72 hours and
rapidly return back to normal level when healing has
occurred or the inflammation subsides. In this case any
alterations in the local CRP levels may have been missed.
In addition the relatively low number of sites
demonstrating attachment level change compromises the
possibility of CRP tests to predict periodontal disease
activity.
In conclusion, the results indicated that CRP concentration
or secretion, using either all the loser and stable sites
or their matched pairs within the patients, failed to
predict the periodontal disease activity measured by
attachment level retrospectively and thus they would not be
useful as diagnostic aid for the periodontal disease
activity.
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5.8 Conclusions, summary and further suggestions
The longitudinal studies on GCF CRP in the patient and
control groups showed for the first time the presence of
CRP in the GCF from healthy and disease sites, and this is
the first report for GCF CRP.
The development of ELISA was confirmed to be a reliable and
valid method for the detection and quantification of CRP
levels in both GCF and saliva as well as in serum. Our
studies reliably quantified CRP in both GCF and saliva.
These studies did not confirm the sources of CRP in either
GCF or saliva. Further investigation of the sources of both
salivary CRP and GCF CRP are required. Further studies
using salivary samples from parotid, submandibular or
sublingual glands or mucosal gland saliva, are required to
investigate its source.
The source of GCF CRP either as a leakage from the serum,
or as locally produced in the periodontium, should be
investigated. Recent studies reported extrahepatic
production of CRP by peripheral blood lymphocytes (Murphy
et al. , 1991; Kuta and Baum, 1986)), and it would be of
interest to investigate CRP production by the migrating
lymphocytes into the periodontium, and its possible
production by the resident cells of the periodontium such
as fibroblasts. Moreover, immunolocalisation of CRP in
gingival biopsies may provide information on CRP deposition
in the gingival tissue and possible participation in the
local immune response of the periodontium particularly as
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an opsonin or scavenger of necrotic tissue or damaged cells
during the inflammatory response. It would be of interest
to investigate if GCF CRP had the same biological function
in controlling the immune response and its cells
particularly the polymorphs which are the important cell in
the inflammatory response of the periodontium.
The studies reported the presence of a decisive parallel
association between the change in attachment level and the
change (response) in GCF CRP levels for both concentration
and secretion. This indicates that a dramatic change in CRP
levels was occurring during the periodontal breakdown at
the same time. This decisive association indicates that CRP
levels change are in association with the presence of
periodontal disease activity or periodontal breakdown as
measured by attachment loss in our studies. So the studies
provided information on the response (change) of CRP in the
GCF in relation to periodontal disease activity. However,
studies aiming to identify mechanisms controlling CRP
dynamics (metabolism and catabolism) in the crevice are
required, in order to find which factors govern its
production and response.
From the current studies it can be speculated that it is
attachment level which influences GCF CRP level changes
since it has already been shown that these factors are not
affected by gingival inflammation or measure of GI, BOP,
PD.and GCF volume. The studies found no significant
difference in the clinical parameters (PI,GI,PD) between
the loser and stable sites on all occasions and for BOP and
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GCF volume on most occasions. Thus these results excluded
an effect of these factors on CRP levels. It could be
concluded that the response in GCF CRP levels was not
governed by any of these factors or variables. It could
also be concluded that the association between attachment
level change and CRP response could not be affected by any
of these variables. So the effect of inflammation either in
the gingival margin (GI) or at the base of the pocket
(BOP), which could increase vascular permeability and
eventually lead to increase GCF flow (the volume), might be
not strong enough to increase GCF CRP. In contrast a strong
episode resulting in attachment level breakdown might have
this effect. Thus, the conclusion can be drawn, that the
dramatic response in GCF CRP levels was due to the strong
inflammatory condition which occurred at the crevice and
led to periodontal tissue breakdown represented by
attachment level loss. This may suggest possible mechanisms
of catabolism and metabolism or production of CRP within
the periodontal tissues. For example, tissue destruction
means cellular change in the periodontal unit and the
predominant presence of lymphocytes, which are the only
extrahepatic source of CRP known at the present time
(Murphy et al., 1991). It also leads to the initiation of
all the steps involved in the immune response actively
within the periodontal tissues which results in bringing
most of the acute phase proteins to this area. The most
likely is CRP, and an increase in its accumulation in the
gingival crevice already confirmed, by our studies, to be
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present in GCF. It could be suggested that CRP increasingly
accumulated or was produced in the crevicular area in order
to participate in the defence systems by expressing its
various biological effects which have already been
mentioned in the review of literature on CRP (section 1.8).
The acute inflammatory process (episode) resulting in
attachment level loss would seem to have its effect on CRP
levels. Thus, it could be suggested at this stage that
attachment level loss may govern CRP level changes or its
kinetics in the gingival crevice.
It would also be interesting to find if the periodontal
breakdown measured by the alveolar bone loss would have any
influence on CRP response in the periodontium as already
previous studies have demonstrated the role of the bone
resorbing factors (IL-1B, and IL-6) in regulating the
synthesis of serum CRP. On the other hand, a correlation
was previously found between bone destruction and high
levels of serum CRP in rheumatoid arthritis patients.
The studies confirmed the presence of a decisive
correlation between the attachment level change and the
change (response) in CRP levels both the short and long
term. However, within the limitations of this study, GCF
CRP levels for both concentration or secretion failed,
prospectively and retrospectively, to predict periodontal
disease activity measured by attachment level. Thus it
could be concluded that CRP would not be a useful predictor
or diagnostic aid for periodontal disease activity, and
could not considered as a marker of the disease activity.
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The Periodontal destruction may, however, occur during
exacerbation episodes of short duration accompanied by
changes in CRP levels. The duration of such episodes may be
much shorter than the intervals at which attachment level
measurements were taken in the present study and,
therefore, the disease activity episode could have occurred
at any point in time during each prescribed period (two
months observation period, and over one year) . It may be
possible that the periodontal episodes, which resulted in
attachment level loss, would either have accompanied or
preceded the change in CRP levels. CRP level change could
have occurred in very short periods during exacerbation of
any inflammatory condition, and then the level could have
returned back to normal after the healing process or when
the stimulus was removed. In this case any alterations in
the local CRP levels may have been missed. This could mean
that the determination of the exact levels of CRP during
these episodes or disease remission might have been missed,
and this may have an influence on its predictability. This
is more likely as CRP is an acute phase protein and whose
changes in serum have been shown to increase rapidly during
severe inflammatory processes within 72 hours and rapidly
return back to normal levels when healing has occurred or
the inflammation subsides. In addition the relatively low
number of sites demonstrating attachment level change
compromises the possibility of CRP tests to predict
periodontal disease activity. However, It could be
suggested that a further investigation should be carried
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out to monitor CRP levels within a very short period, for
example daily or weekly monitoring of CRP level , as this
level rapidly increases during the chronic inflammatory
condition and rapidly goes back to its normal level when
the inflammatory stimulus subsides.
Our studies confirmed the previous studies about the
inability of the clinical parameters (PI,GI,BOP,PD, and GCF
volume), and phase-contrast subgingival bacterial counts
including spirochaetes and motile rods, to predict
periodontal disease activity, and thus clinically, they are
not useful as diagnostic aids for periodontal disease
activity.
Future studies on CRP in periodontal disease could usefully
concentrate on its specific relationship to periodontal
disease activity. This could be further investigated by
careful monitoring of GCF CRP levels over shorter periods
of time, to allow more detailed analysis of relationship of
CRP levels to the destruction process. If CRP levels prove
to be valuable as a biochemical marker of periodontal
disease activity over shorter time periods, it would
provide a valuable tool for the better management of this
major cause of human tooth loss.
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ALM autologous mixed lymphocyte reaction
ANOVA analysis of variance
ATP adenosine triphosphate
BL B lymphocytes
BOP bleeding on probing









DDFM differential dark-field microscopy
ELISA enzyme-linked immunosorbent assay
ESR erythrocyte sedemintation rate
FBS fetal bovine serum
F-CRP fast-CRP
F-test Fisher test
GCF gingival crevicular fluid
GI gingival index






LDLP low density lipoprotein
MCRP membrane CRP
MIF macrophage inhibition factor
MCF migration chemotactic factor
NK natural killer
OHI oral hygiene index
OD optic density
OPD o-Phenylenediamine dihydrochloride.
PAF platelet activating factor
PBMC peripheral blood mononuclear cell
PC phosphorylcholine




PDA periodontal disease activity
PHA phytohaemagglutinin
PF3 platelet factor 3
PG : prostaglandin
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P.gingivalis
PI
PMN
Pn-CPS
PRP
rIL
ROU
SAP
S-CRP
SD
SE
TGF-B
TL
TNF-a
m.w.
mg/1
ng/ml
ug/uL
porphomonous gingivalis
plaque index
polymorphonuclear leukocytes
pneumococcal C-polysaccharide
platelet- rich plasma
recombinant interleukin
recurrent oral ulceration
serum amyloid P
surface CRP
standard deviations
standard error
transforming growth factor-B
T-lymphocytes
tumor necrosis factor-a
molecular weight
milligram per litre
nanogram per millilitre
microgram/microliter
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